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ABSTRACT 
Paediatric high grade glioma (HGG), including diffuse intrinsic pontine glioma (DIPG) 
are highly aggressive tumours with no effective cures. Lack of understanding of the 
molecular biology of these tumours, in part due to lack of well-characterised pre-clinical 
models, is a great challenge in the development of novel therapies. Analysis of paired 
cell culture/biopsy samples in this study revealed that paediatric HGG short-term cell 
cultures retain many of the tumour characteristics in vivo. Using a genome-wide 
approach, copy number, gene and miRNA expression, and methylation changes were 
characterised in 17 paediatric HGG-derived short-term cell cultures including 3 from 
DIPG. The majority of the genomic changes were unique from those arising in adult 
HGG. Approximately 65% (11/17) of paediatric HGG short-term cell cultures had 
balanced genetic profiles resembling normal karyotypes. The most frequent copy 
number gain and loss were detected at 14q11.2 (94%) and 8p11.23-p11.22 (59%), 
respectively. H3F3A (K27M) mutation was present in 2/17 (12%) cases and 
concurrent loss of CDKN2A and BRAFV600E in 1/17 (6%) case. Genes involved in 
reelin/PI3K signaling (DAB1), RTK signaling (PTPRE), and arginine biosynthesis 
(ASS1 and ASL) were frequently deregulated by methylation in these tumours. The anti-
growth and anti-migratory properties of DAB1 and PTPRE were demonstrated in vitro. 
Preliminary investigations validated the therapeutic potential of ADI-PEG20 (arginine 
depletion), and PI-103 (PI3K/mTOR inhibition) in a subset of paediatric HGG short-
term cell cultures. This study has identified novel genetic and epigenetic changes in 
paediatric HGG that may, following further validation, be translated into potential 
biomarkers and/or therapeutic targets.  
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1.1 Cancer  
1.1.1 Incidence and overview 
Cancer has emerged as a major health issue affecting people all over the world 
irrespective of their age, gender and socioeconomic background and accounts for one 
in seven deaths worldwide (Siegel et al., 2015). As per the GLOBOCAN database, 
the global cancer incidence and mortality rates in 2012 were estimated at 14.1 and 
8.2 million cases respectively (Ferlay et al., 2014). With almost no immediate 
likelihood for effective control, annual cancer-related deaths are projected to hit 
nearly 13 million as early as 2030 (American Cancer Society, 2015). 
Cancer is a heterogeneous group of diseases, characterised by cells with unchecked 
proliferative potential that can originate in almost any part of the body, and often 
undergo metastatic spread to distant parts (Stratton et al., 2009). The malignant 
transformation of a cell is a multi-step process during which it acquires several 
properties capacitating it to grow and divide uncontrollably. These malignant traits, 
described by Hanahan and Weinberg as ‗hallmarks of cancer‘ include the ability of 
cells to resist programmed cell death (apoptosis), override growth inhibitory signals, 
replicate limitlessly, proliferate uncontrollably, form new blood vessels 
(angiogenesis), reprogram metabolic machinery to meet the energy requirements of 
the growing tumour, evade destruction by the host immune cells, invade the 
surrounding tissues and metastasise to other organs in the body (Hanahan and 
Weinberg, 2011). In line with Darwinian principles, populations of cells that stably 
acquire and retain these oncogenic traits throughout several generations possess 
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growth superiority over normal cells in the local tissue environment and are selected 
for clonal expansion (Greaves and Maley, 2012). 
1.1.2 Cancer as a disease of the genome  
Cancer has long been understood to develop as a consequence of genomic 
disruptions such as mutations, copy number changes, deletions, insertions and non-
homologous recombination (Hanahan and Weinberg, 2011). The first evidence of 
genetic mutation in a cancer-related gene emerged from the identification of G>T 
amino acid substitution (glycine to valine) in codon 12 of HRAS (Reddy et al., 1982). 
Since then, several sequencing efforts including the large scale project initiated by 
the International Cancer Genome Consortium (ICGC) have enabled the identification 
of a vast array of mutations in key genes in more than 50 different cancer types 
(International network of cancer genome projects, 2010). Most of these mutations are 
considered as ‗passengers‘ while only few of them, called ‗drivers‘, actually 
contribute to oncogenic progression. Cancer cells often acquire DNA-repair defects 
resulting in an increase in mutation rate (Puente et al., 2011; Grasso et al., 2012). 
Research in the past decade has underscored the significance of additional and/or 
complementary mechanisms of gene silencing which do not involve changes to the 
primary DNA sequence. These changes, such as DNA methylation and post 
translational histone modifications, collectively called ‗epigenetic‘ changes are stable 
and heritable and suitable for the persistent acquisition of malignant traits during the 
evolutionary process (Baylin and Jones, 2011).  
Recently, studies have revealed that genetic and epigenetic changes work in 
cooperation with each other to cause stable phenotypic changes (You and Jones, 
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2012; Timp and Feinberg, 2013). For example, mutations in epigenetic regulators 
have been identified in renal cell carcinoma (RCC), rhabdoid tumours, bladder 
cancer, hepatocellular carcinoma (HCC), and adult and paediatric brain tumours 
(Versteege et al., 1998; Gui et al., 2011; Varela et al., 2011; Fujimoto et al., 2012; 
Sturm et al., 2012; Wu et al., 2012). Similarly, epigenetic inactivation has been 
reported in DNA repair genes like MLH1, BRCA1, MGMT and WRN (Herman et al., 
1998; Esteller et al, 2000; Hedenfalk et al., 2001; Agrelo et al., 2006) elevating 
mutation rates and contributing to genomic instability. Thus it is becoming 
increasingly apparent that cancer is a manifestation of both genetic and epigenetic 
changes in the cells.  
1.2 Brain tumours 
The annual age-adjusted worldwide incidence of primary brain and CNS tumours is 
3.4 per 100,000 people with a mortality rate of more than two-thirds (2.5 per 100,000 
people per year) (Central Brain Tumour Registry of the United States (CBTRUS), 
(www.cbtrus.org/factsheet/factsheet.html). The world annual incidence of brain and 
CNS tumours in children is lower than in adults with a rate of 1.1 per 100,000 people 
per year (Ostrom et al., 2015). However, brain and central nervous system (CNS) 
tumours are the second most frequent malignancy in children, just after leukaemia 
(CRUK). These tumours account for 24.5% of all tumours in those 0–14 years of age 
and 8.9% in those 15–24 years of age. Moreover, CNS tumours are the most 
common cause of cancer-related deaths in both the 0-14 year and the 15-24 year age 
groups.  
5 
 
1.3 Paediatric glioma 
Glioma represent a heterogeneous group of neuroepithelial tumours originating from 
mature glial cells or their less differentiated precursor cells in the CNS and are the 
most common type of CNS tumours across all age groups (Louis et al., 2007). 
Glioma in children share histopathological features with those in adults and can be 
categorised into various sub types based on the World Health Organisation (WHO) 
classification system (Louis et al., 2007). Based on their presumed cells of origin, the 
major sub types of glioma include astrocytoma, oligodendroglioma and 
oligoastrocytoma (Louis et al., 2007).  
1.3.1 Major clinical subgroups of paediatric glioma 
The majority of glioma arising in children are astrocytomas, which can be further 
classified into two broad clinical categories called ‗low grade‘ (Grades I and II) and 
‗high grade‘ (Grades III and IV) on the basis of a set of defined histological 
characteristics such as cellularity, mitotic activity, nuclear atypia and microvascular 
proliferation (Louis et al., 2007). The assessment of histopathological identities of 
tumour tissues and the assignment of malignancy grades have been historically 
incorporated into routine diagnosis of glioma to estimate the degree of their 
malignant behaviour and to predict clinical outcomes. 
1.3.1.1  Low grade glioma (LGG) 
LGG are the most prevalent CNS tumour in children (30-50%). These tumours are 
generally less aggressive and show considerable response to therapy with a 5-year 
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survival rate of 85%. The two most common histologies include pilocytic 
astrocytoma (PA) (WHO Grade I) and diffuse astrocytoma (WHO Grade II) (Sievert 
and Fisher, 2009). 
Pilocytic astrocytomas (PA) 
PA are the most prevalent glial neoplasm of childhood occurring predominantly 
within the cerebellum and less frequently in the optic tract, the hypothalamus and the 
brain stem (Penman et al., 2015). These are benign tumours with slow growth and 
often show good response to surgical resection (Sievert and Fisher, 2009). They 
appear relatively well-circumscribed, usually with a cystic component within and 
around the tumour tissue (Collins et al., 2015). Typical histopathological features of 
these tumours include low to moderate cellularity with densely fibrillated regions 
that are enriched with Rosenthal fibres consisting of long bipolar processes, as well 
as with loosely textured areas consisting of multipolar cells (Collins et al., 2015). 
The presence of microcysts and eosinophilic granules are common. Mitotic figures 
are rarely encountered. 
Diffuse astrocytoma  
Unlike PA, diffuse astrocytoma are less prevalent in children and occur largely in the 
supratentorial compartment, deep midline structures and the cervicomedullary region 
(Sievert and Fisher, 2009). These tumours are characterised by their ability to 
diffusely infiltrate normal structures of the brain, a property that limits the complete 
resection of these tumours contributing to worse outcomes than PA (Fisher et al., 
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2008). They exhibit moderate cellularity with limited or no mitoses. Vascular 
proliferation and necrosis are mostly absent (Louis et al., 2007). 
1.3.1.2  High grade glioma (HGG) 
Unlike malignant glioma in adults, HGG in children rarely progress from LGG; the 
low-grade to high grade transformation in children and adults occur at a rate of 7% 
and 50% respectively. HGG in children include anaplastic astrocytoma (Grade III), 
Glioblastoma multiforme (GBM) (Grade IV) and DIPG (Grade III and IV) (Louis et 
al., 2007).                                                                                                             
Anaplastic astrocytoma  
Anaplastic astrocytoma show higher cellularity than the low grade tumours with 
more evident nuclear pleomorphism and higher number of mitotic figures. They are 
diffusely infiltrative lesions presented with cytological and nuclear atypia (Louis et 
al, 2007). Necrosis and microvascular proliferation is usually absent (Collins, 2014). 
Glioblastoma multiforme (GBM)  
Morphologically, GBM cells are polygonal to spindle-shaped presented with features 
such as acidophilic cytoplasm, oval or elongated nuclei with irregular nuclear 
membrane, and hyperchromatic chromatin (Schultz et al., 2005). These cells have 
increased nuclear to cytoplasmic ratio and also show moderate nuclear 
polymorphism. Necrotic foci are one of the most distinguishing features of GBM; 
areas of necrosis may be large, focused toward the central area of the tumour, or 
small, surrounded by pseudopalisading areas (Kleihues and Sobin, 2000). They also 
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possess high cellularity and high mitotic activity with florid patterns of 
microvascular proliferation. 
Diffuse intrinsic pontine glioma (DIPG) 
DIPG originate in the brainstem and are the leading cause of brain tumour-related 
deaths in children (Jansen et al, 2012; Broniscer et al, 2013; Buczkowicz and 
Hawkins, 2015). These tumours are highly diffuse in nature and infiltrate the normal 
neural structures of the pons, often extending to neighbouring parts of the brain; one-
third of DIPGs show leptomeningeal dissemination and subventricular spread (Sethi 
et al., 2010; Caretti et al., 2014). These tumours present with intra-tumour histologic 
heterogeneity with features of Grade II or III occurring in a Grade IV specimen 
(Figure 1.1) (Buczkowicz et al., 2014). Thus diagnoses of DIPG based on biopsy are 
highly challenging owing to the presence of histopathological differences within the 
tumour specimens.  
 
 
 
 
Figure 1.1 Histopathology of DIPG. A. DIPG with features of Grade IV GBM with 
pseudopalisading necrosis (*) and microvascular proliferation (inset). B. Section of DIPG with 
features of Grade III such as cellularity, nuclear atypia, pleomorphism and mitotic activity (inset) 
(Buczkowicz et al., 2014). 
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1.4 Epidemiology and aetiology of paediatric HGG 
Although HGG are common in adults, they are a rare occurrence in children 
accounting for approximately 8-12% of all CNS neoplasms in this population (Bondy 
et al., 2008; Fangusaro, 2012). Childhood HGG are predominantly located within the 
supratentorium, with around 30-50% of these diagnosed in the cerebrum and the 
remaining mainly within the thalamus, hypothalamus, third ventricle, and basal 
ganglia (Wolff et al, 2004). Approximately 10% of paediatric HGG are located 
within the brainstem with majority of the cases diagnosed in children aged 6-8 years 
(Jones et al, 2012). Infratentorial glioma that are located within regions outside the 
brainstem are relatively rare in children with the ones within the cerebellum 
accounting only about 5% of all paediatric HGG (Karremann et al., 2013). Despite 
differences in the prevalence and preferential locations in the brain, childhood and 
adult HGG share similar clinical aggressiveness and contribute to significant amount 
of mortality among patients with brain tumours (Jones et al., 2012). 
The causes of paediatric CNS tumours, including HGG are not fully understood. 
However, several factors have been identified that could increase the susceptibility to 
tumour development in children. The contributions of rare genetic conditions have 
been identified to be associated with 10% of HGG development. The most common 
amongst them is Neurofibromatosis type 1, a condition in which the lack of 
neurofibromin and the consequent loss of Ras regulation results from germline 
mutations in NF-1 (Ward and Gutmann, 2005; Rosenfeld et al., 2009). In addition, 
Li-Fraumeni syndrome, resulting from mutations in the TP53 gene (Lane, 1992), has 
also been documented as a risk factor for HGG transformation in children; altered 
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p53 levels lead to loss of control of cell proliferation escalating the chance of 
malignant transformation (Varley, 2003; Melean et al., 2004). A well-established 
factor associated with HGG is a previous exposure to ionizing radiation during 
treatment of other malignancies, such as the most frequent cancer type in children, 
acute lymphoblastic leukemia.  
1.5 Current therapy for paediatric HGG  
The existing standard therapeutic regimen for high grade glioma in children involves 
a combination of surgery, focal radiotherapy and chemotherapy. However, there has 
been no notable improvement in the survival of children with HGG; the 2-year 
survival rates for supratentorial HGG remains <30% and for DIPG is <10% 
(MacDonald et al., 2011; Jones and Baker, 2014). 
1.5.1 Surgery 
The extent of maximal safe resection is considered the most valuable prognostic 
factor in children with high grade glioma (Bucci et al., 2004; Qaddoumi et al., 2009). 
In the Children‘s Cancer Group (CCG)-945 trial on HGG  patients (172 children of 
age 18 months to 21 years) randomised to surgery, radiation and chemotherapy, the 
patients who underwent >90% resection had better survival rates (both progression 
free and overall survival) compared to those who did not (Finlay et al., 1995). Based 
on this, the initial choice of treatment for a child with newly diagnosed HGG 
involves maximal surgical excision of the tumour mass without damaging normal 
brain structures which helps to ease intracranial pressures and improve the 
symptoms. Surgery also provides biopsy material for further tumour analysis and 
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disease follow-up. However, the choice of surgery is mainly dependent on the 
location of the tumour and the degree of involvement of normal brain. Resection is 
impractical for the treatment of DIPG owing to its diffuse and infiltrative pattern of 
growth involving normal neural structures of the brainstem (Vanan and Eisenstat, 
2015).  
1.5.2 Radiotherapy 
Radiotherapy (RT) plays critical roles in the management of HGG as adjuvant 
therapy to surgery. As malignant glioma often has an irregular border and involves 
infiltration of normal brain, absolute excision of the tumour is not achievable. Focal 
RT around the tumour bed is the routine practice in order to achieve maximal 
eradication of the residual tumour cells and target local recurrence of the tumour. 
The standard radiation dose for children with newly diagnosed HGG ranges from 50-
60 Gy administered in daily fractions of about 180-200 cGy over a course of 6 
weeks. As a standalone approach, RT is the gold standard of treatment for inoperable 
brain tumours and plays vital roles in the treatment of DIPG. Despite several 
advancements in RT, the potential toxic effects of X-rays on the developing brain 
restrict its use among children below 3 years of age (Dufour et al., 2006; Sanders et 
al., 2007). In older children, RT has been associated undesirable late effects such as 
cognitive delay, restrictive lung disease leading to respiratory failure or increased 
susceptibility to secondary neoplasms (Jakacki et al., 1995; Neglia et al., 2006).  
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1.5.3 Chemotherapy 
The first and the only substantial evidence in support of chemotherapy emerged from 
the CCG-943 trial in which the patients who received combination chemotherapy 
with prednisone, chloroethyl-cyclohexylnitrosourea (CCNU or lomustine), and 
vincristine (PCV regimen) in addition to post-operative RT reported better 5-year 
EFS (46% over 18%) than those who were treated with RT only (Sposto et al., 1989). 
Subsequent studies which investigated the efficacy of intensive chemotherapy 
including the CCG-945 trial failed to establish convincing roles for chemotherapy in 
providing survival advantage for children with HGG (Wolff et al., 2010). Although 
there is not enough evidence for the benefits of chemotherapy in the treatment of 
paediatric HGG, it is widely accepted as adjuvant and/or concomitant therapy in 
conjunction with surgery and RT for both newly diagnosed and recurrent HGG in 
this patient group.  
The improved survival rates in adult GBM after the addition of temozolomide (TMZ) 
to radiotherapy led to the initiation of similar trials in the paediatric population 
(Stupp et al., 2005). However, the use of TMZ as concomitant and adjuvant 
chemotherapy in addition to radiotherapy in children did not show remarkable 
improvement in their survival rates over the reports from the historic CCG-945 study 
(Cohen et al., 2011). The lack of response was found to be correlated with the 
expression status of O-6-Methylguanine DNA-Methyltransferase (MGMT); the 
patients with MGMT overexpression had a 2-year EFS rate of only 5% while those 
without MGMT overexpression had 17%. Nevertheless, it continues to be used in the 
current standard treatment in combination with radiotherapy probably due to the ease 
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of administration of the drug (oral), relatively low toxicity and lack of more efficient 
therapies.  
1.6 Molecular biology of paediatric HGG 
The low frequency of HGG incidence in children and the difficulty in obtaining 
clinical samples for research are some of the key obstacles to the understanding of 
the molecular mechanisms underlying the biology of HGG in children. In addition, 
early stage investigations in paediatric HGG were based on a candidate gene 
approach with frequently altered genes in adult HGG. Increased biopsy procedures 
and the advancement in high-throughput molecular biology techniques over the last 
few years have resulted in some improvement in our knowledge of these tumours. 
Large scale collaborative efforts of the ICGC and the Paediatric Cancer Genome 
Project (PCGP) (St. Jude Children's Research Hospital and Washington University) 
have begun to provide intriguing insights into the distinct biology underpinning these 
tumours (Downing et al., 2012). 
1.6.1 RTK/Ras/Raf/PI3K pathway alterations 
Dysregulated growth factor signalling by receptor tyrosine kinases (RTKs) and 
abnormalities in the downstream pathways including activation of mitogen activated 
protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K) pathways are the 
most common events in adult HGGs (Cancer Genome Atlas Research Network, 
2008). Genetic aberrations in these pathways are found in paediatric HGG, albeit 
with differing frequencies to those found in adults.  
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Alterations in receptor tyrosine kinases (RTKs)  
Members of the RTK group of kinases are cell surface receptors which are activated 
by extracellular molecules like growth factors, hormones and cytokines (Krause and 
van Etten, 2005).  The extracellular domains of RTKs possess binding sites that can 
interact with specific ligands and are also involved in receptor dimerisation required 
for the activation of intrinsic tyrosine kinase activity. Upon binding to the ligand, 
these receptors are autophosphorylated triggering the activation of Ras and induction 
of Raf, which can further activate the MEK/ERK1/2 and MAP3K pathways. RTK-
autophosphorlyation can also activate the PI3K complex leading to the activation of 
Akt and mTOR (Cancer Genome Atlas Research Network, 2008). All these networks 
contribute to signalling events essential for cellular growth, proliferation, 
differentiation and migration.  
Aberrant RTK signaling is one of the major mechanisms by which tumour cells 
escape the normal regulatory control on growth and proliferation, and the different 
mechanisms of RTK deregulation such as receptor amplification, mutation or 
overexpression or chromosomal translocation contribute to the development of 
various types of cancers (Rusten et al., 2007; Abella et al., 2009). Epidermal growth 
factor receptor (EGFR) is the most predominantly altered RTK in adult HGG, with 
copy number alterations and mutations in the gene found in approximately 60-85% 
of GBM (Brennan et al., 2013). EGFRVIII, the most common EGFR variant 
generated by deletions of exons 2-7 is also frequently altered in adult HGG (Wong et 
al., 1992; Pollack et al., 2006). In contrast, EGFR amplification and EGFRVIII over 
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expression occur at relatively low frequencies in paediatric HGG and DIPG (Bax et 
al., 2009). 
PDGFRA, encoding platelet-derived growth factor receptor-α is the most common 
target of amplification and/or activating mutation in paediatric HGG and DIPG 
(Paugh et al., 2010; Zarghooni et al., 2010; Puget et al., 2012). While amplification 
of PDGFRA is a common event in paediatric glioma (14%, 48 of 351 cases), it is 
relatively rare in adult HGG (10.6%, 22 of 206 cases) (Jones et al., 2012). The 
amplification of PDGFRA was more frequent in the irradiation-induced subset of 
tumours suggesting a potential role of this gene in tumour initiation (Paugh et al., 
2010). Additionally, PDGFRA mutants were shown to induce glioma formation in 
mouse models, these murine-derived glioma displayed gene expression profiles 
characteristic of human diffuse HGGs (Paugh et al., 2013). In the same study, none 
of the samples carried deletions of exons 8 and 9 that were previously reported in 
adult HGG, hinting that there is a distinct mutational spectrum conferring 
tumourigenic activity to PDGFRA in a paediatric setting. PDGFRA overexpression, 
associated with or without amplification is also common in paediatric HGG.  
v-raf murine sarcoma viral oncogene homologue B1 (BRAF) pathway  
BRAF, with serine threonine kinase activity is a component of the 
RAS/RAF/MEK/ERK kinase cascade of the MAPK pathway and contributes to 
regulation of key cellular functions like proliferation, survival and metabolism. 
BRAFV600E, the most common BRAF alteration is a point mutation involving 
amino acid substitution of valine with glutamic acid at position 600 resulting in 
constitutive activation of MAPK pathway.  
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Figure 1.2 BRAF/MEK/ERK pathway.  BRAF participates in signal transduction by growth factor 
signaling. In normal cells, this pathway regulates growth and proliferation in response to extracellular 
signals received from growth factors. In BRAFV600E-mutant cells, the pathway is constitutively 
active and need not receive growth factor stimulation leading to uncontrolled proliferation. 
 
This mutation is found in several cancers including a small proportion of paediatric 
low grade glioma. A study by Schiffman and colleagues (2010) identified 
BRAFV600E mutation in 10% (5/20 Grades III and IV) of paediatric HGG, with 3 of 
5 cases harbouring homozygous deletions of CDKN2A. A subsequent study on the 
incidence of BRAFV600E in larger patient cohorts reported significantly higher 
frequencies of mutations in paediatric GBM accounting for 16.6% (6/36) versus 
7.7% (3/39) found in adult GBM (Dahiya et al., 2013). Anatomically, these 
mutations are observed to be limited to the cortical regions of the brain; no mutations 
have been reported to date in DIPG. 
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PI3K/Akt pathway alterations 
Mutations, amplifications and deletions affecting the PI3K complex itself as well as 
its downstream effectors occur in adult and paediatric HGG, albeit at differing 
frequencies. In adult HGG, mutation rates in the catalytically active subunit 
(PIK3CA/p110α) and the regulatory subunit (PI3KR1) of PI3K occur at a frequency 
of 7-21% and 6-11% respectively (Parsons et al., 2008). In paediatric HGG including 
DIPG, mutations in PIK3R1 occur at a similar frequency as in adults (5-12%). 
Interestingly, mutations in PIK3CA are less frequent in supratentorial HGG (5%) but 
more frequent in DIPG (15-25%) (Broderick et al., 2004; Gallia et al., 2006; Grill et 
al., 2011; Buczkowicz et al., 2014; Strum et al., 2014), indicating a location 
dependent selection for mutations in this pathway. The feedback regulation of the 
PI3K pathway is mediated by phosphatase and tensin homolog (PTEN) that causes 
dephosphorylation of PIP3 and consequent inhibition of Akt activation. Mutations in 
PTEN are found in about 25-40% of adult HGGs while they occur at a very low rate 
in paediatric HGG (5-15%) (Pollack et al., 2006; Zarghooni et al., 2010; Barrow et 
al., 2011; Schwartzentruber et al, 2012; Brennan et al., 2013). Nevertheless, 
overexpression of Akt and its association with poor prognosis are commonly found 
in paediatric malignant glioma (Pollack et al., 2010). 
1.6.2 RB and p53 pathway alterations 
The p53 and RB pathways act in concert with each other to regulate cell division in 
the G1 phase of the cell cycle. In response to mitogenic stimuli, RB protein 
undergoes phosphorylation by the cyclin dependent kinase complex (CDK4 or 
CDK6 coupled with CCND1/2/3) and releases E2F1 transcription factor which then 
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promotes transcription of genes required for G1/S transition, a process kept under 
check by the tumour suppressor proteins p16/p14
ARF
 (CDKN2A) and p21
Cip1
. Under 
conditions of stress like DNA damage, ARF protein activates p53 by degradation of 
MDM2, this enables it to inhibit the cell cycle progression or to promote apoptosis. 
Mutations in TP53 are more common in paediatric HGG than adult HGG, with 
relatively higher frequencies of occurrence reported in DIPGs than in non-brainstem 
HGGs (Sung et al., 2000; Grill et al., 2012; Wu et al., 2014). Homozygous deletions 
of CDKN2A are mostly confined to non-brainstem HGG and mainly absent in 
DIPGs. The amplification of CDK4/6 or CCND1/2/3 has been found in about 30% of 
DIPG (Zarghooni et al., 2010; Paugh et al., 2011; Puget et al., 2012; Warren et al., 
2012). TP53 mutations occur at higher frequency in children >3 years than younger 
children (Pollack et al., 2001). 
1.6.3 Activin A receptor type I (ACVR1) 
ACVR1, also known as activin receptor-like kinase II (ALK2) encoding bone 
morphogenetic protein (BMP) receptor type I is involved in the transduction of 
extracellular signals from BMP protein (Attisano et al., 1993). Recent genome-wide 
studies have identified mutations in ACVR1 in paediatric HGG, exclusively in DIPG 
(range: 20-32%) (Buckowicz et al., 2014; Taylor et al., 2014). This gain-of-function 
mutation encodes amino acid substitutions in the kinase domain or the adjacent GS 
(glycine/serine-rich) inhibitory domain of ACVR1. BMP-ACVR1 binding initiates 
phosphorylation and activation of SMAD transcription factors such as SMAD1, 
SMAD5 or SMAD8 which further activate growth-promoting genes like ID1, ID2 
and ID3 (Buckowicz et al., 2014; Fontebasso et al., 2014) (Figure 1.3).  
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Figure 1.3 BMP signaling pathway.  Binding of BMP to ACVR1 (Type I BMPR) triggers 
phosphorylation of SMAD proteins resulting in activation of growth-promoting genes like ID1, ID2 
and ID3 (Shore and Kaplan, 2010). 
 
Some of the somatic ACVR1 mutations identified in DIPG resemble germline ACVR1 
mutations described in fibrodysplasia ossificans progressiva (FOP), a disease 
associated with abnormal formation of bone without any identified link to cancer 
predisposition. This indicates that ACVR1 may not have tumour initiating potential in 
DIPG but may offer growth advantage in the context of other mutations (Jones and 
Baker, 2014). 
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1.6.4 Isocitrate dehydrogenase 1 (IDH1) mutations 
IDH1, encoding the metabolic enzyme isocitrate dehydrogenase catalyses the 
production of α-ketoglutarate (KG) from the substrate isocitrate via oxidative 
decarboxylation. It is the principal source of NADPH in the brain protecting it from 
oxidative stress (Bleeker et al., 2010). By modulating insulin secretion, IDH1 plays 
important roles in determining cellular responses to glucose concentrations (Guay et 
al., 2013). Recurrent mutations in IDH1 in GBM were first identified in 2008 as part 
of the TCGA project when 5 of 6 secondary adult GBM had mutated IDH1 with no 
mutation in 16 primary GBM included in the cohort. This identification was further 
supported by studies thereafter in larger sample numbers suggestive of its potential 
role as an early event in tumourigenesis in adult glioma (Horbinski et al., 2009). 
Large scale sequencing studies in paediatric HGG reported that IDH1 mutations have 
no significant role in the paediatric setting. Only 4/32 cases (12.5%) had IDH1 
mutations; mutations in IDH2 have not been recorded.  
1.6.5 Chromosomal alterations in paediatric HGG 
Paediatric HGG exhibit a unique set of CNAs and at lower incidence rates in 
comparison to their adult counterparts. For instance, the most frequent chromosomal 
abnormality in adult GBM, the concurrent gain of chromosome 7 and loss of 
chromosome 10q (83-85%), is far less commonly seen in children than adult HGG 
(13-19% and 16-38%, respectively) (Maher et al., 2006; Bax et al., 2010; Paugh et 
al., 2010; Brennan et al., 2013; Sturm et al., 2014). Gain of 1q and loss of 16q are the 
most frequent CNAs in paediatric HGG (Rickert et al., 2001; Bax et al., 2010). The 
other major abnormalities consistently found in paediatric HGG at low frequencies 
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include regions of gains at 1p, 2q, and 21q and losses at 6q, 4q, and 11q (Wong et al., 
2006; Bax et al., 2010; Paugh et al., 2010). To add to the complexity of the genomic 
profiles of paediatric HGG, a subset of paediatric HGG do not possess large scale 
chromosomal imbalances; 2 independent studies led by Paugh et al. (2010) and 
Barrow et al. (2011) reported no major chromosomal aberrations in 15/78 (19%) and 
5/38 (13%) patients respectively. The notable similarities in CNAs exhibited by a 
proportion of paediatric and adult HGG include 13q and 14q losses. 
The expression of chimeric genes involving the C-terminal kinase domain from the 
neurotrophic tyrosine receptor kinase (NTRK) family members (NTRK1, NTRK2 and 
NTRK3) with N-terminal tails of a number of genes has been recently documented in 
paediatric HGG, especially in infants. This report, based on a small cohort of 10 
patients also demonstrated the oncogenic potential of 2 of the fusion genes, TPM3-
NTRK1 and BTBD1-NTRK3 by implanting into Tp53-null mice which resulted in 
HGG formation in vivo (Wu et al., 2014). 
1.6.6 Gene expression profiling  
Integration of copy number and gene expression studies in paediatric HGG have 
revealed molecular sub-groups within these tumours, which share similarities and 
differences with those previously identified in adult HGG (proliferative, proneural 
and mesenchymal). A study by Paugh et al. (2010) identified 3 major sub groups in 
paediatric HGG – HC1, HC2 and HC3. The HC1 subgroup was associated with 
amplification of PDGFRA/PGFRB, gain of 1q and overexpression of genes involved 
in cell cycle regulation; HC2 subgroup was associated with gain of 1q and 
overexpression of genes involved in neuronal differentiation, while HC3 was 
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associated with overexpression of genes involved in cellular matrix-receptor 
interactions and cell adhesion (Faury et al., 2007; Paugh et al., 2010).  
 
1.7 Role of epigenetics in cancer 
1.7.1 The concept of epigenetics 
The concept of epigenetics was first introduced in the early 1940s by Conrad Hal 
Waddington to study the causal interactions between genes and their products that 
result in a particular phenotype (Goldberg et al, 2007). Our knowledge on the 
significance of epigenetic processes in the biology of healthy and disease states has 
come a long way since then and it is now increasingly understood that they have 
immense potential to fine-tune the mechanisms of decoding the genetic blueprint of 
cells (Feinberg and Tycko, 2004; Rodriguez-Paredes and Esteller, 2011). The term 
‗epigenetics‘ refers to stable and heritable phenotypic changes in a cell that are not 
accompanied by changes in the primary DNA sequence and are primarily mediated 
by DNA methylation, histone modification and non-coding RNAs (Bernstein et al., 
2007; Goldberg et al., 2007). These epigenetic mechanisms are well coordinated in 
normal cells and are essential for the establishment and stable propagation of 
appropriate patterns of gene expression during normal developmental processes 
(Berdasco and Estellar, 2010). Disruptions in such regulatory control lead to 
abnormal expression of genes and altered signalling pathways, which are common 
events in cancers (Sharma et al., 2010).  
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1.7.2 DNA methylation 
1.7.2.1 Principles of DNA methylation 
DNA methylation, the most widely investigated of all known epigenetic mechanisms 
(Esteller, 2007; Jones and Baylin, 2007), typically involves the covalent transfer of a 
methyl group (-CH3) from S-adenosylmethionine (SAM) to the 5‘carbon on the 
cytosine (C) moieties within the cytosine-guanosinedinucleotides (CpGs), resulting 
in the formation of 5-methylcytosine (5mC) (Baylin and Jones, 2011). CpG sites are 
distributed across the genome, with a small proportion of them clustered in distinct 
regions called ‗CpG islands‘ (CGIs) and are defined as approximately 500 bp long 
regions with GC content of 55% and an observed-to-expected CpG ratio of 0.65 
(Takai and Jones, 2002). CGIs preferentially span gene promoters, the transcription 
start sites (TSSs), and/or first exons and cover approximately 60% of human gene 
promoters (Tsai and Baylin, 2011). They are most commonly found in the promoter 
regions of housekeeping genes as well as up to 40% of tissue-specific genes and are 
normally unmethylated (Hackenberg et al., 2010). The remaining small proportions 
of CGIs are associated with transcription inactivation essential for X-chromosome 
inactivation (Riggs et al., 1975), genomic imprinting (Li et al, 1993; Zhang et al., 
1993), and tissue-specific differentiation (Okano et al, 1999; Esteller, 2007). DNA 
methylation is also vital for the maintenance of chromosomal stability by preventing 
the transcription of potentially harmful regions of the genome containing repeat 
elements, viral inserts and transposable elements (Bird, 2002; Herman and Baylin, 
2003).  
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1.7.2.2 Enzymes involved in the regulation of DNA methylation  
The process of DNA methylation is tightly regulated by the activities of two groups 
of enzymes, which add and remove methyl groups called DNA methyltransferases 
(DNMTs) and DNA demethylases respectively (Jeltsch and Jurkowska, 2014). The 
DNMT family includes DNMT1, DNMT3 (DNMT3A, DNMT3B) and DNMT3L 
(Herman and Baylin, 2003). DNMT3A and DNMT3B, called de novo 
methyltransferases, can function independent of replication and initiate methylation 
at CpG sites on unmethylated and/or hemimethylated DNA (Okano et al., 1999). On 
the other hand, DNMT1 called the maintenance methyltransferase, acts during 
replication and has about 10-40 fold preference for hemi-methylated DNA 
(Bashtrykov et al., 2012). The recruitment of DNMT1 to the replication fork and to 
hemimethylated DNA are mediated by proliferating cell nuclear antigen (PCNA) and 
the ubiquitin-like containing PHD and RING finger domain protein 1 (Uhrf1 protein) 
respectively (Chuang et al., 1997). However, several studies in recent years have 
challenged the stringent functional classification of DNMTs.  
In addition to their role as de novo methyltransferases, the DNMT3 family of 
enzymes have been identified to have considerable maintenance methylation activity 
found at repeat elements, this activity occurs both independently of, and in 
cooperation with, DNMT1 (Liang et al., 2002; Chen et al., 2003). It has also been 
found that efficient de novo methylation occurs as a result of the combined efforts of 
DNMT3 and DNMT1; DNMT3 can generate methylated CpG sites in only one of the 
strands of DNA due to their preferences for flanking sequences (Handa and Jeltsch, 
2005) as well as their nature of binding to DNA that supports methylation of 
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neighbouring CpG sites in a single binding only resulting in the generation of hemi-
methylated strands that act as substrates for DNMT1. The third member, DNMT3L 
lacks catalytic activity, but can enhance the methyltransferase activities of the other 
members in the family in a context-dependent fashion (Hata et al., 2002; Jurkowska 
et al., 2011; Neri et al., 2013).  
DNA methylation can also be influenced by the activities of DNA demethylases 
which include ten-eleven translocation (TET) dioxygenases, activation-induced 
cytidinedeaminase (AID) and apolipoprotein B mRNA-editing enzyme 1 
(APOBEC1) (Tahiliani et al., 2009; De Carvalho et al., 2010, Ito et al., 2010). The 
TET family of enzymes consisting of TET 1, TET 2 and TET 3 are involved in the 
catalyses of  oxidation of 5-methylcytosine to 5-hydroxymethylcytosine, which is 
further deaminated to form cytosine by the AID and APOBEC1 proteins(Kohli and 
Zhang, 2013; Pastor et al., 2013).  
1.7.2.3 Mechanisms of DNA methylation-mediated gene silencing 
The exact mechanisms of how the information represented by DNA methylation is 
interpreted to bring about gene silencing are not completely clear. Two main models 
have been proposed. Firstly, the physical position of the methyl group of a CpG in 
the major groove of DNA can directly block the binding of transcription factors 
(TFs) (Hervouet et al., 2009). TFs such as c-Myc/Myn, CREB/ATF, E2F and NFκB 
have recognition sites containing CpG sites and are inhibited by methylation (Allis et 
al., 2007). The second mechanism involves the participation of a group of proteins, 
called methyl-CpG-binding proteins (MBPs) that can bind to methylated CpGs 
causing hindrance to the binding of TFs. These proteins have also been associated 
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with histone deacetylases activity and contribute to maintenance of silent chromatin. 
Three families of MBPs have been identified. The first group that contains methyl-
CpG binding domains (MBDs) contributes to transcription repression through the 
action of its four main members - MeCP2, MBD1, MBD2 and MBD3. The second 
group consists of proteins that lack MBDs, but have specialised zinc finger domains 
to detect methylated DNA; these include zinc finger and BTB domain-containing 
protein 4 (ZBTB4), ZBTB33/kaiso, and ZBTB38. The third group includes the SET 
and RING-associated (SRA) domain proteins such as inverted CCAAT box-binding 
protein of 90 kDa (ICBP90) (Unoki et al, 2004). 
1.7.2.4  DNA methylation in cancer 
Altered methylation patterns in the genome manifested as global hypomethylation 
and/or region-specific hypermethylation are common events in cancers. As the basal 
methylation levels vary with tissue-types, ‗hypo‘ or ‗hyper‘ methylation of DNA in a 
particular cancer is a relative measure of the amounts of DNA methylation with 
respect to methylation levels in their corresponding normal tissues (Ehrlich et al., 
1982). The global changes in DNA methylation in normal and tumour cells is 
illustrated in Figure 1.4. 
Although genome-wide DNA hypomethylation was one of the first epigenetic 
alterations to be identified in malignant cells, this phenomenon remains largely 
understudied. Global reduction in methylation can have potentially undesirable 
cellular consequences associated with different stages of cancer development and has 
been reported in several cancers including GBM in adults (Cadieux et al., 2006). 
Hypomethylation is associated with transcriptional activation of protooncogenes, 
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some of which include HRAS in melanoma, cyclinD2 and maspin in gastric cancer, 
and MN/CA9 in renal cell carcinoma. Notably, hypomethylation can lead to genomic 
instability and mitotic recombination resulting in deletions and translocations, and 
the reactivation of various transposable elements (such as long interspersed nuclear 
elements (LINEs) and Alu repeats), viral oncogenes, and/or growth-related imprinted 
genes like IGF2 (Ehrlich, 2009).  
Unlike global hypomethylation, localised DNA hypermethylation has been 
extensively investigated in cancers (Sharma et al., 2010). Promoter-specific DNA 
hypermethylation in cancer cells can turn off tumour suppressor genes and is as 
prevalent as mutational events in cancer development (Jones et al., 2002). DNA 
hypermethylation can contribute to tumourigenesis by causing transcription 
inactivation of a wide array of genes involved various cellular processes such as cell 
cycle, apoptosis, angiogenesis, metastasis, and metabolism (Herman and Baylin, 
2003). Some of these genes are classic tumour suppressors such as RB in 
retinoblastomas and VHL (associated with von Hippel-Lindau disease) in renal cell 
cancers (Herman et al, 1994), while others act as transcription factors, the silencing 
of which in turn affect the expression of numerous other genes controlled by them. 
Hypermethylation can also disrupt the levels of DNA repair genes (eg: MLH1 and 
BRCA1) reducing the capacity of cells to repair genomic errors thereby increasing 
their vulnerability to malignant transformation (Esteller, 2009). 
Identification of hypermethylated genes can serve as a powerful tool for early 
detection of tumours (eg: GSTP1 in prostate cancer) and for predicting response to 
therapy (eg: MGMT predict response to DNA-alkylation agents like TMZ in GBM 
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patients). The reversible property of DNA methylation has also led to the 
development of demethylating therapy for some cancers such as acute myeloid 
leukemia (AML) (Momparler et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Global changes in DNA methylation in normal and tumour cells. In normal cells the 
CpG islands in active promoters are unmethylated allowing the transcription of genes. Aberrant 
methylation of promoter CpG islands often occurs in coding regions in tumour cells. This leads to 
aberrant silencing of tumour suppressor genes in tumour cells. 
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1.7.3 Histone modifications  
1.7.3.1 Principles of histone modifications 
Eukaryotic chromatin is made of repeating units of nucleosomes, each composed of 
roughly 147 base pairs of DNA coiled around an octameric core, containing two 
units each of four types of histone proteins - H2A, H2B, H3 and H4 (Luger et al., 
1997; Cutter and Hayes, 2015). The amino acid moieties of these core histones, 
predominantly the ones located in the N-terminal tails, can undergo dynamic 
chemical modifications such as lysine acetylation, lysine and arginine methylation, 
lysine ubiquitylation, lysine sumoylation, serine/threonine/tyrosine phosphorylation 
and arginine citrullination (Kouzarides et al., 2007; Bannister and Kouzarides, 2011). 
In addition, several less common modifications have been identified in the past few 
years, which include lysine crotonylation, tyrosine hydroxylation, lysine 
butyrylation, lysine propionylation and serine/threonine O-GlcNAcylation (Chen et 
al., 2007; Fujiki et al., 2011; Tan et al., 2011). These modifications, either singly or 
in combination, play decisive roles in the establishment of ‗active‘ (euchromatin) 
versus ‗silent‘ (heterochromatin) chromatin domains in the genome and coordinate 
the execution of crucial DNA-based biological functions like transcription, 
replication and repair (Kouzarides et al., 2007). The functional consequences of these 
modifications depend on the nature of the modification, and the type and number of 
amino acid residues involved in the process (Sharma et al., 2010). For instance, 
acetylation of lysine is associated with transcriptional activation where as 
methylation of lysine may result in activation (as in case of trimethylation of lysine 4 
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on histone H3 (H3K4me3)) or repression (as in cases of trimethylation of H3K9 
(H3K9me3) and H3K27 (H3K27me3)) of transcription.  
Recent studies have unravelled some of the layers of complexity in the ways histone 
modifications operate in cells. These new findings suggest the involvement of cross 
talk between the combinations of modifications occurring in a context-dependent 
manner, making it difficult to predict an exact causal relationship between a 
particular modification and its biological response in the cell (Lee et al., 2010; 
Rothbart and Strahl, 2014). In normal cells, these modifications work under extreme 
coordination to establish specific patterns in particular cell types. For instance, in 
embryonic stem (ES) cells, there occurs a state of ‗bivalency‘ defined by the co-
existence of permissive (H3K4Me3) and repressive (H3K27Me3) histone marks in 
the promoter regions of genes involved in developmental events (Bernstein et al., 
2006). This is regulated by the antagonistic effects of the Trithorax and Polycomb 
group of proteins which favour the activating and repressive marks respectively 
resulting in the commitment of stem and/or progenitor cells into specific lineages. On 
the other hand, this bivalency is lost in differentiated cells enabling them to maintain 
their cell fates over several generations (Mikkelsen et al., 2007). 
1.7.3.2 Enzymatic regulation of histone modifications 
Post-translational histone modifications are regulated by enzymes that catalyse either 
deposition of specific chemical moieties, called chromatin ‗writers‘ (such as histone 
acetylases (HATs)) or their removal, called ‗erasers‘ (such as histone deacetylases 
(HDACs)). The resulting modified structure can turn on the recruitment of effector 
proteins called ‗readers‘, with specialised domains that can bind to such structures 
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and initiate specific chromatin-associated downstream events (Jenuwein, 2001). 
While the ‗writers‘ and ‗erasers‘ can impose a direct effect on histone-DNA binding 
by altering electrostatic charges on the amino acid residues as observed in case of 
lysine acetylation (Shogren-Knaak et al., 2006) and arginine citrullination 
(Christophorou et al., 2014), the ‗readers‘ alter chromatin structure by various 
indirect mechanisms as in case of bromodomain (Dhalluin et al., 1999). In addition 
to the core histone proteins, non-allelic variants of histones such as H3.3 and H2A.Z 
also engage in posttranslational modifications and can modulate gene activity by 
non- covalently altering nucleosome stability as well as by protecting regions of 
DNA against methylation (Talbert and Henikoff, 2010).  
Modifications in the histone/histone variants can interact with chromatin remodelling 
enzyme complexes and alter the positioning and stability of nucleosomes. There are 
currently four major sub families of chromatin remodelling enzyme complexes: 
switching defective/sucrose non-fermenting (SW1/SNF) family, the imitation SWI 
(ISWI) family, the nucleosome remodelling and deacetylation (NuRD)/Mi-2/ 
chromodomain helicase DNA binding (CHD) family, and the inositol requiring 80 
(INO80) (Wang et al., 2007). 
1.7.4 Histone mutations in paediatric HGG 
1.7.4.1 H3.3/H3.1 mutations 
The investigation of paediatric HGG at the global genomic level has identified novel 
mutations in the histone modification machinery and the histone proteins themselves. 
Two independent studies on paediatric GBM and DIPG in 2012 (Schwartzentruber et 
32 
 
al., 2012; Wu et al., 2012) reported the first evidence for tumourigenesis associated 
with direct mutation of histones. Mutations were identified within H3F3A and 
HIST1H3B genes encoding histone variant proteins H3.3 and H3.1 respectively. H3.1 
is synthesised in synthetic phase and is deposited only during DNA replication, and 
H3.3 is present throughout the cell cycle and is incorporated at all phases of the cell 
cycle (Ahmad and Henikoff 2002). These mutations lead to amino acid substitutions 
at 2 important residues within the N-terminal histone tail involving replacement of 
lysine with methionine at position 27 (K27M) and glycine with arginine (G34R) or 
with valine at position 34 (G34V). These mutations were found to have associations 
with specific anatomical regions in the brain; K27M mutations were mainly detected 
in H3F3A and had high frequency of occurrence in DIPG samples (78%) while 
G34R/G34V mutations exclusively found in H3F3A were largely restricted to 
tumours found in cerebral hemispheres.  
Dysregulation of the histone modification machinery is a common event during 
malignant transformation affecting the recruitment of transcription factors and 
patterns of gene expression. The repressive histone mark, H3K27Me3 essential to 
inhibit the expression of genes that oppose normal development and differentiation 
has been observed to be globally reduced in H3F3A (K27M)-mutant paediatric HGG 
and DIPG (Bender et al., 2013). This reduction was associated with inappropriate 
recruitment of the polycomb repressive complex 2 (PRC2) to the mutant H3.3 and 
inhibition of the enzymatic activity of the H3K27me3-establishing methyltransferase 
EZH2. The overall survival of DIPG patients with H3F3A (K27M) mutations was 
reduced compared to their wild type counterparts (Khuong-Quang et al., 2012). 
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1.7.4.2 H3.3/ATRX/DAXX pathway alterations 
Interestingly, the roles of histone modifications in gliomagenesis in children have 
been further cemented by the identification of mutations in the chromatin 
remodelling complex ATRX/DAXX alone and in conjunction with H3.3 and TP53 
mutations. ATRX mutations have been detected in 31% of samples with all of them 
harbouring the G34R/V H3.3 mutation. In some cases, these mutations were detected 
along with TP53 mutations suggesting the contribution to the molecular biology of 
these tumours of the interconnection between these pathways.  
Death domain associated protein (DAXX) forms highly specific, stable complexes 
with H3.3 and functions as histone chaperons in cooperation with α-
thalassemia/mental retardation syndrome protein (ATRX) aiding the deposition of 
H3.3, preferentially at repetitive heterochromatic regions such as telomeric and 
pericentric DNA repeats, and ribosomal repeat sequences (Tang et al., 2004; Lewis et 
al., 2010). Mutations in the H3.3/ATRX/DAXX/TP53 network results in the 
incorporation of mutant H3.3 and the consequent presence of a telomere maintenance 
mechanism called alternative lengthening of telomeres (ALT) which do not require 
the involvement of telomerase. Mutations in TP53 have also been demonstrated to 
have a connection with ALT leading to enhanced lengthening of telomeres that 
confers uncontrolled proliferative ability to cells (Heaphy et al., 2015). 
1.7.4.3 Mutations in histone modifiers and chromatin remodelers 
Recently, Fontebasso and colleagues (2013) identified loss-of-function mutation in 
SETD2 in approximately 15% (11/73) of paediatric HGG and 8% (5/65) of adult 
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HGG. This mutation was exclusively found in HGG arising in the cerebral cortex. 
SETD2 encodes H3K36 trimethyltransferase which catalyses the trimethylation of 
lysine residues of histone H3 at position 36 (Edmunds et al., 2008) and the mutation 
in the gene was associated with decreased levels of H3K36Me3 histone marks. 
H3K36Me3 has dual roles in activation as well as repression of transcription and 
regulates various processes in the cell such as DNA replication and repair. 
1.7.4 Non-coding RNAs 
Non-coding RNAs were once thought as non-functioning products of ‗junk DNA‘; 
today they are known as crucial biological participants in the regulation of gene 
expression (Ling et al., 2015). These encompass a class of RNAs, ranging from small 
to long ncRNAs, including micro RNAs (miRNAs), PIWI-interacting RNAs 
(piRNAs), small nucleolar RNAs (snoRNAs), large intergenic non-coding RNAs 
(lincRNAs) and transcribed ultra conserved regions (T-UCRs). 
1.7.4.1 Overview  
The best studied among the non-coding RNAs are miRNAs, which are small RNAs 
of approximately 18-24 nucleotides in length capable of mediating diverse cellular 
processes essential for normal mammalian development and tissue homeostasis 
(Vidigal and Ventura, 2015). Each miRNA has in its 5‘end a set of nucleotides 
(particularly nucleotides 2-8), called the ‗seed‘ and can bind to corresponding 
sequences (‗seed site‘) on 3‘UTR regions of specific messenger RNA (mRNA) 
targets through complementary base pairing (Lewis et al., 2003; Saito, 2015), 
resulting in mRNA degradation and/or translational repression. In addition to 
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3‘UTRs, miRNAs can also target 5‘UTR regions (Lee et al., 2009), other non-coding 
RNAs and even proteins. More than 1000 human miRNAs have been discovered to 
date; some miRNAs have unique specificity for their targets, whereas others can 
affect hundreds of targets, suggesting that miRNAs may exert control on the 
expression of the vast majority of the protein coding genes.  
1.7.4.2 Biogenesis of miRNAs 
The majority of miRNAs are transcribed in the nucleus from miRNA genes 
(canonical pathway) and about 30% of them from introns of protein-coding genes 
(non-canonical pathway). The transcription of miRNA genes is mediated by RNA 
polymerase II, resulting in long primary transcripts (pri-miRNAs) which are then 
capped at the 5‘end and polyadenylated at the 3‘ end (Lee et al., 2004). Pri-miRNAs 
are processed by the microprocessor complex consisting of RNA polymerase 
III/Drosha and the RNA binding protein, DiGeorge syndrome critical region 8 
(DGCR8). Drosha splices pri-miRNAs to yield 60-70 nucleotide-long hair-pin 
shaped precursor miRNAs (pre-miRNAs) (Lee et al., 2003). In the non-canonical 
pathway, pre-miRNAs are generated in splicing events followed by a 
DROSHA/DICER-independent process involving the lariat-debranching enzyme. 
Pre-miRNAs, thus produced, are bound to a nuclear export factor, Exportin-5 
(XPO5) that transports them to the cytoplasm in a RAN-GTP dependent manner 
(Okada et al., 2009) where they are further processed by Dicer and transactivation-
responsive RNA-binding protein 2 (TARBP2) to yield a dsRNA duplex consisting of 
both the mature miRNA and its complementary strand (miRNA/miRNA
*
). The 
mature miRNA then joins with Argonaute protein (AGO) to assemble into the core 
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of the RNA-induced silencing complex (RISC), while the complementary strand 
(miRNA
*) 
is degraded. The mature miRNA can then lead to mRNA degradation or 
repression of translation (Filipowicz et al., 2008). 
 
 
 
 
 
 
 
 
 
Figure 1.5 Biogenesis of miRNAs. Biogenesis of miRNAs can occur from miRNA genes in the 
canonical pathway or from the introns of protein-coding genes in the non-canonical pathway. The pre-
miRNAs are cleaved and exported to the cytoplasm where they can have several consequences on 
their target genes. Mature miRNAs can cause cleavage of mRNA targets, translational repression and 
deadenylation (Winter et al., 2009). 
 
1.7.4.3 Role of miRNAs in cancer 
Under normal physiologic conditions, miRNAs are very stable and their biosynthesis 
and functional activities are tightly regulated (Mendell and Olson, 2012). This 
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regulatory control is often lost in malignant cells in response to various 
environmental stress signals like hypoxia or DNA damage, resulting in altered levels 
of miRNA expression (Hata and Lieberman, 2015; Orellana and Kasinki, 2015).  
The first major evidence for the participation of miRNAs in cancer was made in 
2002, with the identification of miR-15a/16-1 loci deletions in patients with B cell 
chronic lymphocytic leukemia (B-CLL) (Calin et al., 2002). Over the last few years, 
there has been a rapid increase in the identification of miRNAs and their putative 
targets in a number of cancer types (Orellana and Kasinki, 2015). Based on their 
functions, miRNAs can be oncogenic (oncomiRs), tumour suppressive (tumour 
suppressor miRs), or context-dependent (Zhang et al., 2007; Kasinki and Slack, 
2011; Friedlander et al., 2014). OncomiRs target tumour suppressor genes and are 
usually found upregulated in cancers; for instance, miR-21 can target tumour 
suppressor genes like PTEN, PDCD4, TPM1, SPRY1/2 and TP53BP2 (Leva et al., 
2014). Conversely, tumour suppressor miRs target oncogenes and are generally 
downregulated in cancers; for instance, let-7 family of miRNAs that targets 
oncogenes such as MYC and RAS to suppress tumour growth, are frequently down 
regulated in cancers (Johnson et al., 2005; Kim et al., 2009). The context-dependent 
miRNAs can perform opposing roles in cancers depending on the cellular context, 
for example, miR-221 behaves like an oncogene in liver cancer, but in erythroblastic 
leukemia it exerts tumour suppressive role by targeting KIT oncogene (Felli et al., 
2005; Pineau et al., 2010). 
MiRNAs are potent mediators of several cellular processes such as differentiation, 
and apoptosis which are often deregulated in cancers (Hata and Lieberman, 2015). 
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They can modulate growth factor signalling networks through their interplay with 
specific growth factors. For example, overexpression of miR-7 induced cell cycle 
arrest and reduced invasiveness in GBM by regulation of EGFR expression and Akt 
pathway activity (Kefas et al., 2008). MiRNAs also play important roles in regulating 
glucose metabolism in many cancer types. MiR-195-5p has been shown to have 
sequence-specificity to target glucose transporter member 3 (GLUT3) in bladder 
cancer cells resulting in decreased transportation of glucose into the cells, inhibition 
of growth and promotion of apoptosis (Fei et al., 2012). The suppression of miR-143 
was associated with increased levels of hexokinase 2 (HK2) in head and neck 
squamous cell carcinoma (Peschiaroli et al., 2013), colon cancer (Gregersen et al., 
2012) and GBM (Zhao et al., 2013). The importance of miRNAs in cancer has been 
further highlighted by the observation that miRNAs are found in cancer exosomes 
and can induce tumour formation in normal cells by utilising their own mechanism to 
process mature oncogenic miRNAs from pre-miRNAs (Melo et al., 2014). 
1.7.4.4 Deregulation of miRNAs during tumourigenesis 
Aberrant expression of miRNAs in cancers is often associated with defective miRNA 
biogenesis machinery, which in turn could be attributed to genetic and epigenetic 
alterations. Loss of regulatory control can occur in virtually all steps involved in the 
biogenesis of miRNAs and has been linked with the widespread downregulation of 
miRNAs observed in most cancer types in comparison to their normal counterparts 
(Lu et al., 2005). Decreased production of pri-miRNA transcripts owing to mutations 
in the miR-128b gene in MLL-AF4 acute lymphoblastic leukemia (ALL) results in 
low levels of mature miR-128b and confers resistance to glucocorticoids (Kotani et 
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al., 2010). Mutations in XPO5 contribute to impaired export of pre-miRNA to the 
cytoplasm in tumours with microsatellite instability leading to uncontrolled levels of 
pre-miRNAs in the nucleus (Melo et al., 2010). In addition to impaired miRNA 
biogenesis, the expression levels of miRNAs in cancer cells are also influenced by 
the relative abundance of their mRNA targets. For instance, the increased expression 
of miR-155 in liposarcoma was associated with reduced expression of Dicer 
(Vincenzi et al, 2015). 
1.8 Targeted therapy in paediatric HGG 
Recently, significant progress has been made in the identification of novel 
perturbations affecting the critical components of regulatory networks in paediatric 
HGG including DIPG, and specific molecular subsets within these tumours have 
been delineated (Chamdine and Gajjar, 2014; Buczkowicz and Hawkins, 2015). 
Furthermore, mounting evidence have emphasised differences in the transformed 
phenotype of malignant glioma in children and adults (Jones et al., 2012). These 
findings have prompted clinical trials with novel small molecule inhibitors targeting 
specific aberrations in paediatric HGG. Table 1.1 summarises some of the major 
inhibitors that are currently under clinical investigation in paediatric HGG. 
Genomic profiling of HGG in children have demonstrated simultaneous disruption of 
more than one signalling pathways; for instance, co-amplification of IGFR, along 
with other RTK kinases have been reported in paediatric HGG and DIPG (Puget et 
al., 2012). As a result, combinatorial strategies are adopted, often involving a 
selection of drugs directed against multiple aberrations, to increase the efficacy of the 
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Target Inhibitor Current status of investigation Reference/Clinical trial
EGFR Erlotinib No survival benefit in phase II trial Qaddoumi t al., 2014
Cetuximab Currently in phase II trial NCT01012609
Nimotuzumab
5-year institutional study reported prolonged 
PFS and OS
Cabanas et al., 2013
Gefitinib
Phase I trial in combination with radiation 
(halted due to intratumoural bleeding)
Geyer et al., 2010
PDGFR Imatinib
Phase I trial halted due to intratumoural
haemorrhage
Pollack et al., 2007
Crenolanib Currently in phase I trial NCT01393912
PTEN/ Akt MK-2206 Phase I trial NCT01231919
BRAFv600e Vemurafenib
Complete response in a GBM patient in phase 
I/II trial
Robinson et al., 2014
Dabrafenib Currently in phase I clinical trial
NCT01677741
PARP Veliparib (ABT-888)
Phase I trial in recurrent CNS tumours 
Phase I/II in combination with radiation and
TMZ for newly diagnosed brainstem tumours 
is in progress
Su et al., 2014
NCT00946335
HDAC Valproic acid Phase II trial with Bevacizumab NCT00879437
Vorinostat
Phase II trial in combination with TMZ and 
Bevacizumab
NCT01236560
treatment. For example, pre-clinical data have shown synergistic effect in the 
combined use of imatinib (PDGFR inhibitor) and NVP-AEW54 (IGF1R inhibitor) in 
paediatric HGG in vitro and in vivo (Bielen et al., 2011). Additionally, inhibitors 
directed against some of the common defects in paediatric HGG such as those 
affecting DNA repair or angiogenesis, have been combined with the existing 
treatment strategy (chemoradiation) to enhance the effects of chemotherapy and 
radiotherapy. The administration of veliparib (PARP-inhibitor) in conjunction with 
radiotherapy has shown improved response in paediatric HGG in the phase I trial. 
 
Table 1.1 Targeted therapy in paediatric HGG  
 
 
 
 
 
 
 
PFS, Progression free survival; OS, overall survival (Vanan and Eisenstat, 2015). 
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1.9 Role of amino-acid metabolism in cancer 
Aberrant cellular metabolism is a significant event in the growth and development of 
many cancers (Hanahan and Weinberg, 2011; Cantor and Sabatini, 2012; 
DeBerardinis and Tompson, 2012; Galluzi et al, 2013). Unlike normal cells, cancer 
cells need large inputs of energy to maintain their accelerated rates of proliferation 
and survival (Hirayama et al, 2009; vander Haiden et al., 2009; Kami et al, 2013). 
Accordingly, they undergo continuous metabolic reprogramming ensuring the most 
effective method of utilising cellular energy (Arif et al, 2014; Phan et al., 2014). 
Identification of such metabolic adaptations that are unique to tumour cells has been 
an area of high interest in the development of targeted therapeutics with improved 
tumour-specificity and minimal side effects. For instance, many cancers are 
auxotrophic for particular non-essential amino acids owing to abnormalities in amino 
acid biosynthetic pathways. This property can be advantageous to tumour cells as 
metabolic reactions involved in the synthesis of non-essential amino-acids are highly 
energy-consuming (Zhang and Yang, 2013).  
The rationale for exploiting such auxotrophic tumours using specific enzymes to 
lower the amino-acid levels in the blood began with the use of L-asparaginase (an 
asparagine-degrading agent) for the treatment of paediatric acute lymphoblastic 
leukemia (ALL) (Broome, 1961; Pieters et al, 2011). In contrast to normal cells, ALL 
cells lack the enzyme asparagine synthetase (ASNS) and are incapable of producing 
asparagine. The resulting dependency of ALL cells on ectopic sources of asparagine 
for survival and proliferation can be selectively targeted using asparagine-depletion 
therapy. Currently, both native and pegylated forms of L-asparaginase are under 
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clinical investigation in phase I/II clinical trials in children with ALL, although there 
are few side effects associated with the drug (Parker et al, 2010; Messinger et al, 
2012). Dissecting the molecular biology behind abnormal amino acid metabolism in 
tumours has therefore gained renewed interest in the identification of novel 
druggable biosynthetic pathways (Phillips et al, 2013).  
1.9.1 Role of arginine in cancer  
L-Arginine (L-2-amino-5-guanidino-valeric acid) is a multi-functional amino acid 
that plays diverse roles in both normal and tumour cells (Tapiero et al, 2002). The 
main sources of arginine within the body come from diet, protein-turn over and from 
endogenous synthesis via the intestinal-renal axis (Phillips et al, 2013). Arginine is 
utilised by cells to synthesise proteins via mTOR signalling pathway (Yao et al, 
2008; Bauchart-Thevret et al, 2010). The first evidence of the role of arginine in 
tumour biology dates back to the early 1930s;xenograft models fed on arginine-rich 
diet showed enhanced tumour growth while those on arginine-free diet demonstrated 
reduction in tumour size (Gilroy, 1930). Since then, several investigations have been 
made to unravel the potential functions of arginine in cancer cells. Arginine can act 
as a precursor molecule for the synthesis of nitric oxide (NO), polyamines, proline, 
glutamate, agmatine, urea and creatinine, all of which are implicated in various 
aspects of carcinogenesis. Arginine-derived NO contributes to tumour initiation (by 
inhibiting DNA repair activities) (Roy et al, 2004), tumour angiogenesis (by 
upregulating vascular endothelial growth factor) (Cianchi et al, 2004), metastasis (by 
inhibiting the formation of tumour cell-platelet aggregates thereby evading host 
immune response) (Scott Lind, 2004) and induction of apoptosis or necrosis 
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depending on the types and amounts of NO (Xie and Huang, 2003). Arginine can 
generate polyamines that can modify hypusine-containing eukaryotic translation 
initiation factor 5A-2 (eIF5A-2) and thereby contribute to the higher rates of 
proliferation in tumour cells compared to normal cells (Paul et al, 2006). Being 
positively charged molecules, polyamines can interact with negatively charged DNA, 
RNA, phospholipids and proteins leading to modulation of various cellular processes 
including growth, proliferation and survival. Arginine can also lead to the production 
of proline, which is a key constituent of collagen and thus contributes to wound 
healing (Morris, 2006; Barbul, 2008). Proline can also act as a stress substrate, 
further indicating its putative role in tumourigenesis (Kaul et al., 2008). Arginine can 
also govern the production of the neurotransmitter glutamate, which is known for 
enhanced glutamate signalling in glioma cells (Morris, 2006; Yang et al., 2009). 
1.9.2 Arginine biosynthesis pathway 
Metabolism of arginine is highly dynamic and is modulated by various factors 
including age, cell type, stage of development, diet, state of health, arginine 
transporters across plasma and mitochondrial membranes, and the expression of 
enzymes involved in arginine recycling (Morris, 2007). In normal cells, de novo 
synthesis of arginine from its precursor citrulline is usually sufficient to meet the 
requirements for arginine. In contrast, the arginine demands of tumour cells are 
increased beyond the limits that could be attained by endogenous synthesis; hence it 
is classified as semi essential or conditionally essential amino acid (Morris, 2006).  
The metabolic pathway of arginine biosynthesis, mediated by key enzymes can be 
summarised as follows: argininosuccinate synthetase (ASS1) converts L-citrulline 
44 
 
and aspartic acid into argininosuccinate, argininosuccinate lyase (ASL) then degrades 
argininosuccinate into L-arginine and fumaric acid followed by arginase that 
converts L-arginine to L-ornithine which is then converted back to L-citrulline by 
ornithine carbamyltransferase (OCT) (Haines et al., 2011). Tumours with aberrations 
in this metabolic pathway exhibit arginine auxotrophy and depend on ectopic sources 
of arginine. Therefore, arginine starvation using arginine-catabolising enzymes can 
be used to target such tumours. Studies report abnormalities in key components of 
arginine biosynthesis pathway in a variety of tumour types including renal cell 
carcinoma (RCC), hepatocellular carcinoma (HCC), melanoma, and some 
mesotheliomas making them auxotrophic for arginine (Cheng et al., 2007; Yoon et 
al., 2007; Bowles et al., 2008; Kim et al., 2009; Feun et al., 2012; Kelly et al, 2012; 
Allen et al., 2014). The sensitivity to such agents depends largely on the ability of 
these tumours to regenerate arginine from intermediate components such as 
ornithine, citrulline and argininosuccinate (Wheatley et al, 2005). 
1.9.3 Dysregulation of ASS1 and ASL 
Of the key urea cycle enzymes that regulate the levels of arginine in cells, ASS1 can 
be considered the master switch controlling the rate-limiting step in arginine 
biosynthesis. Accumulating evidences show that ASS1 is abundantly expressed in 
normal tissues as a house-keeping gene, but differentially expressed in many tumours 
(Bowles et al., 2008; Kim et al., 2009; Feun et al., 2012; Syed et al., 2013). While 
overexpression of ASS1 is observed in some cancers such as gastric, colorectal and 
lung, downregulation is reported in numerous cancer types such as hepatocellular 
carcinoma, melanoma, mesothelioma and small cell lung. The mechanism of under 
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expression of ASS1 in these tumours is attributed to hypermethylation in the CpG 
rich region of ASS1 promoter (800-bp long) (Jinno et al., 1985).  
ASL acts immediately downstream of ASS1 and plays a role in channelling arginine 
for the production of NO (Erez et al., 2012). However, the role of ASL in tumours is 
an area that remains underexplored. Studies on hepatocellular carcinoma reveal that 
upregulation of ASL contributes to aggressiveness of the tumour through signalling 
by NO and cyclinA2 (Huang et al., 2013). On the contrary, ASL is reported to be 
silenced by promoter hypermethylation in GBM and combined loss of ASL and ASS1 
conferred better sensitivity to arginine-depleting agents (Syed et al., 2013). 
1.9.4 Targeting arginine-auxotrophic tumours with arginine-degrading 
enzymes 
Arginine can be catabolised using a series of enzymes that include arginine 
deiminase (ADI), arginine decarboxylase (ADC), arginase, and nitric oxide synthases 
(NOS) (Morris, 2004). However ADI is the most commonly used arginine-depleting 
agent in arginine-auxotrophic tumours due to improved arginine-specificity, optimal 
pH and better stability in vivo. ADI is a microbial protein mainly derived from 
mycoplasma and demonstrates diverse anti-cancer activities depending on the types 
of ADI derived from different varieties of microbial strains (Hahn et al., 1974). The 
commonly used ADI produced from M.arginini, comprises of two subunits and has a 
molecular weight of 43 kDa (Sugimura et al, 1990). However, due to its high 
antigenicity and very short half-life (5 hours) ADI is conjugated with polyethylene 
glycol (PEG) to form ADI-PEG20 (Polaris Pharmaceuticals, CA) which has a 
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molecular weight of 20 kDa and an increased half-life of 7 days (Holtsberg et al, 
2002; Ni et al, 2008; Qiu et al., 2013). 
1.9.4.1 ADI-PEG20 
The anti-tumour activity of ADI-PEG20 has been investigated in several types of 
cancers and is an area of renewed interest. The mechanism of arginine-deprivation 
therapy in cancers is shown in Figure 1.6. 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Mechanism of arginine deprivation therapy. A.  In normal cells, ASS1 regulates 
cellular arginine renewal by de novo synthesis of arginine. Tumour cells with promoter CpG 
methylation have defective arginine biosynthesis machinery and rely on external sources of arginine. 
B. ADI-PEG20 depletes arginine in the periphery; normal cell survives, but tumour cell dies.  
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ADI-PEG20 has shown significant clinical response in small cell lung cancer, 
pancreatic cancer, prostate cancer, head and neck cancer, ovarian cancer, 
myxofibrosarcoma, malignant pleural mesothelioma, malignant melanoma (MM) and 
adult GBM (Izzo et al., 2004; Bowles et al., 2008; Kim et al., 2009; Nicholson et al., 
2009; Ott et al., 2012; Kelly et al., 2012; Syed et al., 2013; Szlosarek et al., 2013). 
The exact mechanism of tumour suppression by the drug is not fully understood. 
Studies in breast cancer, prostate cancer and adult GBM suggest that the anti-tumour 
activity of ADI-PEG20 is mainly autophagy-dependent (Kim et al., 2009; Syed et al., 
2013; Qiu et al., 2014). In gastric cancer cells, ADI-PEG20-induced apoptosis has 
been associated with the up-regulation of p-53 and p27Kip1 as well as the 
downregulation of cyclin D1, c-myc and Bcl-xL. In melanoma cells, it has been 
shown that nutrient deprivation by ADI-PEG20 leads to reduced ATP levels leading 
to activation of AMPK which eventually causes inhibition of mTOR signalling and 
decrease in cellular proliferation (Kimura et al, 2003). 
 
1.10 Aims and objectives 
 
The underlying molecular pathology of paediatric HGG including DIPG is not well 
understood resulting in poor clinical responses. Integrative genomic analysis has not 
been extensively employed in biological investigations in paediatric HGG. The aim 
of this study was to utilise high-resolution microarrays and integrative data analysis 
to facilitate the identification of potential therapeutic targets in paediatric HGG using 
well-characterised patient-derived short-term cell cultures. The focus of this study 
was to use genome-wide approaches; 
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 To compare mutation status, copy number, gene and, miRNA expression 
profiles between biopsy and cell culture in paired paediatric HGG biopsy 
samples in order to evaluate patient-derived paediatric HGG short-term cell 
cultures as reliable pre-clinical models.  
 To investigate patterns of copy number changes and to identify non-random 
copy number alterations (CNAs) in paediatric HGG short-term cell cultures 
to extend the current understanding of the genomic changes in paediatric 
HGG.  
 To identify differentially expressed miRNAs in paediatric HGG short-term 
cell cultures in comparison to NHA and to understand deregulated signaling 
pathways influenced by these miRNAs. Unique differentially expressed 
miRNAs and aberrant signaling pathways associated with paediatric HGG 
based on their tumour subtype and H3F3A mutation status were also 
identified.  
 To understand the role of promoter CpG methylation in downregulation of 
genes in DIPG short-term cell cultures compared to non-DIPG short-term cell 
cultures.  
 To identify and evaluate dysregulated candidate genes involved in druggable 
metabolic pathways, particularly genes involved in arginine biosynthesis and 
PI3K signalling. 
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CHAPTER 2 
Materials and methods 
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2.1  Samples  
2.1.1 Paediatric HGG biopsies and short-term cell cultures 
Paediatric HGG biopsy samples were obtained from patients who underwent surgical 
debulking at Great Ormond Street Hospital (Great Ormond Street Hospital for 
Children, UK, REC 04/ Q0508/ 98) during 1980 to 2008. All samples were obtained 
with informed consent and were anonymised. Histological sections of the tumour 
tissues were examined by two neuropathologists and the samples were diagnosed 
according to the WHO classification system (Louis et al., 2007). The tumour tissue 
samples were processed in the laboratory at the Institute of Neurology (London, UK) 
to set up short-term cell cultures as described by Lewandowicz et al. (2000), and 
were stored in liquid nitrogen. For this study, all paediatric HGG short-term cell 
cultures were recovered from liquid nitrogen at low passage (below passage 10) and 
maintained in 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid) (HEPES)-
buffered Ham‘s F-10 media (Life Technologies Ltd, UK) supplemented with 10% 
foetal calf serum (FCS) (Life Technologies Ltd, UK). Paired fresh frozen biopsy 
material was also available for 3 samples. The details of paediatric HGG biopsies 
and short-term cell cultures used in this study are given in Table 1.1. 
2.1.2 Cell lines 
The adult GBM cell line, LN229 (ATCC® Number: CRL-2611™) was generously 
provided by Dr. Nelofer Syed (Imperial College London, UK) and was cultured in 
Dulbecco‘s modified Eagle medium (DMEM) (Life Technologies Ltd, UK) 
supplemented with 10% FCS and 2 mmol/L L-glutamine (Life Technologies Ltd, 
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Samples1 Age2 Sex3 Grade at 
diagnosis4
Location5 Sample 
Type6
IN178 13 M GBM IV L.Temporal CC
IN179 13 M GBM IV Base of skull CC
IN1163 0.2 M GBM IV R.Parietal CC
IN1262 14 M GBM IV L.Parietal CC
IN1419 8.5 F GBM IV Supratentorial CC
IN1523 10 F GBM IV L.Parietal CC
IN1566 6.4 F GBM IV Posterior Fossa CC
IN1930 13 F AA III Temporal CC
IN2087 3 M GBM IV Brainstem CC
IN2102 8 M AAIII Brainstem CC
IN2675 14 M GBM IV Brainstem CC
IN3032 9.5 F AA III L.Thalamic CC
IN3046 15.9 M AA III L.Frontal CC
IN3180 9.8 M AA III Supratentorial CC/B
IN3182 10.2 M GBM IV R.Parietal CC/B
IN3183 6.6 M GBM IV R.Frontal CC/B
IN3205 - M AA III R.Temporal CC
UK). IN699, used as a cell culture model to investigate functional roles of candidate 
genes in vitro, was a cross-contamination of a rhabdomyosarcoma cell line TE-671.  
 Table 1.1 Pathological data of samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samples
1
: IN-Institute of Neurology; Age in years
2
; Sex
3
: M-Male, F-Female; Grade at diagnosis
4
: 
GBM-Glioblastoma multiforme, AA- Anaplastic astrocytoma; Location
5
: L-Left, R-Right; Sample 
type
6
: CC-cell culture, B- Biopsy. 
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2.1.3 Control cells 
As this study involved cultures of astrocytic origin, a culture of normal human foetal 
astrocytes (NHA) was used as a normal control (purchased from Cambrex Bio 
Sciences). 
2.2 Routine cell culture methods 
Routine cell culture procedures were carried out in a sterile class II Laminar flow 
cabinet (Telstar, UK) sterilised with 70% ethanol (Sigma-Aldrich, UK) and 1% 
Trigene (Sigma-Aldrich, UK) solution. A cryovial of cells removed from the liquid 
nitrogen storage tank was thawed at 37ºC. Cells were transferred to a universal 
containing 9 ml of media and centrifuged at 1000 rpm for 5 minutes. The supernatant 
was carefully removed and the cell pellet was re-suspended in 10 ml of fresh media 
in a 25 cm
2 
flask. The cells were incubated at 37ºC in a non-CO2 incubator and the 
media was replaced after 24-48 hours. Cells were regularly monitored for any 
changes in the growth media and cell density. They were usually fed every 3-4 days 
or when there was a change in the colour of media indicating drop in the pH of the 
growth medium. After the media was aspirated from the flasks, cells were washed 
with 1x HBSS and fresh media was added (10 ml of media was added into 25 cm 
2 
flasks and 20 ml into 75
 
cm 
2 
flasks). Cells were routinely passaged to expand their 
population by providing them with enough nutrients and space to grow and divide. 
Following aspiration of the media from the culture flask, cells were washed with 1x 
HBSS (1 ml for 25 cm
2
 flask and 5 ml for 25 cm
2
 flasks). 1x trypsin (Sigma-Aldrich, 
UK) (1 ml for 25 cm
2
 flask and 2-3 ml for 25 cm
2
 flask) was added to the flask, 
spread evenly to cover the entire surface and incubated at 37ºC for approximately 5 
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minutes. Cells were checked under the microscope to ensure they were detached and 
fresh media (3 ml for 25 cm
2
 flask and 6 ml for 25 cm
2
 flasks) was added to 
neutralize the trypsin. The contents of the flask were transferred into a sterile 
universal and centrifuged at 1000 rpm for 5 minutes. After removing the supernatant, 
the cell pellet was re-suspended in fresh media and transferred to flasks of required 
sizes (1x 25 cm
2
 flask to 1 x 75 cm
2
 flask, 1x 75 cm
2
 flask to 3 x 75 cm
2
 flasks). For 
freezing down cell pellets, cell pellets were re-suspended in a volume of FCS 
containing 10% DMSO such that the final cell density was 10
6
 cells/ ml. 1 ml of the 
cell suspension was added to each labelled cryovial (Nalgene Cryoware™ Labware, 
Roskilde, Denmark) and stored at -80ºC for 24 hours. The vials were then transferred 
to liquid nitrogen storage tank (-196ºC). All short-term cultures were routinely tested 
for mycoplasma contamination. Approximately 100,000 cells were cytospun, fixed in 
ice-cold methanol (Sigma-Aldrich, UK), stained with Hoescht dye (Sigma-Aldrich, 
UK) and visualised under a fluorescent microscope for the presence of small, bright 
extranuclear dots.  
2.3 Treatment of cells with 5-Aza-2’deoxycytidine (5-AZA) 
The demethylating agents, 5-AZA (Sigma-Aldrich Ltd, Dorset, UK) was prepared in 
double distilled water and filter-sterilised. Cells were seeded in 75 cm
2
 flasks at low 
densities, depending on their division times, such that they reached 70% confluence 
at the end of the treatment and incubated overnight at 37ºC. The following day, cells 
were treated with 5 µM 5-AZA and the treatment was repeated on alternate days for 
three times to allow the cells to undergo at least 2-3 divisions and enhance the 
incorporation of the drug into DNA thereby causing efficient demethylation. The 
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control cells grown in parallel were cultured in media without the drug. Finally, cells 
were harvested by trypsinisation and centrifuged for 5 minutes at 1000 rpm to collect 
the pellet. Cells were washed by gentle resuspension in 1 ml phosphate buffered 
saline (PBS) (Life Technologies, UK) and spun down at low speed. The pellet was 
kept on ice and used for RNA extraction immediately. 
2.4 Chemosensitivity assays 
2.4.1 Sulforhodamine B (SRB) cell proliferation assay  
The effects of experimental anti-cancer drugs on cellular proliferation were 
determined by the SRB colorimetric assay. Cells were seeded in triplicate in 96-well 
plates at a density of 2000 cells/well and incubated overnight at 37ºC. Twenty-four 
hours later, media was gently aspirated and fresh media (200µl/well) containing 
varying concentrations of the drug were added. Control cells were grown in media 
without the drug. The plates were then incubated at 37ºC for 1-9 days. Following 
incubation, the cells were fixed with 150 µL of 10% (wt/vol) ice-cold trichloroacetic 
acid (TCA) and incubated for 1 hour at 4ºC. The cells were washed 3-4 times in 
water, air-dried, and stained with 100 µL of 0.4% SRB (Sigma-Aldrich, UK) 
(dissolved in 1% (vol/vol) acetic acid) (Sigma-Aldrich Ltd, Dorset, UK) for 15-30 
minutes at room temperature. The cells were then rinsed with water to remove the 
unbound SRB and allowed to air dry. The protein-bound SRB was solubilised in 
10mM Tris base solution (100 µl/ well) for 10 minutes and the optical density (OD) 
values were read at 510 nm with a microplate reader. The results were analysed using 
MS excel and the IC50 value for each drug was calculated. 
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2.4.2 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT) 
cytotoxicity assay 
For MTT assay, cells were seeded in triplicate in 96-well plates at a density of 2000 
cells/well and allowed to attach at 37ºC. Twenty four hours after seeding, media was 
removed from each well and the cells were cultured in media (200 μl) containing 
varying concentrations of the drug and incubated further at 37
o
C for the required 
time. Following incubation, 50 μl of MTT solution (Sigma-Aldrich, UK) (5mg/mL 
prepared in sterile PBS) was added to the wells and the plates were wrapped in an 
aluminium foil and incubated for 3-4hrs at 37°C. At the end of the incubation period, 
media was removed and 80μl of 99.9% DMSO and 20μl glycine buffer were added 
and the absorbances were read at 540 nm. The percentage viability of cells was 
calculated and the IC50 values of the drug were determined. 
2.5 Extraction and assessment of nucleic acids 
2.5.1 Genomic DNA extraction  
Genomic DNA was extracted from short-term cell cultures and frozen biopsies using 
DNeasy blood and tissue kit (Qiagen, Manchester, UK), following the 
manufacturer‘s instructions. For DNA extraction from cells, a suspension containing 
2-3x 10 
6 
cells was centrifuged for 5 minutes at 1000 rpm. After removing the 
supernatant, the pellet was re-suspended in 200 µL PBS, and 20 µl proteinase K was 
added to facilitate the degradation of proteins. For tissues, approximately 25 mg of 
tissue was chopped into very small pieces, 180 µl Buffer ATL was added and the 
sample was homogenised using a syringe and needle to enable efficient lysis. Twenty 
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µl proteinase K was added, vortexed to mix and incubated at 56ºC with occasional 
vortexing until the tissue was completely lysed. The homogenised cell/tissue lysate 
was treated with 4 µl RNase A (100mg/ml) (Qiagen, UK), vortexed to mix and 
incubated for 5 minutes at room temperature to obtain RNA-free genomic DNA. 
Two hundred µl of Buffer AL was then added, mixed thoroughly and incubated at 
56ºC for 10 minutes. Following incubation, 200 µl of 96-100% ethanol was added, 
mixed well and the mixture was applied to a DNeasy mini spin column and 
centrifuged at 8000 rpm for 1 minute. The spin column with membrane-bound DNA 
was washed with 500 µl Buffer AW1 by centrifugation for 1 minute at 10000 rpm 
followed by a second wash for 3 minutes at 14000 rpm with 500 µl Buffer AW2 to 
prevent ethanol carry over to the elution step. Nuclease-free water (Life 
Technologies, UK) (20-30 µL) was added to the centre of the column, incubated for 
1 minute at room temperature and centrifuged at 10000 rpm for 1 minute to elute the 
DNA. 
2.5.2 RNA extraction  
RNA was extracted from short-term cultures and frozen biopsies using RNeasy mini 
kit (Qiagen, Manchester, UK), according to the manufacturer‘s instructions. For 
RNA extraction from cell cultures, pellets with approximately 1-2x10
6 
cells were 
disrupted by adding 350 µl Buffer RLT (containing β-mercaptoethanol at 10 µl per 1 
ml Buffer RLT) and vortexed to mix. For tissues, 20-25 mg of tissue was cut into 
small pieces and homogenised in 600 µl Buffer RLT using a syringe and needle. The 
lysate was centrifuged for 3 minutes at 14000 rpm and the supernatant was carefully 
transferred to a new nuclease-free microcentrifuge tube.  The cleared cell/tissue 
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lysate was mixed with 1 volume of 70% ethanol (350 µl for cells and 600 µl for 
tissues) in order to provide appropriate binding conditions for RNA. The sample (not 
exceeding 700 µl at a time) was applied to an RNeasy mini spin column placed in a 2 
ml collection tube and centrifuged for 15 seconds at 10000 rpm. The spin column 
with membrane-bound RNA was washed with 700 µl Buffer RW1 and 500 µl Buffer 
RPE in two subsequent steps by centrifugation for 15 seconds at 10000 rpm. 
Following an additional wash with 500 µl Buffer RPE, the column was centrifuged 
for 2 minutes at 10000 rpm to prevent ethanol carry over during the RNA elution 
step. RNA was eluted in 20-30 µl nuclease-free water by centrifugation for 1 minute 
at 10000 rpm.  
2.5.3 Nucleic acid assessment  
The quantity and quality of nucleic acids were determined using a NanoDrop 2000 
Spectrophotometer (Thermo Scientific, UK). The concentration of nucleic acids was 
given as ng/µl, based on a modified Beer-Lambert equation, c = (A*ϵ)/b, where c is 
concentration in ng/µL, A is the absorbance in AU (260 nm), ϵ is the wavelength-
dependent extinction coefficient in ng-cm/µL (50 ng-cm/µL for double stranded 
DNA and 40 ng-cm/µL for RNA) and b is the path length in cm.  The quality of the 
sample was determined by the ratio of absorbance at 260 nm and 280 nm (260/280); 
a ratio of 1.8 and 2.0 were accepted for pure DNA and RNA respectively. The 
ratio of absorbance at 260 nm and 230 nm (260/230) was used as a second layer to 
assess the purity of the sample. DNA and RNA were considered highly pure if their 
260/230 ratios were higher than their respective 260/280 ratios (generally in the 
range of 1.8-2.2). 
58 
 
2.6 Polymerase chain reaction (PCR) 
2.6.1 Combined bisulfite restriction analysis (CoBRA) PCR 
2.6.1.1 Bisulfite modification of genomic DNA 
Genomic DNA from short-term cultures and fresh frozen biopsies, along with SAM 
modified positive controls were bisulfite treated using EZ DNA Methylation Gold kit 
(Zymo Research, USA) according to the manufacturer‘s instructions. 130 µL of the 
CT conversion reagent was added to 20 µL of DNA sample (containing 1µg DNA) 
and incubated for 10 minutes at 98ºC followed by 2.5 hours at 64ºC. Following 
incubation, the samples were kept on ice. 600 µL of M-Binding Buffer was mixed 
with each sample in a Zymo-spin IC column and centrifuged for 30 seconds at 14000 
rpm. The column was washed with 100 µL of M-Wash Buffer by spinning for 30 
seconds at maximum speed followed by incubation with 200 µL of M-
Desulphonation Buffer for 15-20 minutes. After incubation, the column was spun at 
full speed for 30 seconds and washed twice with 200 µL of M-Wash Buffer. The 
DNA was eluted in 30 µL of M-Elution Buffer and stored at -20º for later use. 
2.6.1.2  DNA methyltransferase modification of DNA 
To generate fully methylated positive controls, 5 µg of genomic DNA was mixed 
with 5 µl NEB buffer, 2µl of DNMT (4 units), 2µl of SAM (New England Biolabs, 
UK) (32 mM) and PCR grade water to make a final volume of 50 µL and incubated 
for 2 hours at 37°C. 
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2.6.1.3 Primer design and TOUCH-UP gradient PCR  
CoBRA primers were designed using MethPrimer software 
(http://www.urogene.org/methprimer/) using specified settings to maximise 
amplification efficiency. The CGIs of candidate genes were retrieved from UCSC 
Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway) and primers were 
designed to span up to 300 bp on the CGI. Primers were ensured not to have 
recognition sequences (CGCG) of the restriction enzyme, BstUI (New England 
Biolabs, UK). The melting temperature was set to between 50 and 60ºC. The products 
were ensured to have a minimum of 4 CpGs. (The list of primer sequences are 
provided in Appendix II). 
Bisulfite modified DNA (2 µL) was amplified using specific primers in a reaction 
volume of 40 µl containing 2mM dNTP (Sigma-Aldrich, UK), 2.5 mM MgCl2 
(Qiagen, UK), 20µM of each primer (Sigma-Aldrich, UK) and 1 U HotStarTaq DNA 
polymerase (Qiagen, UK). Touch-UP gradient PCR method, previously developed in 
the lab (Rowther et al, 2012) was utilised for DNA amplification. HotStarTaq DNA 
polymerase required an initial activation step of 95°C for 15 min before the start of 
the cycling. In this method, 8 cycles consisting of 95ºC for 30 seconds, 48ºC for 30 
seconds (+0.5ºC every cycle), 72ºC for 1 minute, was performed. The 8-cycle step 
was repeated five times (40 cycles) followed by final extension for 5 minutes. 10 µL 
of the PCR products were separated on ethidium bromide-stained (Sigma-Aldrich, 
UK), 2% agarose gel and visualised using the Gel Doc
TM
EZ imager (Bio-Rad, UK) 
to confirm the amplification of the right product.  
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2.6.1.4 Restriction digestion and Gel electrophoresis 
Following confirmation, another 10 µL of the products were digested by BstUI 
(CGCG) at 37°C for 2 hours at room temperature. The digested products along with 
equal volumes of corresponding undigested amplification products were 
electrophoresed on ethidium bromide-stained, 4% agarose gel. SAM modified DNA 
was used as positive control to assess methylation. 
2.6.2 Methylation specific (MS-PCR) 
2 µL of bisulphite modified DNA (protocol as described in) was added to a reaction 
mix consisiting of 2 µL 10xPCR Buffer, 0.4 µL dNTPs, 0.4 µL forward primer, 0.4 
µL reverse primer, 0.8 µL MgCl2, 13.8 µL PCR grade water and 0.2 µL HotStarTaq 
DNA polymerase to make a final volume of 20 µL. For each sample, two sets of 
PCR reactions were performed with primers specific for methylated sequences and 
unmethylated sequences. Universal methylated primers and universal unmethylated 
primers were included as positive and negative controls, respectively. A no template 
control was used to ensure all reagents were free of contamination. The samples were 
placed on a thermal cycler; the cycling conditions included initial heat activation of 
94ºC for 15 minutes, followed by 30 cycles of 94ºC for 1 minute, 56ºC for 1 minute 
and 72ºC for 1 minute, then a final extension of 72ºC for 10 minutes. The products 
were electrophoresed on ethidium bromide stained, 2% agarose gel and visualised 
using Gel Doc
TM
EZ imager. 
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2.6.3 Semi-quantitative RT- PCR  
2.6.3.1  RT-PCR primer design 
RT primers were designed using Primer 3 software (http://primer3.ut.ee/). Exon 
sequences of the desired genes were retrieved from Ensembl Genome Browser 
(http://www.ensembl.org/index.html) and a chunk of it was pasted in Primer 3. 
Primer sizes ranged from 18-25 bases with melting temperature 56-60ºC. (The list of 
primer sequences are given in Appendix II). To ensure that the product was 
amplified from cDNA and not from any DNA contaminant, primer pairs were 
selected in such a way that at least one of the primers encompassed an intron-exon 
junction. The maximum 3‘ complementarity was set to 0 to avoid primer-dimers. 
2.6.3.2  Complementary DNA (cDNA) synthesis 
Complementary DNA (cDNA) was synthesised from total RNA using Quantitect 
Reverse Transcription Kit (Qiagen, UK). 500 ng- 1µg of total RNA was mixed with 
2 µL 7x gDNA Wipeout Buffer and a volume of nuclease-free water to make a final 
volume of 14 µL and incubated for 2 minutes at 42ºC to eliminate genomic DNA. 
The samples were then quickly placed on ice, transferred to tubes containing 6 µL of 
reverse-transcription master mix (1 µL Quantiscript Reverse Transcriptase, 4 µL 5x 
Quantiscript RT Buffer, 1 µL RT Primer Mix), mixed and incubated for 30 minutes 
at 42ºC followed by 3 minutes at 95ºC to inactivate Quantiscript Reverse 
Transcriptase. The reactions were placed on ice for immediate use or at -20ºC for 
long term storage.  
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2.6.3.3  PCR amplification and gel electrophoresis 
For each RT-PCR reaction, 1µl prepared cDNA was used and a reaction mixture of 
20µl was prepared with 2µl 10X PCR buffer (500 mM Tris-HCL), 2.5 mM MgCL2, 
2.5 mM dNTP, 0.8 µM of each primer and 1U HotStarTaq DNA polymerase. PCR 
cycling conditions comprised of an initial activation step at 95ºC for 15 minutes 
followed by 94ºC denaturing for 30 seconds and annealing of 50-60 ºC for 1 minute 
for 40 cycles, and final extension at 72 ºC 10 minutes. The house keeping gene, β-
actin was used as positive control. The PCR products were electrophoresed on 
ethidium bromide-stained, 2% agarose gels in 1x TBE buffer (Geneflow, UK) and 
visualised using Gel Doc
TM
EZ imager connected to Syngene Gel Documentation and 
analysis software. A 100 bp DNA ladder (ThermoScientific, UK) was used to 
confirm the amplification of the product. 
2.6.4 Quantitative PCR (Q-PCR) 
The expression levels of candidate genes were quantitatively determined using 
Solaris qPCR Gene Expression assays (Thermo Scientific, UK) with FAM reporter 
(Ogrean et al., 2010). The assay includes a pre-designed primer-pair and a unique 
probe for each target under investigation. GAPDH was used as endogenous reference 
control. One µg of total RNA was reverse transcribed as described in 2.6.3.2. For 
each test sample, 2 µL of the cDNA was added to a reaction mix consisting of 10 µL 
2X Solaris qPCR master mix, 1 µL 20X Solaris Primer/Probe set and 7 µL PCR 
grade water to make a final volume of 20 µL. A no-template control (NTC) was 
included to assess any reagent contamination. All reactions were performed in 
triplicate. The plate was sealed with an optically clear seal, gently tapped to remove 
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any air bubbles and run on ABI Prism 7900 HT Sequence Detection System (Applied 
Biosystems, UK). PCR cycling conditions consisted of initial enzyme activation at 
95ºC for 15 minutes, followed by denaturation at 95 ºC for 1 minute and annealing at 
60 ºC for 1 minute for 40 cycles, and final extension at 72 ºC 10 minutes. Data were 
exported to MS Excel 2007 for statistical analysis. The expression levels of target 
gene were normalised to GAPDH and the fold change (as a measure of relative 
expression) was calculated using comparative CT (2 
-∆∆CT
) method. 
2.7 Direct DNA sequencing 
For direct sequencing, 100 ng of DNA was amplified using gene-specific primers 
and HotStarTaq DNA polymerase. The amplification of the desired fragments were 
verified by gel electrophoresis (2% agarose gel for 1 hour at 120 V). The amplified 
products were purified from residual primers, unincorporated nucleotides, excess 
enzyme and salts using GenElute PCR Clean-Up Kit (Sigma-Aldrich, UK) according 
to the manufacturer‘s instructions. All centrifugation steps were done at 13000 rpm. 
Briefly, 500 µL of the Column Preparation Solution was added to a GenElute 
Miniprep Binding Column placed in a collection tube and centrifuged for 1 minute 
and the flow through was discarded. Ten µL of the amplification product, mixed with 
50 µL of Binding Solution was applied to the spin column and spun down for 1 
minute. The column was washed with 500 µL of diluted Wash Solution by 
centrifugation for 1 minute followed by 2 minutes without the wash solution to 
remove residual ethanol. A volume of 10-15 µL of nuclease-free water was applied 
to the centre of the column, incubated at room temperature for 1 minute and 
centrifuged for 1 minute to elute the DNA. The purified DNA was measured using 
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NanoDrop 2000 spectrophotometer and a sample volume at a concentration of 1ng/µl 
per 100 base pairs was used for the sequencing reaction conducted by Source 
BioScience LifeSciences (Cambridge, UK). The results were analysed using 
Sequence Scanner v 2.0 (Applied Biosystems Ltd, UK). 
2.8 Microarray 
2.8.1 CGH microarray 
DNA samples were labelled using a genomic DNA ULS labelling kit and hybridised 
on Agilent 1x 244K CGH arrays (Agilent technologies Inc., USA) according to the 
recommended protocol for ULS labelling of cells v3.4.  
2.8.1.1  Heat fragmentation and labelling 
Genomic DNA was extracted from short-term cell cultures and fresh frozen biopsies 
as described in 2.5.1 with a modification in the final wash step; Buffer AW2 was 
replaced by freshly prepared 70% ethanol. Commercially available human genomic 
DNA was used as reference sample. The quantity and quality of both tumour and 
reference DNA (Promega, UK) were determined using a NanoDrop 2000 
spectrophotometer. Good quality tumour and reference DNA samples (200-300 ng) 
were heat fragmented at 94ºC for 0, 5 and 10 minutes and run on 1% agarose gel to 
evaluate the integrity of the DNA prior to labelling as well as to determine the 
fragmentation time required to achieve the optimal DNA fragment size range (1000-
3000 bp) for aCGH. Equal amounts (1.5 µg) of tumour DNA and sex-matched 
reference DNA were individually heat fragmented at 95ºC for 10 minutes followed 
by incubation on ice for 3 minutes. Tumour and reference DNA were mixed with 
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Cy3 and Cy5 labelling master mixes (1.5 µL of Cy3/Cy5 in 2 µL 10x Labelling 
solution) respectively. The mixture was incubated at 85ºC for 30 minutes followed 
by 4ºC for 3 minutes. The contents were then spun down for 1 minute at 8000 rpm. 
The labelled DNA was purified by removing the unincorporated ULS-dye in the 
sample using the Agilent-KREA pure purification column. Initially, the column 
material was resuspended by brief vortexing, the bottom closure snapped off and 
centrifuged for 1 minute at 14000 rpm. The column was centrifuged at the same 
speed for 1 minute with 300 µl of nuclease-free water followed by the labelled DNA 
(20 µl) and 1.5 µl of each sample was used to determine the concentration and 
degree of labelling, calculated by the formula: Degree of labelling = (340x pmol per 
µL dye/ ng per µL gDNAx1000) x100% Cy3 and Cy5 labelled samples were 
combined appropriately on the basis of the degrees of labelling of the dyes. The 
optimal Cy3 and Cy5 labelling ranged between 1.75% and 3.5%, and 0.75% and 
2.5% respectively with Cy3 minus Cy5 ranging between 1% and 2%.  
2.8.1.2  Hybridisation 
Blocking agent (100x) (Agilent Technologies, UK) was prepared with nuclease-free 
distilled water, vortexed and incubated at room temperature for 60 minutes, and 
stored at -20ºC. Hybridisation master mix (353 µL) was prepared by adding 50 µl of 
Cot-1 DNA (1mg/mL), 5.2 µl of Agilent 100x Blocking agent, 37.8 µl of 
DNAse/RNase-free distilled water and 260 µl of 2x HI-RPM Hybridisation buffer 
(Agilent Technologies, UK). The reaction mix was added to the sample, mixed and 
quickly spun down in a centrifuge. The contents were incubated for 3 minutes at 
95ºC followed by 30 minutes at 37ºC. Following incubation, 520 µL of Agilent-CGH 
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block was added to remove background noise on the array. A volume of 490 µL of 
the sample was then hybridised onto the microarray slide, which was assembled in a 
slide chamber. The chamber was placed in the rotator rack in a hybridisation oven 
(Agilent Technologies, UK) set at 65ºC and incubated for 40 hours with rotator speed 
of 20 rpm. 
2.8.1.3  Microarray wash 
The microarray slide chamber was carefully disassembled in a slide staining dish 
filled with Agilent Oligo aCGH/ChiP-on-Chip wash Buffer 1 at room temperature 
The array slide was washed with wash buffer 1 at room temperature for 5 minutes, 
followed by wash buffer 2 at 37°C for 1 minute, acetonitrile (Sigma-Aldrich, UK) at 
room temperature for 10 seconds and stabilisation and drying solution (Agilent 
Technologies, UK) at room temperature for 30 seconds. The slides were place in a 
slide holder and wrapped in an aluminium foil until ready to be scanned in order to 
prevent oxidising of the Cy5 dye.  
2.8.1.4  Scanning and feature extraction 
The slides were scanned on a Agilent DNA Microarray Scanner (model G2565B) 
(Agilent Technologies, UK) at 5 µM resolution and the resulting images were 
extracted using Agilent Feature Extraction Software. The software normalises the 
signal intensity of both dyes at each probe and computes their ratios expressed on a 
logarithmic scale. It also generates a set of Quality Control (QC) metrics including 
the Derivative Log Ratio Spread (DLRS), background signal (noise) and signal-to-
noise ratio enabling the evaluation of data reliability.  
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2.8.1.5  Data analysis 
Excellent and Good quality data as determined by the QC thresholds were analysed 
using Agilent CytoGenomics (v2.7, Agilent Technologies Ltd, UK) and Nexus copy 
number software (Biodiscovery Inc., USA) using various algorirthms as described 
below.  
ADM-2 algorithm 
DNA copy number analysis was performed using the ADM-2 algorithm in Agilent 
cytogenomics software (v3.0.1.1, Agilent Technologies, USA). This algorithm 
calculates a statistical score, which is a measure of the weighted average of the 
normalised log ratios from its expected value of zero computed using Derivative 
Log2 Ratio Standard Deviation algorithms. Aberrant intervals are then identified in 
samples with consistently low or high log ratios based on their statistical score. The 
following parameters were used for analysis: stringency threshold=6, minimum 
absolute average log ratio per region=0.25, maximum number of aberrant 
regions=100000, minimum number of consecutive probes per region=3, Diploid 
Peak Centralization-ON, and Combine Replicates (Intra Array) =ON. Genome 
positions were mapped to NCBI build 36.1 (hg18). 
Segmentation analysis 
For downstream statistical analysis, normalised raw data were dye swapped and 
processed using the recommended settings for Agilent FE files in Nexus Copy 
number (v8.0, Biodiscovery Inc., USA). The replicate probes within an array were 
combined using the mean values, probe log2 ratios were re-centered to the median, 
68 
 
and the sequential loess method was applied for systematic correction of wave 
artifact (Lepretre et al., 2010) with the smoothing parameter (default=0.2) in the 
recommended settings. Robust variance sample QC calculation was performed using 
the default value of 3, which removes 3% of extreme outliers in the data.  
Rank segmentation algorithm 
The Rank Segmentation algorithm is similar to the Circular Binary Segmentation 
(CBS) algorithm (Olshen et. al. 2004), but uses the probe‘s log-ratio rank order 
rather than the log-ratio value used in CBS to make copy number calls. For rank 
segmentation, the significance threshold for segmentation was set at 1.0E-5 and 
required a minimum number of 3 probes per segment. The maximum contiguous 
probe spacing (the space between two adjacent probes before making a segment) was 
set to 1000 kb. The log ratio thresholds for copy number gain and copy number loss 
were set at 0.2 and -0.23 respectively. High-copy gain and homologous loss were 
defined by log ratio thresholds of 1.14 and -1.1 respectively. Genome positions were 
mapped to NCBI build 36.1 (hg18). 
FASST2 segmentation algorithm 
The FASST2 Segmentation Algorithm is a Hidden Markov Model (HMM) based 
approach to make copy number calls. However, unlike other common HMM 
methods for copy number detection it does not restrict the estimation of the copy 
number state to each probe but uses multiple states to include the possibilities, such 
as mosaic events. These state values are then used to make copy number calls based 
on a log-ratio threshold. In this study, FASST2 segmentation algorithm was 
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performed with significance threshold for segmentation set to 1.0E-5 and requiring a 
minimum of 3 probes per segment. The maximum contiguous probe spacing was set 
to 1000 kb. The thresholds for copy number estimation were the same as used for 
rank segmentation algorithm. 
2.8.2 Methylation microarray 
2.8.2.1     Illumina Infinium HumaMethylation 450K BeadChip 
The microarray-based DNA methylation analysis of DIPG derived short-term 
cultures was performed with Infinium Human Methylation 450 K BeadChip 
(Illumina Inc., CA, USA), which enables the quantitative probing of methylation at 
more than 485,000 CpG dinucleotides located across the genome (including CpG 
islands, shores, shelves, non-CpG sites and miRNA promoter regions). The beadchip 
covers 99% of Refseq genes with approximately 17 CpG sites per gene spanning 
across the promoter, 5‘UTR, first exon, gene body and 3‘UTR. 
2.8.2.2  Labelling, hybridisation and data analysis 
DNA was extracted from short-term cultures as described in 2.5.1, and the yield and 
purity was determined using NanoDrop 2000 spectrophotometer. The subsequent 
sample processing for methylation analysis using the Infinium 
HumanMethylation450 BeadChip Kit was conducted at Cambridge genomic services 
(University of Cambridge, UK) following the manufacturer‘s recommendations. 
Briefly, 500 ng of DNA was bisulfite treated to convert unmethylated cytosines to 
uracil, leaving methylated cytosines unaffected. The modified DNA was amplified, 
fragmented and hybridised to unique oligomer probes on the HM-450 Beadchip 
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(Illumina, catalog number: WG-314-1003). After hybridisation, the unhybridised 
DNA was washed off and the probes on the beadchip were extended using a labelled 
nucleotide. The BeadChip was fluorescently stained, scanned using HiScan SQ 
(Illumina) and the methylation signals were extracted with Illumina Genome Studio 
software. The data were background corrected and normalised and β values were 
computed using the software.  
The normalised data were analysed using Partek genomics suite v 6.6 (Partek Inc., 
USA) to perform exploratory data analysis. Data were analysed using Microsoft 
Excel to identify differentially methylated genes on the basis of specified probe beta 
scores. 
2.8.3 Gene expression microarray 
2.8.3.1   Affymetric U133A plus microarray 
The genome-wide analysis of gene expression profiles of the samples analysed in 
this study were carried out using Affymetrix U133A plus 2.0 arrays, which have 
54675 mounted probes on each array slide representing about 20,000 genes. This 
represents about 6500 additional genes from the previous Affymetrix platform 
enabling better characterisation of samples based on their gene expression profiles. 
2.8.3.2  Labelling, hybridisation and data analysis 
Labelling and hybridisation procedures were carried out using aRNA amplification 
protocol (Life Technologies, UK) according to recommended protocols of 
Affymetrix. The first strand cDNA was synthesised by reverse transcription using 
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8µg of RNA, DEPC-treated water, T7-oligo (dT) primer and kept on ice. The reverse 
transcription master mix was added and incubated for 2 hours at 42ºC. This was 
followed by the second strand synthesis for which 80µl of second strand master mix 
was added and incubated for 2 hours at 16ºC. The cDNA was purified through a 
series of washes in the spin cartridges. The biotin labelled aRNA was then 
synthesised by mixing 20 µl of IVT master mix to each sample and incubated for 4-
14 hours at 37ºC. A volume of 60µl of nuclease-free water was added to each 
sample. The aRNA wad then purified by passing the sample through a filter 
cartridge. The aRNA was then eluted in 100µl of nuclease-free water. The aRNA 
was then fragmented by mixing the sample with aRNA fragmentation mix and 
incubated at 94ºC for 35 minutes. The subsequent hybridisation and wash steps were 
conducted at Nottingham University. The normalised data were log transformed and 
analysed using Partek Genomics suite (v6.6, Partek Inc., USA). 
2.8.4 MiRNA microarray 
2.8.4.1 MiRNA extraction from frozen tissues/cell cultures 
MiRNA was isolated from frozen tumour tissues or tumour-derived short-term 
cultures using mirVana miRNA isolation kit (Life Technologies, UK) in accordance 
with the manufacturer‘s protocol for isolation of total RNA. The procedure involves 
disruption of the sample in a lysis solution that stabilises RNA followed by organic 
extraction of the lysate with Acid: Phenol chloroform and purification of RNA using 
a glass-fiber filter, specifically formulated for miRNA retention. 
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For extraction of miRNA from tissues, approximately 30 mg of the tumour tissue 
was chopped into fine pieces in 300 µl Lysis/Binding Buffer (10 volumes of the 
Buffer was used per tissue mass) in a weigh boat kept on ice. The sample was 
transferred to a microcentrifuge tube, and homogenised using a syringe and needle. 
For miRNA isolation from cell cultures, cells were detached as described 2.2.3 and a 
suspension containing 1-2 x 106 cells was centrifuged and the pellet was washed in 
1 ml PBS by centrifugation at low speed. The supernatant was removed and 300 µl 
Lysis/Binding solution was added to the pellet, mixed by pipetting to obtain a 
homogenous lysate. To the homogenised lysate from either sample type, 1/10 volume 
(30 µl) of miRNA Homogenate Additive was added and mixed by inverting the tube 
several times and the mixture was left on ice for 10 minutes. Subsequently, a volume 
of Acid-Phenol: Chloroform equal to the initial lysate volume (300 µl) was added , 
vortexed for ̴ 1 minute and spun for 5 minutes at 10000 rpm at room temperature. 
Following centrifugation, the upper layer (aqueous phase) was carefully recovered in 
a fresh tube without disturbing the lower layer (organic phase) and 1.25 volumes of 
room temperature 100% ethanol was then added to the tube and mixed well. The 
mixture (700 µl at a time) was passed through a Filter Cartridge placed into a 
collection tube by spinning down the unit for 15 seconds at 10000 rpm; the flow 
through containing contaminants was discarded. The filter-bound RNA was washed 
with 700 µl miRNA Wash Solution 1, followed by two additional wash steps with 
500 µl Wash Solution 2/3 one after the other. The filter was transferred to a new 
collection tube and the RNA was eluted in 20-30 µl pre-heated nuclease-free water 
by centrifugation for 30 seconds at 13000 rpm. 
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2.8.4.2  Labelling and hybridisation  
High resolution miRNA expression profiles of paediatric HGG were generated 
utilising 3D-Gene® miRNA oligo chip (ver.16; Toray Industries, Japan), containing 
probes representing 1719 human miRNAs selected from the miRBase miRNA 
database, release 19. Total RNA was isolated from cell cultures and frozen biopsies 
as described in 2.5.2 and the quantity and quality of RNA determined using 
NanoDrop 2000 spectrophotometer as described in 2.5.3. The experimental 
procedures of the microarray were conducted by Cambridge Genomic Services 
(Department of Pathology, University of Cambridge, UK). Briefly, the integrity of 
the RNA was determined using Agilent 2100 bioanalyser (Agilent Technologies Ltd, 
UK) and the quality control reports showing the RNA Integrity Number (RIN) values 
for each sample were assessed. Good quality RNA samples (250 ng each) were then 
labelled with Hy5 using the miRCURY LNA Array miR labeling kit (Exiqon, 
Vedbaek, Denmark) according to the manufacturer‘s recommendations and 
subsequently hybridised on the 3D-Gene miRNA chip for 16 hours at 37ºC in a 
hybridisation oven with a rotator rack set at 250 rpm. Following hybridisation, the 
oligo chips underwent three stringent washes and the fluorescent signals were 
scanned with the 3D-Gene Scanner (Toray Industries).  
2.8.4.3  Data analysis 
The scanned images were processed using the 3D-Gene Extraction software (Toray 
Industries). The raw data were normalised and the relative expression levels of 
miRNA were calculated. The normalised data were analysed using Partek Genomics 
Suite v 6.6. 
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2.9 Protein detection methods 
2.9.1 Protein extraction and quantification 
Cells harvested by trypsinisation were washed with PBS and pelleted at 1500 rpm for 
5 minutes. Cells were lysed in 100-200 µl (depending on the size of the pellet) of ice-
cold RIPA buffer (Life Technologies, UK) containing protease and phosphatase 3 
inhibitor cocktail (Roche, Germany) and incubated on ice for 5 minutes. The lysate 
was sonicated for 30-40 seconds for further cell disruption and proteins were 
extracted after centrifugation at 14000 rpm for 15-20 minutes at 4ºC. The 
concentrations of the extracted proteins were determined using a Bio-Rad protein 
Assay kit (Bio-Rad, UK), with Bovine Serum Albumin (BSA) (Sigma-Aldrich, UK) 
as the protein standard. The concentration of proteins in each sample was calculated 
based on the standard curve obtained by plotting absorbance versus protein 
concentrations of BSA. 
2.9.2 Western blotting 
Each protein sample (30-100 µg) was prepared in a final volume of 25 µL with 
loading buffer (4X), 100mM DTT (Sigma Aldrich, UK) and distilled water, and 
incubated on a heat block for 10 minutes at 96ºC. The proteins were resolved on 6% 
SDS-PAGE gels in 1x SDS-PAGE running buffer (Geneflow, UK) for 50-60 minutes 
at 200V. 10 µL of SeeBlue Plus2 Pre-stained Protein Standard (Life technologies, 
UK) was run on each gel to estimate the molecular weight of protein. Following 
electrophoresis, the proteins in the gel were transferred onto a polyvinylidene 
difluoride (PVDF) membrane (Amersham Hybond ™ - P (PVDF membrane), GE 
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Healthcare, UK) in transfer buffer in a semi-dry transfer unit. The membrane and gel 
were sandwiched between three layers of blotting papers pre-wet with transfer 
buffer. The transfer was done for 1.5 hours at 20 V and 200 mA. The membrane was 
blocked in 5 % non-fat milk for 2 hours at room temperature and probed with the 
primary antibody of interest by overnight incubation at 4ºC. The unbound antibody 
was removed by washing the membrane twice with 1xTBST (Geneflow, UK) for 10 
minutes. The membrane was then incubated with the appropriate horseradish 
peroxide-conjugated secondary antibody solution for 1-2 hours at room temperature. 
Following incubation, the membrane was washed twice in 1xTBST for 10 minutes. 
The signals were detected using EZ-ECL chemiluminescent detection kit (Geneflow, 
UK) according to the manufacturer‘s instructions. The membrane was exposed to X-
ray film (Kodak Medical X-ray film, Sigma-Aldrich, UK) in a dark room. The 
membrane was stripped by washing in 1X TBST for 20-30 minutes and re-probed 
with anti-mouse β-tubulin monoclonal antibody in order to confirm equal loading of 
protein. 
2.10 Molecular cloning 
2.10.1 Preparation of LB agar plates 
LB (Luria-Bertani) agar medium was prepared by autoclaving 25 g LB broth (Sigma, 
UK) and 20 g agar (Sigma, UK) in 1 L of deionised water. Once the media was 
cooled to 50 ºC, 25 µg/ml kanamycin (Sigma-Aldrich, UK) was added and mixed 
well. About 15 ml media were poured into 10 cm
2
 petri dishes and allowed to 
solidify at room temperature.  
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2.10.2 Transformation 
To an aliquot of 50 µl DH5 competent cells (Life Technologies, UK), 500 ng of 
plasmid DNA was added and incubated on ice for 30 minutes. The mixture of DNA 
and cells were subjected to heat shock by incubation at 42ºC for exactly 30 seconds 
followed by immediate transfer to ice. A volume of 250 µL SOC recovery medium 
(Sigma Aldrich, UK), was added to the cells and incubated at 37 ºC for 1 hour with 
agitation. After incubation, 100 µL of the transformation mixture was spread evenly 
on an LB agar plate containing 25 µg/mL kanamycin and incubated overnight at 37 
ºC.  
2.10.3 Plasmid DNA mini-prep  
A single bacterial colony from a freshly streaked selective plate was used to 
inoculate 5 ml of LB broth with 25 µg/mL kanamycin and incubated overnight at 
37ºC with agitation. Plasmid DNA was purified from the overnight culture using 
Plasmid mini prep kit (Norgen biotek corporation, UK) following the manufacturer‘s 
instructions.  
All centrifugation steps were carried out at room temperature at 14000 rpm. 1.5 mL 
overnight bacterial culture containing the desired plasmid was centrifuged for 30 
seconds. The cell pellet was resuspended in 200 µl of RNAse containing 
Resuspension Solution AZ and incubated for 5 minutes followed by 250 µl of Lysis 
Buffer N added to the suspension and gently mixed to denature cellular proteins and 
genomic DNA. Buffer TN (350 µL) was then added, quickly mixed by inverting the 
tube several times and spun down for 10 minutes to clarify the lysate. The lysate was 
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transferred into a spin column placed in a collection tube and centrifuged for 1 
minute; the flow through was discarded. The spin column was washed with 600 µL 
Wash Solution E by spinning down for 1 minute followed by an additional 
centrifugation for 2 minutes to dry the membrane. Finally, 50 µL of nuclease-free 
water was added to the centre of the column placed in a fresh collection tube, 
allowed to stand for 1 minute and centrifuged for 2 minutes to elute the DNA.  
2.10.4 Restriction digestion 
The purified DNA was quantified using NanoDrop 2000 spectrophotometer, digested 
with specific restriction enzymes for 2 hours at 37ºC and separated by 
electrophoresis on 1% agarose gel along with 10 µl of 1 kb DNA ladder to confirm 
the isolation of the extracted plasmid with the insert based on the molecular weight. 
2.10.5 Creating a glycerol stock 
To prepare glycerol stocks of bacteria for long term storage, 75 µL of sterile glycerol 
was added to 425 µL of overnight bacterial culture, mixed, snap frozen in liquid 
nitrogen and stored at -80ºC. 
2.10.6 Plasmid DNA maxi-prep 
A single bacterial colony was inoculated into 5 ml LB both and cultured for 8 hours 
at 37ºC, shaking at 300 rpm. The starter culture was diluted 1:500 into 500 ml LB 
broth and incubated at 37 ºC for 12-16 hours, shaking at 300 rpm. Purification of 
plasmid DNA was done using Qiagen maxi prep kit (Qiagen, UK) according to the 
manufacturer‘s instructions. 
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Briefly, bacterial cells containing the plasmid of interest were centrifuged at 6000 
rpm for 15 minutes at 4ºC. The pellet was thoroughly resuspended in 10 mL of 
RNase containing Buffer P1 by vortexing. Ten mL Buffer P2 was added to the lysate 
and mixed by inverting the tube several times; the mixture was incubated at room 
temperature for 5 minutes. Following incubation, 10 mL of pre-chilled buffer P3 was 
added and quickly mixed to incubate on ice for 20 minutes. The solution was 
centrifuged for 20000 g for 30 minutes at 4ºC. The supernatant containing plasmid 
was carefully removed and centrifuged again at 20000 g for 15 minutes at 4ºC to 
prevent suspended material from clogging the QIAGEN-tip. The supernatant was 
collected in a universal. 10 ml Buffer QBT was applied to a QIAGEN-tip 500 and 
allowed to drain by gravity flow. The supernatant from the previous step was 
allowed to pass through the equilibrated QIAGEN-tip and allowed to enter the resin 
by gravity flow. The QIAGEN-tip was then washed with 2x 30 mL Buffer QC and 
the DNA was eluted in 15 ml Buffer QF. DNA was precipitated with 10.5 mL room 
temperature isopropanol and was centrifuged at 15000 g for 30 minutes at 4ºC. The 
DNA pellet was washed with 5 ml of room temperature 70% ethanol and centrifuged 
at 15000 g for 10 minutes. The supernatant was carefully removed without disturbing 
the pellet, which was then air dried for 10-15 minutes and redissolved in 100-200 µl 
nuclease-free water. The concentration of the purified plasmid DNA was measured 
using NanoDrop 2000 spectrophotometer. Restriction digests of plasmid DNA were 
carried out using appropriate restriction enzymes in their optimal buffers and 
incubated at 37ºC for 2 hours. Agarose gel electrophoresis was performed to confirm 
the expected insert size. 
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2.10.7 Transfection       
Cells were seeded at a density of 500,000 cells per well in 6-well plates and 
incubated overnight at 37ºC. The following day, a mixture of 10 µL lipofectamine 
2000 transfection reagent (Life Technologies, UK) with 250 µL of OPTI-MEM 
reduced serum media (Life Technologies, UK) was prepared and incubated for 5 
minutes at room temperature. After 5 minutes, the contents of the tube were 
combined with a mixture of 4 µg of plasmid DNA in 250 µL of OPTI-MEM reduced 
serum media and incubated for 20 minutes at room temperature. The procedure was 
repeated with equal concentration of the empty vector in parallel. Equal volumes of 
the transfection mixture were added to the cells drop-by-drop by simultaneously 
moving the plate back and forth. The plates were incubated at 37ºC for 24 hours.  
2.10.8 siRNA-mediated gene knockdown  
RNA interference (RNAi) method was used to transiently knock down genes in 
paediatric HGG short-term cultures using Silencer select pre-designed siRNAs 
(Ambion, USA). Cells were seeded in 6-well plates in 2 ml media at a density of 
500,000 cells/well and incubated overnight at 37ºC. Following incubation, cells were 
transfected with siRNA oligos directed against the chosen gene. Cells were mock-
transfected with negative siRNA oligos in parallel. Briefly, 20 pmol each of siRNA 
of interest and negative siRNA was separately diluted in 250 µL OPTI-MEM 
reduced serum media and mixed gently. To each mixture, 10 µL lipofectamine 2000 
reagent (Invitrogen, UK) diluted in 250 µL OPTI-MEM reduced serum media after 
incubation for 5 minutes at room temperature, was added and incubated for 20 
minutes at room temperature to allow the formation of siRNA: Lipofectamine 2000 
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complexes. Equal volumes (500 µL) of each mixture were then added to cells by 
simultaneously moving the plate back and forth. The cells were incubated at 37ºC for 
48 hours. Western blot analysis was carried out to confirm the knock down of genes.  
2.11 Functional assays 
2.11.1 In vitro colony formation assay 
The roles of candidate genes on growth properties of tumour cells were determined 
by in vitro colony formation assays. Cells were transfected in triplicate with 4 µg of 
plasmid DNA and an equal molar amount of empty vector as described in 2.10.7. 
Forty-eight hours after transfection, cells were harvested by a brief treatment with 
trypsin/EDTA, centrifuged, resuspended in fresh media and seeded in a serial 
dilution in petri dishes. Cells were maintained in media containing 250µg/ ml G418 
(Geneticin) (Life Technologies, UK) and monitored for formation of colonies. 
Twenty five days after initial seeding, colonies were washed in PBS and stained with 
0.4% crystal violet in 50% methanol. The stained colonies were counted and images 
were captured.  
2.11.2 Migration assay 
The migratory potential of tumour cells upon overexpression of candidate genes was 
investigated with CytoSelect™ 24-Well Cell Migration and Invasion Assay (8 µm, 
Colorimetric Format) (Cell biolabs, UK) using the Cell migration portion of the kit, 
according to the manufacturer‘s instructions. Prior to setting up the assay, the plate 
was allowed to warm up at room temperature for 10 minutes. Cells were harvested 
by trypsinisation, centrifuged, resuspended in serum-free media, counted and placed 
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in the insert at a concentration of 0.5x 10
6
 cells/ ml in 300 µl of media (150, 000 
cells). In the lower well of the plate, 500 µl of serum containing media was added as 
a chemoattractant. After incubation at 37ºC for 24 hours, the media from the inserts 
were carefully aspirated and the non-migratory cells from the inside of the inserts 
were gently removed using a wet cotton-tipped swab without damaging the 
membrane. The inserts were then transferred to a clean well containing 400 µl of 
Cell Stain Solution and incubated for 10 minutes at room temperature to stain the 
migratory cells. The stained inserts were gently washed several times in water, air-
dried, transferred to new wells with 200 µl of Extraction Solution and incubated for 
10 minutes on a shaker. One hundred µl of this solution was then added to a 96-well 
plate and the optical density was read at 560nm using a plate reader (GloMax-Multi+ 
Microplate Multimode Reader, Promega, UK). 
2.11.3 Invasion assay 
Invasive abilities of tumour cells after transient knock down of genes were assessed 
with CytoSelect™ 24-Well Cell Migration and Invasion Assay (8 µm, Colorimetric 
Format) utilising the Cell Invasion portion of the kit, following the manufacturer‘s 
instructions. 
The 24-well invasion chamber plate containing polycarbonate membrane inserts (8 
µm pore size) was allowed to warm up at room temperature for 10 minutes. Three 
hundred µl of warm serum-free media was added to the insert to moisten the dried 
basement membrane layer, coated with matrix solution and incubated at room 
temperature for one hour. Meanwhile, cells were harvested and suspensions 
containing 0.5x 10
6
 cells/ ml were prepared in serum free media. A volume of 500 µl 
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of serum containing media was added to the lower well of the plate as a 
chemoattractant. Following incubation, the rehydration media were gently aspirated 
without disturbing the basement membrane. Three hundred µl (150,000 cells) of the 
cell suspension was added to each insert and the plate was incubated at 37ºC for 48 
hours. The media from the insert was gently removed and the non-invasive cells 
from the inside of the insert were gently swabbed using a wet cotton swab, without 
puncturing the membrane. The inserts were transferred to new wells with 400 µl of 
Cell Stain solution and incubated for 10 minutes at room temperature. The stained 
inserts were gently washed several times in water, air-dried and incubated with 200 
µl of Extraction Solution in new wells for 10 minutes on a shaker. Optical density of 
100 µl of the solution was then determined at 560 nm using a plate reader. 
2.12 Statistical tests 
2.12.1 Student’s t-test 
To determine the statistical significance of the difference between two groups by 
comparing their means, student‘s t-test was utilised, which was carried out in 
Graphpad prism software (http://www.graphpad.com/quickcalcs/contMenu/). The 
difference was considered to be significant if the p-value was less than 0.05. 
2.12.2 Fisher’s exact test 
To assess the difference in the frequency of occurrence of an event between 2 
groups, Fisher‘s exact test was used. 
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2.12.3 One-way analysis of variance (ANOVA) 
To assess the significant differences between the means more than 2 unrelated 
groups, one-way ANOVA was performed using Partek Genomics suite (v6.6, Partek 
Inc., USA). 
2.12.4 Principal component analysis (PCA) 
To assess the level of similarity between 2 samples, PCA was utilised, performed 
using Partek Genomics suite (v6.6, Partek Inc., USA). For PCA, the dispersion 
matrix was calculated using correlation method that adjusts the data to be 
standardised to mean of 0 and standard deviation of 1. The distance between 2 
samples indicate the level of similarity between them in high dimensional space. 
Samples that are close to each other are similar in a large number of the variables, 
while the samples that are far apart are different in a large of number of the variables. 
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CHAPTER 3 
Evaluation of paediatric HGG-derived 
short-term cell cultures as in vitro models 
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3.1 Introduction 
Despite continuous efforts to identify novel therapeutic targets in paediatric HGG, 
there has been very limited success in the development of effective chemotherapeutic 
agents that can significantly prolong the survival of children diagnosed with HGG 
(Hargrave et al., 2006; Chassot et al., 2012). One of the main obstacles in the 
validation of molecular targets in vitro and the translation of small molecule 
inhibitors of specific molecular targets from in vitro through in vivo models to the 
actual clinical setting in patients is the relative scarcity of well-characterised pre-
clinical models. 
 Fresh frozen tumour biopsies and formalin fixed paraffin embedded tumour tissues 
have been utilised for molecular biology studies in paediatric HGG for many years. 
These studies have led to the identification of various candidate genes, which later 
developed as therapeutically relevant targets (Pollach et al., 2006; Andrae et al., 
2008; Bax et al., 2009; Paugh et al., 2013). However, there are fewer investigations 
conducted in paediatric HGG in comparison to adult glioma mainly due to the lack of 
availability of tumour tissues. For tumours such as DIPG, surgical procedures are 
relatively rare owing to the critical location of these tumours in the brainstem 
(Warren et al., 2012; Fontebasso et al., 2014). Additional issues confined to the 
paediatric population include difficulties in procuring autopsy consents from parents 
of the affected children (Angelini et al., 2010).  
For several years, established cell lines have been used to evaluate the efficacy of 
experimental therapeutics in vitro and to understand their mechanisms of action. 
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Although they have contributed to our existing understanding of tumour biology, 
they do not accurately represent the tumour in the patient as there is a tendency to 
acquire additional genetic alterations with increasing passage numbers (Gillet et al., 
2011). Furthermore, it is difficult to recapitulate the genetic and epigenetic 
heterogeneity present between individual tumours as well as within the same tumour 
tissue (Lima et al., 2010; Sottoriva et al., 2013; McGranahan and Swanton, 2015). 
Studies have shown that primary cultures derived from tumour biopsies can retain a 
considerable proportion of the characteristic gene expression profiles of the biopsies 
(Ross and Perou, 2001; Bignotti et al., 2006). Moreover, a study by Yost et al. (2013) 
reported that GBM-derived cell cultures retained mutation and copy number changes 
detected in the tumour biopsy. 
The aim of this study was to understand whether paediatric HGG short-term cell 
cultures are representative of the tumour in vivo by investigating the genomic 
profiles of paired biopsies and their derived cell cultures to determine if the 
characteristic aberrations of the tumour are maintained in vitro. In addition, the 
mutation status of HGG associated genes was ascertained in these paired paediatric 
HGG samples. 
3.2 Results 
3.2.1 Comparison of copy number changes in paediatric HGG biopsies and 
their derived short-term cultures 
In order to assess whether copy number alterations (CNAs) in paediatric HGG 
biopsies are retained in their derived short-term cell cultures, genome-wide copy 
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number profiles were generated for 2 paediatric HGG biopsies/cell culture pairs 
(IN3182 and IN3183) using Agilent Human Genome 244K CGH microarrays.  
Genomic DNA was isolated from the biopsies and derived short-term cell cultures of 
the 2 pairs and the purity and integrity of the isolated DNA were verified as 
described in 2.5.1 and 2.5.3 respectively. Each test sample was sex-matched with the 
reference normal DNA; the test and the reference DNA were then differentially 
labelled with Cy3 (green) and Cy5 (red) fluorescent dyes respectively and co-
hybridized onto the microarray as described in 2.8. The arrays were scanned using an 
Agilent SureScan Microarray scanner (Agilent Technologies) and the data were 
extracted from the resulting Tagged Image File (TIF) images, followed by dye-
normalisation and log2ratio calculation using Feature Extraction Software (v9.5, 
Agilent technologies). The QC report of each sample was carefully assessed to 
determine the level of background noise on the array. One of the most important QC 
metrics, which is an indicator of noise, is DLRS that calculates the probe-to-probe 
log ratio noise of an array. Agilent recommends DLRS value <0.2 for excellent, 
between 0.20 and 0.30 for good and >0.30 for poor quality arrays. All 4 samples in 
this analysis had DLRS values <0.20. 
To assess the level of similarity between biopsies and their respective derived short-
term cell cultures, PCA was performed with 2 paediatric HGG pairs (IN3182 B/CC 
and IN3183 B/CC) using Partek Genomics suite (v6.6, Partek Inc., USA) as 
described in 2.12.4. The results of PCA are shown in Figure 3.1 with each dot on the 
scatter plot representing a sample and X, Y and Z axes representing the first 3 
principal components (PC1, PC2 and PC3) respectively. The distance between 2 
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PCA mapping 100%
IN3182 B/CC
IN3183 B/CC
samples indicate the level of similarity between them in high dimensional space. 
Samples that are close to each other are similar in a large number of the variables, 
while the samples that are far apart are different in a large of number of the variables.  
PCA showed that the biopsies and their derived short-term cell cultures in both the 
pairs (IN3182 and IN3183) did not group together but neither did the 2 short-term 
cell cultures nor the 2 biopsies.   
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Three-dimensional PCA plot of paediatric HGG paired biopsies. PCA plot of IN3182 
and IN3183 paired biopsies generated using the first three PCs, PC 1 (53%), PC 2 (28.1%) and PC 3 
(18.9%). Each dot on the scatter plot represents a sample. Biopsy and derived short-term cell culture 
of the same B/CC pair are shown by the same colour. IN3182 pair is represented by green and IN3183 
pair is represented by blue. B-biopsy; CC-cell culture. 
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CNAs in both pairs were identified using the ADM-2 algorithm in Agilent 
cytogenomics software (v3.0.1.1, Agilent Technologies, USA) as described in 
2.8.1.5. The following parameters were used for analysis: stringency threshold=6, 
minimum absolute average log ratio per region=0.25, maximum number of aberrant 
regions=100000, minimum number of consecutive probes per region=3, Diploid 
Peak Centralization-ON, and Combine Replicates (Intra Array) =ON. Genome 
positions were mapped to NCBI build 36.1 (hg18).  
In the IN3182 B/CC pair, there were 35 CNAs consisting of 9 gains, 22 losses and 4 
deletions in the biopsy sample while there were 70 CNAs consisting of 51 gains, 8 
losses and 11 deletions in its derived short-term cell culture. Approximately 43% 
(15/35) of the CNAs in the biopsy were maintained in the short-term cell culture. 
These consisted of 7 gains, 3 losses and 5 deletions and are listed in Table 3.1. The 
chromosome view illustrating representative CNAs shared by IN3182 B and CC such 
as gains at 10q21.1 and 20q12-q13.33 and losses at 6q14.1 and 13q21.1 and 20p13 
are shown in Figure 3.2 A. There were CNAs involving large regions of 
chromosomes that were only present in the culture including gains of chromosomes 7 
and 9, and loss of chromosome 22 and there were also large CNAs that were not 
retained in the cell culture such as loss of chromosome 19 (Figure 3.2 B).  
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Chr Cytoband Start Stop CN event Probes
Probe 
median
p-value Gene Names
chr1 q21.1 147,307,637 147,499,105 Deletion 9 -1.140 1.15E-36 No genes in this region
chr1 q21.3 151,027,357 151,036,494 Deletion 3 -1.779 2.90E-21 LCE1E, LCE1D
chr2 p11.2 87,178,812 88,041,911 Gain 13 0.588 4.45E-21 NCRNA00152, PLGLB2, PLGLB1, RGPD1, RGPD2
chr6 q14.1 79,035,891 79,080,047 Deletion 3 -2.686 3.42E-23 No genes in this region
chr7 p14.1 38,259,147 38,336,023 Gain 13 1.287 6.50E-14 TARP
chr10 q21.1 56,122,417 56,135,443 Gain 3 1.939 1.69E-43 PCDH15
chr13 q21.1 56,658,479 56,673,242 Deletion 3 -3.357 3.31E-32 No genes in this region
chr14 q11.2 19,273,289 19,467,571 Gain 25 0.381 8.42E-19 OR4Q3, OR4M1, OR4N2, OR4K2, OR4K5
chr14 q11.2 21,662,700 22,052,858 Gain 48 0.491 1.75E-48 No genes in this region
chr14 q32.33 105,105,322 105,349,987 Loss 24 -0.376 2.11E-18 No genes in this region
chr15 q11.2 18,874,663 19,786,714 Loss 35 -0.376 4.01E-12 GOLGA6L6, GOLGA8C, BCL8, LOC646214, CXADRP2, POTEB, NF1P1, LOC727924
chr17 q12 31,461,588 31,486,599 Gain 4 1.141 2.78E-23 No genes in this region
chr17 q21.31 41,508,943 41,841,246 Loss 19 -0.317 9.58E-13 KIAA1267, LRRC37A, ARL17B, NSFP1
chr20 p13 1,516,966 1,539,201 Loss 3 -1.102 1.23E-12 SIRPB1
chr20 q12 - q13.33 38,605,932 62,379,118 Gain 2162 0.818 4.900e-324
MAFB, TOP1, PRO0628, PLCG1, ZHX3, LPIN3, EMILIN3, CHD6, PTPRT, SRSF6, L3MBTL, SGK2, IFT52, MYBL2, GTSF1L,
TOX2, JPH2, C20orf111, GDAP1L1, FITM2, R3HDML, HNF4A, TTPAL, SERINC3, PKIG, ADA, WISP2, KCNK15, RIMS4,
YWHAB, PABPC1L, TOMM34, STK4, KCNS1, WFDC5, WFDC12, PI3, SEMG1, SEMG2, SLPI, MATN4, RBPJL, SDC4, SYS1,
SYS1-DBNDD2, TP53TG5, DBNDD2, PIGT, WFDC2, SPINT3, WFDC6, SPINLW1, WFDC8, WFDC9, WFDC10A, WFDC11,
WFDC10B, WFDC13, SPINT4, WFDC3, DNTTIP1, UBE2C, TNNC2, SNX21, ACOT8, ZSWIM3, ZSWIM1, C20orf165, NEURL2,
CTSA, PLTP, PCIF1, ZNF335, MMP9, SLC12A5, NCOA5, CD40, CDH22, SLC35C2, ELMO2, LOC100240726, ZNF334,
C20orf123, SLC13A3, TP53RK, SLC2A10, EYA2, ZMYND8, LOC100131496, NCOA3, SULF2, LOC284749, PREX1, ARFGEF2,
CSE1L, STAU1, DDX27, ZNFX1, NCRNA00275, SNORD12C, MIR1259, SNORD12B, SNORD12, KCNB1, PTGIS, B4GALT5,
SLC9A8, SPATA2, RNF114, SNAI1, UBE2V1, TMEM189-UBE2V1, TMEM189, CEBPB, PTPN1, MIR645, FAM65C, PARD6B,
BCAS4, ADNP, DPM1, MOCS3, KCNG1, NFATC2, ATP9A, SALL4, ZFP64, TSHZ2, ZNF217, SUMO1P1, BCAS1, CYP24A1,
PFDN4, DOK5, CBLN4, MC3R, C20orf108, AURKA, CSTF1, CASS4, C20orf43, GCNT7, C20orf106, C20orf107, TFAP2C, BMP7,
SPO11, RAE1, MTRNR2L3, RBM38, CTCFL, PCK1, ZBP1, PMEPA1, C20orf85, PPP4R1L, RAB22A, VAPB, APCDD1L, STX16,
NPEPL1, MIR296, MIR298, GNASAS, GNAS, TH1L, CTSZ, TUBB1, ATP5E, SLMO2, ZNF831, EDN3, PHACTR3, SYCP2,
C20orf177, PPP1R3D, CDH26, C20orf197, MIR646, CDH4, MIR1257, TAF4, LSM14B, PSMA7, SS18L1, GTPBP5, HRH3,
OSBPL2, ADRM1, LAMA5, RPS21, CABLES2, C20orf151, GATA5, C20orf200, C20orf166, MIR1-1, MIR133A2, SLCO4A1,
LOC100127888, NTSR1, C20orf20, OGFR, COL9A3, TCFL5, DPH3B, DIDO1, C20orf11, SLC17A9, BHLHE23, LOC63930,
NCRNA00029, LOC100144597, HAR1B, HAR1A, MIR124-3, YTHDF1, BIRC7, NKAIN4, FLJ16779, ARFGAP1, COL20A1,
CHRNA4, KCNQ2, EEF1A2, PPDPF, PTK6, SRMS, C20orf195, PRIC285, GMEB2, STMN3, RTEL1, TNFRSF6B, ARFRP1,
ZGPAT, LIME1, SLC2A4RG, ZBTB46, C20orf135, TPD52L2, DNAJC5, MIR941-1, MIR941-2, MIR941-3, UCKL1, MIR1914,
MIR647, UCKL1AS, ZNF512B, SAMD10, PRPF6, NCRNA00176, SOX18, TCEA2, RGS19, OPRL1, C20orf201, NPBWR2, MYT1,
PCMTD2
Table 3.1 CNAs maintained in IN3182 paediatric HGG short-term cell culture 
 
 
 
 
 
 
 
 
 
 
CNAs were identified in IN3182 biopsy and its derived short-term cell culture using ADM-2 algorithm in Agilent Cytogenomics (Agilent technologies Inc., USA). CNAs 
maintained in IN3182 short-term cell culture are shown. Chr-chromosome; CN-copy number. 
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Figure 3.2 Comparison of copy number changes in IN3182 B and CC. A. Copy number changes maintained in IN3182 paediatric HGG short-term cell culture. Copy 
number analysis was performed in IN3182 B and CC using ADM-2 algorithm in Agilent cytogenomics (Agilent technologies Inc., USA). Each dot represents a single probe 
on the array. The log-ratio of each probe is plotted against chromosomal position shown on the ideogram on the left. Copy number gain (+1) and copy number loss (-1) shift 
the log-ratios to the right and left respectively, of the baseline (0).  Red indicates copy loss and blue indicates copy gain; Chr- chromosome number; B-biopsy; CC-cell culture. 
A. Copy number changes maintained in IN3182 paediatric HGG short-term cell culture. Representative examples of CNAs maintained in IN3182 short-term cell culture 
such as -6q41, +10q21.1, -13q21.1, -20p13 and +20q12-q13.33 are shown. 
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B. Copy number changes in IN3182 CC not representative of IN3182 B. Gains of chromosomes 7 and 9, and loss of 22q were not present in IN3182 B, but were detected 
in IN3182 CC. Loss of chromosome 19 in IN3182 B was not maintained in IN3182 CC. 
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Chr Cytoband Start Stop
CN 
event
Probes
Probe 
median
p-value Gene Names
chr1 q21.3 150,839,754 150,848,568 Deletion 3 -1.074215 2.06E-13 LCE3C
chr1 q23.1 157,138,568 157,178,411 Loss 4 -0.826835 4.33E-13 PYHIN1
chr1 q44 246,822,838 246,862,088 Loss 7 -0.838577 4.18E-22 OR2T10, OR2T11
chr2 p11.2 89,377,632 90,982,989 Gain 18 0.517607 2.78E-24 No genes in this region
chr2 q13 110,234,644 110,340,992 Loss 15 -0.886895 6.18E-53 NPHP1, NCRNA00116
chr3 q11.2 98,483,619 98,517,809 Loss 5 -0.846896 5.10E-16 EPHA6
chr3 q26.1 164,038,917 164,101,835 Loss 6 -0.650289 1.26E-13 No genes in this region
chr6 p21.32 32,567,382 32,629,907 Gain 6 0.828468 1.16E-12 HLA-DRB5, HLA-DRB6
chr7 p14.1 38,259,147 38,336,023 Gain 13 0.502437 2.01E-16 TARP
chr8
p11.23 -
p11.22
39,356,595 39,505,315 Gain 20 0.397046 9.43E-16 ADAM5P, ADAM3A
chr11 q11 55,118,214 55,195,049 Gain 12 0.449675 6.34E-13
OR4C11, OR4P4, 
OR4S2, OR4C6
chr12 p13.31 9,528,590 9,585,215 Gain 3 1.105748 2.25E-15 No genes in this region
chr14 q11.2 21,505,880 22,046,156 Gain 67 0.451051 8.51E-63 No genes in this region
chr20 p13 1,516,966 1,539,201 Loss 3 -0.985807 3.24E-12 SIRPB1
In the IN3183 B/CC pair, there were 240 CNAs consisting of 5 high copy gains, 20 
gains and 216 losses, while there were only 16 CNAs consisting of 9 gains, 6 losses 
and 1 deletion in its derived short-term cell culture. Only 6% (14/240) of the CNAs 
in the biopsy sample were maintained in the cell culture. However, only 2 CNAs 
were additionally acquired by the cell culture. The CNAs maintained in IN3183 
short-term cell culture are listed in Table 3.2 and chromosome views of 
representative regions are shown in Figure 3.3 A. There were large CNAs in the 
biopsy that were not maintained in the cell culture such as losses of 9, 17, 19 and 22q 
(Figure 3.3 B). 
Table 3.2 CNAs maintained in IN3183 paediatric HGG short-term cell culture 
 
 
 
 
 
 
 
 
CNAs were identified in IN3183 biopsy and its derived short-term cell culture using ADM-2 
algorithm in Agilent Cytogenomics (Agilent Technologies Inc., USA). CNAs maintained in IN3183 
short-term cell culture are shown. Chr-chromosome; CN-copy number. 
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Figure 3.3 Comparison of copy number changes in IN3183 paired biopsy. A. CNAs maintained in IN3183 paediatric HGG short-term cell culture. Copy 
number analysis was performed in IN3183 B and CC using ADM-2 algorithm in Agilent cytogenomics (Agilent technologies Inc., USA). Each dot represents a 
single probe on the array. The log-ratio of each probe is plotted against chromosomal position shown on the ideogram on the left. Copy number gain (+1) and copy 
number loss (-1) shift the log-ratios to the right and left respectively, of the baseline (0).  Red indicates copy loss and blue indicates copy gain; Chr- chromosome 
number; B-biopsy; CC-cell culture. A. Representative examples of CNAs maintained in IN3183 short-term cell culture such as -1q21.3, -2q13, +6p21.32 and -
20p13 are shown. 
95 
 
IN3183 CC
IN3183 B
 
 
 
 
 
 
 
 
 
 
 
igure 3.3 B. Copy number changes in IN3183 CC not representative of IN3183 B. Losses of chromosomes 9, 17, 19 and 22q present in IN3183 B were not 
maintained in IN3183 short-term cell culture. 
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3.2.2 Comparison of gene expression profiles of tumour biopsies and their 
derived short-term cell cultures  
To investigate whether paediatric HGG short-term cell cultures can represent the 
tumour in vivo at the mRNA level, 3 paediatric HGG short-term cell cultures and 
their parent biopsy samples (IN3180 B/CC, IN3182 B/CC and IN3183 B/CC) were 
profiled for gene expression changes using Affymetrix U133A plus 2 arrays as 
described in 2.8.3. The median log transformed data of 54675 mounted probes on 
each array from all 3 pairs were filtered to remove the control probes (n=61) prior to 
further statistical analysis using Partek Genomics suite (v6.6, Partek Inc., USA). 
PCA was performed using the remaining 54614 informative probes in all 3 paired 
samples to visually assess the level of similarity between the cell culture and biopsy 
sample in each pair, as described in 2.12.4. The results of PCA are illustrated as a 3-D 
scatter plot in Figure 3.4. 
PCA revealed that the biopsies and derived short-term cell cultures of IN3180 and 
IN3183 pairs had different gene expression profiles and did not group together. 
Moreover, the gene expression profiles of IN3180 CC and IN3183 CC were 
relatively similar although their respective biopsies were different from each other, 
suggesting that artificial culture conditions may significantly alter gene expression 
profiles. Interestingly, the biopsy and the derived short-term cell culture in the third 
pair (IN3182 B/CC) had similar expression profiles and were clustered together. 
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Figure 3.4 PCA plot of 3 paediatric HGG biopsies and their derived short-term cell cultures. 
PCA scatter plot of 3 paediatric HGG biopsies and their derived short-term cell cultures plotted using 
the first three PCs (PC1=31.7 %, PC2=21.4 % and PC3=19.5 %). Each dot on the PCA plot denotes a 
sample. Biopsy and derived short-term cell culture of individual pairs are represented using similar 
coloured dots. B-Biopsy, CC-cell culture. 
Unsupervised hierarchical clustering of 54614 probes in 3 paediatric HGG paired 
biopsies was used to cluster samples according to the similarity of their expression 
profiles. The analysis was performed using the average linkage hierarchical 
clustering algorithm with Euclidean distance as similarity metric. The results are 
illustrated as a dendrogram in Figure 3.5, with samples having similar expression 
profiles clustered together. The dendrogram demonstrated that 2 biopsy samples 
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IN3180 B IN3183 B IN3182 B IN3182CC IN3180 CC IN3183 CC
B CC
2.04-2.04 0.00
(IN3180 B and IN3183 B) were independent of any other sample, while the 
remaining samples were divided into 2 clusters. The shorter cluster had the 2 cell 
cultures of IN3180 and IN3183 paired samples clustered together, while the other 
cluster consisted of IN3182 B and CC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Unsupervised hierarchical clustering of paediatric HGG paired biopsies. 
Unsupervised hierarchical clustering analysis was performed using 54675 probes across 3 paediatric 
HGG paired biopsies using average linkage hierarchical clustering algorithm with Euclidean distance 
as similarity metric. Each row on the dendrogram represents the expression of a single probe and each 
column represents the expression levels for a single sample. Green and red colours indicate high and 
low expression respectively. B and CC in the IN3182 pair cluster together; B and CC in the IN3180 
and IN3183 pairs do not cluster together. B-biopsy; CC-cell culture. 
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To determine the effect of cell culture-induced changes on cellular pathways, probes 
with >2-fold differential expression in the cell cultures compared to the biopsies in 
the 3 paediatric HGG paired samples were identified using one-way ANOVA test. A 
comparison of the number of differentially expressed probes in all 3 pairs is shown in 
Figure 3.6. 
 
 
 
 
 
 
 
 
Figure 3.6 Comparison of differentially expressed probes in cell cultures compared to biopsies 
in paediatric HGG paired samples.  Probes with 2-fold change in expression in paediatric HGG 
short-term cell cultures in comparison to their biopsies were identified in 3 paediatric HGG paired 
biopsies using one-way ANOVA test. The graph is plotted with paediatric HGG paired biopsies on x-
axis and differentially expressed probes on y-axis. n represents the number of differential probes in 
cell culture compared to biopsy 
 
For the IN3180 pair, there were 10826 differentially expressed probes, of which 
4732 probes were upregulated and 6094 probes were downregulated in the cell 
culture. There were 8916 differentially expressed probes in IN3183 CC compared to 
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its biopsy consisting of 4116 upregulated and 4800 downregulated probes 
respectively. In comparison, IN3182 CC had only 6910 differentially expressed 
probes, of which 3431 were upregulated and 3479 were downregulated, confirming 
the relatively higher level of similarity between the cell culture and the biopsy in 
comparison to the other paired samples. The probes that were commonly upregulated 
in all the 3 pairs are displayed in a Venn diagram in Figure 3.7. Similarly, the probes 
that were commonly downregulated in all the 3 pairs are displayed in a Venn 
diagram in Figure 3.8. Overall, there were 1498 differentially expressed probes that 
were common to all 3 pairs. These comprised 677 upregulated and 821 
downregulated probes.  
 
 
 
 
 
 
 
Figure 3.7 Venn diagram of commonly differentially upregulated expression probes in 3 
paediatric HGG paired biopsies. Differentially upregulated (>2-fold) miRNAs in short-term cell 
culture compared to its parent biopsy were identified in 3 paediatric HGG paired biopsies (IN3180, 
IN3182 and IN3183) using one-way ANOVA test. The number of upregulated miRNAs in each pair is 
shown in parentheses. 
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Figure 3.8 Venn diagram of commonly differentially downregulated expression probes in 3 
paediatric HGG paired biopsies. Differentially upregulated (>2-fold) miRNAs in short-term cell 
culture compared to its parent biopsy were identified in 3 paediatric HGG paired biopsies (IN3180, 
IN3182 and IN3183) using one-way ANOVA test. The number of downregulated miRNAs in each 
pair is shown in parentheses. 
To determine the effect of cell culture-induced changes on cellular pathways, Gene 
Ontology (GO) analysis was performed using the commonly differentially expressed 
probes in all 3 pairs and the enrichment scores for the most affected pathways were 
calculated. The key biological processes associated with these probes were cell 
proliferation (2.91), cellular process (0.90), pigmentation (0.78), growth (0.66), viral 
reproduction (0.25), and metabolic process (0.16) (Figure 3.9). Thus, it can be 
understood that the increase in the number of differentially expressed probes in cell 
cultures compared to the biopsies was induced by artificial culture conditions. 
However, the degree of differential expression of large number of probes was within 
2-fold, indicating that paediatric HGG short-term cell cultures retain gene expression 
changes present in their parent biopsies. 
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Figure 3.9 GO biological processes associated with commonly differentially expressed probes in 
3 paediatric HGG paired biopsies. The commonly differentially expressed probes in 3 paediatric 
HGG short-term cell cultures (IN3180, IN3182 and IN3183) compared to their respective biopsies 
were used to perform GO analysis. The enrichment scores of the key biological processes are shown. 
The percentages in parentheses indicate the fraction of the total number of genes present in the GO 
biological process.  
3.2.3 Comparison of miRNA expression profiles of tumour biopsies and their 
derived short-term cell cultures  
To examine whether paediatric HGG short-term cell cultures retain the miRNA 
expression profiles of their parent biopsy samples, global miRNA expression profiles 
were generated for 3 paediatric HGG paired biopsies (IN3180 B/CC, IN3182 B/CC 
and IN3183 B/CC) using 3D-Toray miRNA Oligo chip as described in 2.8.4. The 
median-normalised data from all 3 paired biopsies provided by Toray Industries were 
filtered to remove unreliable probes that did not have any detected dye signal in 
biopsies and cell cultures for all 3 pairs. The remaining 807 informative probes were 
used for miRNA expression analyses using Partek Genomics Suite (version 6.6; 
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Partek Inc., USA). PCA was performed using the 3 paired samples to visually assess 
the level of similarity in the expression profiles between biopsies and their derived 
short-term cell cultures as described in 2.12.4. The results of PCA are illustrated as a 
3-D scatter plot in Figure 3.10.PCA showed that the biopsy and the derived short-
term cell culture in all 3 pairs (IN3180, IN3182 and IN3183) did not have similar 
expression profiles. However, the biopsy samples and the cell culture samples also 
did not form separate groups. Two paediatric HGG short-term cell cultures (IN3182 
CC and IN3183 CC) had relatively similar miRNA expression profiles compared to 
the rest of the samples.  
 
 
 
 
 
 
 
 
 
Figure 3.10 PCA plot of 3 paediatric HGG biopsies and their derived short-term cell cultures. 
PCA scatter plot of 3 paediatric HGG biopsies and their derived short-term cell cultures, plotted using 
the first three PCs (PC1=38.7 %, PC2=26.3 % and PC3=15 %). Each dot on the PCA plot denotes a 
sample. Biopsy and derived short-term cell culture of individual pairs are represented using similar 
coloured dots. B-Biopsy, CC-cell culture. 
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Unsupervised hierarchical clustering was performed using 807 reliable probes in all 3 
paediatric HGG paired samples with the distance between 2 clusters calculated by 
the average linkage hierarchical clustering algorithm with Euclidean distance as a 
similarity metric. The results are illustrated as a dendrogram in Figure 3.11, with 
samples having similar expression profiles clustering together.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Unsupervised hierarchical clustering of paediatric HGG paired biopsies. 
Unsupervised hierarchical clustering analysis was performed using 807 probes across 3 paediatric 
HGG paired biopsies using average linkage hierarchical clustering algorithm with Euclidean distance 
as similarity metric. Each row on the dendrogram represents the expression of a single probe and each 
column represents the expression levels for a single sample. Green and red colours indicate high 
(2.04) and low (-2.04) expression respectively. B-biopsy; CC-cell culture. 
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The dendrogram showed that the 3 paediatric HGG paired biopsies formed 2 clusters, 
one containing IN3180 B, IN3180 CC and IN3182 B, with relatively similar 
expression profiles between the 2 biopsies (IN3180 B and IN3182 B), and the other 
containing IN3183 B and CC and IN3182 CC, with the 2 cell culture samples 
(IN3182 CC and IN3183 CC) having relatively similar expression profiles. The 
greatest difference in the miRNA expression profiles between the tumour biopsy and 
its derived short-term cell culture was observed in the IN3182 pair. The remaining 
pairs (IN3180 and IN3183) had comparatively similar expression profiles. 
To further compare the miRNA expression profiles between the biopsies and their 
respective derived short-term cell cultures, the number of differentially expressed 
miRNAs in the cell culture sample compared to its parent biopsy sample was 
determined in each pair using one way ANOVA test. The miRNA probes with no 
detected signal intensities in both the biopsy and its derived short-term cell culture in 
each pair were excluded from the analysis. The miRNAs with 2-fold change in 
expression in the cell culture sample compared to its biopsy in IN3180, IN3182 and 
IN3183 pairs were determined. These miRNAs were then discounted from the total 
number of probes analysed in each paired biopsy to obtain the fraction of miRNAs 
that did not vary significantly in the cell culture sample compared to its biopsy. A 
comparison of the similarities and differences in the number of differentially 
expressed miRNAs in the cell culture sample compared to its parent biopsy across 
the 3 pairs (IN3180, IN3182 and IN3183) are shown in Figure 3.12. There were large 
numbers of miRNAs with 2-fold change in expression in the cell culture compared to its 
respective biopsy in all 3 paediatric HGG paired biopsies, demonstrating the influence of 
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cell culture conditions on miRNA expression profiles. The highest number of 
differentially expressed miRNAs was identified in the IN3182 pair (471miRNAs) 
followed by the IN3180 (438 miRNAs) and IN3183 (328 miRNAs) pairs respectively. 
However, a considerable fraction of miRNAs had less than 2-fold change in expression 
in the cell culture compared to the biopsy sample in each paediatric HGG paired biopsy, 
indicating that short-term cell cultures do retain some of the miRNA expression changes 
of the tumour in vivo. The IN3183 pair had the highest number of miRNAs (306) with 
less than 2-fold differential expression in the cell culture compared to its parent biopsy, 
followed by the IN3180 (250) and IN3182 (207) pairs respectively. 
 
 
 
 
 
 
 
 
 
Figure 3.12 Comparison of differentially expressed miRNAs in paediatric HGG paired biopsies. 
MiRNAs with 2-fold differential expression in CC compared to biopsy in 3 paediatric HGG paired 
biopsies are shown. Green indicates miRNAs with more than 2-fold change in expression in CC 
compared to B. Red indicates miRNAs with less than 2-fold change in expression in CC compared to 
biopsy. ‗n‘ indicates the total number of informative miRNAs used for the analysis in each pair (ie, 
miRNAs with detectable signal intensities in either B or CC). B-Biopsy, CC-Cell culture. 
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To investigate the effect of cell culture conditions on the miRNA expression profiles, the 
commonly differentially expressed miRNAs in all 3 paediatric HGG short-term cell 
cultures were identified. The upregulated miRNAs and the downregulated miRNAs in all 
3 pairs were identified independently. There were 191 upregulated miRNAs in the 
IN3180 pair, 146 miRNAs in the IN3182 pair and 172 miRNAs in the IN3183 pair. 
There were 15 miRNAs that were commonly upregulated in all 3 cell culture samples 
(Figure 3.13).  
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Venn diagram of commonly upregulated miRNAs in 3 paediatric HGG paired 
biopsies. Differentially upregulated (>2-fold) miRNAs in short-term cell culture compared to its 
parent biopsy were identified in 3 paediatric HGG paired biopsies (IN3180, IN3182 and IN3183) 
using one-way ANOVA test. The number of differentially upregulated miRNAs in each pair is shown 
in parentheses. 
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Similarly, there were 247, 325 and 156 downregulated miRNAs in the IN3180, 
IN3182 and IN3183 pairs respectively. There were 36 miRNAs that were commonly 
downregulated in all 3 pairs, as shown in Figure 3.14.  
 
 
 
 
 
 
 
 
Figure 3.14 Venn diagram of commonly downregulated miRNAs in 3 paediatric HGG paired 
biopsies. Differentially upregulated (>2-fold) miRNAs in short-term cell culture compared to its 
parent biopsy were identified in 3 paediatric HGG paired biopsies (IN3180, IN3182 and IN3183) 
using one-way ANOVA test. The number of differentially downregulated miRNAs in each pair is 
shown in parentheses. 
 
As illustrated in the Venn diagrams, there were 51 miRNAs that were commonly 
differentially expressed in cell cultures compared to biopsies in all pairs, of which 15 
were upregulated and 36 were downregulated. 
To understand the cellular pathways affected by miRNA expression changes induced 
by cell culture conditions, the commonly differentially expressed miRNAs were used 
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KEGG pathway p-value Genes miRNAs
Prostate cancer 0 52 14
ErbB signaling pathway 0 46 15
Lysine degradation 1.11E-16 20 14
Pathways in cancer 5.55E-16 137 11
Adherens junction 5.55E-15 47 12
TGF-beta signaling pathway 2.02E-14 40 11
Ubiquitin mediated proteolysis 1.47E-13 61 9
Transcriptional misregulation in cancer 8.41E-13 76 11
Endometrial cancer 5.00E-12 30 13
PI3K-Akt signaling pathway 2.36E-11 129 11
to perform KEGG pathway analyses using the pathways union module in DIANA-
miRPath v3.0, (http://www.microrna.gr/miRPathv3). The putative mRNA targets of 
the deregulated miRNAs were identified using microT-CDS target prediction 
algorithm (minimum threshold of 0.80), which identifies miRNA targets both in 
3‘untranslated region (3‘UTR) and in coding sequences (CDS) (Reczko et al, 2012). 
This resulted in 38 significantly enriched pathways (p<0.05). The 10 most 
significantly enriched pathways associated with the commonly differentially 
expressed miRNAs in the 3 paediatric HGG pairs are listed in Table 3.3. These 
included prostate cancer, ErbB signaling pathway, lysine degradation, pathways in 
cancer, adherens junction, TGF-beta signaling pathway, ubiquitin-mediated 
proteolysis, transcriptional misregulation in cancer, endometrial cancer and PI3K-
Akt signaling pathway. 
Table 3.3 KEGG pathways associated with commonly differentially expressed miRNAs in 
paediatric HGG paired biopsies 
 
 
 
 
 
Significantly enriched KEGG pathways associated with 51 commonly differentially expressed 
miRNAs in 3 paediatric HGG paired biopsies were identified using the ‗pathways union‘ module 
(microT-threshold 0.8) in DIANA mirPath v3.0. The 10 most significantly enriched pathways (p-
value<0.05 (FDR ON)) are shown. The table is ranked by enrichment p-value. 
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3.2.4 Mutation analysis of key genes in paediatric HGG short-term cell 
cultures 
To investigate if paediatric HGG short-term cell cultures maintained gene mutations 
present in biopsies, mutation status of key genes H3F3A, HIST1H3B, BRFAV600E 
and ACVR1 involved in paediatric HGG tumourigenesis were determined in 3 
paediatric HGG biopsy/cell culture pairs and 14 additional paediatric HGG-derived 
short-term cell cultures (including 3 DIPG-derived short-term cell cultures) using 
direct sequencing as described in 2.7. The sequencing data were analysed using ABI 
Sequence Scanner v1.0. Heterozygous mutations in H3F3A involving an amino acid 
change from lysine to methionine (K27M) were detected in 2 out of 18 (11%) 
paediatric HGG short-term cultures, which included 1 DIPG (IN2675) (33%) and 1 
non-DIPG (IN1566) (13%) short-term cell cultures. The sequencing chromatogram 
of a representative K27M mutant short-term cell culture is shown in Figure 3.15 A. 
H3F3A (K27M) mutations were not detected in any paediatric HGG biopsy/cell 
culture pairs included in this analysis. Also, none of the samples had mutations in 
HIST1H3B involving K27M substitutions. A mutation in BRAF leading to amino 
acid change from valine to glutamic acid (BRAFV600E) was identified in 1 (1/18, 
6%) paediatric HGG short-term cell culture (IN179) (Figure 3.15 B). Mutations in 
ACVR1, which encodes activin A type I receptor ALK2 have been identified 
predominantly in DIPGs (Taylor et al., 2014). In this study, none of the DIPG and 
non-DIPG short-term cell cultures had ACVR1 mutations. None of the paired 
samples had mutation in any of the genes analysed. The summary of mutation 
analyses of all 4 genes in paediatric HGG paired biopsies and short-term cell cultures 
is provided in Table 3.4. 
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Figure 3.15 Mutations in H3F3A and BRAF in paediatric HGG short-term cell cultures. Sanger 
sequencing chromatogram of representative H3F3A or BRAF heterozygous mutations in paediatric 
HGG short-term cell cultures are shown. A. Mutation in H3F3A involving lysine to methionine 
(K27M) in IN1566 and IN2675. B. Mutation in BRAF involving valine to glutamine amino acid 
substitution (V600E) in IN179.  Arrow denotes mutated nucleotide. IN178, IN179 and IN1566 are 
non-DIPG short-term cell cultures and IN2675 is a DIPG short-term cell culture. WT-wild type; 
MUT-mutant. 
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Samples H3F3A HIST1H3B BRAF ACVR1
Paediatric HGG short-term cell cultures
IN178 WT WT WT WT
IN179 WT WT V600E WT
IN1163 WT WT WT WT
IN1262 WT WT WT WT
IN1419 WT WT WT WT
IN1523 WT WT WT WT
IN1566 K27M WT WT WT
IN1930 WT WT WT WT
IN2087 WT WT WT WT
IN2102 WT WT WT WT
IN2675 K27M WT WT WT
IN3032 WT WT WT WT
IN3046 WT WT WT WT
IN3180 WT WT WT WT
IN3182 WT WT WT WT
IN3183 WT WT WT WT
IN3205 WT WT WT WT
Paediatric HGG biopsy samples
IN3180 WT WT WT WT
IN3182 WT WT WT WT
IN3183 WT WT WT WT
Table 3.4 Mutation status of H3F3A, HIST1H3B, BRAF and ACVR1 in paediatric HGG short-
term cell cultures 
 
 
 
 
 
 
 
 
 
The mutation status of H3F3A, HIST1H3B, BRAF and ACVR1 in 17 paediatric HGG short-term cell 
cultures and 3 biopsy samples is listed. DIPG are highlighted in red and non-DIPG is highlighted in 
blue.  
3.3 Discussion 
The feasibility of using primary tumour cultures for identification of novel candidate 
genes (tumour suppressors and/or oncogenes) and as experimental models for in vitro 
testing of therapies has often been debated. Genome-wide copy number, gene and 
miRNA expression analysis of paediatric HGG paired biopsies conducted in this 
study revealed variation between the tumour biopsies and their derived short-term 
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cell cultures. However, a considerable proportion of the genetic changes in the 
biopsies were maintained in their derived short-term cell cultures.  
Paediatric HGG short-term cell cultures retain CNAs in culture 
The comparative analysis of copy number profiles of the one of paired tumour 
samples, IN3182, demonstrated that although there were differences in the copy 
number profiles between cell culture and biopsy, the cell culture retained a 
considerable proportion of CNAs that were present in the tumour biopsy (43%).  
Conversely, for the IN3183 paired sample, only 6% of CNAs detected in the biopsy 
were also present in the culture.  It is evident from the chromosome views of CNAs 
shown in Figures 3.2 A and B that the aCGH profile of IN3183 biopsy DNA sample 
had a characteristic ‗wave‘ pattern of probe distribution. The data analysis of this 
sample resulted in over-segmentation indicating that many of these CNAs were not 
true copy number events. ‗Waviness‘ in aCGH data is a common technical artefact 
that results mainly from the GC content of the probes and the samples or from other 
factors that are not very clear (Marioni et al., 2007; Sykulski et al., 2013). Although 
there are few algorithms that can correct the GC waves (van de Wiel et al., 2009; Leo 
et al., 2012), there is often the risk of large CNAs in samples to be smoothed away. 
As this analysis involved comparison of 2 samples, smoothing was not done so that 
the experimental bias can be kept minimal.  The technical solutions to eliminate such 
wave patterns are not clear. Therefore, the experiment was repeated and a second 
profile was generated for this biopsy sample. Although the new aCGH profile had a 
DLRS value of 0.14 and fitted into the excellent QC range, the issue of waviness was 
not resolved (Appendix II). Overall, the large disproportion in the number of CNAs 
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in the IN3183 pair compared to IN3182 pair is likely to be an overrepresentation of 
the actual number of CNAs as segmentation algorithm often generates too many 
segments when such waviness is detected (van de Wiel et al., 2009; Przybytkowski, 
et al., 2011) 
Other possible reasons for the observed variation in both paired samples could be 
attributed to the intratumour heterogeneity of the tumour biopsy sample, from which 
the short-term cell culture was established. Intratumour heterogeneity is a 
characteristic property of glioma and has been demonstrated at both cellular and 
molecular levels (Bonavia et al., 2011). In a study by Sottoriva et al., (2013), 
genome-wide assessment of CNAs in 38 tumour fragments from nine patients 
showed that all tumours exhibited variations in shared and unique copy number 
aberrations. In addition, it was observed that 2/4 fragments from a patient had no 
PDGFRA aberrations while the remaining 2 fragments displayed gain of the same 
region. The heterogeneous property of tumour cells may develop from expansion of 
clonal subpopulations of cells and incorporation of mutations during tumour 
progression (Greaves and Maley, 2012). The copy number profile of a tumour-
derived short-term cell culture may therefore represent only a fraction of the various 
subpopulations present in the tumour tissue. It was also found that in one of the 
paired tumour biopsies (IN3182), there were additional CNAs in the cell culture 
compared to the biopsy such as gain of whole chromosome 7, which may have 
occurred due to artificial culture conditions. A similar finding was reported by 
Sareen and colleagues (2009) who observed chromosome 7 and 19 trisomy in human 
neural progenitor cell cultures. On the other hand, although IN3183 cell culture 
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retained only about 6% of CNAs present in its biopsy and also failed to maintain 
large regions of deletions, it was interesting to observe that there was minimal 
acquisition of additional CNAs in this culture (2 CNAs).  
As both the biopsy DNA samples analysed in this study were extracted using the 
same protocol, it is less likely that the artefact may have got introduced during the 
DNA extraction step. Therefore, it can be speculated that source of this artefact may 
be the actual tumour tissue as biopsies are often a mixture of non-neoplastic cells, 
blood and lipid substances. A fresh preparation of DNA sample from a different area 
of the biopsy may have resulted in a smoother aCGH profile. However, due to 
concerns of scarcity of tumour samples, the experiment couldn‘t be repeated.  
Paediatric HGG short-term cell cultures retain gene expression changes of tumour 
in vivo 
The gene expression profiles of paediatric HGG paired tumour samples investigated 
here showed large number of differentially expressed genes between the biopsies and 
their derived short-term cell cultures in 2/3 pairs, indicating the possible influence of 
culture conditions on gene expression profiling. The differentially expressed genes 
were involved in cell proliferation, growth and metabolism, indicating the possible 
influence of the availability of oxygen and nutrients in the in vitro environment that 
enables cells to acquire additional gene expression changes under artificial culture 
conditions. Such changes could be attributed to tumour heterogeneity. In the study by 
Sottoriva et al. (2013), 51 tumour fragments from 10 patients were profiled for gene 
expression changes using microarrays and each sample was classified into proneural, 
classical, mesenchymal and neural subtypes according to an 840-gene signature 
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(Verhaak, 2010). It was found that tumour samples taken from the same patient could 
be stratified into at least two GBM subtypes in about 60% (6/10) of the patients. 
However, it was found that a considerable number of expression probes did not vary 
more than 2-fold in the derived cell-cultures in both the pairs compared to their 
biopsies indicating that paediatric HGG short-term cell cultures do retain expression 
changes of the tumour in vivo. A study by Potter et al. (2009) has shown that 
although differential gene expression was induced in short-term cell cultures derived 
from paediatric PA in comparison to their biopsies, a molecular signature of 608 
genes could differentiate PA and adult GBM tumours irrespective of the sample 
source (cell culture or biopsy). As large number of differentially expressed genes did 
not differ more than 2-fold between the cell culture and the biopsy, these cultures can 
be used to evaluate the efficacy of drugs designed to act on specific molecular targets 
and may also indicate better likelihood of these responses to be translated to the 
tumour in vivo. 
MiRNA expression changes in paediatric HGG short-term cell cultures are 
representative of tumour in vivo 
The utility of tumour-derived short-term cell cultures for the investigation of miRNA 
expression changes in paediatric HGG have not been explored yet. The miRNA 
expression profiles of paediatric HGG paired biopsies analysed in this study showed 
large differences between the biopsies and their derived short-term cell cultures. One 
of the reasons for this could be the difference in the intrinsic stability of miRNAs in 
cell populations. Bail et al., (2010) reported that miRNAs possess distinct intrinsic 
stabilities, which determine the level of miRNAs in different cells. They 
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demonstrated that the processing of some miRNAs from primary and preliminary to 
mature stages continued to occur even after termination of transcription. The changes 
in miRNA expression in the tumour cell cultures relative to their biopsies could also 
be due to epigenetic changes like promoter hypermethylation in miRNA genes 
leading to transcriptional silencing. Abnormal methylation of genes under artificial 
culture conditions have been previously reported in various cancer cell lines (Varley 
et al., 2013). The increased downregulation of miRNAs can in turn induce gene 
expression changes further leading to alterations in expression levels of other 
miRNAs. This is supported by the observation that large numbers of differentially 
expressed (>2-fold) miRNAs common to all 3 pairs were downregulated than 
upregulated (36 versus 15). The commonly differentially expressed miRNAs (2-fold 
change) in the cell cultures compared to their biopsies were involved in several 
cancer-related pathways demonstrating their role in providing the cells with 
increased growth potential in culture. However, paediatric HGG short-term cell 
cultures also maintained changes in miRNA-expression that were present in the 
tumour biopsies as illustrated by PCA and hierarchical clustering of the 3 paired 
biopsies. In addition, there was also a considerable number of miRNAs that had less 
than 2-fold differential expression in the cell-culture compared to the biopsy in each 
pairs. 
Paediatric short-term cell cultures retain signature gene mutations of paediatric 
HGG 
 In the current study, the mutation status of 4 vital genes (H3F3A, HIST1H3B, 
BRAFV600E and ACVR1) involved in paediatric HGG tumourigenesis was evaluated 
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in 17 paediatric HGG short-term cell cultures and 3 biopsies. Of the 4 genes, 
mutations were detected in H3F3A and BRAFV600E in 11% (2/18) and 6% (1/18) 
paediatric HGG short-term cell cultures respectively. Recurrent somatic mutations in 
H3F3A encoding histone H3.3 are relatively more frequent in DIPGs than 
supratentorial HGGs (Wu et al., 2012). Although this study was constrained by very 
small sample numbers, the frequency of H3F3A mutation detected in this study was 
also higher in DIPG (33.3%, 1/3) compared to the non-DIPG short-term cell cultures 
(6.6%, 1/15). The overall low frequency of mutations detected in the cohort of 
paediatric HGG short-term cell cultures investigated in this study may be due to the 
artificial culture conditions that select only certain populations of cells in culture. 
However, the mutation burden in paediatric HGG is generally very low (Paugh et al., 
2010). Therefore, extending this investigation in additional paired samples to find 
biopsies with mutations and then determine if they are retained in culture may 
provide better insights into whether paediatric HGG-derived short-term cell cultures 
maintain gene mutations.  
Limitations 
One of the main limitations of this investigation is the small sample number that was 
available. Inclusion of more paired tumour biopsies as well as several segments of 
the same tumour biopsy for comparison studies may provide better insights into the 
influence of tumour heterogeneity in introducing variation in genomic profiles of 
paediatric HGG short-term cell cultures. In addition, studies comparing tumour-
derived short-term cell cultures over a number of passages may provide information 
to assess the effect of culture conditions on such variation over time.  
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3.3 Conclusions 
Distinct genetic and epigenetic changes have been identified to drive paediatric HGG 
tumourigenesis depending on the tumour location, indicating the selective pressures 
of specific tumour environments (Jones and Baker, 2014). Hence, cell culture models 
that can closely resemble the actual tumour conditions should be essentially 
developed in order to identify and target the key tumour-associated genomic 
aberrations in paediatric HGG. Nevertheless, paediatric HGG short-term cell cultures 
with specific molecular defects may serve as preclinical models for in vitro testing of 
targeted therapeutics. For instance, IN179 short-term cell culture in this study could 
be used as an in vitro model for evaluating the efficacy and mode of action of 
BRAFV600E inhibitor such as PLX4720. Thus, well-characterised tumour-derived 
short-term cell cultures may be used as in vitro models for molecular studies with 
careful evaluation. This is particularly useful to extend the molecular studies on 
paediatric HGG, which remain largely understudied in comparison to other tumours. 
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CHAPTER 4 
Genome-wide investigation of copy number 
changes in paediatric HGG short-term cell 
cultures 
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4.1 Introduction 
Paediatric HGG are highly aggressive and extremely resistant to existing cancer 
therapeutic strategies such as surgery, chemo and radiotherapy. In comparison with 
adult glioma, HGG in children (including anaplastic astrocytoma and GBM) occur at 
much less frequency. However, paediatric HGG exhibit similar histological 
characteristics to those of adult HGG and patients of all ages have extremely poor 
prognosis (Puget et al., 2012). The median survival rate remains 12-15 months for 
patients with paediatric HGG and only 9-12 months for children with DIPG (Jones et 
al, 2012). Patients with DIPG exhibit particularly poor prognosis due to the highly 
infiltrative growth in the most critical part of the brain making surgical resection of 
these tumours virtually impossible (Vanan and Eisenstat, 2015). There is a 
compelling need for novel therapies or manipulation of existing treatment strategies 
to improve their clinical outcome. 
Paediatric HGG is a highly complex and heterogeneous disease characterised by 
unique genetic abnormalities. Genome-wide profiling of DNA copy number changes 
in paediatric HGG using high-resolution microarrays have identified unique genetic 
differences between paediatric and adult HGGs. Some of the most frequent DNA 
copy number changes in adults such as gain of chromosome 7 (74%) and loss of 10q 
(80%) occur in only 12% and 27% of cases, respectively in the paediatric population 
(Paugh et al., 2010; Puget et al.; 2010, Qu et al., 2010; Jones et al., 2012). The copy 
number abnormalities that are more frequent in paediatric HGG compared to adult 
HGG include gain of 1q (20% versus 9% of cases), loss of 16q (18% versus 7% of 
cases) and loss of 4q (15% versus 2% of cases). Such studies have also reported that 
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paediatric HGG exhibit comparatively fewer DNA copy number changes than their 
adult counterparts (Paugh et al., 2010). An unbiased approach involving a 
comprehensive analysis of genetic aberrations in paediatric HGG is therefore critical 
to identify the distinct, non-random genetic changes in these tumours. The 
determination of such genetic changes can provide a better understanding of the 
disease and identify potential prognostic markers and therapeutic targets. One of the 
other major drawbacks for investigations in paediatric HGG is the availability of 
tumour samples. The utility of astrocytoma-derived short-term cell cultures in DNA 
copy number investigations using analogue CGH has been previously reported 
(Potter et al., 2009). The results presented in Chapter 3 have also demonstrated that 
paediatric HGG short-term cell cultures do retain a considerable proportion of 
genetic changes present in the tumour biopsies from which they were derived. The 
aim of this study was to conduct a comprehensive analysis of genome-wide DNA 
copy number changes in paediatric HGG short-term cell cultures using high-
resolution microarrays in order to identify non-random genomic CNAs.  
4.2 Results 
4.2.1 QC evaluation of microarray data from pediatric HGG short-term cell 
cultures 
Genomic DNA was isolated from 17 paediatric HGG short-term cell cultures 
(comprising 14 non-DIPG and 3 DIPG) and the purity and integrity of the isolated 
DNA were verified as described in 2.5.1 and 2.5.3 respectively. Each test sample was 
sex-matched with the reference normal DNA; the test and the reference DNA were 
then differentially labelled with Cy3 (green) and Cy5 (red) fluorescent dyes 
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respectively and co-hybridized onto Agilent Human Genome 244K CGH 
microarrays as described in 2.8.1. The details of the samples used in this study are 
given in Table 1.1. The arrays were scanned using an Agilent SureScan Microarray 
scanner (Agilent Technologies) and the data were extracted from the resulting 
Tagged Image File (TIF) images, followed by dye-normalisation and log2ratio 
calculation using Feature Extraction Software (v9.5, Agilent technologies).  
The QC report of each sample was carefully assessed to determine the level of 
background noise on the array. Evaluation of data quality is important in microarray 
experiments as the presence of background noise may interfere with true copy 
number calls. One of the crucial QC metrics, which is an indicator of noise, is the 
DLRS value. The Agilent QC guidelines suggest a DLRS value<0.3 for good quality 
samples. Data were also analysed using Nexus copy number software (v 8.0, 
Biodiscovery Inc., USA). The robust variance QC value in Nexus, which is a 
measure of probe-probe variance, was obtained for each sample. Nexus suggests QC 
scores of 0.2 as the upper limit for good quality samples. For each sample, both 
DLRS value (obtained using Agilent Feature Extraction software) and the QC value 
(obtained using Nexus copy number software) were thoroughly examined. Based on 
the recommended values for each factor, the samples were segregated into 3 groups. 
The data quality of the samples with DLRS value<0.20 and QC value<0.2 were 
considered ‗Excellent‘; those with DLRS value between 0.20 and 0.30 and QC 
value<0.2 as ‗Good‘; and those with DLRS value >0.30 or QC value>0.2 as ‗Poor‘. 
The DLRS and the QC values for 17 paediatric HGG short-term cell cultures are 
given in Table 4.1.  
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Sample Tumour type DLRS value QC value Quality
IN178 non-DIPG 0.35 0.26 Poor
IN179 non-DIPG 0.28 0.15 Good
IN1163 non-DIPG 0.22 0.11 Good
IN1262 non-DIPG 0.13 0.03 Excellent
IN1419 non-DIPG 0.14 0.04 Excellent
IN1523 non-DIPG 0.17 0.05 Excellent
IN1566 non-DIPG 0.12 0.02 Excellent
IN1930 non-DIPG 0.15 0.04 Excellent
IN3032 non-DIPG 0.14 0.04 Excellent
IN3046 non-DIPG 0.12 0.02 Excellent
IN3180 non-DIPG 0.38 0.29 Poor
IN3182 non-DIPG 0.21 0.09 Good
IN3183 non-DIPG 0.16 0.05 Excellent
IN3205* non-DIPG 0.15 0.05 Excellent
IN2087 DIPG 0.38 0.29 Poor
IN2102 DIPG 0.24 0.13 Good
IN2675 DIPG 0.17 0.06 Excellent
With the exception of 3 paediatric HGG short-term cell cultures (IN178, IN3180 and 
IN2087 (DIPG)), the array data from all other members in the cohort were either 
excellent or good quality and were analysed using significance threshold for 
segmentation set at 1.0E-5.  
Table 4.1 Summary of microarray data quality 
 
 
 
 
 
 
 
 
 
 
 
 
 
DLRS and QC values of microarray data from 17 paediatric HGG short-term cell cultures are shown. 
DLRS-Derivative Log-Ratio Spread; QC-Quality Control; Excellent-DLRS value<0.20 and QC 
value<0.2; Good- DLRS value between 0.20 and 0.30 and QC value<0.2; Poor-DLRS value>0.30 and 
QC value>0.2. *indicates sample analysed with high stringent analysis setting (significant threshold 
for segmentation set at 1.0E-6) despite excellent quality as determined by the recommended DLRS 
and QC values. 
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The stringency of analysis was increased (significance threshold for segmentation set 
at 1.0E-6) for samples with poor quality in order to minimise the detection of false 
positive copy number calls. Despite excellent quality determined by the DLRS and 
QC values, the distribution of probes was not uniform in the array data from IN3205. 
Hence, this sample was treated as a poor quality array and analysed with significance 
threshold for segmentation set at 1.0E-6. The probe distribution of a representative 
sample for each tumour is shown in Figure 4.1. 
 
 
 
 
 
 
 
 
 
Figure 4.1 Evaluation of microarray data quality in paediatric HGG short-term cell cultures. 
This figure shows the chromosome view in Agilent Cytogenomics 3.0.1.1 software of chromosome 1 
in samples with excellent, good and poor data quality. Sample names are given in parenthesis. The 
probes are distributed more uniformly in the excellent and good quality array data compared to the 
poor quality array data. Each dot represents a single probe on the array. The log-ratio of each probe is 
plotted against chromosomal position shown on the ideogram on the left. Copy number gain (+1) and 
copy number loss (-1) shift the log-ratios to the right and left respectively, of the baseline (0).  Red 
indicates copy loss and blue indicates copy gain; Chr- chromosome number. 
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4.2.2 Evaluation of segmentation algorithms to determine CNAs in paediatric 
HGG short-term cell cultures 
The choice of segmentation algorithm is another crucial factor in the determination 
of accurate copy number aberrations. The sample with the highest number of 
aberrations (IN1523) was analysed using ADM-2 (Agilent), Rank segmentation and 
FASST2 segmentation (Nexus), as described in 2.8.1.5, and the resultant genomic 
profiles were compared. In comparison to Rank segmentation algorithm, the 
FASST2 segmentation algorithm resulted in a much higher segmentation. This meant 
that higher number of CNAs was detected when the FASST2 algorithm was applied 
compared to ADM-2 and Rank segmentation algorithms. In addition, the genomic 
profile generated using Rank segmentation showed higher concordance with that 
obtained using ADM-2 algorithm. An example of the copy number calls on 
chromosomes 1, 5 and 10 in IN1523 short-term cell culture using Rank, FASST2 and 
ADM-2 algorithms are shown in Figure 4.2. Data analysis in this study was 
performed using Rank segmentation algorithm. Data were also analysed with ADM-
2 algorithm and representative images of shared CNAs were used for appropriate 
illustrative purposes. 
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Figure 4.2 Illustration of copy number changes in IN1523 detected using Rank, FASST2 and ADM-2 algorithms. Copy number analysis was performed in 
IN1523 using FASST2 (Nexus copy number software), Rank (Nexus Copy number software) and ADM-2 (Agilent Cytogenomics software) algorithms A) There are 
more small interstitial gains seen on the q arm in FASST2 compared to Rank and ADM-2 algorithms. B) The gained region at 5p15.2 is retained by all the 3 algorithms, 
while more number of interstitial losses is detected by FASST2 compared to Rank and ADM-2 algorithms. C) Chromosome 10 shows no copy number changes by 
ADM-2, while higher number of interstitial losses is detected by FASST2 compared to Rank algorithm. In the chromosome view in Nexus copy number software, blue 
and red shaded region to the right and left respectively, of the baseline (0) indicates large region of copy number gain and loss; blue and red lines indicate focal copy 
number gain and loss respectively. In the chromosome view in Agilent Cytogenomics, each dot represents a probe on the array. Blue and red dots to the right and left, 
respectively of the central baseline (0) indicate copy number gain and loss. Large regions of gain are indicated by blue shaded blocks to the right of the baseline (0).
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4.2.3  PCA of paediatric HGG short-term cell cultures  
To examine similarities amongst paediatric HGG short-term cell cultures, PCA was 
performed using aCGH microarray data from 17 paediatric HGG short-term cell 
cultures as described in 2.12.4. The results are illustrated as a 3-D PCA plot in Figure 
4.3. PCA showed that 12/17 paediatric HGG short-term cell cultures (IN178, 
IN1163, IN1262, IN1419, IN1566, IN1930, IN3032, IN3046, IN3183, IN3205, 
IN2102 (DIPG), and IN2675 (DIPG)) clustered together, while the remaining 5 
samples did not cluster with the main group. Of these 5 samples, 2 grouped together 
(IN3180 and IN2087 (DIPG)), whilst the other 3 samples were all independent 
(IN179, IN1523, and IN3182).  
 
 
 
 
 
 
 
 
Figure 4.3 PCA of 17 paediatric HGG short-term cultures. The 3-D PCA plot of 17 paediatric 
HGG short-term cell cultures plotted with the first three principal components, PC1 (19.8%), PC2 
(15.5%) and PC3 (11.7%) is shown. Each dot on the 3-D plot represents a sample; DIPG and non-
DIPG short-term cell cultures are represented by red and blue-coloured dots respectively.  
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4.2.4 DNA copy number profiling in paediatric HGG short-term cell cultures 
DNA copy number profiles were generated for 17 paediatric HGG short-term cell 
cultures using Rank segmentation algorithm in Nexus copy number software (v8.0, 
Biodiscovery Inc., USA) as described in section 2.8.1.5. For this analysis, the CNAs 
on Y-chromosome were as these are often unreliable (Hu et al., 2004). A summary of 
the overall DNA copy number changes in individual paediatric HGG short-term cell 
cultures is shown in Figure 4.4 and a quantitative summary of the CNAs identified in 
the dataset is given in Table 4.2. The majority of the paediatric HGG short-term cell 
cultures (11/17 cases, 64.71%) did not show large regions of copy number 
imbalances involving whole chromosome arms. These comprised IN178, IN1163, 
IN1262, IN1566, IN1930, IN2087, IN2102, IN3032, IN3046, IN3180, and IN3183. 
The number of CNAs per sample in this group ranged from 11-19 (median-16), 
which accounted to less than 1% of genomic changes in each sample. Three 
paediatric HGG short-term cell cultures (17.65%), IN1419, IN2675 and IN3205 
showed large regions of genomic changes involving single chromosomes with the 
number of CNAs per sample in the group ranging from 21-48 (median-27), 
accounting for 3-6% of genomic changes in each sample. The remaining 3 paediatric 
HGG short-term cell cultures (IN179, IN1523 and IN3182) comprising 17.65% of 
the cohort) demonstrated CNAs across large regions on multiple chromosomes, with 
the number of CNAs per sample ranging from 54-85 (median-62), accounting for 17-
59% of genomic changes. 
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Figure 4.4 Genomic profiles of 17 paediatric HGG short-term cell cultures. aCGH profiles of 17 paediatric HGG short-term cell cultures were generated 
using Nexus copy number software v8.0. X-axis shows chromosomes and y-axis shows paediatric HGG short-term cell cultures ranked by the order of genomic 
changes. The paediatric HGG short-term cell culture with the highest proportion of genomic changes is shown at the bottom. The aberrations on all chromosomes 
excluding Y are displayed. Gains are represented in blue and losses are represented in red blocks above and below the threshold line (black) respectively, in each 
sample. 
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Samples
% Genome 
Changed
Total 
CNAs
One copy 
gain 
One copy 
loss 
High copy 
gain 
Homozygous 
copy loss 
IN1262 0.14 14 10 4 0 0
IN1163 0.14 16 8 8 0 0
IN1930 0.21 18 11 7 0 0
IN1566 0.22 18 10 7 0 1
IN2102 0.22 21 9 12 0 0
IN2087 0.24 16 9 6 0 1
IN3180 0.25 19 9 8 0 2
IN3183 0.25 16 10 6 0 0
IN178 0.29 11 3 6 0 2
IN3032 0.32 16 9 6 0 1
IN3046 0.70 18 4 8 0 3
IN2675 3.57 27 17 10 0 0
IN1419 5.05 19 9 7 0 2
IN3205 5.81 48 37 3 0 2
IN3182 17.24 54 19 25 1 5
IN179 26.33 62 33 25 1 3
IN1523 58.42 85 32 44 2 3
Table 4.2 Summary of DNA copy number analysis in paediatric HGG short-term cell cultures 
using Rank segmentation algorithm 
 
 
 
 
 
 
 
 
 
 
 
 
 
DNA copy number analysis was performed in 17 paediatric HGG short-term cell cultures using Rank 
segmentation algorithm in Nexus copy number software with thresholds for copy number gain and 
copy number loss set at 0.2 and -0.23 respectively. High-copy gain and homologous loss were defined 
by log ratio thresholds of 1.14 and -1.1 respectively. The samples are ranked by the order of % 
genome changed. The sample with the highest % of genomic changes is shown at the bottom. 
Subgroup 1 (genomic changes <1%) is highlighted in red, subgroup 2 (genomic changes-3.57-5.81%) 
in blue and subgroup 3 (genomic changes 17.24-58.42%) in green respectively. CNA- copy number 
alteration. 
Overall, a total of 460 segments of CNAs were identified, of which the frequency of 
single copy gains (n=239, 51.96%) was relatively higher than those of single copy 
losses (n=192, 41.74 %). Gains were also more frequent than losses in individual 
cases of paediatric HGG short-term cell cultures. Conversely, the frequency of high 
copy gains (n=4, 0.87%) was much lower in comparison to that of homozygous 
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Chr 1 Chr 2 Chr 3 Chr 4 Chr 5 Chr 6 Chr 7 Chr 8 Chr 9 Chr 10 Chr 11 Chr 12
Chr 13 Chr 14 Chr 15 Chr 16 Chr 17 Chr 18 Chr 19 Chr 20 Chr 21 Chr 22 Chr X Chr  Y
losses (n=25, 5.43%). A cumulative summary of all the genomic changes in all 
samples is given in Figure 4.5. 
 
 
 
 
 
 
 
 
 
Figure 4.5 Summary of copy number aberrations on all chromosomes. DNA copy number 
analysis in 17 paediatric HGG short-term cell cultures using Rank segmentation algorithm in Nexus 
copy number software identified CNAs across all chromosomes, with the lowest number of CNAs on 
chromosomes 5 and 19. This figure shows a compact view of CNAs on all chromosomes. Red and 
blue shaded regions to the left and right of each ideogram respectively, indicates copy number loss 
and gain. Chr- Chromosome number. 
4.2.5 Chromosome arm aberrations  
The most frequent chromosome aberrations involving whole chromosomes were 
gains of chromosomes 7 and 9, which occurred concurrently in 3 cases (17.6%) 
comprising IN179, IN1523, and IN3182. The aCGH profiles of IN179, IN1523 and 
IN3182 paediatric HGG short-term cell cultures are shown in Figure 4.6, Figure 4.7 
and Figure 4.8 respectively. 
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 Figure 4.6 aCGH profile of IN179 paediatric HGG short-term cell culture. The ideogram (A) 
displays copy number gains represented by blue bar/arrow to the right and copy number losses by red 
bar/arrow to the left of each chromosome. High-copy gain is represented by double blue arrows to the 
right and homozygous loss is represented by double red arrows to the left of each chromosome. The 
probe distribution across the entire genome is also shown with chromosomes lined end to end (B). The 
thresholds for copy number gain and loss are indicated by blue and red horizontal lines, respectively 
in the copy number plots. The yellow line along the baseline (0) in the plot represents the moving 
average value. 
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Figure 4.7 aCGH profile of IN1523 paediatric HGG short-term cell culture. The ideogram (A) 
displays copy number gains represented by blue bar/arrow to the right and copy number losses by red 
bar/arrow to the left of each chromosome. High-copy gain is represented by double blue arrows to the 
right and homozygous loss is represented by double red arrows to the left of each chromosome. The 
probe distribution across the entire genome is also shown with chromosomes lined end to end (B). The 
thresholds for copy number gain and loss are indicated by blue and red horizontal lines, respectively 
in the copy number plots. The yellow line along the baseline (0) in the plot represents the moving 
average value. 
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Figure 4.8 aCGH profile of IN3182 paediatric HGG short-term cell culture. The ideogram (A) 
displays copy number gains represented by blue bar/arrow to the right and copy number losses by red 
bar/arrow to the left of each chromosome. High-copy gain is represented by double blue arrows to the 
right and homozygous loss is represented by double red arrows to the left of each chromosome. The 
probe distribution across the entire genome is also shown with chromosomes lined end to end (B). The 
thresholds for copy number gain and loss are indicated by blue and red horizontal lines, respectively 
in the copy number plots. The yellow line along the baseline (0) in the plot represents the moving 
average value. 
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The list of chromosome arm aberrations and their frequencies of occurrence in 17 
paediatric HGG short-term cell cultures is shown in Table 4.3. The most frequent 
chromosome arm aberration was gain of 3q, observed in 3 cases (17.6%) comprising 
IN179, IN1523 and IN2675 (DIPG). This was the only large CNA present in the 
DIPG short-term cell cultures. Gain of chromosome X and chromosome arms 3p and 
20q, and loss of chromosome 16 and chromosome arms 10q, and 22q, were each 
seen in 2 cases (11.8%). Of these, gain of chromosome 3, loss of 10q, and loss of 
chromosome 16 occurred concurrently (IN179 and IN1523). Gain of chromosomes 
1, 6, 11, and 18, and chromosome arms 13q and 21q, and loss of chromosomes 2, 4, 
and 12, and chromosome arm 15q, were each seen in a single case only (5.9%). 
Aneuploidies of chromosomes 5, 8, 10p, 14, 15, 17q, 19 and 20p were not detected in 
any samples. 
 
 
137 
 
1p 1q 2p 2q 3p 3q 4p 4q 5 6p 6q 7p 7q 8 9p 9q 10p 10q 11p 11q 12p 12q 13p 13q 14 15p 15q 16p 16q 17p 17q 18p 18q 19 20p 20q 21p 21q 22p 22q Xp Xq
IN1262
IN1163
IN1930
IN1566
IN2102
IN2087
IN3180
IN3183
IN178
IN3032
IN3046
IN2675
IN1419
IN3205
IN3182
IN179
IN1523
Gain (%) 5.9 5.9 11.8 17.6 5.9 5.9 17.6 17.6 17.6 17.6 5.9 5.9 5.9 5.9 5.9 11.8 5.9 11.8 11.8
Loss (%) 5.9 5.9 5.9 5.9 11.8 5.9 5.9 5.9 11.8 11.8 5.9 5.9 5.9 5.9 11.8 5.9 5.9
Table 4.3 Summary of chromosome arm aberrations in paediatric HGG short-term cell cultures 
 
 
 
 
 
 
 
 
 
 
 
The table shows the aberration status of chromosome arms in 17 paediatric HGG short-term cell cultures. The chromosomes (excluding chromosome Y) are arranged in columns; 
samples are arranged in rows; copy number gain and copy number loss are represented by blue and red boxes respectively. The frequencies of gain and loss of chromosome arms is 
shown at the bottom.  DIPG short-term cell cultures are highlighted in yellow.  
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Chromosome Region No. of samples Samples with gain Genes
3 q26.1 2 (non-DIPG) IN179, IN1523 -
6 q27 1 (non-DIPG) IN1523 LINC00473, LINC00602
7 p14.1 1 (non-DIPG) IN3182 TARP
4.2.6 Focal genomic CNAs in paediatric HGG short-term cell cultures 
4.2.6.1  High copy gain 
The high-copy gains identified in 17 paediatric HGG short-term cell cultures in this 
study are listed in Table 4.4. Three regions of high-copy gain were identified 
comprising 3q26.1, 6q27 and 7p14.1. The high copy-gain at 3q26.1 occurred in 2 
paediatric HGG short-term cell cultures (IN179 and IN1523), but no genes have been 
mapped to this location. The high copy gain at 6q27 encompassing 2 long intergenic 
non-protein coding RNA genes (LINC00473 and LINC00602) occurred in a single 
case (IN1523). The high-copy gain at 7p14.1 encompassing TARP (TCR gamma 
alternate reading frame protein) was also found in a single case (IN3182). Notably, 
the paediatric HGG short-term cell cultures with high-copy gains were all non-DIPG.  
Table 4.4 High copy gains in paediatric HGG short-term cell cultures 
 
 
 
This table shows the regions of high-copy gains (determined by log2ratio threshold of 1.1) identified 
in paediatric HGG short-term cell cultures using Rank segmentation algorithm in Nexus copy number 
software. The CNAs are ranked by the order of chromosomal location.  
4.2.6.2  Homozygous copy loss 
The homozygous copy losses identified in 17 paediatric HGG short-term cell cultures 
are listed in Table 4.5. These CNAs were detected across chromosomes 1, 2, 3, 4, 5, 
6, 8, 9, 11 and 22.  
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Chromosome Region
No of 
samples 
Samples with loss Genes
1 q21.1 1 IN3182
NBPF25P,LOC388692,
FAM231D,FCGR1C
2 p14 1 IN1523
LOC400958, SLC1A4, CEP68, 
RAB1A, ACTR2, SPRED2
3 q26.1 1 IN3180 No genes in region
4 q13.2 5
IN1419, IN1523, IN2087,
IN3032, IN3205
TMPRSS11E, UGT2B17, UGT2B15
5 p15.33 1 IN3182 No genes in region
6 p25.3 - p25.2 1 IN3182 GMDS,GMDS-AS1
6 q22.2 1 IN3182 ROS1, DCBLD1, GOPC
6 q22.31 1 IN3182 MIR3144
8 p11.23 - p11.22 6
IN178, IN179, IN1523, 
IN3046, IN3180, IN3205
ADAM5, ADAM3A
9 p21.3 1 IN179 CDKN2A, CDKN2B
11 q11 3 IN178, IN179, IN3046
OR4C11,OR4P4,OR4S2,
OR4C6
22 q11.23 3 IN1419, IN1566, IN3046
GSTTP1,LOC391322,
GSTT1-AS1,GSTT1, GSTTP2
Table 4.5 Regions of homozygous loss in paediatric HGG short-term cultures 
 
 
 
 
 
 
 
 
 
 
 
 
The table shows the regions of homozygous loss identified in paediatric HGG short-term cell cultures. 
The CNAs are ranked by the order of chromosomal location. DIPG short-term cell culture is 
highlighted in blue.  
Of these, the most frequent loss involved 8p11.23-p11.22 encompassing ADAM5 and 
ADAM3A and occurred in 6 cases (IN178, IN179, IN1523, IN3046, IN3180 and 
IN3205). Homozygous loss of 4q13.2 encompassing TMPRSS1E, UGT2B17 and 
UGT2B15 occurred in 5 cases (IN1419, IN1523, IN2087 (DIPG), IN3032 and 
IN3205). This was the only homozygous loss detected in a DIPG short-term cell 
culture.  
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A B
BRAF (wild type) BRAFV600E (mutant)
A G     T     G      A A A G   A    G     A A
C
One short-term cell culture (IN179) had homozygous loss of 9p21.3, encompassing 
CDKN2A/CDKN2B (Figure 4.9). Loss of CDKN2A/CDKN2B associated with 
oncogenic mutation in BRAF (BRAFV600E) has been previously identified as a 
distinct characteristic of a subset of paediatric HGG (Schiffman et al., 2012) and the 
BRAFV600E mutation was also present in IN179 (as previously shown in Figure 
3.15). 
 
 
 
 
 
 
 
 
Figure 4.9 Concurrent loss of 9p21.3 and BRAFV600E mutation in IN179 paediatric HGG 
short-term cell culture. A) Chromosome view displaying loss of 9p21.3 in IN179 paediatric HGG 
short-term cell culture. Each dot represents a single probe on the array. The log2ratios of the probes 
are plotted against the chromosomal location. Copy number gain and copy number loss shifts the 
log2ratios to the right and left respectively, of the baseline (0). Gain is represented by blue and Loss is 
represented by red respectively B) Probe details of region of loss at 9p21.3 showing 13 probes in the 
region of loss with mean -2.9396 and median -3.1369. The chromosome position is shown on the x-
axis and log2ratios are shown on the y-axis. The horizontal dotted line represents the baseline (0). C) 
BRAFV600E mutation causing amino acid substitution from valine to glutamic acid at position 600. 
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The other frequent regions of homozygous loss that have not been previously 
reported in paediatric HGG occurred at 11q11 (IN178, IN179 and IN3046) and 
22q11.23 (IN1419, IN1566 and IN3046), each in 3 cases. Chromosome 11q11 
contains 4 members of the olfactory family of genes such as OR4C11, OR4P4, 
OR4S2 and OR4C6. Chromosome 22q11.23 encompasses LOC391322, GSTT1-AS1, 
GSTT1, GSTTP1 and GSTTP2. There were 3 novel regions of homozygous loss on 
chromosome 6 (6p25.3-25.2, 6q22.2 and 6q22.31) all occurring in the same 
paediatric HGG short-term cell culture (IN3182). The miRNA gene, MIR3144 maps 
to 6q22.31. The regions of homozygous loss at 1q21.1 (LOC388692) and 2p14 
(LOC400958) occurred in single case only and involved lnc RNA genes.  
4.2.6.3  Frequent and statistically significant CNAs 
Recurrent and statistically significant CNAs in paediatric HGG short-term cell 
cultures were independently identified by 2 frequency significance tests; Significance 
Testing for Aberrant Copy number (STAC) (Diskin et al., 2006) and Genomic 
Identification of Significant Targets in Cancer (GISTIC) (Beroukhim et al., 2007). 
STAC identifies copy number events that are stacked on top of each other such that it 
would not occur randomly. A p-value is generated which indicates the level of 
significance of an event that occurs at a particular frequency, as defined by the 
aggregate % cut-off option. However, STAC may not identify statistically significant 
regions present in a lower frequency of cases. GISTIC identifies statistically high 
frequency of CNAs over background aberrations. A G-score, which indicates both 
the frequency of occurrence of a copy number event and the level of copy number 
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change in each of the sample in the data set, was generated. FDR multiple testing 
was applied to generate a q-bound value indicating the significance of the event.  
The list of CNAs identified as significant (p<0.05) by STAC in a minimum of 4/17 
(23.5%) paediatric HGG short-term cell cultures is given in Table 4.6. A total of 23 
significantly altered regions were identified, which involved gains on chromosomes 
2, 7, 10, 11, 14, 15 and 22, and losses on chromosomes 1, 4, 6, 11, 14, 15 and 17. 
The frequencies of these CNAs were compared between non-DIPG and DIPG short-
term cell cultures and are given in Table 4.7. 
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Chr
Region Length 
(bp)
Cytoband 
Location
Event Frequency (%) P-Value
% of CNV 
Overlap
Gene count Genes of interest
14 386482 q11.2 CN Gain 94.12 0 100 0 No genes in region
7 62512 p14.1 CN Gain 76.47 0 100 1 TARP
8 142664 p11.23 - p11.22 CN Loss 58.82 0 100 2 ADAM5, ADAM3A
11 69664 q11 CN Gain 58.82 0 100 4 OR4C11,OR4P4,OR4S2,OR4C6
15 629510 q11.2 CN Loss 41.18 0 100 16
NBEAP1, LOC646214,CXADRP2, MIR3118-2, MIR3118-3, MIR3118-
4, POTEB2,  POTEB, POTEB3, NFIP2, MIR5701-1, MIR5701-2, 
MIR5701-3, LINC01193, LOC727924, LOC101927079
1 24645 q31.3 CN Loss 35.29 0 100 1 CFHR1
6 103506 p21.32 CN Loss 35.29 0 100 3 HLA-DRB5, HLA-DRB6, HLA-DRB1
14 222794 q11.2 CN Loss 35.29 0 100 6 OR4Q3, OR4M1,OR4N2,OR4K2,OR4K5,OR4K1
17 211312 q21.31 CN Loss 35.29 0 100 4 KANSL1, KANSL1-AS1, LRRC37A, ARL17B
1 50830 q44 CN Loss 29.41 0 100 3 OR2T10, OR2T11, OR2T35
2 163679 q32.2 CN Gain 29.41 0 28 2 COL5A2, MIR3129
4 422840 q13.2 CN Loss 29.41 0 100 3 TMPRSS11E, UGT2B17, UGT2B15
10 123161 q11.22 CN Gain 29.41 0 100 4 GPRIN2,NPY4R, CH17-360D5.1, LINC00842
11 47731 q11 CN Loss 29.41 0 100 3 OR4P4, OR4S2, OR4C6
14 199613 q11.2 CN Gain 29.41 0 100 5 OR4Q3, OR4M1, OR4N2, OR4K2, OR4K5 
14 176973 q32.33 CN Loss 29.41 0 100 5 MIR8071-1, MIR8071-2, ELK2AP
15 621648 q11.2 CN Gain 29.41 0 100 17
HERC2P3, GOLGA6L6, GOLGA8CP, LOC646214,NBEAP1, 
CXADRP2, MIR3118-2, MIR3118-3, MIR3118-4, POTEB2,  POTEB, 
POTEB3, NFIP2, MIR5701-1, MIR5701-2, MIR5701-3, LINC01193
1 457712 q21.1 CN Loss 23.53 0 100 4 NBPF25P,LOC388692,FAM231D,FCGR1C
8 142024 p11.23 CN Gain 23.53 0 100 2 ADAM5
10 183002 q23.33 CN Gain 23.53 0 22 1 MYOF
14 21696 q32.33 CN Gain 23.53 0.009 100 0 No genes in region
15 516123 q11.2 CN Gain 23.53 0 100 12
LOC727924,LOC101927079,OR4M2,OR4N4,OR4N3P,
MIR1268A,REREP3,MIR4509-1, MIR4509-2, MIR4509-3, 
GOLGA8DP, GOLGA6L1
22 53584 q11.23 CN Gain 23.53 0 100 5 GSTTP1,LOC391322,GSTT1-AS1,GSTT1, GSTTP2
Table 4.6 Frequent and statistically significant CNAs identified by STAC 
 
 
 
 
 
 
 
 
 
 
 
 
CNAs identified as significant (p<0.05) by STAC algorithm in an aggregate of 23% (4/17 cases) of paediatric HGG short-term cell cultures are shown. The CNAs are 
ranked by the order of frequency of occurrence. The CNA with the least frequency of occurrence is at the bottom. Chr-Chromosome; bp-base pair; CN-copy number; 
CNV-copy number variation. 
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Chromosome Cytoband Length (bp)
IN
1
7
8
IN
1
7
9
IN
1
1
6
3
IN
1
2
6
2
IN
1
4
1
9
IN
1
5
2
3
IN
1
5
6
6
IN
1
9
3
0
IN
3
0
3
2
IN
3
0
4
6
IN
3
1
8
0
IN
3
1
8
2
IN
3
1
8
3
IN
3
2
0
5
IN
2
0
8
7
IN
2
1
0
2
IN
2
6
7
5 Overall 
frequency 
(%)
non-DIPG 
(%)
DIPG
(%)
14 q11.2 386482 94.12 13 (92.9) 3 (100)
7 p14.1 62512 76.47 12(85.7) 1 (33.3)
8 p11.23 - p11.22 142664 58.82 9 (64.3) 1 (33.3)
11 q11 69664 58.82 8 (57.1) 2 (66.6)
15 q11.2 629510 41.18 6 (42.9) 1 (33.3)
1 q31.3 24645 35.29 5 (35.7) 1 (33.3)
6 p21.32 103506 35.29 6 (42.9) 0
14 q11.2 222794 35.29 6 (42.9) 0
17 q21.31 211312 35.29 5 (35.7) 1 (33.3)
1 q44 50830 29.41 5 (35.7) 0
2 q32.2 163679 29.41 4 (28.6) 1 (33.3)
4 q13.2 422840 29.41 4 (28.6) 1 (33.3)
10 q11.22 123161 29.41 4 (28.6) 1 (33.3)
11 q11 47731 29.41 5 (35.7) 0
14 q11.2 199613 29.41 3 (21.4) 2 (66.6)
14 q32.33 176973 29.41 3 (21.4) 2 (66.6)
15 q11.2 621648 29.41 4 (28.6) 1 (33.3)
1 q21.1 457712 23.53 4 (28.6) 0
8 p11.23 142024 23.53 3 (21.4) 1 (33.3)
10 q23.33 183002 23.53 2 (14.3) 2 (66.6)
14 q32.33 21696 23.53 2 (14.3) 2 (66.6)
15 q11.2 516123 23.53 4 (28.6) 0
22 q11.23 53584 23.53 2 (14.3) 2 (66.6)
Table 4.7 Frequencies of significant CNAs identified by STAC algorithm in DIPG and non-DIPG short-term cell cultures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frequent and significant CNAs (aggregate of 23.53% and p<0.05) in 17 paediatric HGG short-term cell cultures were identified by STAC algorithm in Nexus copy number 
software. The frequencies of occurrence of 23 significant CNAs in 14 non-DIPG and 3 DIPG short-term cell cultures are shown. DIPG are highlighted in yellow; red boxes 
indicate copy number loss and blue boxes indicate copy number gain; CNAs absent in DIPG short-term cell cultures are highlighted in pink; CNAs that are significantly 
different (differential threshold of 25% and p<0.05) from non-DIPG are highlighted in green; bp-base pair. 
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Chr 14A B
Significantly altered regions of copy number gain 
The most frequent CNA in the cohort was gain at 14q11.2 (94.12%, 16/17 cases) 
covering 386,482 bp. With the exception of IN1523, gain of this region was observed 
in all paediatric HGG short-term cell cultures. However, there were no genes located 
in this region. Gain of 14q11.2 in a representative paediatric HGG short-term cell 
culture (IN1566) is shown in Figure 4.10. 
 
 
 
 
 
 
 
 
 
Figure 4.10 Gain of 14q11.2 in IN1566 paediatric HGG short-term cell culture. A) Chromosome 
view displaying the gained region at 14q11.2 in IN1566 paediatric HGG short-term cell culture. Each 
dot represents a single probe on the array. The log2ratios of the probes are plotted against the 
chromosomal location. Copy number gain and copy number loss shifts the log2ratios to the right and 
left respectively, of the baseline (0). Gain is represented by blue and Loss is represented by red 
respectively. B) Probe details of the gained region at 14q11.2 showing 66 probes in the gained region 
with mean 0.3708 and median 0.3797. The chromosome position is shown on the x-axis and 
log2ratios are shown on the y-axis. The horizontal dotted line represents the baseline (0).  
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Chr 7A B
Gain at 7p14.1 (62512 bp) encompassing TARP occurred in 76.47% (13/17) of cases 
comprising 12 non-DIPG (IN179, IN1163, IN1262, IN1419, IN1523, IN1566, 
IN1930, IN3032, IN3046, IN3182, IN3183 and IN3205) and 1 DIPG (IN2675) short-
term cell cultures. Gain of 7p14.1 in a representative paediatric HGG short-term cell 
culture (IN3046) is shown in Figure 4.11. 
 
 
 
 
 
 
 
 
 
Figure 4.11 Gain of 7p14.1 in IN3046 paediatric HGG short-term cell culture. A) Chromosome 
view displaying the gained region at 7p14.1 in IN3046 paediatric HGG short-term cell culture. Each 
dot represents a single probe on the array. The log2ratios of the probes are plotted against the 
chromosomal location. Copy number gain and copy number loss shifts the log2ratios to the right and 
left respectively, of the baseline (0). Gain is represented by blue and loss is represented by red 
respectively B) Probe details of the gained region at 7p14.1 showing 16 probes in the gained region 
with mean 1.1670 and median 1.2135.  Chromosome position is shown on the x-axis and log2ratios 
are shown on the y-axis. The horizontal dotted line represents the baseline (0).  
 
Gain of 11q11 (69,664 bp) occurred in 58.82% (10/17) cases, which included 8 non-
DIPG (IN1262, IN1419, IN1523, IN1930, IN3032, IN3182, IN3183 and IN3205) 
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and 2 DIPG (IN2087 and IN2675) short-term cell cultures. This region contains 4 
genes, namely OR4C11, OR4P4, OR4S2 and OR4C6, all members of the olfactory 
family genes. 
Four regions of gain, 2q32.2 (163679 bp), 10q11.22 (123161 bp), 14q11.2 (199613 
bp), and 15q11.2 (621648 bp) were present in 29.41% (5/17) of paediatric HGG 
short-term cell cultures. Gain of 2q32.2, encompassing COL5A2 and a miRNA gene, 
MIR3129 was present in 4 non-DIPG (IN179, IN1930, IN3180 and IN3205) and 1 
DIPG (IN2087) short-term cell cultures. COL5A2 encodes an alpha chain for one of 
the low abundance fibrillar collagens and is associated with axon guidance, 
extracellular matrix organization and ossification and may be involved in binding 
SMAD proteins. Gain of 10q11.22 was present in 4 non-DIPG (IN1419, IN1930, 
IN3180 and IN3182) and 1 DIPG (IN2102) short-term cell cultures. This region 
contains GPRIN2, NPY4RCH17-360D5.1 and LINC00842. Gain of 14q11.2 (199613 
bp) occurred in 3 non-DIPG (IN1262, IN3032 and IN3182) and 2 DIPG (IN2102 and 
IN2675) short-term cell cultures and encompasses 5 genes, namely OR4Q3, OR4M1, 
OR4N2, OR4K2, and OR4K5. Gain of 15q11.2 occurred in 4 non-DIPG (IN1566, 
IN1930, IN3183 and IN3205) and 1 DIPG (IN2675) short-term cell cultures, and 
contains 17 genes comprising HERC2P3, GOLGA6L6, GOLGA8CP, LOC646214, 
NBEAP1, CXADRP2, POTEB2, POTEB, POTEB3, NFIP2,LINC01193 and 2 clusters 
of miRNA genes including MIR3118-2, MIR3118-3, MIR3118-4, MIR5701-1, 
MIR5701-2 and MIR5701-3.The less frequent gains at 10q23.33 (142024 bp), 
14q32.33 (21696 bp), 15q11.2 (516123 bp) and 22q11.23 (53584 bp) were present in 
23% (4/17 cases) of paediatric HGG short-term cell cultures.  
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Chr 8
A B
Significantly altered regions of copy number loss 
The most frequent and statistically significant copy number loss occurred at 8p11.23-
p11.22 encompassing ADAM5 and ADAM3A (minimal region of loss covered 
ADAM3A). The chromosome view illustrating loss of ADAM3A in a representative 
paediatric HGG short-term cell culture (IN1523) is shown in Figure 4.12.  
 
 
 
 
 
 
 
 
Figure 4.12 Loss of 8p11.23-p11.22 in IN1523 paediatric HGG short-term cell culture. A) 
Chromosome view displaying loss of 8p11.23-p11.22 in IN1523 paediatric HGG short-term cell 
culture. Each dot represents a single probe on the array. The log2ratios of the probes are plotted 
against the chromosomal location. Copy number gain and copy number loss shifts the log2ratios to the 
right and left respectively, of the baseline (0). Gain is represented by blue and loss is represented by 
red. B) Probe details of the gained region at 7p14.1 showing 16 probes in the gained region with mean 
1.1670 and median 1.2135.  Chromosome position is shown on the x-axis and log2ratios are shown on 
the y-axis. The horizontal dotted line represents the baseline (0). 
Loss of this region covering 142, 664 bp, occurred in 58.82% (8/17) of samples, 
comprising 7 non-DIPG (IN179, IN1163, IN1262, IN1523, IN3046, IN3180, 
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IN3205) and 1 DIPG (IN2102) short-term cell culture (Table 4.7). Of these, 
homozygous loss of the locus was observed in 6/8 cases consisting of IN178, IN179, 
IN1523, IN3046, IN3180 and IN3205. This was also a region of gain in 4/17 cases, 
comprising IN1419, IN2675, IN3182 and IN3183.  
The heat map showing loss of 8p11.23-p11.22 in paediatric HGG short-term cell 
cultures is shown in Figure 4.13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 Heat map of CNA involving ADAM3A at 8p11.23-p11.22 in paediatric HGG short-
term cell cultures. The heat map shows the minimal region of loss at 8p11.23-p11.22 encompassing 
ADAM3A in 10/17 cases, no change in copy number in 3/17 cases and copy number gain in 4/17 cases 
(complete-3, partial-1). X-axis shows chromosomal location; y-axis shows the overall frequency of 
CNA in 17 paediatric HGG short-term cell cultures; red thin line on the heatmap represents regions of 
loss, red thick line represents regions of homozygous loss, and blue thin line represents regions of 
gain.  
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The next most frequent region of loss was at 15q11.2 (629,510 bp) and occurred in 
41.18% (7/17) paediatric HGG short-term cell cultures comprising 6 non-DIPG 
(IN178, IN179, IN1523, IN3046, IN3180 and IN3182) and 1 DIPG (IN2102) 
samples. There were 16 genes in this region, which included NBEAP1, LOC646214, 
CXADRP2, MIR3118-2, MIR3118-3, MIR3118-4, POTEB2, POTEB, POTEB3, 
NFIP2, MIR5701-1, MIR5701-2, MIR5701-3, LINC01193, LOC727924, and 
LOC101927079. 
Loss of 1q31.3 (24645 bp), 6p21.32 (103506), 14q11.2 (222794 bp), and 17q21.31 
(211312 bp) occurred in 35.29% (6/17) of paediatric HGG short-term cell cultures. 
The minimal region of loss at 1q31.3 was present in 5 non-DIPG (IN179, IN1163, 
IN1262, IN1419, IN3046) and 1 DIPG (IN2675) short-term cell cultures and 
encompassed a single gene CFHR1. Loss of 6p21.32 was exclusively present in non-
DIPG short-term cell cultures (IN179, IN1566, IN1930, IN3032, IN3182 and 
IN3205) and encompassed the genes, HLA-DRB1, HLA-DRB5, and HLA-DRB6.  
Loss of 14q11.2 was also present exclusively in non-DIPG short-term cell cultures 
(IN178, IN179, IN1163, IN1523, IN1930 and IN3205) and encompassed 6 genes 
namely OR4Q3, OR4M1, OR4N2, OR4K2, OR4K5, and OR4K1. However, this was 
also a region of gain that occurred in 3 non-DIPG (IN1262, IN3032 and IN3182) and 
2 DIPG (IN2102 and IN2675) short-term cell cultures. Loss of 17q21.31 containing 
KANSL1, KANSL1-AS1, LRRC37A, and ARL17B, occurred in 5 non-DIPG (IN1419, 
IN1523, IN1566, IN3046 and IN3182) and 1 DIPG (IN2102) short-term cell 
cultures.  
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Approximately 29.41% (5/17) paediatric HGG short-term cell cultures showed 
significant regions of losses at 1q44 (50830 bp), 4q13.2 (422840 bp), 11q11 (47731 
bp) and 14q32.33 (176973 bp). Loss of 1q44 covering the genes OR2T10, OR2T11, 
and OR2T35 was found in non-DIPG short-term cell cultures (IN1163, IN1930, 
IN3032, IN3205 and IN3183) only. Loss of 4q13.2 was found in 4 non-DIPG 
(IN1419, IN1523, IN3032 and IN3205) and 1 DIPG (IN2087) short-term cell 
cultures. The genes of interest in this region included TMPRSS11E, UGT2B17, and 
UGT2B15. Loss of 11q11 involving OR4P4, OR4S2, and OR4C6 occurred in non-
DIPG short-term cell cultures (IN178, IN179, IN1163, IN1566 and IN3046) only. 
Loss of 14q32.33, covering MIR8071-1, MIR8071-2, and ELK2AP was present in 3 
non-DIPG (IN179, IN1163 and IN3180) and 2 DIPG (IN2087 and IN2102) short-
term cell cultures.     
Overall, the majority of the CNAs (17/23) that occurred in the non-DIPG short-term 
cell cultures were also present in at least 1 DIPG short-term cell culture. The CNAs 
identified as significant in the non-DIPG short-term cell cultures, but were not 
present in any DIPG short-term cell cultures involved gain of 15q11.2 and losses at 
1q44, 1q21.1, 6p21.32, 11q11 and 14q11.2. There were 3 significantly altered 
regions involving gains at 10q23.33, 14q32.33 and 22q11.23, which occurred at a 
relatively higher frequency in DIPGs (66.6%) compared to the non-DIPGs (14.3%).          
To maximise the identification of significantly altered regions that may be present in 
a smaller number of samples, significance testing was also performed using GISTIC 
algorithm in Nexus copy number software (v8.0, Biodiscovery Inc., USA). The list 
of highly statistically significant CNAs identified by GISTIC with a q-bound value 
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<0.25 (Beroukhim et al., 2007) and G-score cut-off value of 1.0 are listed in Table 
4.8.  
Twenty four CNAs were identified as statistically significant by GISTIC significance 
testing algorithm, including gains of Xp11.4 and Xq25. Of the remaining 22 CNAs, 
13 were also identified by STAC. The CNA with the highest G-score and the lowest 
q-value was loss of 8p11.23-p11.22, which was also the most frequent and 
significant CNA in loss identified by STAC. Furthermore, the most significant gains 
such as 14q11.2 and 7p14.1 were also the most frequent and significant gains 
identified by STAC. The additional CNAs identified as significant by GISTIC were 
gains at 6p12.1, 3q24-q26.1, 7q34, 9p23, 9q34.11 and 16p11.2, and losses at 3q26.1, 
5p15.33 and 22q11.23. Of note, these included copy number events on chromosomes 
that were shown to be unaltered by STAC analysis such as those involving 
chromosomes 3, 9 and 16. Among the identified CNAs, gains at 3q24-q26.1 and 
16p11.2, and loss at 3q26.1 do not have genes mapping to these locations. The gain 
at 6p12.1 contains DST, which is associated with cell adhesion, cell cycle arrest, cell 
motility, cytoskeleton organization and extracellular matrix organization. The gains 
at 9p23 and 9q34.11 predominantly contain non-coding RNA genes.  
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Chr Cytoband Event Q-Bound G-Score % of CNV 
Overlap
Genes
1 q21.1 CN Loss 0.06 3.996 100 NBPF25P,LOC388692,FAM231D,FCGR1C
2 q32.2 CN Gain 0.21 2.589 28 COL5A2, MIR3129
3 * 3q26.1 CN Loss 0.06 4.497 100 No genes in region
3 * 3q24-q26.1 CN Gain 0.21 3.319 100 No genes in region
4 q13.2 CN Loss 0.00 12.491 100 TMPRSS11E, UGT2B17, UGT2B15
5 * 5p15.33 CN Loss 0.15 3.523 100 No genes in region
6 * p12.1 CN Gain 0.21 1.685 52 DST
7 p14.1 CN Gain 0.00 6.642 100 TARP
7 * q34 CN Gain 0.21 3.665 100 MTRNR2L6,  PRSS1
8 p11.23 -
p11.22
CN Loss 0.00 16.960 100 ADAM5, ADAM3A
8 p11.23 CN Gain 0.21 2.001 100 ADAM3A
9 * p23 CN Gain 0.21 2.421 42 TYRP1, LURAP1L-AS1, LURAP1L
9 * q34.11 CN Gain 0.21 2.417 100 SLC25A25-AS1,PTGES2, PTGES2-AS1, LCN2, 
C9orf16, CIZ1, DNM1, MIR199B, MIR3154, 
GOLGA2
10 q11.22 CN Gain 0.21 2.332 100 GPRIN2,NPY4R, CH17-360D5.1, LINC00842
11 q11 CN Loss 0.00 8.546 100 OR4P4, OR4S2, OR4C6
11 q11 CN Gain 0.21 4.392 100 OR4C11,OR4P4,OR4S2,OR4C6
14 q11.2 CN Gain 0.00 7.269 100 No genes in region
14 q32.33 CN Gain 0.21 2.242 100 MIR8071-1, MIR8071-2, ELK2AP
15 q11.2 CN Gain 0.21 1.976 100 HERC2P3, GOLGA6L6, GOLGA8CP, 
LOC646214,NBEAP1, CXADRP2, MIR3118-2, 
MIR3118-3, MIR3118-4, POTEB2,  POTEB, 
POTEB3, NFIP2, MIR5701-1, MIR5701-2, MIR5701-
3, LINC01193
16 * p11.2 CN Gain 0.21 1.577 100 No genes in region
22 * q11.23 CN Loss 0.03 5.070 100 GSTTP1,LOC391322,GSTT1-AS1,GSTT1, GSTTP2
22 q11.23 CN Gain 0.21 2.433 100 GSTTP1,LOC391322,GSTT1-AS1,GSTT1, GSTTP2
Table 4.8 CNAs identified as significant by GISTIC algorithm in paediatric HGG short-term 
cell cultures. 
 
 
 
 
 
 
 
 
 
 
 
 
The table shows the CNAs identified as significant by GISTIC (q-bound value <0.05 and G-score cut-
off value 1.0.) in 17 paediatric HGG short-term cell cultures. * indicates CNAs that were not 
identified by STAC. Chr-Chromosome; CNV-copy number variation, CN-copy number. 
4.2.7 Identification of association between CNAs  
The 2 most frequent and significant CNAs identified in this study (gain of 7p14.1 
and loss of 8p11.23-p11.22) were investigated to examine the association of their 
occurrence with other significant CNAs. In both the cases, the region that was 
completely covered by the aberration was included in the analysis (the region 
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involving TARP at 7p14.1 and the region involving ADAM3A at 8p11.23-p11.22). In 
each case, the Fisher‘s exact test was performed between two sample groups 
(samples with the copy number event versus samples without the copy number 
event) using the concordance tool in Nexus copy number software (v8.0, 
Biodiscovery Inc., USA). The CNAs with significant differences in occurrence 
(p<0.05) between the two sample groups at a differential threshold of 25% were 
identified (Table 4.9). The significant copy number events that co-occurred with loss 
of 8p11.23-p11.22 included loss at 14q11.1-q11.2 (p=0.044) covering 690,253 bp 
and 2 regions of loss at 15q11.2 covering 56,099 bp (p=0.044) and 353,868 bp 
(p=0.044) respectively (Table 4.9 and Figure 4.14). In all cases, the CNAs occurred 
at a frequency of 50% in samples with loss of 8p11.23-p11.22 versus 0% in samples 
without loss of the region. The region 14q11.1-q11.2 encompasses pseudogenes such 
as DUXAP10, BMS1P17, BMS1P18 and BMS1P22. Of these, DUXAP10 (double 
homeobox A pseudogene 10) is a homeobox gene that encodes DNA-binding 
proteins and may have potential involvement in early embryonic development. In 
addition, the region also covers POTEG, POTEM, OR11H2, non-coding RNA genes 
such as POTEH-AS1, LINC01296 and 2 uncharacterised genes such as 
LOC101929572 and LOC100508046. Of the two regions located in 15q11.2, no 
genes map to the first region. The genes found in the second region included 
LOC727924, LOC101927079, OR4M2, OR4N4, OR4N3P, MIR1268A, and REREP3. 
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Chr Cytoband 
Location
Event Region 
Length 
(bp)
Frequency 
in samples 
with 
ADAM3A 
loss (%)
Frequency 
in samples 
without  
ADAM3A 
loss (%)
Frequency 
difference
Probe-
level p-
value
p-value Genes
14 q11.1 -
q11.2
CN Loss 690253 50 0 50 0.13 0.04 LOC101929572, 
POTEH-AS1, 
POTEG, 
LINC01296, 
DUXAP10, 
BMS1P17, 
BMS1P18, 
BMS1P22, POTEM, 
LOC100508046, 
OR11H2
15 q11.2 CN Loss 56099 50 0 50 0.05 0.04 No genes in region
15 q11.2 CN Loss 353868 50 0 50 0.00 0.04 LOC727924, 
LOC101927079, 
OR4M2, OR4N4, 
OR4N3P, 
MIR1268A, 
REREP3
Table 4.9 CNAs associated with loss of ADAM3A in paediatric HGG short-term cell cultures.  
 
 
 
 
 
 
 
CNAs that co-occurred in samples with ADAM3A loss in comparison to samples without the loss 
(minimum difference in threshold between the sample groups-25% and p<0.05) were identified. CN- 
copy number; bp- base pair. 
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A B
Q=ADAM3A
A= 4q11-q11.2
B=15q11.2
Loss
50%
0%
0%
50%
0%
50%
(10) Frequency in samples 
with ADAM3A loss
(7) Frequency in samples 
with ADAM3A loss
(10) Frequency in samples 
without ADAM3A loss
(7) Frequency in samples 
without ADAM3A loss
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 CNAs associated with loss of ADAM3A in paediatric HGG short-term cell cultures. A. The circular plot illustrates the association of loss of ADAM3A 
(Q) with loss of 14q11-q11.2 (A) and loss of 15q11.2 (B). Black lines indicate higher frequency of occurrence of the concordant copy number events in samples with 
ADAM3A loss compared to samples without ADAM3A loss. Red rectangular box indicates copy number loss. B. Chromosome view showing the relative frequencies of 
significantly associated alterations in samples with ADAM3A loss compared to samples without loss. X-axis shows the regions on chromosomes; y-axis shows the 
percentage frequencies of the concordant copy number events. The number of samples in each group is given in parenthesis. Loss of 14q11.1-q11.2 was seen in 50% of 
samples with ADAM3A loss. Loss of 15q11.2 (regions 1 and 2) was seen in 50% of samples with ADAM3A loss. 
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Chr Cytoband 
Location
CN
Event
Region 
Length 
(bp)
Frequency in 
samples with 
TARP gain 
(%)
Frequency in 
samples without  
TARP gain
(%)
Frequency 
difference
Probe-
level p-
value
p-value Genes
11 q11 Gain 6731 75 0 75 0.11 0.01
No genes
in region
11 q11 Gain 15073 58.33 0 58.33 0.21 0.04
No genes
in region
Regions combined  
11 q11 Gain 21804 63.48 0 58.33 0.05 0.04
No genes
in region
The significant CNAs that co-occurred with gain of TARP included 2 regions of loss 
at 11q11 covering 6731 bp and 15073 bp respectively. Loss at 11q11 covering 
21,804 bp, after the 2 adjacent regions were combined occurred at a frequency of 
63.48% in samples with gain of TARP versus 0% in samples without gain of TARP 
(Table 4.10 and Figure 4.15), with a frequency difference of 58.33%.   
 
Table 4.10 CNAs associated with gain of TARP in paediatric HGG short-term cell cultures 
 
 
 
 
 
CNAs that co-occurred in samples with gain of TARP in comparison to samples without the gain 
(difference in threshold between the sample groups 25% and p<0.05) were identified.  CN- Copy 
number; bp- base pair. 
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Q=7p14.1 (TARP)
A= 11q11
(5) Frequency in samples 
without TARP gain
Gain
A
B
63.5%
0%
(12) Frequency in samples 
with TARP gain
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 CNAs associated with gain of TARP in paediatric HGG short-term cell 
cultures. A) The circular plot shows the association between gain of TARP (Q) and gain of 11q11 (A) 
in paediatric HGG short-term cell cultures. The black line indicates higher frequency of the 
concordant copy number event in samples with gain of TARP as opposed to samples without gain of 
TARP. Blue box indicates copy number gain. B). Chromosome view showing the relative frequency of 
alteration of the concordant event in samples with gain of TARP versus sample without gain of TARP. 
X-axis shows the region of CNA on the chromosome and y-axis shows the percentage frequency of 
the concordant CNA between the two groups. Blue line indicates the frequency of the event in 
samples with gain of TARP and red line indicates the frequency of the event in samples without gain 
of TARP. The blue line (shown by the arrow) indicates the region of concordant CNA. The number of 
samples with or without gain of TARP is given in parenthesis. Blue colour indicates copy number gain 
and red colour indicates copy number loss. 
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4.2.8 Hierarchical clustering identifies subgroups within paediatric HGG short-
term cell cultures 
To identify subgroups of paediatric HGG short-term cell cultures based on copy 
number aberration profiles, hierarchical clustering analysis was performed on 17 
paediatric HGG short-term cell cultures using complete linkage hierarchical 
clustering algorithm in Nexus copy number software (v8.0, Biodiscovery Inc., USA). 
Euclidean distance metric was used to calculate the distances between clusters. For 
this analysis, the CNAs on sex chromosomes were excluded. Tumour subtype (DIPG 
or non-DIPG) was assigned to individual paediatric HGG short-term cell cultures to 
examine the influence of this factor on clustering. The resultant dendrogram is shown 
in Figure 4.16. The dendrogram revealed that IN1523 had a distinct genomic profile 
and did not cluster with any other paediatric HGG short-term cell culture. It was 
possible to identify 3 main clusters within the remaining members of the cohort. 
Cluster 1 (n=3) included IN1262, IN3046 and IN3180; cluster 2 (n=7) included 
IN178, IN179, IN1163, IN1566, IN2102, IN3032, and IN3205; and cluster 3 (n=6) 
included IN1419, IN1930, IN2087 (DIPG), IN2675 (DIPG), IN3182 and IN3183. 
The tumour subtype did not affect the clustering as DIPG and non-DIPG short-term 
cell cultures did not form separate clusters.  
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non-DIPG
DIPG
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 Hierarchical clustering an alysis. Hierarchical clustering analysis of 17 paediatric HGG 
short-term cell cultures was performed using complete linkage hierarchical clustering algorithm, 
excluding CNAs on the sex chromosomes. The dendrogram of 17 paediatric HGG short-term cell 
cultures branches into 3 major clusters represented by green, blue and pink respectively. IN1523 was 
independent. DIPG and non-DIPG short-term cell cultures are represented by yellow and blue blocks 
respectively. 
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CNAs C1 C 2 C3
7p14.1
14q11.2
8p11.23-p11.22
11q11 
4q13.2
6p21.32
1q31.3
3q26.1
9p21.3
14q11.1-q11.2
1q21.1
1q44
4p16.3
5p15.33
6p25.3-p25.2
6p22.31
22q11.23
10q11.2
15q11.2
Gain Loss No change
Identification of CNAs by clusters 
Both STAC and GISTIC significance testing algorithms were applied independently 
to identify significant CNAs within each cluster. STAC identified CNAs were 
defined by p-value<0.05 and occurring in a minimum of 50% of samples in each 
cluster. GISTIC significant CNAs in each cluster were defined by q-bound values 
<0.25 and G-score cut-off values <1.0. A combined list of CNAs identified by both 
algorithms and their distribution in clusters 1, 2 and 3 are shown in Figure 4.16.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 CNAs identified in clusters 1, 2 and 3. The CNAs identified as significant by STAC 
(aggregate- 50%, p<0.05) and GISTIC (q<0.25, G –score cut-off-1) in clusters 1, 2 and 3. Red 
indicates copy number loss; blue indicates copy number gain. C-Cluster. 
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With the exception of gained regions at 7p14.1 and at 14q11.2, CNAs identified as 
significant showed different patterns in the clusters. Loss of 8p11.23-p11.22 was 
seen in clusters 1 and 2, while gain of this region was found in cluster 3. The region 
involving 11q11 demonstrated copy loss in cluster 2, copy gain in cluster 3 and no 
change in copy number in cluster 1. Clusters 2 and 3 showed 2 distinct CNAs such as 
loss of 4q13.2 and loss of 6p21.32 that were not seen in cluster 1. Loss of 1q31.3 and 
loss of 3q26.1 were identified as significant and distinct in cluster 1, while loss of 
9p21.3 and gain of 14q11.1-q11.2 were identified in cluster 2. The unique CNAs 
identified as significant in cluster 3 included losses involving 1q21.1, 1q44, 4p16.3, 
5p15.33, 6p25.3-p25.2, 6p22.31, and 22q11.23, and gains involving 10q11.2 and 
15q11.2. 
4.2.9 CNAs in glioma-associated genes in paediatric HGG short-term cell 
cultures 
The aberrations of well-known glioma-associated genes were examined in paediatric 
HGG short-term cell cultures (Table 4.12). For this analysis, only genes that were 
completely included in the CNA and identified as significant by both STAC and 
GISTIC were included. Probe median was computed in each case. Copy number 
gains of genes CDK6, EGFR, and MET were found in 17.65% of paediatric HGG 
short-term cell cultures including IN178, IN1523 and IN3182. Gain of PIK3CA was 
also seen in 17.65% of cases, which included 2 non-DIPG (IN179, IN1523) and 1 
DIPG (IN2675) short-term cell cultures. Gain in other glioma- associated oncogenes 
such as FGFR1, MYC, MYCN, and PDGFRA were absent in the cohort. Loss of 
CDKN2A was present in 1 case (IN179) as previously shown in Figure 4.9. Losses 
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Genes
CN Gain 
(%)
CN Loss 
(%)
Samples with CN event
Chromosome 
location
CDK6 17.65 0 IN179 , IN1523, IN3182 7q21.2 
CDKN2A 0 0.0588 IN179 9p21.3 
EGFR 17.65 0 IN179 , IN1523, IN3182 7p11.2
FGFR1 0 0 - 8p12 
MET 17.65 0 IN179 , IN1523, IN3182 7q31.2
MYC 0 0 - 8q24.21
MYCN 0 0 - 2p24.3
PDGFRA 0 0 - 4q12
PIK3CA 17.65 0 IN179, IN1523, IN2675 3q26.32
PTEN 0 0 - 10q23.31
TP53 0 0 - 17p13.1
involving PTEN and TP53 were absent in the paediatric HGG short-term cell 
cultures analysed here. 
Table 4.11 Summary of frequencies of CNAs in known glioma-associated genes in paediatric 
HGG short-term cell cultures 
 
 
 
 
 
 
 
DIPG short-term cell culture is highlighted in blue. CN-copy number 
 
4.3 Discussion 
This study has characterised genome-wide DNA copy number changes in 17 
paediatric HGG short-term cell cultures (comprising 14 non-DIPG and 3 DIPG short-
term cell cultures) using high-resolution aCGH technology. The findings of this 
study not only validated some of the genetic changes previously reported in 
paediatric HGG but also revealed novel CNAs not previously described in these 
tumours.   
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Distinct subgroups within paediatric HGG 
Genomic changes in the paediatric HGG short-term cell cultures in this study varied 
from a minimum of 0.14% to a maximum of 58.42% involving both broad and focal 
CNAs on different chromosomes, indicating genetic instability. The majority of the 
paediatric HGG short-term cell cultures (65%) including 2/3 DIPG short-term cell 
cultures did not have large regions of DNA copy number imbalances involving 
whole chromosome arms. Such balanced genomic profiles have been previously 
reported in paediatric HGG (Bax et al., 2010; Barrow et al., 2011) as well as in other 
paediatric brain tumours such as ependymoma (Johnson et al., 2010), CNS PNETs 
(Li et al., 2009) and cribriform neuroepithelial tumours (CRINET) of the CNS (Gessi 
et al., 2015), indicating possible similarities in the developmental origins of these 
tumours. Moreover, these types of genomic profiles are not common in adult HGG, 
suggesting that the relatively normal profiles observed in this study may reflect the 
characteristic difference in paediatric HGG from their adult counterparts. Instead, 
samples in this study had very small, yet significant CNAs, some of which were not 
previously detected by conventional cytogenetic studies.  
Subgroups of paediatric HGG with genetic changes resembling those found in adult 
HGG have been previously reported and were associated with worst prognosis 
(Paugh et al., 2010; Puget et al., 2010). Similar to these findings, large regions of 
chromosome aberrations were restricted to a small subgroup of paediatric HGG 
short-term cell cultures (IN179, IN1523 and IN3182). Two major genetic changes 
that reflected the characteristic chromosomal abnormalities seen in adult HGG were 
gain of 7 (Hun et al., 1999; Koschny et al., 2002; Lopez-Gines et al., 2005; Crespo et 
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al., 2011) and loss of 10q (Lopez-Gines et al., 2005). Chromosome 7 harbours 
important genes that are associated with gliomagenesis. Interestingly, the gain of 
chromosome 7 in this subgroup included the focal and significant (q<0.25) gain of 
EGFR (7p11.2). However, it should be noted that trisomy 7 can also be acquired by 
cells maintained under artificial culture conditions (Briand et al., 1996; Sareen et al., 
2009). For instance, human neural progenitor cells (hNPCs) isolated from foetal 
brain tissue were found to have additional copies of chromosomes 7 and 19 as well 
as increased expression of EGFR, after 9-15 weeks in culture (Sareen et al., 2009). A 
comparison of CNAs in biopsy and its derived short-term cell culture in 2 B/CC pairs 
previously described in 3.2.1 revealed that trisomy 7 was absent in the biopsy, but 
present in the derived short-term cell culture for one of the pairs (IN3182 B/CC), 
while it was not present in either the biopsy or the derived culture for the other pair 
(IN3183 B/CC). Further studies in more B/CC pairs may provide a better 
understanding of the relevance of trisomy 7 in paediatric HGG. Loss of 10q is the 
most frequent large chromosome abnormality seen in adult GBM, which includes the 
loss of PTEN (10q23) (Mohapatra et al., 1998; Paugh et al., 2010; Qu et al., 2010). It 
also distinguishes adult from paediatric HGG, with frequencies of 80% in adult 
HGG compared with 27% in paediatric HGG (Paugh et al., 2010, Qu et al., 2010; 
Barrow et al., 2011, Jones et al., 2012). In this study, either complete or partial loss 
of 10q was seen in 2/3 members of this subgroup, which were not associated with 
loss of PTEN. PTEN is an important tumour suppressor gene that functions as a 
major negative regulator of PI3K/Akt signaling by catalysing PIP3 to PIP2 (Maher et 
al., 2001; Cully et al., 2006). This suggests that alternative mechanisms of activation 
of PI3K/Akt pathway may be active in these tumours.  
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Overall, 3 subgroups were identified within the paediatric HGG short-term cell 
cultures based on their genomic profiles: the subgroup without large scale 
chromosomal imbalances, and 2 other subgroups with large chromosomal 
imbalances involving either single or multiple chromosomes. Interestingly, the study 
by Bax et al., (2010) has identified similar genomic subtypes within paediatric HGG, 
which had prognostic potential. In that study, the tumours had either stable, 
aneuploid, highly rearranged or amplifier genomic profiles. The subtype with stable 
genomes had better prognosis, while those with amplifier genomes had poor 
prognosis. Therefore, specific patterns of genomic profiles may have roles as 
prognostic indicators in paediatric HGG.  
Similarities of CNAs between paediatric and adult HGG 
The most predominant chromosome arm aberrations previously reported in paediatric 
HGG include gains of 1q and losses of 4q and 16q (Bax et al., 2010; Barrow et al., 
2011; Paugh et al., 2010). Gain of 1q and loss of 4q were seen in 5.9% and loss of 
16q in 11.8% of paediatric HGG short-term cell cultures, respectively. The low 
frequencies of occurrence of these CNAs may be due to the low sample number 
(n=17) in this study. The highest frequencies of chromosome arm aberrations in this 
cohort were gains involving 3q, 7p, 7q, 9p and 9q each seen in 17.6% of paediatric 
HGG. Although gain of chromosome 7 (Paugh et al., 2010; Barrow et al., 2011) and 
9q (Paugh et al., 2010) have been previously described in paediatric HGG, frequent 
gains of 3q and 9q have not been reported. Chromosome 7 and 9 gains occurred 
concurrently, the relevance of which has not been investigated in these tumours. Of 
particular interest was the gain of chromosome 3q as this was also present in 1 DIPG 
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short-term cell culture (IN2675). Moreover, chromosome 3q harbours several 
important genes involved in DNA damage response and repair (ATR, MBD4, 
PSMD2, SENP2, TP63 and ZMAT3), BMP signaling (SLC33A1 and FSTL1), bone 
morphogenesis (OSTN, BBX and IFT8), and cell cycle arrest (SKIL) (GO enrichment 
analysis, Nexus copy number software (v8.0, Biodiscovery Inc., USA)). Importantly, 
it also contains genes involved in PI3K/Akt pathway (PIK3CA, PIK3CB and 
PIK3R4), suggesting a potential role for this pathway in paediatric HGG including 
DIPG. Gain of 3q in all cases was concordant with focal gain of PIK3CA and 
PIK3CB. In a study by Warren et al., (2012), the gained region on 3q encoding PAK2 
(p21 protein (Cdc42/Rac)-activated kinase 2), an apoptosis-related gene, was found 
in both the low-grade and high-grade regions of a DIPG sample from the same 
patient. It has also been associated with tumour progression in glioma (Vranova et 
al., 2007), tumour aggressiveness in epithelial cancers (Chaluvally-Raghavan et al., 
2014), invasiveness in cervical carcinoma (Rao et al., 2004) and poor prognosis in 
early stage cervical squamous cell carcinoma (Huang et al., 2007). Gain of 3q may 
therefore be an alternative mechanism of activation of PI3K pathway in these 
tumours which do not typically harbour PTEN loss. 
Frequent CNAs in paediatric HGG 
Genes with oncogenic roles in cancers are often found in gained/amplified genomic 
regions, while those with tumour suppressors may be found in regions of 
loss/deletion. Considering these, genomic CNAs recurring in a minimum of 4/17 
paediatric HGG short-term cell cultures were evaluated to identify candidate genes 
that may function either as drivers or as passengers through their cooperative 
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interaction with other genes and contribute to tumourigenesis or progression. In 
addition, significance tests were performed to eliminate CNAs that may have 
occurred due to chance phenomena. The unbiased approach in this study has led to 
the identification of gains at 14q11.2 and 7p14.1 as the most frequent (94% and 
76.4% respectively) CNAs in the paediatric HGG short-term cell cultures, with high-
copy gain of 7p14.1 observed in one of them (IN3182). Both these CNAs have not 
been previously identified in paediatric HGG. The gain at 7p14.1 encompassed 
TARP, which encodes a protein expressed in prostate cancer cells as well as in 
adenocarcinoma of prostate and breast cancers (Wolfgang et al., 2000). Interestingly, 
CNVs at 7p14.1and 14q11.2 have been reported to be associated with Dupuytren‘s 
disease, a fibroproliferative disorder characterised by deformities in the fingers (Shih 
et al., 2012). A similar connection in genetic aberrations between paediatric HGG 
and an inherited disorder has been reported in DIPG patients with ACVR1 mutations, 
which were also found in patients with Fibrodysplasia ossificans progressiva (FOP), 
a disorder that causes ossification of soft tissues leading to muscular deformities. It is 
therefore likely that developmental processes may have a role in tumourigenesis of 
paediatric HGG. In this study, gain of a region at 11q11 appeared to have 
significantly co-occurred with gain of 7p14.1 at a frequency of approximately 63.5% 
in paediatric HGG with gain of 7p14.1. The co-occurrence of 7p14.1 and 11q11 may 
be an indicator of poor prognosis in paediatric HGG, but this requires detailed 
investigation. 
Paediatric HGG including DIPG are characterised by diffuse infiltration into the 
surrounding normal brain structures making them less vulnerable to therapeutic 
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intervention (Demuth and Berens, 2004; Buczkowicz and Hawkins, 2015). The 
invasive phenotype of these tumour cells is the net result of their interactions with 
the tumour microenvironment, primarily composed of stromal cells and the 
extracellular matrix (ECM) (Payne and Huang, 2013). Collagens form the major 
components of ECM and play vital roles in modulating cell invasion, growth and 
survival of glioma. Recently, Cockle et al. (2015) demonstrated efficacy of anti-
migratory agents in paediatric HGG and DIPG cells using 2D and 3D assays. In this 
study, approximately 30% of paediatric HGG short-term cell cultures including 1 
DIPG (IN2087) had gain of chromosome 2q32, which contains COL5A2, an 
important collagen encoding gene. COL5A2 encodes an alpha chain for one of the 
low abundance fibrillar collagens. Genetic aberrations in this gene have not been 
previously identified in paediatric HGG. Novel mutations in this gene have been 
identified in Ehlers-Danlos syndrome, a rare inherited connective tissue disorder 
characterised by joint hypermobility (Ritelli et al., 2013). Chromosome 2q32 also 
contains MIR3129, a novel miRNA gene the role of which has not been investigated. 
 Potential role of CNAs in non-coding RNA genes in paediatric HGG 
The significance of non-coding elements of the human genome such as non-coding 
RNA genes and pseudogenes as markers of cellular identity and prognosis in various 
types of cancers are being increasingly understood (Chan et al., 2013; Han et al., 
2014; Rutnam et al., 2014; Guo et al., 2015). Bioinformatic analysis in adult glioma 
has identified a specific six-pseudogene signature consisting of TDH, LPAL2, 
CLCA3P, SP3P, PTTG3P and ANXA2P3 that revealed prognostic significance, 
independent of patient age and gender (Gao et al., 2015). TDH was identified to have 
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a protective role, while the other 5 genes were considered high risk and were 
associated with reduced overall survival. In this study, several pseudogenes were 
identified predominantly in the regions of copy number loss. The most frequent loss 
at 8p11.23-p11.22 found in 58.82% of paediatric HGG short-term cell cultures 
contains 2 pseudogenes ADAM5 and ADAM3A. This was also the most frequent 
region of homozygous loss detected in the paediatric HGG short-term cell cultures 
(35.3%). Interestingly, the minimal region of deletion at 8p11.23 encompassing 
ADAM3A was also a region of gain in a small subgroup that consisted of 4 paediatric 
HGG short-term cell cultures (IN1419, IN2675 (DIPG), IN3182 and IN3183), 
suggesting that ADAM3A may be a target of frequent genetic disruption in paediatric 
HGG.  
The members of the ADAM family of genes encode catalytically active or inactive 
membrane-bound metalloproteases, which participate in various cellular processes 
such as adhesion, cell-cell and cell-matrix interactions (Wolfsberg et al., 1995; 
Brocker et al., 2009). Predominantly expressed in testicular cells, ADAM3A belongs 
to the catalytically inactive subgroup that lacks protease activity. The basic function 
of this gene is associated with integrin-dependent binding and fusion of gamete 
plasma membrane during fertilisation (Yuan et al., 1997; McLaughlin et al., 2001). 
Recent studies indicate that dysregulation of ADAM3A may be associated with 
cancer.  For instance, homozygous loss of ADAM3A has been previously reported in 
paediatric HGG (Barrow et al., 2011), as well as in other cancers such as laryngeal 
basaloid squamous cell carcinoma (Ecsedi et al., 2012), lung cancer (Liu et al., 
2012), malignant mesothelioma (Klorin et al., 2013) and NK/T-cell lymphoma (Sun 
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et al., 2014). The loss of ADAM3A in NK/T-cell lymphoma was associated with 
significantly poor survival (P=0.024). Frequent amplification and overexpression of 
ADAM3A was reported in conjunctival squamous cell carcinoma (Asnaghi et al., 
2014) and gain was reported in CNS CRINETs (Gessi et al., 2015), a rare type of 
paediatric brain tumour. It was interesting to note that the majority of these studies 
were published after 2011 and involved the use of high-resolution microarrays, 
emphasising the strength of these arrays in detecting aberrations that were previously 
unidentified in cancers. The loss of ADAM3A in this study was significantly 
concordant (p<0.05) with losses at 14q11.1-q11.2 and 15q11.2. Both 14q11.1-q11.2 
and 15q11.2 contain several non-coding RNA genes and pseudogenes, suggesting a 
possible role for other pseudogenes in ADAM3A regulation. Of interest, 14q11.1-
q11.2 included a homeobox gene, DUXAP10 with potential involvement in early 
embryonic development. The region covered by 15q11.2 contains a miRNA gene, 
MIR1268A which has not been previously reported in cancer. Given the role of 
pseudogenes and their interactions with non-coding RNA genes as well as protein 
coding genes in cancer (Xiao-Jie et al., 2014), ADAM3A may be a potential candidate 
gene in paediatric HGG and further investigations are required to validate this 
finding. The loss at 1q21.1 contains 2 pseudogenes NBPF25P, a member of the 
neuroblastoma breakpoint family gene and FCGR1C. A CNV at 1q21.1, which 
included NBPFX has been identified as susceptibility locus in the childhood cancer 
neuroblastoma (Diskin et al., 2009), and a CNV at this locus, which included 
NBPF23 has been reported in paediatric GBM (Giunti et al., 2014). Therefore, this 
raises the question whether a potential likelihood of inherited predisposition to 
cancer exists in a subset of paediatric HGG, and if so, whether pseudogenes play any 
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role in this process, but this requires further investigation. Pseuodegenes were also 
found in regions of copy number gain as at 15q11.2, which included HERC2P3, 
GOLGA8CP, NBEAP1 and CXADRP2. This region also had 2 clusters of miRNAs, 
MIR5701 and MIR3118. Interestingly, the role of pseudogenes in regulating the 
effects of miRNAs on their mRNA targets by competing with miRNAs has been 
reported in cancers. For instance, deletion of PTENP1 (the pseudogene of PTEN) in 
melanoma has been observed to cause enhanced miRNA-mediated inhibition of 
PTEN and tumour progression (Poliseno et al., 2011). The CNA in gain at 9q34.11 
had protein coding genes including a sense-antisense gene pair (PTGES2 and 
PTGES2-AS1), also present along with miRNA genes such as MIR199B and 
MIR3154. Recently, prognostic significance for sense-antisense gene pairs has been 
reported in cancers (Balbin et al., 2015). These suggest a putative cross-
communication between coding and non-coding genes in paediatric HGG. Genomic 
studies have shown that DIPG and non-DIPG HGG may share certain genomic 
CNAs despite their origins in different locations in the brain (Barrow et al., 2011). 
Homozygous loss at 4q13 has been previously reported in paediatric HGG (Barrow 
et al., 2011, Giunti et al., 2014) including DIPG. However, no studies have 
established its role in these tumours. In this study, homozygous loss of 4q13.2 was 
found in approximately 30% of paediatric HGG, including 1 DIPG. This was the 
only homozygous loss detected in the DIPG short-term cell cultures (IN2087). This 
region contains TMPRSS11E, a type II transmembrane serine protease, involved in 
the degradation of ECM (Hooper et al., 2001). The genes found in this region encode 
members of the UDP-glucuronosyltransferases (UGT) family of enzymes (UGT2B15 
and UGT2B17), that catalyze the transfer of glucuronic acid from uridine 5‘-
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diphosphoglucuronic acid to a variety of substrates with functional groups of oxygen, 
nitrogen, sulphur or carbon, making them water-soluble and less-toxic for easy 
elimination from the body (Tukey and Strassburg, 2000). In prostate cancer cells, 
UGT2B15 and UGT2B17 participate in the degradation of dihydrotestosterone 
(DHT) and the failure of these enzymes to completely degrade DHT may be 
associated with cancer susceptibility (Park et al., 2007). Loss of 4q13.2 may 
therefore play a role in causing increased susceptibility to carcinogens in paediatric 
HGG. Several recent investigations have led to the identification of the prominent 
role of epigenetic mechanisms in paediatric HGG, particularly DIPG. Copy number 
loss of 17q21.31 detected in approximately 35% of paediatric HGG short-term cell 
cultures including 1 DIPG (IN2102) in this study, contains genes that encode 
chromatin modifiers, notably KANSL1. This gene encodes a nuclear protein 
participating in histone acetylation. In addition, genome-wide association studies 
(GWAS) have revealed association of 17q21.31 locus with susceptibility to ovarian 
cancer (Couch et al., 2013), suggesting this as an important site of genetic disruption 
that may likely increase the risk of cancer development. 
Concurrent loss of 9p21.3 and BRAFV600E mutation in a subset of paediatric 
HGG 
Deletion at 9p21.3 encompassing CDKN2A/CDKN2B has been reported in paediatric 
and adult HGG (McLendon et al., 2008; Paugh et al., 2010). The co-occurrence of 
homozygous loss of 9p21.3 and oncogenic BRAFV600E point mutation has been 
identified as a characteristic genetic signature associated with a subset of paediatric 
HGG (Schiffman et al, 2010; Huillard et al., 2012). In this study, loss of 9p21.3 and 
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BRAFV600E mutation was concordant in a single case (IN179), further validating the 
existence of this tumour subset within paediatric HGG. Interestingly, this was not a 
DIPG-derived short-term cell culture, further supporting the previous reports of 
extremely low frequency of CDKN2A/CDKN2B deletion in DIPG (2/119 cases, 2%) 
relative to paediatric HGG (p<0.0001). From a clinical perspective, patients with 
these characteristic genetic changes may benefit from a combined treatment strategy 
that targets both the aberrations. CDKN2A is a well-known tumour suppressor gene 
that stabilises p53 through its interaction with the E3 ubiquitin-protein ligase MDM2, 
resulting in degradation of p53 and is a frequent target of mutation or deletion in 
several types of tumours. CDKN2B lies adjacent to CDKN2A, which encodes a 
protein that forms a complex with CDK4 or CDK6 inhibiting activation of the CDK 
kinases. 
Comparison between DIPG and non-DIPG 
Differences in copy number changes that differentiate DIPG from both non-DIPG as 
well as adult HGG have been reported, indicating that these tumours may form 
unique subgroups within paediatric HGG (Bax et al., 2010; Paugh et al., 2010; Paugh 
et al., 2011). In the current study, there was no significant difference at the copy 
number level that distinguished DIPG from their non-DIPG counterparts, but this 
may be due to the relatively low numbers of DIPG short-term cell cultures available 
for this study. However, there were 2 genomic CNAs (gains at 10q23.33 and 
22q11.23) that were relatively more frequent (66.6%) in the DIPG compared to the 
non-DIPG (14.3%) short-term cell cultures, although the differences in their 
frequencies of occurrence between the 2 tumour subgroups were not quite 
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statistically significant (p=0.06). Interestingly, both these CNAs encompassed genes 
that have not been previously linked to DIPG tumour biology. Chromosome 
10q23.33 contains MYOF, which encodes a member of the ferlin family of 
membrane proteins involved in plasma membrane fusion events, repair and 
endocytosis (Cipta and Patel, 2009). Initially identified as a muscle specific protein 
(Davis et al., 2000), increased expression of MYOF at mRNA or protein levels has 
been reported in breast cancer (Labhart et al., 2005), pancreas ductal carcinoma 
(lacobuzio-Donahue et al., 2003) and oropharyngeal squamous cell carcinoma 
(OSCC) (Kumar et al., 2016) cells. In OSCC, MYOF has been identified to be 
associated with poor clinical outcome. Excessive production of MYOF in breast 
cancer cell lines have shown to cause increased invasion and secretion of MMPs, 
while silencing of the gene reverses the process possibly by degradation of EGFR 
signaling pathway (Li et al., 2012; Turtoi et al., 2013). Another major reason for the 
extremely poor clinical response in DIPG patients is the inherent drug-resistance of 
these tumours. For instance, DIPG patients have failed to show clinical response in 
trials involving radiotherapy and concomitant TMZ (Buczkowicz and Hawkins, 
2015), despite the lack of expression of MGMT that repairs TMZ alkylated O6-
guanine nucleotides and contribute to resistance (Zarghooni et al., 2010). The gain at 
22q11.23 contains members of the glutathione-S-transferase family of genes such as 
GSTT1, GSTTP1 and GSTTP2, which encode detoxification enzymes that catalyze 
the conjugation of glutathione with xenobiotic compounds thereby protecting the 
cells from a variety of toxic substances such as carcinogens and chemotherapeutic 
agents (Frova, 2006). This may have a role in predicting drug response in DIPG as 
increased expression of these enzymes may lead to accelerated detoxification of 
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drugs resulting in poor clinical response. Copy number gain of GSTT1 has been 
reported as a predictive marker for poor response to imatinib in gastrointestinal 
stromal tumours (Lee et al., 2013).  
Notably, gain of 22q11.23 was found in 2 DIPG (IN2102 and IN2675), and 2/3 non-
DIPG short-term cell cultures that carried large genomic rearrangements (IN179 and 
IN1523), while this was also a region of deletion in 3 paediatric HGG short-term cell 
cultures (IN1419, IN1566 and IN3046) with relatively less number of CNAs 
(average, 18 CNAs per sample). Deletion of 22q11.23 has been found in ovarian, 
cervical and endometrial carcinoma cells (Ueda et al., 2003; Howells et al., 2001) 
and also reported to cause predisposition in cells to p53 mutation in breast cancer 
(Gudmundsdottir et al., 2001). Therefore, paediatric HGG with loss of 22q11.23 may 
be more susceptible to environmental and genotoxic stress leading to the 
development and progression of tumours.  
Key focal CNAs and genomic clusters 
The hierarchical clustering analysis stratified the paediatric HGG short-term cell 
cultures into three major clusters, while one of them (IN1523) that had highly 
rearranged genomic profile was independent. There were 4 regions, the copy number 
statuses of which differentiated the three clusters and consisted of 8p11.23-p11.22, 
11q11, 4q13.2 and 6p21.32. It is likely that these aberrations have prognostic roles in 
paediatric HGG. However, these subgroups were not similar to the subgroups that 
were described earlier based on the proportion of genomic changes.  
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Limitations 
High-resolution DNA microarray is indeed a powerful molecular biology technology 
that aids the precise detection of genomic DNA copy number changes. However, 
accurate detection of CNAs depends largely on good microarray data quality and 
optimised segment analysis. Extraction of good quality microarray data from samples 
can be challenging as background noise may be introduced at any stage between 
sample processing to the final wash step, which may affect the DLRS ratios and lead 
to false copy number calls. To avoid this, the analysis criteria that were used to 
assess the data quality as well as for the segmentation analysis were kept at the 
higher end of stringency. At the same time, as the majority of the paediatric HGG 
short-term cell cultures in this study had very small focal CNAs, care was also taken 
to identify as precisely as possible, the most significant events in these tumours using 
2 significance testing algorithms, STAC and GISTIC. However, it is likely that these 
processes may have resulted in the loss of some data. In addition, segmentation 
algorithms vary from software to software influencing the outcome of analysis to 
some extent. In this study, the 3 segmentation algorithms tested using the cell culture 
with the highest number of CNAs revealed that the different algorithms retained the 
major chromosome changes, while some of the smaller changes were not concordant 
among them. This is crucial especially for analysis of tumours like paediatric HGG 
that do not have many copy number changes. It would also be interesting to compare 
the level of concordance in the detected segments using additional cultures in the 
cohort.  
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3.3 Conclusions 
 
The utilisation of high-resolution DNA microarrays has enabled the identification of 
several small interstitial CNAs which were not previously detected by conventional 
cytogenetic studies that were of comparatively low-resolution. The detection in this 
study of previously reported genomic changes in paediatric HGG strengthens the 
utility of paediatric HGG derived-short-term cell cultures for genome-wide copy 
number studies. The novel CNAs detected in this study contribute to the current 
understanding of tumour biology in paediatric HGG including DIPG. These CNAs, 
which included coding and non-coding genetic elements, reveal the genetic 
complexity in paediatric HGG. Further investigations in an extended cohort of 
samples may provide valuable insights into their roles in the development and 
progression of these devastating tumours, which may lead to the identification of 
effective prognostic and therapeutic targets. 
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CHAPTER 5 
Genome-wide miRNA expression profiling in 
paediatric HGG short-term cell cultures 
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5.1 Introduction 
MiRNAs are a family of small non-coding RNAs of 18-25 nucleotides in length 
that are key post-transcriptional regulators of gene expression, mediating various 
aspects of the tumourigenic process including migration, invasion, proliferation, 
apoptosis evasion, angiogenesis, and metabolism (Farazi et al., 2013). They interact 
with protein-coding genes based on complementary base-pairing between sequences 
in their seed regions (nucleotides 2-8) and 3‘UTRs of their target mRNAs leading to 
translation inhibition or mRNA degradation. Widespread dysregulation of miRNAs 
has been reported in almost all types of cancers (Birks et al., 2011; Kotani et al., 
2010; Farazi et al., 2013).  
Microarray-based high-throughput analyses have provided valuable insights into the 
significance of miRNAs as diagnostic, prognostic and therapeutic biomarkers in 
cancers (Yanaihara et al., 2006; Greither et al., 2009; Valladares-Ayerbes et al., 
2011). It has been increasingly recognised that miRNAs can not only distinguish 
tumours from their normal counterparts, but also differentiate tumour subtypes as 
well as different stages of tumour progression (Calin et al., 2004; Lu et al., 2005). In 
adult glioma, several studies have identified significant involvement of miRNAs in 
almost all aspects of gliomagenesis. For instance, mir-7 exerts tumour suppressive 
roles in glioma by inhibition of EGFR pathway as well as by independent 
suppression of Akt (Kefas et al., 2008). MiR-10b is identified as an oncomiR in 
malignant glioma cells that can target CDKN1A and CDKN2A (Gabriely et al., 2011). 
Besides individual miRNAs, characteristic miRNA expression signatures with 
potential therapeutic significance have also been identified in adult glioma. A 
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comprehensive analysis of miRNA expression profiles of 261 glioma from the 
TCGA data has identified a set of 121 miRNAs that stratified these tumours into five 
different subclasses (Kim et al., 2011).  
Among the very few studies conducted in paediatric HGG, genome-wide miRNA 
expression analysis in a panel of 24 paediatric CNS tumours including 4 paediatric 
HGGs has identified dysregulation of miR-129, miR-142-5p and miR-25. 
Hierarchical clustering of these tumour subtypes revealed distinct patterns of miRNA 
expression among the tumour sub groups, particularly paediatric GBMs (Birks et al., 
2011). Recently, Jha et al. (2014) reported differential expression of miRNAs such as 
miR-10b, miR-891a, miR-182, (upregulated), miR-138, miR-7 and miR-129 
(downregulated) in supratentorial paediatric HGG compared to normal brain. They 
also identified unique miRNAs regulating PDGFR and SMAD 2/3 pathways in 
paediatric HGG compared to adult HGG.  
Studies have shown that paediatric HGG are distinct tumour entities characterised by 
unique molecular changes compared to their adult counterparts (Jones et al., 2014). 
Mutations in H3F3A involving lysine to methionine amino acid substitution (K27M) 
have been identified as characteristic driver mutations in paediatric HGG, 
particularly DIPG. A study by Jha et al. (2014) has reported miRNAs associated with 
H3F3A mutation that can potentially target genes involved in the regulation of 
apoptosis, cell cycle, and proliferation such as CDK6, FOXO1, FOXG1 and MEIS2. 
It is probable that distinct patterns of miRNA expression may exist in these tumours 
that could be exploited for the development of diagnostic, prognostic or therapeutic 
biomarkers. Work in Chapter 3 has identified H3F3A (K27M) mutation involving 
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lysine to methionine amino acid substitution at position 27, in 2 out of 17 paediatric 
HGG short-term cell cultures. 
Recently, homozygous loss of ADAM3A, a pseudogene was observed in paediatric 
HGG glioma including DIPG, (Barrow et al., 2011) but further studies investigating 
the consequence of this genetic aberration in paediatric HGG have not been reported. 
The work in Chapter 4 detected copy number loss of ADAM3A in a subgroup of 
paediatric HGG short-term cell cultures (10/17 cases).  
The aims of this chapter were to investigate the differential expression of miRNAs in 
paediatric HGG short-term cell cultures compared to NHA and to identify 
deregulated gene targets of these miRNAs using integrative analyses of miRNA and 
mRNA expression profiles in the same samples. The miRNA expression patterns 
associated with tumour subtypes (DIPG or non-DIPG), H3F3A mutation, and copy 
number loss of ADAM3A in paediatric HGG short-term cell cultures were also 
investigated. 
5.2 Results 
5.2.1 Differential expression of miRNAs between paediatric HGG short-term 
cell cultures and normal human astrocytes (NHA) 
Using Toray‘s 3D-Gene Human miRNA Oligo chips (Toray industries, Tokyo, 
Japan), the expression patterns of 1719 miRNAs were investigated in 17 paediatric 
HGG short-term cell cultures (comprising 14 non-DIPG and 3 DIPG) and a control 
population of Normal Human Astrocytes (NHA), as described in 2.8.4. Data analysis 
183 
 
was performed using Partek Genomics Suite (version 6.6; Partek Inc., USA). The 
data obtained from processed microarray images were normalised with log2 median 
and filtered to remove unreliable probes prior to downstream statistical analysis. 
These consisted of control probes as well as miRNAs without detectable expression 
in any of the samples (n=866). PCA was performed with the remaining 853 
informative miRNA probe sets across 17 paediatric HGG short-term cell cultures and 
NHA as described in 2.12.4. Tumour subtype (non-DIPG or DIPG) and H3F3A 
(K27M) mutation status (mutant or wild type) were assigned to each paediatric HGG 
short-term cell culture. The results are illustrated as a 3-D scatter plot in Figure 5.1. 
PCA showed that the paediatric HGG short-term cell cultures and NHA clustered 
separately.  
 
 
 
 
 
 
Figure 5.1 PCA plot of 17 paediatric HGG short-term cell cultures and NHA. PCA scatter plot of 
17 paediatric HGG short-term cell cultures and NHA, plotted using the first three PCs (PC1=23.6%, 
PC2=13.3% and PC3=8.68%). Each dot on the PCA plot denotes a sample. NHA, non-DIPG and 
DIPG short-term cultures are represented by red, blue and dark purple, respectively. Tetrahedron 
indicates H3F3A (K27M) mutation.  
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Of the 17 paediatric HGG short-term cell cultures, 14 clustered together, which 
included the 2 H3F3A-mutant (K27) samples (IN1566 and IN2675 (DIPG)), while 
the remaining 3 samples (IN3046, IN3180 and IN2087 (DIPG) did not cluster with 
the main group and were independent of each other. Unsupervised hierarchical 
clustering was performed using the average linkage hierarchical clustering algorithm 
with Euclidean distance as similarity metric. Figure 5.2 shows the resultant 
dendrogram illustrating samples with similar expression profiles clustered together. 
With the exception of a single case (IN3180), paediatric HGG short-term cell 
cultures clustered distinctly from NHA. There were sub clusters within the large 
group, but these did not differentiate the tumour subtypes. However, the 2 H3F3A-
mutant paediatric HGG short-term cell cultures clustered together within the large 
group. 
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Figure 5.2 Unsupervised hierarchical clustering of 893 miRNAs in 17 paediatric HGG short-term cell cultures and NHA. Unsupervised hierarchical 
clustering of samples performed using average linkage algorithm in Partek Genomics suite v6.6. The dendrogram shows samples with similar expression 
profiles clustered together. On the heat map, the rows represent miRNAs and the columns represent samples. Green and red colours represent high and low 
levels of miRNA expression respectively. WT- H3F3A (K27) wild type, MUT- H3F3A (K27M) mutant. 
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miRNA FC (pHGG vs. NHA) p-value Accession 
hsa-miR-142-3p 337.09 0.005 MIMAT0000434
hsa-miR-144 151.50 0.015 MIMAT0000436
hsa-miR-138 32.17 0.013 MIMAT0000430
hsa-miR-496 24.33 0.000 MIMAT0002818
hsa-miR-98 18.31 0.030 MIMAT0000096
hsa-miR-3174 14.86 0.000 MIMAT0015051
hsa-miR-4258 12.61 0.002 MIMAT0016879
hsa-miR-563 10.17 0.003 MIMAT0003227
hsa-miR-3142 2.47 0.035 MIMAT0015011
hsa-miR-544 2.11 0.025 MIMAT0003164
5.2.2 Differentially expressed miRNAs in paediatric HGG short-term cell 
cultures compared to NHA 
To determine differentially expressed miRNAs between paediatric HGG short-term 
cell cultures and NHA, one-way ANOVA test was performed with 893 reliable 
miRNAs, using Partek Genomics Suite (version 6.6; Partek Inc., USA). Of 893 
analysed miRNAs, 162 were significantly differentially expressed (p<0.05) with a 
minimum of 2-fold change in expression in the paediatric HGG short-term cell 
cultures compared to NHA. These comprised 152 (93.83%) downregulated and 10 
(6.17%) upregulated miRNAs. The upregulated miRNAs are listed in Table 5.1 and 
dot-plots of these miRNAs are shown in Figure 5.3. 
Table 5.1 Upregulated miRNAs in paediatric HGG short-term cell cultures compared to NHA. 
 
 
 
 
 
 
Significantly upregulated miRNAs (2-fold change, unadjusted p-value<0.05) were identified by one-
way ANOVA test in paediatric HGG short-term cell cultures versus NHA. FC- fold change.
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Figure 5.3 Dot-plots of upregulated miRNAs in paediatric HGG short-term cell cultures compared to NHA. Each dot represents a sample. Red represents 
NHA and blue represents paediatric HGG short-term cell cultures. 
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MiR-142-3p showed the largest upregulation with a 337.09-fold change in 
expression in the paediatric HGG short-term cell cultures compared to NHA. This 
was followed by miR-144 with a 151.50 fold change in expression. Six miRNAs 
comprising miR-138, miR-496, miR-98, miR-3174, miR-4258 and miR-563 showed 
a minimum of 10-fold change in expression, while 2 miRNAs, miR-3142 and miR-
544 had relatively low level of upregulation with fold changes in expression just over  
2-fold.  
Of the 152 downregulated miRNAs, miR-3621 showed the largest downregulation 
(45 fold), which was followed by miR-759 and miR-1237 with minimum of 40-fold 
change in expression in paediatric HGG short-term cell cultures compared to NHA. 
In total, there were 16 miRNAs with minimum of 20 fold-change in expression, 
which were investigated further (Table 5.2). The other downregulated miRNAs were 
miR-520a-3p, miR-136, miR-4769-3p, miR-921, miR-191, miR-613, miR-4306, 
miR-4505, miR-4778-5p, miR-1286, miR-4505, miR-4690-3p and miR-200 c. The 
dot-plots of the 10 most downregulated miRNAs are shown in Figure 5.4. 
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miRNA FC (pHGG vs. NHA) p-value Accession 
hsa-miR-3621 -44.94 0.009 MIMAT0018002
hsa-miR-759 -42.02 0.040 MIMAT0010497
hsa-miR-1237 -41.86 0.007 MIMAT0005592
hsa-miR-520a-3p -38.40 0.017 MIMAT0002834
hsa-miR-136 -36.91 0.018 MIMAT0000448
hsa-miR-4769-3p -27.47 0.021 MIMAT0019923
hsa-miR-921 -27.35 0.006 MIMAT0004971
hsa-miR-191 -24.37 0.034 MIMAT0000440
hsa-miR-613 -23.40 0.031 MIMAT0003281
hsa-miR-4306 -22.94 0.005 MIMAT0016858
hsa-miR-4505 -22.70 0.000 MIMAT0019041
hsa-miR-4778-5p -22.10 0.043 MIMAT0019936
hsa-miR-1286 -22.09 0.021 MIMAT0005877
hsa-miR-4506 -21.86 0.000 MIMAT0019042
hsa-miR-4690-3p -20.88 0.007 MIMAT0019780
hsa-miR-200c -20.61 0.033 MIMAT0000617
Table 5.2 Downregulated miRNAs in paediatric HGG short-term cell cultures compared to 
NHA 
 
 
 
 
 
 
 
 
 
 
 
Significantly downregulated miRNAs (2-fold change and unadjusted p-value <0.05) identified by one-
way ANOVA in paediatric HGG short-term cell cultures versus NHA are shown. FC-fold change. 
To understand the biological impact of the differentially expressed miRNAs, KEGG 
pathway analyses were performed using DIANA-miRPath v3.0, 
(http://www.microrna.gr/miRPathv3). The putative mRNA targets of the deregulated 
miRNAs were identified using microT-CDS target prediction algorithm (minimum 
threshold of 0.70), which identifies miRNA targets both in 3‘untranslated region 
(3‘UTR) and in coding sequences (CDS) (Reczko et al, 2012), increasing the 
sensitivity of target prediction. 
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Figure 5.4 Dot plots of the 10 most downregulated miRNAs in paediatric HGG short-term cell cultures compared to NHA (FC<20). Each dot represents a 
sample. NHA is represented by red and paediatric HGG short-term cell cultures are represented by blue dots respectively. 
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Using the ‗genes union‘ module in DIANA-miRPath v3.0 
(http://www.microrna.gr/miRPathv3), a union set of miRNA targets were generated. 
The enrichment analysis was performed using Fisher‘s exact test (hypergeometric 
distribution) and Benjamini-Hochberg adjustment was used for multiple test 
correction. This identifies pathways that are significantly enriched with all genes 
targeted by at least 1 miRNA in the list. The significantly enriched (p<0.05) KEGG 
pathways associated with the upregulated miRNAs that were identified using ‗genes 
union module‘ is given in Table 5.3. In total, there were 42 KEGG pathways, of 
which the 10 most significantly enriched were mucin type O-glycan biosynthesis, 
TGF beta signaling pathway, thyroid hormone signaling pathway, Hippo signaling 
pathway Glioma, Signaling pathways regulating pluripotency of stem cells, FoxO 
signaling pathway, Proteoglycans in cancer, Pathways in cancer and Pancreatic 
cancer. Besides these, there were other significantly enriched cancer-related 
pathways such as MAPK signaling pathway, Wnt signaling pathway, Ras signaling 
pathway, ErbB signaling pathway, PI3K/Akt pathway and mTOR signaling pathway 
and Rap1 signaling pathway. 
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KEGG pathway p-value Genes miRNAs
1 Mucin type O-Glycan biosynthesis 0 19 8
2 TGF-beta signaling pathway 0 40 9
3 Thyroid hormone signaling pathway 0 53 9
4 Hippo signaling pathway 0 63 10
5 Glioma 0 33 7
6 Signaling pathways regulating pluripotency of stem cells 0 64 10
7 FoxO signaling pathway 0 63 8
8 Proteoglycans in cancer 0 85 10
9 Pathways in cancer 0.001 152 10
10 Pancreatic cancer 0.002 33 8
11 Chronic myeloid leukemia 0.002 35 8
12 MAPK signaling pathway 0.002 103 10
13 Wnt signaling pathway 0.002 64 10
14 Melanoma 0.002 35 7
15 Focal adhesion 0.004 86 9
16 Prolactin signaling pathway 0.005 32 8
17 AMPK signaling pathway 0.005 54 9
18 Axon guidance 0.006 52 9
19 Ras signaling pathway 0.008 90 10
20 ErbB signaling pathway 0.008 41 8
21 cAMP signaling pathway 0.008 81 9
22 PI3K-Akt signaling pathway 0.008 129 10
23 Lysine degradation 0.017 20 8
24 mTOR signaling pathway 0.018 29 8
25 Colorectal cancer 0.020 27 8
26 Prostate cancer 0.021 41 9
27 Endocytosis 0.021 77 9
28 Adrenergic signaling in cardiomyocytes 0.021 59 9
29 Adherens junction 0.023 30 9
30 Platelet activation 0.026 52 9
31 Ether lipid metabolism 0.029 21 7
32 Neurotrophin signaling pathway 0.030 51 8
33 Small cell lung cancer 0.034 37 8
34 cGMP-PKG signaling pathway 0.034 66 9
35 Acute myeloid leukemia 0.036 26 7
36 Insulin signaling pathway 0.036 57 9
37 Thyroid hormone synthesis 0.038 24 8
38 Rap1 signaling pathway 0.042 76 10
39 Endometrial cancer 0.045 23 8
40 Long-term potentiation 0.045 30 9
41 Transcriptional misregulation in cancer 0.045 67 9
42 Choline metabolism in cancer 0.047 42 9
Table 5.3 KEGG pathways associated with upregulated miRNAs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significantly enriched KEGG pathways associated with upregulated miRNAs were identified using 
the ‗genes union‘ module (microT-threshold 0.7) in DIANA mirPath. Pathways with enrichment p-
value<0.05 (FDR ON) are shown. The table is ranked by enrichment p-value. 
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KEGG pathway p-value Genes miRNAs
ECM-receptor interaction 0 16 2
Mucin type O-Glycan biosynthesis 0 17 5
Lysine degradation 0.001 15 3
Hippo signaling pathway 0.007 22 2
Adherens junction 0.011 17 1
Thyroid hormone signaling pathway 0.020 16 2
TGF-beta signaling pathway 0.021 24 3
Proteoglycans in cancer 0.022 36 1
Furthermore, the most commonly targeted pathways associated with the upregulated 
miRNAs were identified using the ‗pathways union module‘ in DIANA-miRPath 
v3.0 (http://www.microrna.gr/miRPathv3). This identified 8 significantly enriched 
pathways (p-value <0.05, FDR-ON) as shown in Table 5.4. The heat map showing 
the clusters of miRNAs associated with the enriched pathways is shown in Figure 
5.5. Two major clusters of miRNAs were observed, one comprising miR-142-3p, 
miR-3142, miR-496, miR-3174, and miR-4258, and the other comprising miR-138-
5p, miR-144-3p, miR-544a, miR-563 and miR-98-5p. 
Table 5.4  Commonly targeted KEGG pathways associated with upregulated miRNAs 
 
 
 
 
Commonly targeted pathways by upregulated miRNAs were identified using the ‗pathways union‘ 
module (microT-threshold 0.7) in DIANA mirPath. Pathways with enrichment p-value<0.05 (FDR 
ON) are shown. The table is ranked by enrichment p-value. 
As shown in Table 5.4, the most significant pathway was ECM-receptor interaction. 
Notably, the most number of miRNAs were associated with mucin type O-Glycan 
biosynthesis. The upregulated miRNAs and their putative gene targets affecting 
various components of mucin type O-Glycan biosynthesis are illustrated in Figure 
5.6. 
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Figure 5.5 Heat map of pathways associated with upregulated miRNAs. Commonly targeted 
pathways by upregulated miRNAs (microT-CDS>0.70, p<0.05, FDR ON) identified by ‗pathways 
union‘ module in DIANA mirPath v3.0. On the heat map, each row represents a miRNA and each 
column represents a pathway. 
 
 
 
 
195 
 
miR-138-5p
miR-98-5p
miR-144-3p
miR-144-3p
miR-144-3p
miR-138-5p
miR-144-3p
miR-98-5p
miR-3142
miR-3142
miR-3142
miR-144-3p
miR-98-5p
miR-563
miR-563
miR-563
miR-98-5p
miR-3142
miR-563
miR-98-5p
miR-3142
miR-563
miR-98-5p
miR-3142
miR-98-5p
miR-3142
miR-98-5p
miR-3142
miR-98-5p
miR-3142
miR-563
miR-98-5p
miR-3142
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Upregulated miRNAs associated with Mucin type O-glycan biosynthesis pathway. 
Upregulated miRNAs and their gene targets (highlighted in yellow) are shown.  
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The significantly enriched (p<0.05, FDR ON) KEGG pathways associated with the 
16 most downregulated miRNAs (FC<20) using ‗genes union‘ module is shown in 
Table 5.5. There were 52 pathways associated with the downregulated miRNAs, 
most of which were associated with tumourigenic processes. Among the most 
significant pathways, those which are cancer-related included mucin type O-glycan 
biosynthesis, axon guidance, endocytosis, hippo signalling pathway ErbB signalling 
pathway, proteoglycans in cancer, TGF beta signalling pathway, ECM-receptor 
interaction, and glioma. 
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KEGG pathway p-value Genes miRNAs
Mucin type O-Glycan biosynthesis 0 18 11
Axon guidance 0 80 15
Endocytosis 0 128 16
Glycosphingolipid biosynthesis - lacto and neolacto series 0 17 11
Hippo signaling pathway 0 89 15
ErbB signaling pathway 0 59 16
Proteoglycans in cancer 0 116 14
TGF-beta signaling pathway 0 50 15
Circadian entrainment 0 63 14
Endocrine and other factor-regulated calcium reabsorption 0 32 14
Glioma 0 42 14
GABAergic synapse 0 53 14
Adherens junction 0 50 14
Morphine addiction 0 54 14
Retrograde endocannabinoid signaling 0 65 15
Lysine degradation 0 28 13
Phosphatidylinositol signaling system 0.001 50 15
Thyroid hormone signaling pathway 0.001 72 15
Pathways in cancer 0.001 217 15
Adrenergic signaling in cardiomyocytes 0.002 90 14
Colorectal cancer 0.002 42 13
Neurotrophin signaling pathway 0.002 75 15
Glutamatergic synapse 0.004 69 14
Bacterial invasion of epithelial cells 0.004 50 14
Glycosphingolipid biosynthesis - ganglio series 0.005 11 10
Renal cell carcinoma 0.006 43 15
Circadian rhythm 0.008 23 11
Melanoma 0.009 45 14
MAPK signaling pathway 0.009 141 15
Nicotine addiction 0.010 24 14
Calcium signaling pathway 0.010 102 15
Ras signaling pathway 0.010 132 15
cGMP-PKG signaling pathway 0.013 94 14
Rap1 signaling pathway 0.013 116 15
Type II diabetes mellitus 0.015 31 12
Chronic myeloid leukemia 0.017 42 14
Pancreatic cancer 0.017 42 14
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.019 45 14
p53 signaling pathway 0.019 44 15
Glycosphingolipid biosynthesis - globo series 0.022 10 10
Wnt signaling pathway 0.022 78 14
Focal adhesion 0.024 114 16
Gap junction 0.028 50 15
Cholinergic synapse 0.029 63 14
RNA degradation 0.029 49 15
Amino sugar and nucleotide sugar metabolism 0.030 29 11
Aldosterone-regulated sodium reabsorption 0.035 26 13
Sphingolipid signaling pathway 0.043 64 13
mTOR signaling pathway 0.048 37 14
Thyroid hormone synthesis 0.048 39 13
Inflammatory mediator regulation of TRP channels 0.049 57 14
Vasopressin-regulated water reabsorption 0.050 27 14
Table 5.5 KEGG pathways associated with downregulated miRNAs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significantly enriched KEGG pathways associated with downregulated miRNAs were identified using 
the ‗genes union‘ module (microT-threshold 0.7) in DIANA mirPath. Pathways with enrichment p-
value<0.05 (FDR ON) are shown. The table is ranked by enrichment p-value. 
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KEGG pathway p-value Genes miRNAs
Morphine addiction 0 44 7
ECM-receptor interaction 0 25 3
Fatty acid degradation 0 4 3
Proteoglycans in cancer 0 67 4
Axon guidance 0 62 5
Glycosphingolipid biosynthesis - lacto and neolacto series 0 11 4
Lysine degradation 0 21 6
Steroid hormone biosynthesis 0 8 1
ErbB signaling pathway 0 39 4
Fatty acid metabolism 0 5 3
Circadian entrainment 0 49 5
Other types of O-glycan biosynthesis 0.004 7 2
TGF-beta signaling pathway 0.020 28 3
Glioma 0.037 23 3
KEGG pathway enrichment was also performed using the downregulated miRNAs  
using the ‗pathways union‘ module with microT-threshold 0.07 and p-value<0.05 
(FDR ON). The results are shown in Table 5.6. The most significant cancer-related 
pathway was ECM-receptor interaction and the most number of miRNAs involved in 
a cancer-related pathway was in Lysine degradation. The miRNAs associated with 
Glioma were miR-520a-3p, miR-613 and miR-4778-5p. Mir-520a-3p had 13 gene 
targets including BRAF, EGFR, CDK6, PIK3CA, PTEN and the experimentally 
validated target, CCND1. Mir-613 had 9 targets including IGF1, PDGFA, EGFR and 
MAPK1. Mir-4778-5p had 12 targets including PIK3R1, PIK3CA, CDK6, BRAF and 
MTOR. 
Table 5.6 Commonly targeted KEGG pathways associated with downregulated miRNAs 
 
 
 
 
 
 
KEGG pathways targeted by downregulated miRNAs were identified using the ‗pathways union‘ 
module (microT-threshold 0.7) in DIANA mirPath. Pathways with enrichment p-value<0.05 (FDR 
ON) are shown. The table is ranked by enrichment p-value. 
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Figure 5.7 Heat map of pathways associated with downregulated miRNAs. KEGG pathways 
targeted by downregulated miRNAs (microT-CDS>0.70, p<0.05, FDR ON) were identified by 
‗pathways union‘ module in DIANA mirPath v3.0. On the heat map, each row represents a miRNA 
and each column represents a pathway. 
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5.2.3 Integrated miRNA and mRNA expression analysis to identify mRNA 
targets of deregulated miRNAs in paediatric HGG short-term cell cultures  
To identify the most reliable mRNA targets of the deregulated miRNAs, miRNA 
expression data were integrated with the mRNA expression data from the same 
dataset using Partek Genomics suite (v 6.6, Partek Inc., USA). The mRNA 
expression profiles of paediatric HGG short-term cell cultures analysed in this study 
were previously generated in the laboratory by Dr. Nicola Potter using Affymetrix 
Gene Chip HG_U133A (unpublished data). Normalised mRNA expression data were 
available for 13/17 paediatric HGG short-term cultures and NHA, which were 
profiled for miRNA expression.  
Data were log2 transformed and one-way ANOVA test was used to identify genes 
that were significantly differentially expressed between paediatric HGG short-term 
cell cultures and NHA. This identified 853 probes (759 downregulated and 94 
upregulated), which showed significant (p<0.05) and 2-fold change in expression in 
paediatric HGG short-term cell cultures compared to NHA. The spreadsheet 
containing differentially expressed mRNAs was then integrated with the spreadsheet 
containing differentially expressed miRNAs (n=162) using the ‗correlate microRNA 
and mRNA data‘ integration tool in Partek Genomics suite (v6.6, Partek Inc., USA). 
This approach identifies putative mRNA targets of differentially expressed miRNAs 
from TargetScan 7.0 database and computes a Pearson correlation coefficient and p-
value for each miRNA and its predicted gene target. Positive correlation indicates 
that high expression level of the miRNA is associated with high expression of its 
predicted mRNA, while negative correlation indicates that high expression of the 
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miRNA is associated with low level of its predicted gene target. The integrated 
analysis identified 192 miRNA-mRNA interaction pairs that consisted of 170 
positive and 22 negative associations. The statistically significant miRNA-mRNA 
pairs were defined by p<0.05 and Pearson correlation coefficient threshold of 0.50 
(medium strong correlation). This resulted in 81 miRNA-mRNA interaction pairs, of 
which 78 were positive and only 3 were negative. The positive associations included 
5 mRNAs that were each represented by 2 probes. Discounting the repeated probes, 
73 unique miRNA-mRNA positive associations remained. 
As expected, each miRNA had multiple mRNA targets. MiR-520a-3p had the highest 
number of targets (21 targets), followed by miR-613, miR-4306, miR-378f, miR-
502-3p, miR-369-3p, and miR-4676-3p with 19, 13, 9, 8, 7 and 4 gene targets 
respectively. Conversely, there were 12 genes targeted by multiple miRNAs. ZFHX4 
was targeted by the highest number of miRNAs (4 miRNAs), followed by AAK1, 
CADM4, IGF1, INHBA, NDST1, PRIM2, RAI14, RUNX1, SLC23A2, TRHDE and 
TRIM2 each targeted by 2 miRNAs.   
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Count miRNA Gene Symbol Pearson correlation 
coefficient
p-value
1 hsa-miR-520a-3p NBEAL2 0.871 0.0001
2 hsa-miR-520a-3p AAK1 0.817 0.0004
3 hsa-miR-4306 GTPBP1 0.799 0.0006
4 hsa-miR-4306 NLRP1 0.794 0.0007
5 hsa-miR-520a-3p ZFHX4 0.793 0.0007
6 hsa-miR-520a-3p EIF5 0.779 0.0010
7 hsa-miR-378f KSR1 0.760 0.0016
8 hsa-miR-613 ZFHX4 0.758 0.0017
9 hsa-miR-378f PRIM2 0.755 0.0018
10 hsa-miR-520a-3p MINK1 0.748 0.0021
11 hsa-miR-378f ALPK3 0.746 0.0022
12 hsa-miR-4676-3p IGF1 0.742 0.0024
13 hsa-miR-613 SLC23A2 0.739 0.0025
14 hsa-miR-520a-3p PDLIM5 0.736 0.0027
15 hsa-miR-4306 TMC5 0.735 0.0027
16 hsa-miR-502-3p ZFHX4 0.726 0.0033
17 hsa-miR-502-3p LUZP1 0.720 0.0037
18 hsa-miR-369-3p ZFHX4 0.718 0.0038
19 hsa-miR-520a-3p MINK1 0.714 0.0041
20 hsa-miR-613 SIM2 0.704 0.0049
21 hsa-miR-4306 PRIM2 0.703 0.0051
21 hsa-miR-520a-3p POU6F1 0.698 0.0055
22 hsa-miR-520a-3p FBXO11 0.697 0.0056
23 hsa-miR-520a-3p RAI14 0.682 0.0072
24 hsa-miR-520a-3p ESR1 0.672 0.0084
25 hsa-miR-613 RRBP1 0.666 0.0093
26 hsa-miR-4306 NDST1 0.658 0.0105
27 hsa-miR-520a-3p ST3GAL5 0.657 0.0106
28 hsa-miR-4306 SIX3 0.655 0.0110
29 hsa-miR-378f AAK1 0.649 0.0119
30 hsa-miR-520a-3p CNN1 0.649 0.0120
31 hsa-miR-520a-3p TRHDE 0.648 0.0122
33 hsa-miR-502-3p OGT 0.647 0.0123
34 hsa-miR-613 KCTD13 0.645 0.0128
35 hsa-miR-613 FNBP1L 0.642 0.0132
36 hsa-miR-613 ROR1 0.642 0.0133
37 hsa-miR-4306 EIF5A 0.638 0.0140
38 hsa-miR-502-3p SEMA4G 0.636 0.0145
39 hsa-miR-369-3p ACTC1 0.634 0.0149
40 hsa-miR-520a-3p TRIM2 0.632 0.0154
41 hsa-miR-378f IGF1 0.622 0.0176
42 hsa-miR-502-3p OGT 0.621 0.0177
43 hsa-miR-502-3p FBN2 0.618 0.0184
44 hsa-miR-613 NDST1 0.616 0.0190
45 hsa-miR-613 RUNX1 0.609 0.0209
46 hsa-miR-378f CADM4 0.605 0.0219
47 hsa-miR-520a-3p RUNX1 0.604 0.0221
48 hsa-miR-4676-3p INHBA 0.604 0.0223
Table 5.7 Summary of miRNA-mRNA associations in paediatric HGG short-term cell cultures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
203 
 
contd.
49 hsa-miR-4676-3p IGF2BP2 0.602 0.0229
50 hsa-miR-613 WDR6 0.601 0.0232
51 hsa-miR-520a-3p INHBA 0.600 0.0234
52 hsa-miR-520a-3p FRMD4A 0.598 0.0237
53 hsa-miR-4306 NR1D1 THRA 0.597 0.0241
54 hsa-miR-4306 NR1D1 THRA 0.597 0.0241
55 hsa-miR-613 NEDD4L 0.593 0.0254
56 hsa-miR-369-3p FOXO1 0.593 0.0255
57 hsa-miR-378f ZNF335 0.586 0.0275
58 hsa-miR-378f SKP2 0.586 0.0277
59 hsa-miR-613 DLG1 0.583 0.0287
60 hsa-miR-613 TRHDE 0.575 0.0313
61 hsa-miR-520a-3p TM4SF1 0.574 0.0318
62 hsa-miR-613 TRIM2 0.566 0.0347
63 hsa-miR-502-3p PTBP2 0.565 0.0352
64 hsa-miR-613 PARVA 0.565 0.0353
65 hsa-miR-502-3p RAI14 0.561 0.0369
66 hsa-miR-4306 LIF 0.560 0.0374
67 hsa-miR-520a-3p METAP1 0.558 0.0383
68 hsa-miR-520a-3p FGF16 0.553 0.0403
69 hsa-miR-613 GPR125 0.549 0.0420
70 hsa-miR-4306 TCF12 0.547 0.0431
71 hsa-miR-369-3p ECE1 0.543 0.0448
72 hsa-miR-369-3p ZDHHC17 0.540 0.0464
73 hsa-miR-378f SLC38A1 0.539 0.0465
74 hsa-miR-369-3p ZDHHC17 0.538 0.0473
75 hsa-miR-4306 CADM4 0.537 0.0477
76 hsa-miR-613 FUBP1 0.535 0.0485
77 hsa-miR-4676-3p SLC23A2 0.535 0.0487
78 hsa-miR-613 ROR1 0.533 0.0499
1 hsa-miR-4306 CYB561 -0.554 0.0400
2 hsa-miR-613 MR1 -0.687 0.0067
3 hsa-miR-369-3p TMX4 -0.765 0.0014
 
 
 
 
 
 
 
 
 
 
 
 
 
Pearson correlation coefficients of differentially expressed miRNAs and their predicted mRNA targets 
were calculated using Partek Genomics suite v6.6. The significant (p<0.05, R-0.50) miRNA-mRNA 
associations are shown with the table ranked by P-values. Negative associations are highlighted 
yellow. The strong positive (R>0.70) and strong negative (R<0.70) miRNA-mRNA pairs are shown in 
bold. MiRNA with single gene target is coloured green; genes targeted by multiple miRNAs are 
coloured blue (ZFHX4) or red (PRIM2).  
The strongest positive correlation was observed between miR-520a-3p and NBEAL2, 
followed by miR-520a-3p and AAK1 with Pearson correlation coefficients of 0.871 
and 0.817 respectively (Figure 5.8 A and B). The strongest negative correlation was 
observed between miR-369-3p and TMX4 (Figure 5.8 C).  
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Figure 5.8 Scatter plot of miRNA-mRNA interaction pairs in paediatric HGG short-term cell 
cultures.  Each dot represents a sample. NHA is represented by red and paediatric HGG short-term 
cell cultures are represented by blue coloured dots respectively. 
To further identify the most genuine miRNA-mRNA matches, the results were 
filtered based on Pearson correlation coefficient cut-off value 0.70 (strong positive, 
r>0.70 and strong negative, r<0.70). This identified 22 miRNA-mRNA associations, 
of which 21 were positive and 1 was negative. These are shown in bold in Table 5.7. 
Among the positive associations, MINK1 was represented by 2 probes (therefore, the 
number of unique positive associations=20). Interestingly, miR-520a-3p that had the 
highest number of targets also made the highest number of strong positive 
associations (6 associations, r>0.70). These gene targets comprised AAK1, ZFHX4, 
EIF5, MINK1, NBEAL2, and PDLIM5. With the exception of miR-4676-3p, all other 
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miRNA Target 
count
Targets microT-CDS 
score
Experimentally 
supported
Additional targets
hsa-miR-520a-3p 6 AAK1 0.912 Yes
ZFHX4 (0.854), LUZP1 (0.716), IGF1 
(0.624)
EIF5 0.633
MINK1 0.880
NBEAL2 0.634
PDLIM5 0.633
hsa-miR-4306 4 GTPBP1 -
KSR1 (0.895), SLC23A2 (0.792), ALPK3
(0.747), IGF1 (0.726), MINK1 (0.696),  
LUZP1 (0.678)
NLRP1 -
TMC5 -
PRIM2 -
hsa-miR-613 3 SIM2 -
IGF1 (0.986), MINK1 (0.704), AAK1
(0.626), SLC23A2 (0.678)
SLC23A2 -
ZFHX4 0.616
hsa-miR-378f 3 ALPK3 0.689 IGF1 (0.667)
KSR1 0.642
PRIM2
hsa-miR-502-3p 2 LUZP1 0.629 Nil
ZFHX4 0.882 Yes
hsa-miR-369-3p 2 TMX4 0.687
IGF1 (0.832), PDLIM5 (0.765),AAK1, 
SIM2 (0.709)
ZFHX4 0.612 Yes
hsa-miR-4676-3p 1 IGF1 0.768
EIF5 (0.783), ZFHX4 (0.745), SLC23A2 
(0.687)
miRNAs had multiple mRNA targets. In addition, all 4 miRNAs that targeted 
ZFHX4 involved strong positive associations (r>0.70). PRIM2 was targeted by 2 
miRNAs comprising hsa-miR-378f and hsa-miR-4306. As TargetScan cannot 
identify mRNA targets in the coding sequences, the gene targets of the identified 
miRNAs were compared with those predicted by microT-CDS. Table 5.8 shows 
microT-CDS scores of the miRNA-mRNA interaction pairs that were predicted by 
TargetScan.  
Table 5.8 Comparison of gene targets of deregulated miRNAs in miRNA-mRNA interaction 
pairs predicted by TargetScan and microT-CDS (threshold 0.60) algorithm  
 
 
 
 
 
 
 
 
The most significant miRNA-mRNA interaction pairs (Pearson correlation coefficient threshold 0.6) 
as predicted by TargetScan miRNA target prediction algorithm in Partek Genomics suite (v6.6, Partek 
Inc., USA) were analysed for targets predicted by micro T-CDS algorithm (threshold 6) in DIANA 
miRPath, v3.0 and Tarbase, v7.0 (experimentally supported). 
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With the exception of the predicted gene targets of miR-4306, the majority of the 
target predictions by TargetScan were concordant with those predicted using microT-
CDS. There were additional associations predicted by microT-CDS, some of them 
with high prediction scores as in case of hsa-miR-613- IGF1 (microT-CDS=0.986) 
and miR-4306-KSR1 (microT-CDS=0.895). 
To investigate the biological significance of the deregulated miRNA-mRNA 
interactions in paediatric HGG short-term cell cultures, GO and KEGG pathway 
analyses were performed using DIANA-miRPath v3.0 
(http://www.microrna.gr/miRPathv3). This analysis was performed using all 81 
significant miRNA-mRNA associations. The enrichment p-value was calculated 
using Fisher‘s exact test (hypergeometric distribution) and corrected by Benjamini-
Hochberg adjustment. The GO biological processes associated with the miRNA-
mRNA interaction pairs are shown in Table 5.9. Fourteen significant GO biological 
processes (p<0.05) were associated with the dysregulated miRNAs and mRNAs. 
Regulation of neural precursor cell proliferation was the most significantly enriched 
biological process. Other notable biological processes included actin-mediated cell 
contraction, cellular protein-modification process, cellular nitrogen compound 
metabolic process, cell-cell signaling, glycolate metabolic process, 
phosphatidylinositol-mediated signaling and cytoskeleton organisation. The most 
number of miRNAs (7 miRNAs) were associated with cell-cell signaling and 
biological process.  
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GO Category p-value Genes miRNAs
1 regulation of neural precursor cell proliferation 0.003 3 4
2 actin-mediated cell contraction 0.011 2 3
3 cellular protein modification process 0.012 13 6
4 lung lobe morphogenesis 0.028 2 4
5 water homeostasis 0.028 2 5
6
prostate epithelial cord arborization involved in 
prostate glandular acinus morphogenesis
0.028 2 6
7 cellular nitrogen compound metabolic process 0.028 18 6
8 lung vasculature development 0.029 2 4
9 biosynthetic process 0.035 16 6
10 cell-cell signaling 0.035 6 7
11 glycolate metabolic process 0.039 1 4
12 phosphatidylinositol-mediated signaling 0.039 3 5
13 biological_process 0.039 45 7
14 cytoskeleton organization 0.042 6 6
Table 5.9 Significant GO biological processes associated with miRNA-mRNA interaction pairs 
 
 
 
 
 
 
 
 
 
 
Significantly enriched GO biological processes associated with miRNA-mRNA pairs were identified 
using the ‗categories union‘ module (microT-threshold 0.7) in DIANA mirPath. Pathways with 
enrichment p-value<0.05 (FDR ON) are shown. The table is ranked by enrichment p-value. 
The significantly enriched KEGG pathways associated with the miRNA-mRNA 
interaction pairs consisted of important cancer-related pathways such as 
transcriptional misregulation in cancer, FoxO signalling pathway, pathways in cancer 
and estrogen signalling pathway (Table 5.10).   
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KEGG pathway p-value Genes miRNAs
Transcriptional 
misregulation in cancer
0
RUNX1, IGF1, 
FOXO1
hsa-miR-369-3p, hsa-miR-520a-3p, 
hsa-miR-4306, hsa-miR-4676-3p, hsa-
miR-613,
FoxO signaling pathway 0.003
SKP2, IGF1, 
FOXO1
hsa-miR-369-3p, hsa-miR-378f, hsa-
miR-4306, hsa-miR-4676-3p, hsa-miR-
613
Pathways in cancer 0.013
RUNX1, SKP2, 
IGF1, FGF16, 
FOXO1
hsa-miR-369-3p, hsa-miR-378f, hsa-
miR-520a-3p, hsa-miR-4306, hsa-miR-
613, hsa-miR-4676-3p
Estrogen signaling 
pathway
0.027 ESR1 hsa-miR-520a-3p, hsa-miR-502-3p
Table 5.10  Significant KEGG pathways associated with miRNA-mRNA interaction pairs 
 
 
 
 
 
 
Significantly enriched KEGG pathways associated with the miRNA-mRNA pairs were identified 
using the ‗genes union‘ module (microT-threshold 0.7) in DIANA mirPath. Pathways with enrichment 
p-value<0.05 (FDR ON) are shown. The table is ranked by enrichment p-value. 
 
5.2.4 Comparison of miRNA expression profiles between non-DIPG and DIPG 
short-term cell cultures relative to NHA 
To compare the miRNA expression profiles between non-DIPG (n=14) and DIPG 
(n=3) short-term cell cultures, one-way ANOVA test was performed in each tumour 
group relative to NHA. There were 153 miRNAs that were significantly 
differentially expressed (2-fold change, p<0.05) in non-DIPG (10 upregulated and 
143 downregulated), where as 145 miRNAs were significantly differentially 
expressed in DIPG (8 upregulated and 137 downregulated) as compared to NHA. 
These differentially expressed miRNAs were then compared between the 2 groups. 
The Venn diagram in Figure 5.9 shows the independent comparison of 
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downregulated miRNAs and upregulated miRNAs between DIPG and non-DIPG 
short-term cell cultures as compared to NHA. 
 
 
 
 
Figure 5.9 Venn diagram of deregulated miRNAs in non-DIPG versus DIPG short-term cell 
cultures. A. Venn diagram of upregulated miRNAs in non-DIPG and DIPG short-term cell cultures. 
There are 6 miRNAs common to non-DIPG and DIPG subgroups, while 4 miRNAs are unique to non-
DIPG and 2 miRNAs are unique to DIPG subgroups.  B. Venn diagram of downregulated miRNAs in 
non-DIPG and DIPG short-term cell cultures. There are 106 miRNAs common to non-DIPG and 
DIPG subgroups, while 37 miRNAs are unique to non-DIPG and 31 miRNAs are unique to DIPG 
subgroups. The numbers in parenthesis show the total number of differentially expressed 
(upregulated/downregulated) miRNAs in comparison to NHA. 
On comparison, there were 112 differentially expressed miRNAs (6 upregulated and 
106 downregulated) that were common to both non-DIPG and DIPG subgroups, 41 
miRNAs (4 upregulated and 37 downregulated) were unique to the non-DIPG 
subgroup, and a total of 33 miRNAs (2 upregulated and 31 downregulated) were 
unique to the DIPG subgroup. The unique differentially expressed miRNAs in non-
DIPG and DIPG subgroups of paediatric HGG short-term cell cultures are shown in 
Table 5.11. 
To investigate the role of dysregulated miRNAs in each subgroup of paediatric HGG 
short-term cell cultures, KEGG pathway analyses were performed using DIANA-
miRPath v3.0 (http://www.microrna.gr/miRPathv3). The enrichment p-value was 
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calculated using Fisher‘s exact test (hypergeometric distribution) and corrected by 
Benjamini-Hochberg adjustment. The microT-CDS threshold for gene target 
prediction was set to 0.70. The significantly enriched pathways associated with non-
DIPG-specific differentially expressed miRNAs are shown in Table 5.12 and those 
associated with DIPG-specific differentially expressed miRNAs are shown in Table 
5.13. Among the 10 most significantly enriched pathways associated with each 
subgroup, 4 pathways were common to both subgroups, comprising proteoglycans in 
cancer, Mucin type O-glycan biosynthesis, Glioma and ErbB signaling pathway. 
Notably, 2 important cancer-related pathways were identified in DIPG. These were 
Estrogen signalling pathway and signalling pathways regulating pluripotency of stem 
cells. 
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Upregulated
miRNAs Accession
1 hsa-miR-138 MIMAT0000430
2 hsa-miR-144 MIMAT0000436
3 hsa-miR-3142 MIMAT0015011
4 hsa-miR-98 MIMAT0000096
Downregulated
miRNAs Accession
1 hsa-miR-16-2* MIMAT0004518
2 hsa-miR-191 MIMAT0000440
3 hsa-miR-1915* MIMAT0007891
4 hsa-miR-200c MIMAT0000617
5 hsa-miR-3074-3p MIMAT0015027
6 hsa-miR-3121-5p MIMAT0019199
7 hsa-miR-34a* MIMAT0004557
8 hsa-miR-3659 MIMAT0018080
9 hsa-miR-3671 MIMAT0018094
10 hsa-miR-3917 MIMAT0018191
11 hsa-miR-3923 MIMAT0018198
12 hsa-miR-421 MIMAT0003339
13 hsa-miR-425 MIMAT0003393
14 hsa-miR-432* MIMAT0002815
15 hsa-miR-4324 MIMAT0016876
16 hsa-miR-4454 MIMAT0018976
17 hsa-miR-4467 MIMAT0018994
18 hsa-miR-4478 MIMAT0019006
19 hsa-miR-4493 MIMAT0019028
20 hsa-miR-4498 MIMAT0019033
21 hsa-miR-4503 MIMAT0019039
22 hsa-miR-4535 MIMAT0019075
23 hsa-miR-4638-5p MIMAT0019695
24 hsa-miR-4757-3p MIMAT0019902
25 hsa-miR-4769-3p MIMAT0019923
26 hsa-miR-4778-5p MIMAT0019936
27 hsa-miR-4783-5p MIMAT0019946
28 hsa-miR-4787-5p MIMAT0019956
29 hsa-miR-4802-3p MIMAT0019982
30 hsa-miR-4803 MIMAT0019983
31 hsa-miR-502-3p MIMAT0004775
32 hsa-miR-504 MIMAT0002875
33 hsa-miR-520a-3p MIMAT0002834
34 hsa-miR-521 MIMAT0002854
35 hsa-miR-613 MIMAT0003281
36 hsa-miR-759 MIMAT0010497
37 hsa-miR-769-3p MIMAT0003887
Upregulated
miRNAs Accession
1 hsa-miR-181a-2* MIMAT0004558
2 hsa-miR-3144-3p MIMAT0015015
Downrregulated
miRNAs Accession
1 hsa-miR-1225-3p MIMAT0005573
2 hsa-miR-1231 MIMAT0005586
3 hsa-miR-1233 MIMAT0005588
4 hsa-miR-1234 MIMAT0005589
5 hsa-miR-125b MIMAT0000423
6 hsa-miR-1272 MIMAT0005925
7 hsa-miR-1827 MIMAT0006767
8 hsa-miR-2277-5p MIMAT0017352
9 hsa-miR-296-3p MIMAT0004679
10 hsa-miR-3136-3p MIMAT0019203
11 hsa-miR-3155b MIMAT0019012
12 hsa-miR-3159 MIMAT0015033
13 hsa-miR-3185 MIMAT0015065
14 hsa-miR-3607-3p MIMAT0017985
15 hsa-miR-3647-3p MIMAT0018067
16 hsa-miR-371-3p MIMAT0000723
17 hsa-miR-3960 MIMAT0019337
18 hsa-miR-4291 MIMAT0016922
19 hsa-miR-4508 MIMAT0019045
20 hsa-miR-4529-3p MIMAT0019068
21 hsa-miR-4639-3p MIMAT0019698
22 hsa-miR-4640-3p MIMAT0019700
23 hsa-miR-4692 MIMAT0019783
24 hsa-miR-4704-5p MIMAT0019803
25 hsa-miR-4742-5p MIMAT0019872
26 hsa-miR-4747-5p MIMAT0019882
27 hsa-miR-4774-5p MIMAT0019929
28 hsa-miR-4793-5p MIMAT0019965
29 hsa-miR-501-5p MIMAT0002872
30 hsa-miR-549 MIMAT0003333
31 hsa-miR-616 MIMAT0004805
A B
Table 5.11 Differentially expressed miRNAs unique to tumour subgroups within paediatric 
HGG short-term cell cultures 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Differentially expressed miRNAs unique to non-DIPG paediatric subgroup. B. Differentially 
expressed miRNAs unique to DIPG subgroup. 
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KEGG pathway p-value Genes miRNAs
1 Proteoglycans in cancer 0 149 33
2 Mucin type O-Glycan biosynthesis 0 23 26
3 Pancreatic cancer 0 58 32
4 Choline metabolism in cancer 0 84 33
5 Glioma 0 53 32
6 ErbB signaling pathway 0 72 35
7 Thyroid hormone signaling pathway 0 93 33
8 Colorectal cancer 0 53 33
9 Adherens junction 0 61 34
10 Endocytosis 0 153 37
11 mTOR signaling pathway 0 52 32
12 Renal cell carcinoma 0 56 32
13 GABAergic synapse 0 65 31
14 Phosphatidylinositol signaling system 0 61 33
15 Melanoma 0 59 32
16 Ras signaling pathway 0 163 34
17 MAPK signaling pathway 0 183 37
18 Hippo signaling pathway 0 110 37
19 Endometrial cancer 0 44 30
20 Pathways in cancer 0 276 38
21 Lysine degradation 0.001 37 32
22 Axon guidance 0.001 91 36
23 Prostate cancer 0.001 69 30
24 ABC transporters 0.001 38 24
25 Platelet activation 0.001 94 34
26 FoxO signaling pathway 0.001 100 33
27 Non-small cell lung cancer 0.002 44 32
28 Gap junction 0.002 65 35
29 HIF-1 signaling pathway 0.002 80 31
30 Bacterial invasion of epithelial cells 0.002 59 31
31 Glutamatergic synapse 0.002 83 34
32 Endocrine and other factor-regulated calcium reabsorption 0.002 34 31
33 Chronic myeloid leukemia 0.002 55 32
34 Insulin signaling pathway 0.003 103 33
35 Neurotrophin signaling pathway 0.004 89 36
36 Circadian rhythm 0.004 26 25
37 Focal adhesion 0.006 145 36
38 Rap1 signaling pathway 0.006 146 34
39 Signaling pathways regulating pluripotency of stem cells 0.006 99 34
40 Fc gamma R-mediated phagocytosis 0.007 68 32
41 AMPK signaling pathway 0.007 88 34
42 Nicotine addiction 0.008 30 32
43 Sphingolipid signaling pathway 0.008 81 34
44 TGF-beta signaling pathway 0.008 59 34
45 Acute myeloid leukemia 0.008 45 30
46 PI3K-Akt signaling pathway 0.008 228 36
47 Morphine addiction 0.009 66 32
Table 5.12 KEGG pathways associated with differentially expressed miRNAs unique to non-
DIPG short-term cell cultures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significantly enriched KEGG pathways associated with differentially expressed miRNAs unique to 
non-DIPG subgroup of paediatric HGG were identified using the ‗genes union‘ module (microT-
threshold 0.7) in DIANA mirPath. Pathways with enrichment p-value<0.05 (FDR ON) are shown. The 
table is ranked by enrichment p-value. 
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KEGG pathway p-value Genes miRNAs
1 Mucin type O-Glycan biosynthesis 0 22 16
2 Pathways in cancer 0 255 30
3 ErbB signaling pathway 0 68 26
4 Estrogen signaling pathway 0 68 27
5 Signaling pathways regulating pluripotency of stem cells 0 99 27
6 Cocaine addiction 0 37 27
7 Renal cell carcinoma 0 53 25
8 Glioma 0 48 25
9 Proteoglycans in cancer 0 128 28
10 Glutamatergic synapse 0 77 29
11 Endocrine and other factor-regulated calcium reabsorption 0 36 26
12 Adrenergic signaling in cardiomyocytes 0 97 29
13 Axon guidance 0 84 28
14 Prostate cancer 0 64 28
15 Ubiquitin mediated proteolysis 0 96 26
16 Dopaminergic synapse 0 87 29
17 Thyroid hormone signaling pathway 0 80 28
18 Amphetamine addiction 0 46 27
19 Ras signaling pathway 0 141 31
20 Prion diseases 0.001 17 17
21 Endometrial cancer 0.001 39 27
22 Melanoma 0.001 51 25
23 Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate 0.001 14 13
24 Chronic myeloid leukemia 0.001 51 25
25 Colorectal cancer 0.001 44 26
26 Endocytosis 0.001 135 30
27 Non-small cell lung cancer 0.001 40 24
28 Cholinergic synapse 0.001 78 26
29 Prolactin signaling pathway 0.002 47 28
30 Hepatitis B 0.003 92 29
31 Wnt signaling pathway 0.003 89 28
32 Choline metabolism in cancer 0.004 68 26
33 Neurotrophin signaling pathway 0.004 80 30
34 Melanogenesis 0.004 67 28
35 TGF-beta signaling pathway 0.004 50 26
36 cGMP-PKG signaling pathway 0.004 104 29
37 Thyroid hormone synthesis 0.005 46 26
38 Gap junction 0.005 58 27
39 cAMP signaling pathway 0.005 125 30
40 Long-term potentiation 0.006 47 29
41 Adherens junction 0.008 50 26
42 GnRH signaling pathway 0.008 61 26
43 Rap1 signaling pathway 0.009 129 29
44 Pancreatic cancer 0.009 45 22
45 Sphingolipid signaling pathway 0.009 72 26
46 Phosphatidylinositol signaling system 0.009 54 25
47 FoxO signaling pathway 0.009 84 27
Table 5.13 KEGG pathways associated with differentially expressed miRNAs unique to DIPG 
short-term cell cultures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significantly enriched KEGG pathways associated with differentially expressed miRNAs unique to 
DIPG subgroup of paediatric HGG were identified using the ‗genes union‘ module (microT-threshold 
0.7) in DIANA mirPath. Pathways with enrichment p-value<0.05 (FDR ON) are shown. The table is 
ranked by enrichment p-value.  
214 
 
5.2.5 Differential expression of miRNAs between H3F3A-mutant and wild 
type paediatric HGG short-term cell cultures 
To determine the association between miRNA expression and H3F3A mutation 
(K27M) in paediatric HGG short-term cell cultures, the miRNA expression profiles 
were generated for H3F3A-mutant and wild-type subgroups of paediatric HGG short-
term cell cultures as compared to NHA. A one-way ANOVA test was performed to 
identify significantly differentially expressed miRNAs (FC-2, p<0.05) in each 
subgroup versus NHA using Partek Genomics suite v6.6 (Partek Inc., USA). There 
were 164 miRNAs (22 upregulated and 142 downregulated) that were significantly 
differentially expressed in H3F3A-mutant subgroup and 151 miRNAs (12 
upregulated and 139 downregulated) that were significantly differentially expressed 
in the H3F3A-wild type subgroup as compared to NHA. Both common and unique 
miRNAs in these 2 subgroups are displayed as a Venn diagram as shown in Figure 
5.10. 
There were 124 miRNAs common (5 upregulated and 119 downregulated) between 
the 2 subgroups. There were 39 miRNAs (17 upregulated and 22 downregulated) 
unique to H3F3A-mutant subgroup and 27 miRNAs (7 upregulated and 20 
downregulated) unique to the wild type subgroup. KEGG pathway analysis was 
performed using the unique miRNAs identified in each subgroups using DIANA-
miRPath v3.0 (http://www.microrna.gr/miRPathv3). Using the ‗pathways union‘ 
module in DIANA mirPath, a union set of significantly enriched pathways were 
generated. The gene targets of miRNAs were predicted using microT-CDS algorithm 
(threshold-0.7). The enrichment analysis was performed using Fisher‘s exact test 
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(hypergeometric distribution); Benjamini-Hochberg adjustment was used for 
multiple test correction. The significantly enriched (p<0.05) KEGG pathways 
associated with the H3F3A-mutant subgroup and the wild-type subgroup are given in 
Table 5.15 and Table 5.16 respectively. 
 
 
 
 
 
Figure 5.10 Venn diagram showing common and unique miRNAs in H3F3A (K27M)-mutant 
and wild type paediatric HGG short-term cell cultures. A. The upregulated miRNAs (2-fold 
change, p<0.05) in H3F3A (K27M) mutant and upregulated miRNAs in wild type subgroups relative 
to NHA are compared. The H3F3A-mutant subgroup had 17 unique miRNAs; the H3F3A-wild type 
subgroup had 7 unique miRNAs, while 5 miRNAs were common to both the subgroups. The numbers 
in parenthesis show the total number of differentially upregulated miRNAs identified in each 
subgroup. B. The downregulated miRNAs (2-fold change, p<0.05) in H3F3A (K27M) mutant and 
downregulated miRNAs in wild type subgroups relative to NHA are compared. The H3F3A-mutant 
subgroup had 22 unique miRNAs; H3F3A-wild type subgroup had 20 unique miRNAs, while 119 
miRNAs were common to both the subgroups. The numbers in parenthesis show the total number of 
differentially upregulated miRNAs identified in each subgroup. 
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Upregulated
miRNAs Accession
hsa-miR-138 MIMAT0000430
hsa-miR-142-3p MIMAT0000434
hsa-miR-144 MIMAT0000436
hsa-miR-183* MIMAT0004560
hsa-miR-199a-5p MIMAT0000231
hsa-miR-4258 MIMAT0016879
hsa-miR-98 MIMAT0000096
Downregulated
miRNAs Accession
hsa-miR-1266 MIMAT0005920
hsa-miR-136 MIMAT0000448
hsa-miR-16-2* MIMAT0004518
hsa-miR-191 MIMAT0000440
hsa-miR-1915* MIMAT0007891
hsa-miR-200c MIMAT0000617
hsa-miR-3074-3p MIMAT0015027
hsa-miR-3121-5p MIMAT0019199
hsa-miR-3185 MIMAT0015065
hsa-miR-3917 MIMAT0018191
hsa-miR-425 MIMAT0003393
hsa-miR-4516 MIMAT0019053
hsa-miR-4535 MIMAT0019075
hsa-miR-4638-5p MIMAT0019695
hsa-miR-4674 MIMAT0019756
hsa-miR-4703-3p MIMAT0019802
hsa-miR-4749-3p MIMAT0019886
hsa-miR-4795-5p MIMAT0019968
hsa-miR-4803 MIMAT0019983
hsa-miR-759 MIMAT0010497
Upregulated
miRNAs Accession
hsa-miR-100* MIMAT0004512
hsa-miR-1539 MIMAT0007401
hsa-miR-30d* MIMAT0004551
hsa-miR-3126-3p MIMAT0015377
hsa-miR-3591-5p MIMAT0019876
hsa-miR-4656 MIMAT0019723
hsa-miR-4677-5p MIMAT0019760
hsa-miR-4699-5p MIMAT0019794
hsa-miR-4713-5p MIMAT0019820
hsa-miR-4776-5p MIMAT0019932
hsa-miR-518f* MIMAT0002841
hsa-miR-520g MIMAT0002858
hsa-miR-548g MIMAT0005912
hsa-miR-575 MIMAT0003240
hsa-miR-181a-2* MIMAT0004558
hsa-miR-3622a-3p MIMAT0018004
hsa-miR-486-5p MIMAT0002177
Downregulated
miRNAs Accession
hsa-miR-1236 MIMAT0005591
hsa-miR-1272 MIMAT0005925
hsa-miR-212 MIMAT0000269
hsa-miR-3065-3p MIMAT0015378
hsa-miR-324-5p MIMAT0000761
hsa-miR-3616-3p MIMAT0017996
hsa-miR-3687 MIMAT0018115
hsa-miR-369-3p MIMAT0000721
hsa-miR-380* MIMAT0000734
hsa-miR-3937 MIMAT0018352
hsa-miR-4278 MIMAT0016910
hsa-miR-4291 MIMAT0016922
hsa-miR-4326 MIMAT0016888
hsa-miR-4440 MIMAT0018958
hsa-miR-4640-3p MIMAT0019700
hsa-miR-4692 MIMAT0019783
hsa-miR-4704-5p MIMAT0019803
hsa-miR-4774-5p MIMAT0019929
hsa-miR-4778-5p MIMAT0019936
hsa-miR-4787-5p MIMAT0019956
hsa-miR-502-3p MIMAT0004775
hsa-miR-549 MIMAT0003333
hsa-miR-616 MIMAT0004805
A B
Table 5.14 Differentially expressed miRNAs unique to H3F3A (27M)-mutant and wild type 
subgroups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A)  Differentially upregulated miRNAs unique to H3F3A (K27M)-mutant subgroup B) Differentially 
upregulated miRNAs unique to H3F3A (K27M)-wild type subgroup. 
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KEGG pathway p-value Genes miRNAs
ECM-receptor interaction 0 26 4
Lysine degradation 0 25 8
Fatty acid degradation 0 5 4
Mucin type O-Glycan biosynthesis 0 14 3
Steroid hormone biosynthesis 0 10 2
Proteoglycans in cancer 0.001 84 5
Morphine addiction 0.001 24 5
Fatty acid metabolism 0.002 8 4
Thyroid hormone signaling pathway 0.004 35 4
Hippo signaling pathway 0.016 50 3
Phosphatidylinositol signaling system 0.016 33 5
A
KEGG pathway p-value Genes miRNAs
Prion diseases 0 2 3
Mucin type O-Glycan biosynthesis 0 14 9
ECM-receptor interaction 0 33 9
TGF-beta signaling pathway 0 49 9
Biosynthesis of unsaturated fatty acids 0 5 5
Lysine degradation 0 15 6
Signaling pathways regulating pluripotency of stem cells 0 61 5
Proteoglycans in cancer 0.005 115 6
Estrogen signaling pathway 0.017 49 7
Hippo signaling pathway 0.019 69 6
B
Table 5.15 KEGG pathways associated with differentially expressed miRNAs unique to H3F3A-
mutant paediatric HGG short-term cell cultures 
 
 
 
 
 
 
 
Commonly targeted pathways by H3F3A-mutant paediatric HGG identified using the ‗pathways 
union‘ module (microT-threshold 0.7) in DIANA mirPath. Pathways with enrichment p-value<0.05 
(FDR ON) are shown. The table is ranked by enrichment p-value. Pathways that are unique to H3F3A-
mutant in comparison to H3F3A-wild type are highlighted in blue. 
 
Table 5.16 KEGG pathways associated with differentially expressed miRNAs unique to H3F3A-
wild type paediatric HGG short-term cell cultures  
 
 
 
 
 
 
 
Commonly targeted pathways by H3F3A-wild type paediatric HGG identified using the ‗pathways 
union‘ module (microT-threshold 0.7) in DIANA mirPath. Pathways with enrichment p-value<0.05 
(FDR ON) are shown. The table is ranked by enrichment p-value. Pathways that are unique to H3F3A-
wild type in comparison to H3F3A-mutant are highlighted in blue. 
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The miRNAs associated with ‗signaling pathways regulating pluripotency of stem 
cells‘ were miR-212-3p, miR-369-3p, miR-4704-5p, miR-520g-3p and miR-548g-3p. 
The miRNAs associated with prion diseases were miR-1272, miR-30d-3p and miR-
520g-3p, and those associated with TGF-beta signaling pathway were miR-1236-3p, 
miR-212-3p, miR-369-3p, miR-4326, miR-4704-5p, miR-4778-5p, miR-520g-3p, 
miR-548g-3p and miR-486-5p. 
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Figure 5.11 Heat map of miRNAs versus pathways. Commonly targeted pathways by differentially 
expressed miRNAs (microT-CDS>0.70, p<0.05, FDR ON) identified by ‗pathways union‘ module in 
DIANA mirPath v3.0. A. Pathways associated with H3F3A-mutant paediatric HGG short-term 
cell cultures. 
220 
 
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Heat map of miRNAs versus pathways. Commonly targeted pathways by differentially 
expressed miRNAs (microT-CDS>0.70, p<0.05, FDR ON) identified by ‗pathways union‘ module in 
DIANA mirPath v3.0. On the heat map, each row represents a miRNA and each column represents a 
pathway. B. Pathways associated with H3F3A-wild-type paediatric HGG short-term cell 
cultures. 
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5.2.6 Association between copy number loss of ADAM3A and miRNA 
expression profiles in paediatric HGG short-term cell cultures. 
To determine the association of miRNA expression with copy number loss of 
ADAM3A in paediatric HGG short-term cell cultures, the miRNA expression profiles 
were compared between the subgroup of paediatric HGG short-term cell cultures 
with copy number loss of ADAM3A (n=10) and the subgroup without the copy 
number loss (n=7) as compared to NHA. Of the 7 members in the subgroup without 
ADAM3A loss, 4 members had gain of ADAM3A. Therefore, in order to identify 
specific changes associated with ADAM3A-loss, the subgroup with gain of ADAM3A 
gene was considered as separate subgroup. One-way ANOVA test was performed to 
identify differentially expressed and significant (FC-2, p<0.05) miRNAs in each 
group (samples with loss/gain/no change) as compared to NHA.  
There were 128 miRNAs (119 downregulated and 9 upregulated) that were 
differentially expressed in the subgroup of paediatric HGG with ADAM3A loss; 180 
miRNAs (171 downregulated and 9 upregulated) in the subgroup with ADAM3A gain 
and 216 miRNAs (208 downregulated and 8 upregulated) in the subgroup with intact 
ADAM3A. The unique miRNAs in each subgroup are represented as a Venn diagram 
in Figure 5.12. There were 112 differentially expressed miRNAs common among all 
subgroups, of which 5 were upregulated and 107 were downregulated. There were 3 
miRNAs (1 upregulated and 2 downregulated) unique to the subgroup with ADAM3A 
loss, 10 miRNAs (10 downregulated) unique to the subgroup with ADAM3A gain and 
47 miRNAs (2 upregulated and 45 downregulated) unique to the subgroup with 
intact ADAM3A. The uniquely differentially expressed miRNAs associated with 
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ADAM3A loss were miR-3142 (upregulated), and miR-3140-3p and miR-4503 
(downregulated). 
 
 
 
 
 
 
Figure 5.12 Venn diagram of differentially expressed miRNAs between samples with loss, gain 
and no change in copy number of ADAM3A. A. Upregulated miRNAs. There are 5 miRNAs 
common to all subgroups; 1 miRNA unique to ADAM3A loss. B. Downregulated miRNAs. There are 
107 miRNAs common to all subgroups; 2 miRNAs unique to ADAM3A loss. The numbers in 
parentheses indicate the differentially expressed miRNAs as compared to NHA. 
 
The KEGG pathways associated with the unique miRNAs associated with ADAM3A 
loss in paediatric HGG short-term cell cultures were identified by DIANA-miRPath 
v3.0 (http://www.microrna.gr/miRPathv3). The gene targets of deregulated miRNAs 
were predicted using microT-CDS algorithm (threshold 0.70). The p-value for 
enrichment was calculated using Fisher‘s exact test. The results are shown in Table 
5.17. 
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KEGG pathway p-value
Gene 
count
Genes
Mucin type O-Glycan biosynthesis 0 8 GALNT7, GALNT4, GALNT3
Ras signaling pathway 0 56
AKT3, EGFR, FGF12, KRAS, PAK2, PDGFC, 
VEGFC 
ErbB signaling pathway 0 27 BRAF, GSK3B,EGFR, ERBB3, PAK6, AKT3
Pathways in cancer 0 83
BRAF, FGF12, EGFR, SMAD2, WNT2B, RAF1, 
CDK6
Glioma 0 19
AKT3, BRAF, EGFR, RB1, MDM2, RAF1, 
PPIK3R5
Focal adhesion 0 51
EGFR, PAK6, RELN, VEGFC, COL4A4, BCL2, 
ROCK2
Proteoglycans in cancer 0.001 45
BRAF, PIK3R5, SMAD2, CAV2, ERBB3, 
COL21A1
Prostate cancer 0.001 24 BRAF, GSK3B, CTNNB1, PDGFC, RB1
Thyroid hormone signaling pathway 0.002 26 FOXO1, MDM2, GSK3B, PRKCA
Endometrial cancer 0.002 16 BRAF, GSK3B, AKT3, EGFR, KRAS, PIK3R1
Prolactin signaling pathway 0.002 18 CCND1, PIK3R1, KRAS, MAPK14, RELA, GSK3B
Signaling pathways regulating 
pluripotency of stem cells
0.004 33
SMAD2, SMAD3, SMAD5, INHBA, BMPR2, 
PAX6, SMARCAD1
Axon guidance 0.004 27 SEMA61, ROCK2, NFATC2, SEMA5A
Renal cell carcinoma 0.006 20 BRAF, TGFB2, KRAS, PAK6
Endocytosis 0.009 38 CAV2, TGFB2, SMAd2, SMURF2
Neurotrophin signaling pathway 0.009 29 BRAF, BCL2, PLCG2, IRS1, AKT3
Table 5.17 KEGG pathways associated with miRNAs unique to paediatric HGG short-term cell 
cultures with ADAM3A loss 
 
 
 
 
 
 
 
 
 
Significantly enriched KEGG pathways associated with differentially expressed miRNAs unique to 
subgroup of paediatric HGG with ADAM3A loss, were identified using the ‗genes union‘ module 
(microT-threshold 0.7) in DIANA mirPath. Pathways with enrichment p-value<0.05 (FDR ON) are 
shown. The table is ranked by enrichment p-value. 
5.3 Discussion  
This chapter has focussed on the genome wide investigation of differential miRNA 
expression in 17 paediatric HGG short-term cell cultures compared to NHA, with the 
aim of understanding the involvement of miRNAs in the development and 
progression of paediatric HGG. The expression patterns of miRNAs associated with 
H3F3A (K27M) mutation and copy number loss of ADAM3A, 2 of the distinct 
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genetic aberrations encountered in paediatric HGG were examined. The miRNA 
expression profiles in DIPG and non-DIPG short-term cell cultures were also 
compared with respect to NHA. Furthermore, mRNA targets of dysregulated 
miRNAs were identified using integrated analyses of miRNA and mRNA expression 
profiles in the paediatric HGG short-term cell cultures versus NHA. The findings of 
this study highlight the link between miRNAs and paediatric HGG pathogenesis.  
Global expression analysis in this study revealed distinct miRNA expression profiles 
for paediatric HGG short-term cell cultures compared to their normal counterparts. 
This is encouraging as identification of candidate miRNAs could lead to the 
development of biomarkers for early diagnosis of this disease. Large-scale variation 
in miRNA expression was observed amongst the paediatric HGG short-term cell 
cultures as identified by PCA and hierarchical clustering, which may reflect the 
characteristic heterogeneity of glioma. Each paediatric HGG short-term cell culture 
used in this study was established from a distinct population of cells from individual 
tumour biopsies and the miRNA expression profile of each paediatric HGG short-
term cell culture reflects the average expression levels of miRNAs in these 
population of cells. Regional intra-tumour heterogeneity comprised of core necrotic 
cells surrounded by cells that are highly proliferative and vascular is a well-
documented characteristic of GBM. Lages et al., (2011) reported that a set of 
miRNAs consisting of miR-15b, miR-16, miR-17, miR-20a, miR-210, let-7a, let-7b, 
let-7d and let-7f showed increased expression in the core cells that are characterised 
by hypoxic conditions.  
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MiRNA down regulation is predominant in paediatric HGG compared to normal 
cells 
In this study, the expression of 853 miRNAs was examined in 17 paediatric HGG 
short-term cell cultures in comparison to NHA. There were 162 significantly 
differentially expressed miRNAs (FC-2, p<0.05) with strikingly higher number of 
downregulated than upregulated miRNAs (152 versus 10 miRNAs). Such relative 
abundance of downregulated miRNAs has been observed in other cancers (Lu et al., 
2005). One of the reasons for this enhanced downregulation could be attributed to the 
influence of genetic aberrations on miRNA expression. It has been identified that 
about 52.5% of miRNA genes are located in regions of chromosomal instability such 
as common fragile sites that are regions of deletion (Calin et al., 2004), which may 
have an impact on the transcription of miRNA genes. Epigenetic mechanisms such as 
hypermethylation in miRNA gene promoters may also cause reduced expression of 
miRNAs. Promoter-hypermethylation-induced downregulation of miRNAs has been 
reported in several cancers (Chen et al., 2012; Lopez-Serra and Esteller, 2012; 
Menigatti et al., 2013; Vrba et al., 2013). Moreover, defective miRNA biogenesis 
could cause decreased miRNA expression. For instance, hemizygous deletion of the 
gene encoding DICER1 has been reported in 27% of various tumours and the 
reductions in DICER1 is linked to defective miRNA processing (Kumar et al., 2009).  
MiRNAs not previously reported in paediatric HGG 
The dysregulated miRNAs identified in this study included known miRNAs with 
putative oncogenic and/or tumour suppressive roles as well as miRNAs that were not 
previously reported in cancers. The 3 most significantly upregulated miRNAs were 
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miR-142-3p, miR-144, miR-138. None of these miRNAs have been previously 
reported in paediatric HGG, although increased expression of miR-142-5p has been 
identified in paediatric brain tumours such as atypical teratoid/rhabdoid tumour, 
ependymoma, adult GBM, medulloblastoma, and pilocytic astrocytoma compared to 
normal cells (Birks et al., 2011). Interestingly, deregulation of these miRNAs has 
been identified in adult glioma, suggesting similarities in miRNA deregulation 
between paediatric and adult HGG. For instance, increased expression of miR-142-
3p, the miRNA with the highest upregulation observed in this study (FC-337.09), has 
been reported in GBM cell lines (Chaudhry et al., 2010). The functional significance 
of mir-142-3p has also been observed in other cancer types. Taichi et al. (2014) 
reported a role for miR-142-3p in regulating the tumourigenicity of breast cancer 
stem cells possibly through the involvement of the canonical WNT signaling 
pathway. It has been identified as crucial in maintaining the balance between 
proliferation and differentiation of mesenchymal cells during lung development 
(Carraro et al., 2014).  
MiR-144 has shown oncogenic roles in adult glioma and other cancers (Lin et al., 
2014; Cai et al., 2015; Zhang et al., 2012), while tumour suppressive roles in uveal 
melanoma (Sun et al., 2015), suggesting context-dependent roles for this miRNA. 
The study by Lin et al., (2014) has identified EZH2 as the gene target of miR-144 in 
glioma. Overexpression of EZH2 has been identified in both adult and paediatric 
HGG (Purkait et al., 2015). MiR-138 has a pro-survival role in tumour-initiating 
glioma stem cells (GSC) and is associated with tumour recurrence, highlighting its 
role as a prognostic marker in malignant glioma (Chan et al., 2012). It has been 
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shown that miR-138 can enhance the oncogenic activity of MYC by targeting MXD1 
that competes with MYC in forming a stable complex with MAX. As MYC is a 
frequently altered target in paediatric glioma (Wu et al., 2014), this prompts 
speculation of a potential role for this miRNA in paediatric HGG. MiR-138 has also 
been shown to promote TMZ resistance in gliomas by binding to BIM, a BCL2 
interacting mediator (Stojcheva et al., 2016). This may contribute to TMZ resistance 
in paediatric HGG. The 2 most significantly downregulated miRNAs included miR-
3621 and miR-759. These miRNAs have not been reported in paediatric HGG and 
their role in other cancers has also not yet been investigated. However, based on the 
functional significance of their predicted targets, it can be speculated that these 
miRNAs may regulate important gene regulatory networks in paediatric HGG 
pathogenesis. For instance, mutations in H3.3-ATRX-DAXX chromatin remodelling 
pathway have been identified almost exclusively in paediatric HGG and in some 
cases have shown strong associations with TP53 mutations (Schwartzentruber et al., 
2012). MiR-3621 can target CHD3 (chromodomain helicase DNA binding protein 3) 
(microT-CDS prediction score-0.771), a key component of the Mi-2/NuRD histone 
deacteylase complex involved in chromatin remodelling by deacetylating histones 
and miR-759 has been identified to target TP53 (Tay et al., 2014), suggesting a 
possible link for these miRNAs to tumourigenic events in paediatric HGG.   
Role of miRNAs in paediatric HGG in modulating cancer-related pathways  
The KEGG pathway analysis of differentially expressed miRNAs in paediatric HGG 
short-term cell cultures (upregulated and downregulated) revealed alterations in 2 
important glycan-related pathways comprising Mucin type O-glycan biosynthesis 
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and Proteoglycans in cancer, indicating the potential significance of aberrant glycan 
biosynthesis in paediatric HGG. Glycans and membrane-bound glyco-conjugates 
constitute a large spectrum of biomolecules mediating a variety of fundamental 
cellular processes associated with cancer development and progression such as cell-
cell and cell-ECM interactions (Pinho et al., 2009; Zhao et al., 2008), inflammation, 
immune surveillance (Rabinovich and Toscano 2009), signal transduction (Dennis et 
al, 2009) and cellular metabolism (Gomes et al., 2013). Mucin-type O-glycosylation, 
the most common form of protein O-glycosylation constitutes glycans attached via 
O-linked N-acetylgalactosamine (GalNAc) to amino acid residues such as serine and 
threonine. Aberrant O-linked glycosylation is associated with many tumour types 
including tumours of brain, breast, ovary and pancreatic cells (Song et al., 2010; 
Hofmann et al., 2015; Pinho and Reis, 2015). Characteristic patterns of glycosylation 
exist in different cancers and identification of such tumour-specific changes in 
glycosylation has shown encouraging results in the development of diagnostic 
biomarkers in some cancers. For instance, α-fetoprotein L3 and α-fetoprotein P4+P5 
can act as early diagnostic biomarkers and differentiate HCC from liver cirrhosis 
(Sato et al., 1993; Song et al., 2010). Given the complexity of the human glycome 
and proteoglycome it is highly challenging to characterise the glcosylation patterns in 
tumours. However, development of high-throughput glycan microarrays (Rillahan 
and Paulson, 2011) may hold promise for the identification of specific glycosylation 
signatures associated with paediatric HGG that could be exploited for the 
development of early diagnostic/prognostic biomarkers and may also help to 
understand their contribution to the heterogeneity of these tumours.  
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Integrative analysis to identify gene targets of miRNAs 
One of the approaches to interpret the effect of miRNA dysregulation in cancers is to 
identify the role of its mRNA targets. However, miRNA target identification is 
highly challenging as each miRNA can target hundreds of mRNAs while a single 
mRNA can also be targeted by several miRNAs (Krek et al., 2005; Lee et al., 
2005). To add to the complexity, multiple miRNAs can also cooperatively target a 
number of mRNAs and miRNAs also exhibit tissue-specific expression signatures 
(Calin et al., 2004; Krek et al., 2005; Lu et al., 2005). Although databases such as 
TargetScan and microT-CDS enable putative identification of miRNA targets based 
on sequence complementarity in 3‘UTR and/or CDS regions, the false positive rates 
for such speculative matches is very high (Friedman et al., 2009). Integrative 
miRNA-mRNA expression analysis helps to identify more accurate miRNA-
mRNA interaction pairs. The integrative analysis in this study identified 22 
miRNA-mRNA interaction pairs, which predominantly included miRNAs with 
multiple gene targets. Six gene targets were identified for miR-520a-3p 
comprising AAK1, EIF5, MINK1, NBEAL2, PDLIM5 and ZFHX4. Little is known 
about the role of these targets in paediatric HGG. PDLIM5 (PDZ and LIM domain 
containing 5) is a member of the PDZ-LIM family of genes that are involved in 
signal transduction between the nucleus and the cytoskeleton and contributes to 
organ development. It has been identified as a novel AMPK (AMP-activated 
protein kinase) substrate and participates in inhibition of cell migration that occurs 
via suppression of the Rac1-Arp2/3 signaling pathway (Yan et al., 2015). Among 
the multiple mRNAs that were targeted by single miRNAs, ZFHX4 (zinc finger 
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homeobox 4) had the highest number of targeting miRNAs comprising miR-520a-
3p, miR-613, miR-502-3p and miR-369-3p. ZFHX4 has been identified to interact 
with the chromatin remodelling complex NuRD and has been shown to regulate 
the tumour initiating cells (TICs) in GBM (Chudnovsky et al., 2014).  
Comparison of miRNA expression profiles between DIPG and non-DIPG short-
term cell cultures 
Comparison of the miRNA expression profiles between DIPG and non-DIPG 
paediatric HGG short-term cell cultures revealed that the majority of the 
differentially expressed miRNAs were common to both the groups, but this could be 
due to the relatively smaller number of DIPG samples analysed here compared to 
non-DIPG. There were 33 miRNAs (8 upregulated and 137 downregulated) that were 
uniquely deregulated in the DIPG short-term cell cultures. The detection of specific 
miRNAs that were deregulated in the DIPG subgroup in this study further supports 
that these tumours indeed harbour unique molecular events. Most of these miRNAs 
have not yet been investigated in DIPG. Interestingly, some of the downregulated 
miRNAs have been previously reported in other cancer types. Of note, miR-125b is 
one of the widely investigated miRNAs and has demonstrated contradicting roles in 
different cancers, suggesting a context-dependent role for this miRNA. For instance, 
upregulation and oncogenic potential of miR-125b has been shown in adult glioma, 
pancreatic and colorectal cancers, while downregulation of this miRNA has been 
identified in breast cancer, head and neck cancers, melanoma, hepatocellular 
carcinoma and osteosarcoma (Xia et al., 2009; Liu et al., 2011; Gong et al., 2013; 
Kappelmann et al., 2013; Nakanishi et al., 2014). Among the most uniquely enriched 
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pathways in DIPG, estrogen signaling pathway and signalling pathways regulating 
pluripotency of stem cells were the most affected. Some GBM cells express estrogen 
receptors (ERs) and specific modulation of ER activity has shown apoptosis 
inhibition activity in vitro and in vivo in ER-negative GBM cells (Hui et al., 2004). 
Combined histone deacetylase and estrogen receptor inhibition has shown apoptotic 
activity in breast cancer through HDAC-mediated Akt1 downregulation in an 
estrogen-dependent mechanism (Thomas et al., 2013). With HDAC1 inhibitors 
holding promise for clinical trials in DIPG, it would be interesting to investigate the 
contribution of estrogen receptors in the progression of these tumours as it may 
provide opportunities for combination therapy and improved clinical response. The 
existence of a tumour sub-population of cells with self-renewing capacities termed as 
‗cancer stem cells‘ or ‗cancer initiating cells‘ has been demonstrated in DIPG (Monje 
et al., 2011; Puget et al., 2012; Caretti et al., 2014). The contribution of these cells to 
treatment resistance and tumour recurrence has been extensively investigated in adult 
GBM as well as in several other cancers. Validation of the identified miRNAs and 
identification their deregulated gene targets in DIPG can therefore help us understand 
more about the clinical heterogeneity and resistance mechanisms in these tumours 
that can accelerate the development of efficient therapeutic targets. 
MiRNAs associated with H3F3A (K27M) mutation 
The H3F3A (K27M) mutation is an important driver event in paediatric HGG, 
particularly DIPG and has raised great interest owing to its connection with 
chromatin remodelling and regulation of other epigenetic mechanisms. Recently, Jha 
et al. (2014) has reported a unique set of 97 miRNAs (62 upregulated and 35 
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downregulated) in H3F3A-mutant paediatric GBM compared to the wild type. In the 
current study, the unique profiles of H3F3A-mutant subgroup was evident from the 
unsupervised hierarchical clustering analysis in which the 2 mutant paediatric HGG 
short-term cell cultures clustered together irrespective of their tumour type or the 
presence/absence of other genetic aberration (ADAM3A loss) (See Figure 5.12). A 
total of 39 miRNAs (17 upregulated and 22 downregulated) were uniquely 
differentially expressed in the H3F3A-mutant subgroup. This clearly indicates that 
H3F3A (K27M) mutation influences the miRNA expression in paediatric HGG. 
Pathway analysis of these miRNAs using their predicted gene targets revealed 
KEGG pathways such as Prion diseases, TGF-beta signaling, biosynthesis of 
unsaturated fatty acids,  signaling pathways regulating pluripotency of stem cells and 
estrogen signaling pathway to be uniquely deregulated in the mutant subgroup. 
Dysregulation of these pathways are associated with highly aggressive tumours. For 
instance, TGF-beta signaling pathway regulates a number of crucial cellular 
processes such as growth, embryogenesis, differentiation, wound healing, and 
apoptosis (Bottner et al., 2000). Increased activation of this pathway confers poor 
prognosis in GBM patients (Bruna et al, 2007). It can also induce the self-renewal 
capacity of glioma-initiating cells (GICs) (Peneulas et al., 2009). Prion proteins 
contribute to invasiveness and doxorubicin-resistance in colon cancer (Chieng and 
Say, 2015) and lower expression of estrogen receptor Erβ has been associated with 
poor clinical outcome (Batistatou et al., 2006). All these point toward a highly 
aggressive phenotype for the mutant subtype and a potential role for miRNAs in 
establishing this phenotype in paediatric HGG. Integrative analysis of miRNA and 
mRNA expression profiles of the mutant and wild type subgroups may provide better 
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insights into how H3F3A mutation regulates the miRNA expression and how it 
affects downstream cellular processes in paediatric HGG. 
MiRNAs associated with ADAM3A loss in paediatric HGG short-term cell cultures 
An important finding in this study was the identification of miRNAs associated with 
loss of the pseudogene, ADAM3A. Over the last few years, there has been increasing 
interest in understanding the role of pseudogenes and their interaction with the 
coding and non-coding part of the genome. Studies have demonstrated in multiple 
cancers that processed transcripts of some pseudogenes share miRNA responsive 
elements (MREs) with their parent genes competing for the same miRNAs and 
thereby regulating the transcription of the parent genes (Chen et al., 2015; Yu et al., 
2014). Interestingly, an extensive genome-wide integrative mRNA-miRNA analysis 
in adult GBM has revealed over 248,000 miRNA-mRNA interactions, of which the 
transcripts of approximately 7000 genes act as competing endogenous RNAs and 148 
genes act through alternative mechanisms (Sumazin et al., 2011). This provides clues 
to the strikingly complex network of cellular events regulated by non-coding 
elements in glioma. In the current study, 3 miRNAs were uniquely expressed in 
paediatric HGG short-term cell cultures with loss of ADAM3A and the predicted 
mRNA targets of all of them have potential links to cancer-related pathways, 
indicating a putative role for ADAM3A in tumourigenesis. The miRNAs associated 
with ADAM3A loss were miR-3142 (upregulated), and miR-3140-3p and miR-4503 
(downregulated); the roles of these miRNAs have not been investigated yet. 
However, as each miRNA can regulate hundreds of targets, it can be speculated that 
the deregulated expression of these miRNAs may have significant consequence on 
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the miRNA-mRNA equilibrium in various cellular pathways. As described in 
Chapter 4, dysregulation of ADAM3A has been observed in paediatric HGG and a 
few other cancer types, but not in adult HGG, suggesting this as a distinguishing 
property of these tumours. Therefore, the potential involvement of ADAM3A-
associated miRNAs in crucial cancer-related pathways highlights the importance of 
future investigation of this finding in paediatric HGG. This may also provide insights 
into the selective pressure that may exist in these tumours for driving the genetic loss 
of ADAM3A. 
Limitations 
There are several limitations to this study. Although the 3D microarray Oligo chip 
used in this study is highly sensitive and can monitor the expression of 1719 
miRNAs, nearly half of these miRNAs did not show any expression in any of the 
samples. A similar issue was reported by Koo and colleagues who used the 3D 
microarray chip with 2019 mounted probes and observed missing valued data for a 
significant proportion of these miRNAs (Koo et al., 2015). However, the number of 
miRNAs with missing values was not mentioned. It is not clear if this observed loss 
of data is a technical fault. A limitation of the integrative analysis in this study was 
that the miRNA and mRNA expression profiling of paediatric HGG short-term 
cultures was not conducted at the same time. Also, not all samples that were 
profiled for miRNA expression were analysed for mRNA expression. 
Simultaneous investigation of miRNA and mRNA expression analysis of the same 
samples is ideal for identification of accurate miRNA-mRNA interaction pairs. 
However, such ideal scenario is difficult to achieve in microarray experiments 
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using paediatric HGG samples due to the difficulty in procuring these rare 
samples. Considering this, only those miRNA-mRNA pairs with strong correlation 
(R=0.70) were chosen as highly statistically significant in order to avoid reporting 
false positives.    
5.3 Conclusions 
To conclude, although the data provided here remain descriptive, evidence suggests 
crucial roles for the identified miRNA targets in cellular processes associated with 
tumourigenesis emphasising the importance of future functional studies to examine 
the roles of these tarets in paediatric HGG. These may lead to the translation of 
miRNAs into useful biomarkers and therapeutic targets for paediatric HGG. 
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CHAPTER 6 
Genome-wide methylation profiling in 
DIPG short-term cultures using illumina 
infinium HumanMethylation 450K 
methylation array 
 
 
 
 
 
237 
 
6.1 Introduction 
Genetic studies in paediatric HGG including DIPGs have primarily focussed on copy 
number events and mutations in genes that contribute to the molecular pathogenesis 
of these tumours (Barrow et al., 2010; Paugh et al., 2010; Jones et al., 2012; Diaz and 
Baker, 2014). However, compared to adult HGG, such genetic changes are found at 
low frequencies in childhood HGG. In addition, a proportion of these tumours do not 
show any major chromosomal aberrations (Bax et al., 2010; Buczkowicz et al., 
2014). Nevertheless, these studies have unveiled valuable information on similarities 
and disparities in genetic alterations between distinct subgroups within paediatric 
HGG, especially between DIPGs and supratentorial HGG (Wu et al., 2012; Jones and 
Baker, 2014; Wu et al., 2014). It is apparent that the development of paediatric HGG 
is not only determined by changes at the DNA level, but also by variations in the 
levels of expression of a range of genes regulated by epigenetic mechanisms. The 
discovery of histone mutations, as well as the identification of miRNA dysregulation 
in paediatric HGG provides further evidence of the influence of epigenetic 
abnormalities on gliomagenesis in the paediatric population (Jha et al., 2014; 
Schwartzentruber et al., 2012; Wu et al., 2012). 
Aberrant DNA methylation in promoter CpG islands and associated gene silencing 
has been the most widely explored epigenetic alteration in cancers (Jones, 2002). 
Promoter hypermethylation-induced gene silencing of multiple tumour suppressor 
genes has been identified in almost all cancers (Jones and Laird, 1999; Jones and 
Baylin, 2007; Esteller, 2008; Morris et al., 2008; Baylin and Herman, 2000; Pellacani 
et al., 2014; Du et al., 2016; He et al., 2016). In adult astrocytoma, DNA 
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hypermethylation has been reported in genes such as MGMT, HIC-1, ABL, PTEN, 
THBS1, TIMP3, CDKN2A, and CDKN2B, among numerous others (Esteller et al., 
2000; Reifenberger et al., 2012; Lee et al, 2015). Promoter methylation of MGMT 
represents an important diagnostic and prognostic biomarker to predicting clinical 
response to alkylating agent therapy in adult GBM patients (Esteller et al., 2000; 
Stupp et al., 2005; Weller et al., 2010). In contrast to methylation studies in adult 
GBM, there are very few comprehensive DNA methylation studies conducted in 
paediatric HGG so far. Jha et al. (2014) conducted methylation profiling of 21 
paediatric GBM tumours using the Infinium HumanMethylation 27 BeadChip and 
reported hypermethylation of some of the known cancer-related genes such as 
RASSF1, TTC12 and CCDC8 in these tumours. They also identified distinct 
differences in methylation profiles between adult and paediatric GBM. There are 
only 2 reported studies that carried out genome-wide methylation profiling in DIPG 
(Buczkowicz et al., 2014; Saratsis et al., 2014). In the study by Buczkowicz et al., 
2014, 3 distinct subgroups within these tumours were identified, which included a 
subgroup with a hypermethylated profile.  
Investigation of DIPG-specific DNA hypermethylation events may aid the  
identification of candidate genes that can provide better insights into the 
pathogenesis of these tumours and may also lead to the identification of biomarkers 
of therapeutic/prognostic/diagnostic significance. The aim of this study was to 
identify candidate genes that were downregulated in DIPG short-term cell cultures 
due to promoter hypermethylation, using Illumina Infinium Human Methylation 
450K BeadChip array. The downregulation of the identified genes was validated in 
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DIPG and non-DIPG short-term cell cultures and the frequencies of downregulation 
of these genes in both the tumour subgroups were compared. In addition, tumour 
suppressive roles of candidate genes were evaluated in cell culture models.   
6.2 Results 
6.2.1 Genome-wide methylation profiling in paediatric DIPG short-term cell 
cultures using Illumina Infinium HumanMethylation 450 K microarray 
To identify candidate genes dysregulated in DIPG short-term cell cultures due to 
promoter CpG hypermethylation, global methylation profiles were generated for 3 
DIPG short-term cultures (IN2087, IN2102 and IN2675) and a normal human 
astrocytes control sample (NHA) using Illumina Infinium HumanMethylation 450K 
BeadChip microarray as described in 2.8.2. The normalised data from these samples 
provided by Cambridge Genome Services, UK, were analysed using a 
comprehensive screening strategy. The Methylation 450 K data for 14 non-DIPG 
short-term cell cultures used in this analysis were generated from the same BeadChip 
by a colleague as part of ongoing research in the laboratory.  
The Infinium microarray interrogates 485,577 probes covering about 99% of Refseq 
genes with several sites in the transcription start site (TSS200 and TSS1500), 5‘UTR, 
first exon, gene body and 3‘UTR. To ensure only promoter-associated genes were 
included in the analysis, the probes spanning 5‘ regions (5‘UTR) of the genes and up 
to 1500 base pairs upstream of their transcription start sites (TSS200 and TSS1500) 
(n=132665) were used for this analysis. This excluded probes with CpGs on the X 
chromosome to avoid gender-related bias. As the focus of this study was to identify 
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methylation of protein-coding genes, the probes representing miRNA genes located 
in 5‘UTR, TSS200 and TSS1500 (n=1100) were also excluded from this analysis. 
Bioinformatic analysis of these miRNA-associated probes in DIPG short-term cell 
cultures were carried out separately, the results of which are presented in 6.2.5.  
The promoter-associated probes were filtered based on their beta values to identify 
those probes that were frequently hypermethylated in DIPG short-term cell cultures 
in comparison to NHA.  A beta value is a quantitative measure of methylation that 
ranges from 0- ‗no methylation‘ to 1- ‗complete methylation‘. This value 
corresponds to the ratio of the methylated probe intensity over the sum of methylated 
and unmethylated probe intensities. Previous methylation 450 K data analyses of 
cancer samples using beta value method have used beta values above 0.75 
(methylated) in tumour and below 0.25 (unmethylated) in its respective normal 
sample to consider probes as differentially methylated (Milani et al., 2010; Lokk et 
al., 2012; Lu et al., 2014). In this study, 2 levels of stringency were applied to 
identify methylated probes in DIPG short-term cell cultures – one with probe beta 
values of >0.75 in tumour and <0.25 in normal control, the other with probe beta 
values of >0.85 in tumour and <0.15 in normal control (more stringent). Based on 
these, 2 approaches were followed in this study to identify differentially methylated 
genes in DIPG short-term cell cultures compared to NHA. The genes identified in 
each approach were subjected to further filters to identify biologically significant 
candidates. A schematic of the screening strategy for identification of candidate 
genes is given in Figure 6.1. 
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As a first approach, a relaxed filter was applied to identify frequently methylated 
genes in DIPG in comparison to NHA. A methylated probe in this approach was 
defined by beta value >0.75 in 2 of 3 DIPG short-term cell cultures and beta value < 
0.25 in NHA, which identified 1054 probes representing 998 genes. To prioritise 
genes to those in which promoter hypermethylation likely induces transcription 
inactivation, an additional filter was applied. The gene expression profiles of the 
same samples were previously generated in the lab using Affymetrix U133A array 
(unpublished data). The normalised and filtered data consisting of 22,215 
informative probes from these samples were available as .txt files with present 
(expressed), absent (not expressed) or marginal (marginally expressed) calls for each 
probe on the array. To identify frequently downregulated genes in DIPG short-term 
cell cultures in comparison to NHA, probes with absent calls in 2 of 3 DIPG short-
term cell cultures, and present calls in NHA were identified, which resulted in 928 
probes representing 805 genes. These genes were then compared with the 
differentially methylated genes, which identified 43 common genes that were both 
frequently methylated and downregulated in DIPG short-term cell cultures. Of these, 
8 genes did not have CpG Island in its promoter region as predicted by the human 
genome browser (www.genome.ucsc.edu) and were excluded, resulting in 35 genes.  
A broad literature review was carried out on the shortlisted genes to prioritise 
candidate genes for further validation. Genes with known associations with cancers 
or with functional significance in cellular processes deregulated in cancers such as 
cell cycle, apoptosis, proliferation, invasion, migration, or angiogenesis were 
prioritised.  
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Figure 6.1 Schematic of the screening strategy used in the identification of candidate genes differentially methylated in DIPG. Methylation 450 K data from 
3 DIPG short-term cell cultures and NHA were analysed using 2 approaches.  Forty genes were shortlisted for validation in the laboratory.  
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As the gene expression data used in this study were run on an older platform of 
Affymetrix microarray (U133A), there were several probes on the array with missing 
annotations. For instance, of the 928 probes with absent calls in 2 of 3 DIPG short-
term cell cultures, 87 probes did not have annotations. Also, taking into account that 
the gene expression and methylation microarray analysis were done at 2 different 
time points, a second approach was followed to identify candidate genes based on 
methylation data only. For this approach, a high stringent filter (β-value>=0.85 in 2/3 
DIPG β-value<=0.15 in NHA) was applied to identify differentially methylated 
probes in 2/3 DIPG short-term cell cultures. Of 215 methylated genes identified by 
this approach, non-coding genes (n=35) and genes without CpG islands in their 
promoter regions (n=51) as predicted by the human genome browser 
(www.genome.ucsc.edu) were eliminated, resulting in 129 unique genes. Literature 
review was carried out on these genes, as described in the first approach and 20 
genes were shortlisted.  
A total of 40 genes identified by both approaches were validated in the laboratory. 
The gene descriptions and functions of 40 genes are given in Table 6.1. 
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Gene 
symbol
NCBI Accession Gene description Function 
A2BP1 NM_145891.2
RNA binding protein, fox-1 homolog 
(C. elegans)
Regulates alternative splicing 
required for neuronal functions 
(Fogel et al., 2012)
ADAMTS18 NM_199355.2
ADAM metallopeptidase with 
thrombospondin type 1 motif 18 
Degradation of matrix
proteoglycans (Porter et al., 2005)
APBB2 NM_004307.1
Amyloid beta (A4) precursor protein-
binding, family B, member 2
Modulation of amyloid precursor 
protein (APP) processing (Penna et 
al., 2013)
BMP3 NM_001201.2 Bone morphogenetic protein 3
Regulation of bone formation 
(Amedee et al., 1994)
CABLES1 NM_138375.2 Cdk5 and Abl enzyme substrate 1 Inhibitor of CDKs (Shi et al., 2015)
CASZ1 NM_001079843.2 Castor zinc finger 1
Regulates transcription by NuRD 
complex recruitement (Liu et al., 
2015)
CAV1 NM_001753.4 Caveolin 1, caveolae protein, 22kD    
Required for caveolae formation 
(Fernández-Rojo et al., 2012)
COL14A1 NM_021110.2 Collagen, type XIV, alpha 1
Regulation of fibrillogenesis 
(Young et al., 2002)
CXCL14 NM_004887.4 chemokine (C-X-C motif) ligand 14
Inhibitor of CXCL12-CXCR4 
pathway (Tanegashima et al., 2013)
DAB1 NM_021080.3
Dab, reelin signal transducer, 
homolog 1 (Drosophila)
Cortical neuronal migration (Chai et 
al., 2009)
DAB2IP NM_032552.3 DAB2 interacting protein
Regulates neuronal migration and 
maturation (Lee et al., 2012)
DLK1 NM_003836.6 delta-like 1 homolog (Drosophila)
Inhibitor of Notch signalling (Falix 
et al., 2012)
EYA4 NM_004100.4
EYA Transcriptional Coactivator 
And Phosphatase 4
Regulator of innate immune 
response (Okabe et al., 2009)
FGFR2 NM_000141.4 Fibroblast growth factor receptor 2
Bone and skeletal development 
(Wilkie et al., 2002)
FHIT NM_002012.2 Fragile histidine triad
Prevents double strand DNA breaks 
(Waters et al., 2015)
GRM8 NM_000845.2 Glutamate receptor, metabotropic 8
Potential driver cancer gene in 
endometrial cancer (Liang et al., 
2012)
KRT8 NM_001256282.1 Keratin 8
Regulates TNF and fas-mediated 
cell death (Oshima et al., 2002)
MGMT NM_002412.4
O-6-methylguanine-DNA 
methyltransferase
DNA damage repair (Pegg et al., 
1990)
MICAL2 NM_014632.3
Microtubule associated 
monoxygenase, calponin and LIM 
domain containing 2
Regulation of actin stress fibers 
(Giridharan et al., 2012)
MYH10 NM_001256012.1 Myosin, heavy chain 10, non-muscle
Regulates primary cilia  biogenesis 
(Rao et al., 2014)
PARP4 NM_006437.3
Poly(ADP-ribose) polymerase family 
member 4
Role in telomerase activity (Liu et 
al., 2004)
Table 6.1 Genes hypermethylated in DIPG short-term cultures compared to NHA 
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PDE4B NM_002600.3
Phosphodiesterase 4B, cAMP-
specific
Regulation of cyclic nucleotides (Millar et 
al., 2005)
PDE4D NM_001104631.1
Phosphodiesterase 4D, cAMP-
specific
Regulates cAMP signalling (Mika et al., 
2015)
PDPN NM_006474.4 Podoplanin
Metastasis (martin Villar et al., 2006), 
Actin remodelling (Wicki et al., 2006)
PKNOX2 NM_022062.2 PBX/knotted 1 homeobox 2
Homeobox containing gene, transcription 
regulator (Imoto et al., 2001)
PLCH2 NM_014638.3 Phospholipase C, eta  2
Calcium mobilisation in cells (Suh et al., 
2008)
PLXNB1 NM_002673.5 Plexin B1
Semaphorin 4D receptor, induces growth 
cone collapse (Oinuma et al., 2010)
PRKG2 NM_006259.2
protein kinase, cGMP-
dependent, type II
Development of growth plate (Koltes et 
al., 2015)
PRR5L NM_001160167.1 Proline rich 5 like
mTOR-associated protein, regulates 
apoptosis (Thedieck et al., 2007)
PTPRE NM_006504.5
protein tyrosine phosphatase, 
receptor type, E
Regulation of insulin signalling (Moller et 
al., 1995)
RANBP17 NM_022897.4 RAN binding protein 17
Member of importin beta family (Kutay et 
al., 2000)
RFX3 NM_002919.3
regulatory factor X, 3 
(influences HLA class II 
expression)
Regulation of ciliogenesis (Bonnafe et al., 
2004)
RHBDF2 NM_024599.5
rhomboid 5 homolog 2 
(Drosophila)
Regulation of EGF ligand secretion 
(Adrain and Freeman, 2012)
SBNO2 NM_014963.2
strawberry notch homolog 2 
(Drosophila)
Regulation of inflammatory gene 
expression (Kasmi et al., 2007)
SEMA6A NM_001300780.1
Sema domain, transmembrane 
domain (TM), and 
cytoplasmic domain
Regulator of VEGF signalling (Segarra et 
al., 2012)
SETBP1 NM_015559.2 SET binding protein 1
Binds SET oncoprotein (Minakuchi et al., 
2001)
SH3BP4 NM_014521.2 SH3-domain binding protein 4
Negative regulator of Rag GTPases (Kim 
et al., 2013)
SIPA1L3 NM_015073.2
Signal-induced proliferation-
associated 1 like 3
Component of tight junction (Matsuda et 
al., 2008)
TRIM2 NM_015271.4 Tripartite motif containing 2
Regulates neuronal polarization (Khazaei
et al., 2011)
Table 6.1 contd. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methylation 450K data from 3 DIPG short-term cell cultures and NHA were analysed using 2 
different approaches. Forty genes were identified; gene descriptions and functions of these genes are 
provided. 
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6.2.2 Comparison of differential expression of genes in DIPG and non-DIPG 
short-term cultures by RT-PCR analyses 
To confirm downregulation of 40 candidate genes, their expression levels were 
determined in the 3 DIPG short-term cell cultures and NHA using RT-PCR analysis 
as described in 2.6.3. The expression levels of these genes were also determined in 
14 non-DIPG short-term cultures and the frequencies of downregulation of 40 genes 
were compared between DIPG and non-DIPG short-term cultures with respect to 
their expression levels in NHA. The summary of downregulation status of 40 genes 
in DIPG and non-DIPG short-term cultures is shown in Table 4.1.  
It was observed that 50% (20/40) of analysed genes demonstrated satisfactory 
correlation with the microarray results in DIPG short-term cell cultures i.e. these 
genes were expressed in NHA and downregulated and/or silenced in at least 1 DIPG 
short-term cell culture. These genes were stratified into 2 groups according to their 
expression patterns in DIPG short-term cell cultures and the frequencies of 
downregulation in DIPG were compared to those in the non-DIPG short-term cell 
cultures (Table 6.2 and Figure 6.2). The first group consisted of 12 genes (60%), 
which were frequently downregulated in DIPG short-term cultures (2/3 cases). Of 
these, 10 genes were also downregulated in at least 64% in the non-DIPG short-term 
cell cultures and comprised ADAMTS18 (100%), RFX3 (100%), PRKG2 (93%), 
PTPRE (93%), RHBDF2 (93%), DAB1 (64%), EYA4 (79%), DLK1 (93%), CXCL14 
(86%) and SBNO2 (79%).  In contrast, 2 genes, SH3BP4 and FGFR2 were 
downregulated in only 29% and 7% respectively in the non-DIPG short-term cell 
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cultures. The RT-PCR gel images of 7 genes that were downregulated in all 3 DIPG 
short-term cell cultures in comparison to NHA are given in Figure 6.3. 
The second group consisting of 8 genes (40%) were infrequently downregulated (1/3 
cases) in the DIPG short-term cultures. Of these, 5/8 genes were also infrequently 
downregulated in the non-DIPG short-term cell cultures with the frequencies of 
downregulation of the genes not exceeding 29%. In contrast, 3 genes demonstrated 
higher frequencies of downregulation in the non-DIPG short-term cultures, which 
included APBB2 (93%), MYH10 (50%) and RANBP17 (43%).  
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0
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IN
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6
2
DIPG 
(n=3)
non-
DIPG 
(n=14)
Genes frequently downregulated in DIPG
ADAMTS18 100 100
RFX3 100 100
PRKG2 100 93
PTPRE 100 93
RHBDF2 100 93
DAB1 100 64
EYA4 100 79
DLK1 67 93
CXCL14 67 86
SBNO2 67 79
SH3BP4 67 29
FGFR2 67 7
Genes infrequently downregulated in DIPG
APBB2 33 93
MYH10 33 50
RANBP17 33 43
COL14A1 33 29
CASZ1 33 29
GULP1 33 21
PARP4 33 21
PLXNB1 33 7
Genes expressed in DIPG
PRR5L 0 36
PKNOX2 0 14
CAV1 0 7
SIPA1L3 0 7
DAB2IP 0 0
TRIM2 0 0
Genes lacking expression in NHA
A2BP1 100 100
PDE4D 100 100
SEMA6A 100 93
KRT8 100 86
FHIT 100 79
SETBP1 100 64
PLCH2 67 71
PDE4B 33 64
GRM8 0 71
PDPN 0 21
CABLES1 0 14
BMP3 0 14
MGMT 0 14
MICAL2 0 0
Table 6.2 Expression status of 40 candidate genes in DIPG and non-DIPG short-term cultures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RT-PCR analysis was performed to determine the expression levels of 40 candidate genes in NHA, 3 
DIPG and 14 non-DIPG short-term cell cultures. Frequencies of downregulation of these genes in 
DIPG and non-DIPG tumour subgroups are shown. Green indicates expression; pink indicates 
downregulation and red indicates silencing of genes.  
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Figure 6.2 Frequency of downregulation of 20 genes in DIPG and non-DIPG short-term cultures.  The frequencies of downregulation of 20 genes that were 
frequently or infrequently downregulated in DIPG short-term cell cultures (n=3) were compared with their frequencies of downregulation in non-DIPG short-term 
cell cultures (n=14). The differences in the frequencies of downregulation of FGFR2 and APBB2 between DIPG and non-DIPG short-term cell cultures are 
approaching statistical significance (p=0.063) (indicated by *). 
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Figure 6.3 RT-PCR analyses of 7 genes frequently downregulated in DIPG short-term cultures. RT-PCR analyses demonstrate the expression statuses of the 
most commonly downregulated genes in DIPG short-term cultures which are also frequently downregulated in the non-DIPG short-term cultures in comparison to 
NHA. Beta actin was used as the endogenous control.  
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The remaining 20 genes (50%) did not demonstrate correlation with downregulation 
and/or methylation observed in the microarray analysis. Of these, 6 genes (PRR5L, 
PKNOX2, CAV1, SIPA1L3, DAB2IP and TRIM2) did not show downregulation in 
any of the DIPG short-term cell cultures. These genes were therefore not assessed 
further. The remaining 14 genes (A2BP1, PDE4D, SEMA6A, KRT8, FHIT, SETBP1, 
PLCH2, PDE4B, GRM8, PDPN, CABLES1, BMP3, MGMT and MICAL2) had no 
detectable mRNA expression in NHA. Seven (50%) of these were frequently 
downregulated (2/3 cases) in the DIPG short-term cultures, and in the non-DIPG 
short-term cell cultures. These included A2BP1 (100% vs 93%), PDE4D (100% vs 
93%), SEMA6A (100% vs 87%), KRT8 (100% vs 87%), FHIT (100% vs 73%), 
SETBP1 (100% vs 60%) and PLCH2 (67% vs 73%). The remaining 7 genes were 
infrequently downregulated in the DIPG short-term cell cultures, of which 6 genes 
were not downregulated in any of the samples. Also, the majority of the genes (5/7 
cases) which were not downregulated in the DIPG short-term cultures were also not 
downregulated in most of the non-DIPG short-term cultures. These included PDPN 
(0% vs 27%), CABLES1 (0% vs 20%), BMP3 (0% vs 13%), MGMT (0% vs 13%), 
and MICAL2 (0% vs 0%). Two genes, PDE4B (33% vs 67%) and GRM8 (0% vs 
67%) had relatively higher frequencies of downregulation in the non-DIPG short-
term cell cultures.  
Overall, there were no major differences between the DIPG and the non-DIPG short-
term cell cultures based on the downregulation of the identified genes in these 
tumours. On a global scale, these tumour subgroups did not show unique methylation 
profiles, which were evident from the PCA scatter plot, as shown in Figure 6.4. The 
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PCA mapping (46.4%)
NHA
DIPG
non-DIPG
normalised Methylation 450 K data from NHA, 3 DIPG and 14 non-DIPG short-term 
cell cultures were used to perform PCA using Partek Genomics Suite (v6.6, Partek 
Inc., USA) as described in 2.12.4. 
 
 
 
 
 
 
 
 
Figure 6.4 Principal component analyses of NHA, DIPG and non-DIPG short-term cultures. 
PCA plot of NHA, 3 DIPG and 14 non-DIPG short-term cell cultures generated using the first three 
PCs, PC 1 (23.3%), PC 2 (13.7%) and PC 3 (9.38%). Each point on the scatter plot represents a 
sample. NHA is represented by green, and DIPG and non-DIPG short-term cell cultures are 
represented by red and blue colours respectively.  
 
PCA confirmed that the normal and the tumour samples had distinct methylation 
profiles and clustered separately. It was evident that the DIPG and the non-DIPG 
short-term cultures did not form separate clusters. Two of 3 DIPG short-term cell 
cultures clustered closely together, indicating similarities in their methylation 
profiles while the third sample (IN2675) was independent. Interestingly, IN2675 was 
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H3F3A (K27M)-mutant, while the other 2 were H3F3A wild type, as shown in 3.15. 
However, the non-DIPG H3F3A (K27M)-mutant short-term cell culture (IN1566) 
did not group with the mutant-DIPG short-term cell culture.  
6.2.3 Validation of methylation status of downregulated genes in DIPG short-
term cultures 
To confirm the role of methylation in downregulation of the identified genes, 10 
paediatric HGG short-term cell cultures (1 DIPG and 9 non-DIPG) were treated with 
the global demethylating agent, 5-AZA to reactivate the downregulated genes, as 
described in 2.3, and changes in gene expression were measured by RT-PCR 
analyses as described in 2.6.3. Seven genes (ADAMTS18, RFX3, PRKG2, PTPRE, 
RHBDF2, DAB1 and EYA4) that were expressed in NHA and downregulated in all 3 
DIPG short-term cell cultures were prioritised for this validation analysis. The re-
expression of 7 genes in paediatric HGG short-term cell cultures following 
demethylation with 5-AZA as determined by RT-PCR analysis is shown in Figure 
6.5. With the exception of PRKG2, all other genes were re-expressed in the DIPG 
short-term cell culture (IN2102) following 5-AZA treatment. The frequencies of re-
expression of these genes in paediatric HGG short-term cell cultures following 
treatment with 5-AZA are given in Table 6.3.   RHBDF2 had the highest frequency 
of re-expression after treatment with 5-AZA (90%) followed by DAB1 (78%), 
PTPRE (60%), ADAMTS18 (50%), EYA4 (50%), PRKG2 (50%) and RFX3 (36%) 
respectively.  
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Figure 6.5 Re-expression of candidate genes in DIPG and non-DIPG short-term cultures following demethylation with 5-AZA. One DIPG and 9 non-DIPG 
short-term cell cultures were treated with 5-AZA and gene expression following treatment was determined using RT-PCR analyses. Re-expression of 7 genes 
(RHDBF2, DAB1, PTPRE, ADAMTS18, EYA4, PRKG2 and RFX3) after treatment with 5-AZA are shown. Red stars indicate re-expression. Beta actin was used as 
endogenous control. 
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Genes No. of cases of gene
re-expression after 
demethylation
Frequency of 
re-expression
(%)
RHBDF2 9 90 (n=10)
DAB1 7 78 (n=9)
PTPRE 6 60 (n=10)
ADAMTS18 5 50 (n=10)
EYA4 5 50 (n=10)
PRKG2 5 50 (n=10)
RFX3 4 36 (n=11)
Table 6.3 Frequencies of re-expression of candidate genes in paediatric HGG short-term cell 
cultures following demethylation 
 
 
 
 
 
 
 
Ten paediatric HGG short-term cell cultures (1 DIPG and 9 non-DIPG) were treated with the 
demethylating agent, 5-AZA; untreated cells were used as control. RT-PCR analyses were performed 
to determine expression levels of 7 candidate genes in treated and untreated samples. Frequencies of 
re-expression of genes in 5-AZA treated paediatric HGG short-term cell cultures are shown. ‗n‘ 
indicates cell cultures with low basal level expression of genes. 
It was also noted that some of these genes were downregulated following treatment 
with 5-AZA. The most evident cases were downregulation of DAB1 in IN3182, 
PRKG2 in IN1566 and ADAMTS18 in IN1566 and IN3182 respectively. This is a 
common event as 5-AZA is a global demethylating agent and demethylates the 
genome indiscriminately leading to dysregulation of several networks of genes. 
 To evaluate the functional role of candidate genes, genes were further prioritised 
based on their frequencies of re-expression in paediatric HGG short-term cell 
cultures following treatment with 5-AZA. Three genes (RHBDF2, DAB1 and 
PTPRE), demonstrated re-expression in more than 50% paediatric HGG short-term 
cell cultures treated with 5-AZA. Of these, DAB1 and PTPRE have been identified to 
have roles in the druggable PI3K pathway and the functional significance of these 
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was investigated further. DAB1 encodes the intracellular adaptor protein of reelin 
signaling pathway. PTPRE has been identified as a physiological inhibitor of ERK.  
6.2.4 Functional analyses of DAB1 and PTPRE in paediatric HGG in vitro 
The putative functional roles of 2 genes (DAB1 and PTPRE) were further 
investigated. The tumour suppressor activities of these genes were assessed by 
colony formation and wound healing assays. A non-expressing cell culture (IN699) 
was used as an in vitro experimental model to study the effects of re-expressing these 
genes on in vitro growth and migratory characteristics. Wild-type DAB1 or PTPRE 
expression plasmids (PCMV6/DAB1 or PCMV6/PTPRE) were each transiently 
transfected into IN699. An empty vector (PCMV6) was transfected into the same 
cells and used as control as described in 2.10.7. The overexpression of DAB1 and 
PTPRE in IN699 was verified by western blot analyses, 48 hours after transfection, 
as shown in (Figure 6.6). 
 
 
 
 
 
Figure 6.6 Overexpression of DAB1 and PTPRE in IN699 cells as determined by western blot 
analysis.  Western blot analysis was performed with empty vector and DAB1 expression plasmid after 
transfection. Tubulin was used as the loading control.  
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6.2.4.1  Ectopic overexpression of DAB1 and PTPRE reduces colony formation 
ability in vitro 
To assess the effect of re-expressing DAB1 or PTPRE on in vitro growth 
characteristics, wild-type DAB1 or PTPRE expression plasmids (PCMV6/DAB1 or 
PCMV6/PTPRE) were each transiently transfected into IN699. An empty vector 
(PCMV6) transfected into the same cells was used as control (as described in 2.10.7). 
Forty-eight hours after transfection, diluted cell suspensions (containing 25,000 cells) 
were plated in triplicates and were maintained in media containing geneticin 
(250µg/ml). After 25 days, colonies were stained with crystal violet and were 
counted. As shown in Figure 6.7, the number of IN699 colonies expressing DAB1 
was reduced by 55% (p=0.028) in comparison to the control cells transfected with 
the empty vector. Re-expression of PTPRE in IN699 cells also demonstrated a 
statistically significant reduction in colony formation ability to 35% of that observed 
in control cells (p=0.003). As evident from Figure 6.7, the colonies formed by DAB1 
or PTPRE- transfected cells were smaller in sizes compared to those formed by their 
respective control cells.  
 
 
 
 
 
258 
 
0
20
40
60
80
100
120
140
160
Control PTPRE
C
o
lo
n
y
 c
o
u
n
t
**
IN699
*
A B
DAB1 PTPRE
0
10
20
30
40
50
60
70
80
90
100
Control DAB1
C
o
lo
n
y
 c
o
u
n
t
IN699
 
 
 
 
 
 
 
 
Figure 6.7 Ectopic overexpression of DAB1 and PTPRE decreases colony formation capacity in 
IN699.  A. Equal amounts of wild type PCMV6/DAB1 or PCMV6/PTPRE plasmids or EV were 
transfected into IN699 cells. Twenty five days later, the colonies were stained and counted. A. IN699 
cells transfected with DAB1 showed statistically significant reduction (p=0.028) in the number of 
colonies compared to the control cells. B. IN699 cells transfected with PTPRE showed statistically 
significant reduction (35.36%, p=0.003) in the number of colonies compared to the control cells. 
Graphs represent the average number of colonies; error bars represent standard deviation. * indicates 
p<0.05, ** indicates p<0.005. Representative images of the plates showing reduced number of 
colonies following re-expression of genes are given below each graph. 
6.2.4.2  Transient overexpression of DAB1 reduces migratory potential of cells 
in vitro 
The role of DAB1 in migratory potential of cells was assessed using transwell assays. 
For this assay, IN699 cells were transiently transfected with wild type DAB1 
expression plasmids (PCMV6/DAB1) and the same cells transfected with empty 
vector were used as control as described in section 2.10.7. The transfected cells were 
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seeded in transwells and allowed to migrate across the polycarbonate membrane 
inserts. Forty-eight hours later, the migrated cells were stained and quantified in a 
colorimetric assay.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 Transient overexpression of DAB1 reduces migratory ability of cells in vitro A. IN699 
cells were transfected with wild type DAB1 expression plasmid or EV. The transfected cells were 
seeded in transwells and allowed to migrate. Twenty four hours later, the migrated cells were stained 
and quantitatively assessed by colorimetric method. Cells transfected with DAB1 show statistically 
significant reduction in the migratory capacity than the control cells (p=0.006). The experiment was 
set up in triplicate; error bars represent standard error. Images of migratory cells in control versus 
DAB1-transfected cells captured at 4x magnification are shown below the graph. 
DAB1-overexpressing cells exhibited statistically significant reduction (24%, 
p=0.006) in migration compared to the control cells. Images of stained cells in both 
control and DAB1-transfected cells were captured at 4x magnification (Figure 6.8).  
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6.2.4.3 Reduced expression of DAB1 promotes migratory ability of paediatric 
HGG short-term cell culture 
The role of DAB1 in the migratory potential of cells was further assessed in a 
paediatric HGG short-term cell culture (IN1523) that expressed endogenous levels of 
DAB1. DAB1 was knocked down in IN1523 culture using RNAi methodology and 
the migratory potential of these cells was assessed in a transwell assay as described 
in 2.10.8. The knock-down of DAB1 in IN1523 after transfection was confirmed by 
western blot analysis as shown in Figure 6.9.  IN1523 cells transfected with non 
targeting siRNA oligos were used as control.  
 
 
 
 
 
 
 
 
Figure 6.9 Western blot analysis confirms knockdown of DAB1 in IN1523 paediatric HGG 
short-term cell culture. IN1523 transfected with DAB1 siRNA or negative siRNA were used to 
perform western blot analysis.  
In a cell migration assay, siDAB1IN1523 cells or siNT control IN1523 cells were 
seeded in transwells and incubated for 24 hours before staining of migrated cells. 
siDAB1 cells were significantly more migratory compared to the siNT control cells 
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(p=0.0005), as shown in Figure 6.11. Following incubation and staining of migrated 
cells, DAB1-knocked down cells were more migratory compared to the control cells. 
Colorimetric quantification of migrated cells revealed statistically significant 
increase (p=0.0005) in the optical density, (indicative of more cells) compared to the 
control cells. 
 
 
 
 
 
 
 
 
 
Figure 6.10 Reduced expression of DAB1 increases migratory ability of paediatric HGG short-
term culture. A. The migratory capacity of IN1523 cells were evaluated in transwell assays. Upon 
DAB1 knockdown, IN1523 cells displayed increased migratory capacity in comparison to control cells 
transfected with non-targeting siRNA oligos The experiment was done in triplicate; error bars 
represent standard error. Images of increased number of migratory cells in DAB1-transfected cells 
compared to control are shown below the graph. 
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6.2.5 Analysis of methylation 450K data to identify hypermethylated 
promoters of genes associated with H3F3A (K27M)-mutant DIPG short-term 
cell cultures 
H3F3A (K27M) mutation is an important genetic event that drives tumourigenesis in 
paediatric HGG, particularly DIPG (Schwartzentruber et al., 2012; Wu et al., 2012; 
Castell et al., 2015). Distinct miRNA expression changes were associated with this 
mutation in paediatric HGG short-term cell culture, as described in Chapter 5. To 
investigate promoter hypermethylation-induced changes associated with H3F3A 
(K27M) mutation in DIPG short-term cell cultures, genes with promoter CpG 
hypermethylation in H3F3A (K27M)-mutant compared to wild-type DIPG short-term 
cell cultures were identified. 
To identify genes regulated by promoter hypermethylation, those probes located in 
the 5‘UTR regions and up to 1500 bases upstream of the TSS (TSS200 and 
TSS1500) were utilised (n=132665), as described earlier in 6.2.1. Those probes with 
beta value >0.85 (highly methylated) in the H3F3A (K27M)-mutant DIPG short-term 
cell culture, IN2675 and <0.15 (unmethylated) in NHA and the wild-type cultures 
(IN2087 and IN2102) were identified, resulting in 37 probes representing 23 genes. 
A comprehensive literature review was carried out on these genes using PubMed, 
GeneCards (www.genecards.org) and OMIM (www.ncbi.nlm.nih.gov/omim) to 
investigate the role of these genes in cancers. Most of these genes were participants 
in regulating apoptosis, cell proliferation, invasion and migration in a variety of 
cancers. The promoter hypermethylated genes associated with H3F3A (K27M) 
mutation in the DIPG short-term cell cultures and their potential significance in 
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Probe ID Probe 
location
Gene name Gene description Gene function/association with 
cancer
Chr
cg26808747
cg05237641
cg14621053
cg13488201
TSS1500
TSS200
TSS200
TSS200
ADAM12 ADAM Metallopeptidase
Domain 12
Cell adhesion and fusion, 
ECM remodelling, cell signaling 
(Nyren-Erickson et al., 2013)
10
cg12191938 5'UTR AGAP11 nkyrin Repeat And 
GTPase Domain Arf
GTPase Activating Protein 
11
Arf GTPase activator activity, potential 
role in cell migration and invasion 
(Campa et al., 2008)
10
cg07925085 TSS1500 CCDC114 Coiled-Coil Domain 
Containing 114
Required for ciliary movement 
(Knowles et al., 2013)
19
cg12944530 5'UTR CFLAR CASP8 And FADD-Like 
Apoptosis Regulator
Regulates apoptosis (Irmler et al., 
1997), and Wnt signaling (Katayama et 
al., 2010)
2
cg13247581 TSS200 ENTPD2 Ectonucleoside 
Triphosphate 
Diphosphohydrolase 2
Regulates proliferation of neural 
progenitor cells (Gampe et al., 2015)
9
cg05298677
cg13133961
TSS200
TSS200
ETV7 Ets Variant 7 Transcription factor associated with 
regulation of cell proliferation (Bisio et 
al., 2014)
6
cg21461470 TSS1500 HIST2H2AA4 Histone Cluster 2, H2aa4 Downregulated in epithelial ovarian 
cancer (Morone et al., 2012)
1
cg14666564 5'UTR HOXD3 Homeobox D3 Cell proliferation and differentiation 
(Yunhong et al., 2012)
2
cg00976453
cg10951120
TSS1500
TSS200
KCNB1 Potassium Channel, 
Voltage Gated Shab
Related Subfamily B, 
Member 1
Associated with proneural subtype of 
GBM (Brennon et al., 2009)
20
cg02033258
cg09877947
cg11843238
TSS200
TSS200
TSS200
PDLIM4 PDZ And LIM Domain 4 Inhibits growth in prostate cancer 
(Krishna Vanaja et al., 2011), tumour 
suppressor in RCC (Morris et al., 
2010;)
5
cg17575602 TSS1500 PGCP Carboxypeptidase Q Biomarker for Hepatitis C-virus 
associated HCC (Smith et al., 2003)
8
cancers are provided in Table. Notably, there were 2 homeobox genes (HOXD3 and 
SATB2), associated with early development, genes regulating stem cell fate (KCNB1, 
ENTPD2 and PIWIL1) and a single gene encoding the histone variant H2A.2 
(HIST2H2AA4). 
Table 6.4 Promoter hypermethylated genes in H3F3A (K27M) DIPG short-term cell culture 
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cg13900773 5'UTR PIWIL1 Piwi-Like RNA-Mediated 
Gene Silencing 1
Required for stem cell self-renewal 
and division (Cox et al., 1998), 
regulates EMT (Chen et al, 2015), 
negatively regulates cell invasion in 
ovarian cancer (Ly Lim et al., 2014)
12
cg19942237 TSS1500 PRR15 Proline Rich 15 Role in early development (Purcell et 
al., 2009)
7
cg07075840 TSS200
cg01206378
cg20701556
cg26537280
TSS1500
TSS1500
TSS1500
RWDD3 RWD Domain Containing 3 Regulates tumour suppressive 
function of VHL (Gerez et al., 2015)
1
cg07855083 5'UTR SATB2 SATB Homeobox 2 Inhibits cell proliferation and 
migration in gastric cancer (Wu et al., 
2015), Inactivates MEK5/ERK5 
signaling in colorectal cancer 
(Mansour et al, 2015)
2
cg01934626 TSS200 SCGB3A1 Secretoglobin, Family 3A, 
Member 1
Tumour suppressive role in breast 
(Krop et al., 2001), ovarian (Wu et 
al., 2007), and esophageal squamous 
cancer (Guo et al., 2008) 
5
cg24486037
cg26065909
TSS200
TSS200
SELENBP1 Selenium Binding Protein 1 Tumour suppressor in prostate cancer 
(Ansong et al., 2016)
1
cg05302542
cg25326998
TSS1500
TSS1500
SLC25A19 Solute Carrier Family 25 
(Mitochondrial Thiamine 
Pyrophosphate Carrier), 
Member 19
Role in thiamine homeostasis (Kim et 
al., 2015)
17
cg07769015 TSS200 SLC45A4 Solute Carrier Family 45, 
Member 4
Sucrose transport (Bartölke et al., 
2014)
8
cg04096619 TSS1500 SNORD123 Small Nucleolar RNA, C/D 
Box 123
CpG hypermathylation in colorectal 
cancer (Ferreira et al., 2012)
5
cg01332054 5'UTR STRA6 Stimulated By Retinoic Acid 
6
Role in p53-induced apoptosis in 
response to DNA damage (Carrera et 
al., 2013)
15
cg08162803
cg11731626
TSS200
TSS200
TCIRG1 T-Cell, Immune Regulator 1, 
ATPase, H+ Transporting, 
LysosomalV0 Subunit A3
Mutations in TCIRG1 is associated 
with osteopetrosis in children 
(Simanovsky et al., 2016)
11
cg06377106 5'UTR VWA5B1 Von Willebrand Factor A 
Domain Containing 5B1
Homeostasis 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methylation 450 K data from H3F3A (K27M) –mutant and wild type DIPG short-term cell cultures 
were analysed based on the probe beta values (β value >0.85 in H3F3A (K27M) mutant and β value < 
0.15 in NHA and H3F3A wild type).  
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6.2.6 Analysis of methylation 450K data to identify miRNAs deregulated by 
promoter CpG hypermethylation in DIPG short-term cell cultures 
Deregulation of miRNAs in paediatric HGG including DIPG, at genetic and 
transcriptomic levels have been described in Chapters 4 and 5, respectively. 
Recently, there has been great interest in the identification of promoter 
hypermethylation-induced downregulation of miRNAs in various types of cancers 
(Chen et al., 2012; Lopez-Serra and Esteller, 2012; Menigatti et al., 2013; 
Yongsheng et al., 2015). 
To identify miRNAs regulated by promoter hypermethylation in DIPG short-term 
cultures, the Methylation 450K data from the 3 DIPG short-term cell cultures 
(IN087, IN2102 and IN2675) and NHA were utilised. As described in 6.2.1, there 
were 1100 probes representing miRNA genes that were in the 5‘UTR region and up 
to 1500 bases upstream of the TSS (TSS200 and TSS1500). To identify frequently 
methylated miRNAs in DIPG short-term cell cultures, those probes with beta value 
>0.75 (methylated) in 2 of 3 DIPG short-term cell cultures, and beta value <0.25 
(unmethylation) in NHA were identified. This resulted in 21 probes corresponding to 
15 miRNAs. A comprehensive literature review was conducted to determine the 
potential significance of these miRNAs in tumourigenic events. These miRNAs and 
their potential associations with cancers are listed in Table 6.5. Most of these 
miRNAs either had associations with cellular processes linked to cancer or were 
reported as deregulated in cancers and not yet functionally evaluated. 
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Methylated 
Probe ID
Location miRNA Association with cancers Chr
cg22144942 TSS200 MIR1179 Promotes cell invasion in esophageal squamous cell 
carcinoma (Jiang et al., 2015)
15
cg17033471 TSS200 MIR1257 Downregulated in liposarcoma (Hisaoka et al., 2012) 20
cg03599197 TSS1500 MIR187 Regulates ovarian cancer progression by targeting DAB2 
(Chao et al., 2012)
18
cg10420310
cg07665535
cg06273075
cg04018325
cg09918657
TSS1500
TSS200
TSS200
TSS200
TSS1500
MIR193B Promotes cell proliferation by targeting Smad3 in adult 
glioma, (Zhong et al., 2014)
16
cg11869773 TSS1500 MIR299 Regulates proliferation, apoptosis, migration and invasion 
in prostate cancer cells (Formosa et al., 2014) 
14
cg14148088 TSS200 MIR494 Inhibits growth in epithelial ovarian cancer by targeting c-
Myc (Yuang et al., 2016), associated with poor prognosis 
in pancreatic cancer (Ma et al., 2015), Inhibits cell 
proliferation by repressing HOXA10 in oral cancer 
(Libório-Kimura  et al., 2015)
14
cg24091975 TSS200 MIR515-1 Regulates proliferation in breast cancer cells by targeting 
SK1 (Pinho et al., 2013)
19
cg24787924 TSS1500 MIR518E Induces cell cycle arrest in HCC by targeting CCND3 
(Wang et al., 2012)
19
cg22166633 TSS1500 MIR520E Suppresses growth of hepatoma cells by targeting NIK/p-
ERK1/2/NF-κB signaling pathway (Zhang et al., 2012)
19
cg16204151 TSS1500 MIR523 Regulates metastasis in malignant melanoma (Mueller et 
al., 2009)
19
cg01716465 TSS1500 MIR548H3 Methylated in HCC (Shen et al., 2015) 9
cg16530970 TSS200 MIR549 Deregulated in colorectal cancer (Cummins et al., 2006) 15
cg06606539 TSS1500 MIR572 Regulates cell proliferation in ovarian cancer cells (Zhang 
et al., 2015; Wu et al., 2016)
4
cg04726985
cg25837979
TSS1500
TSS1500
MIR708 Suppresses tumour invasion and migration in HCC (Li et 
al., 2015),  regulates the NF-κB pathway by targeting IKKβ 
in leukemia (Baer et al., 2015)
11
cg18604419
cg09337069
TSS1500
TSS1500
MIR889 Regulates cell proliferation in squamous cell carcinoma by 
targeting DAB2IP(Xu et al., 2015)
14
Table 6.5 MiRNAs regulated by promoter hypermethylation in DIPG short-term cell cultures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methylation 450K data from DIPG short-term cell cultures (n=3) and NHA were analysed based on β-
values of probes (β-value >=0.75 in 2/3 DIPG, and <=0.25 in NHA). Twenty one probes representing 
15 miRNAs, and their potential significance in cancers is shown. Chr-chromosome. 
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6.3 Discussion 
DIPG represent extremely severe brainstem lesions of childhood and are currently 
the leading cause of death from brain tumours in children (Buczkowicz and Hawkins, 
2015). Previous genetic studies have identified molecular targets for DIPG, but as 
yet, none of these have been successfully translated into effective therapies (Bailey et 
al., 2013). The identification of recurrent histone mutations in H3.3 and H3.1 histone 
variants in DIPG, and the recent large-scale genomic profiling in these tumours 
indicate that they may have distinct genetic and epigenetic characteristics and may 
require tailored therapeutic strategies (Buczkowicz et al., 2014; Schwartzentruber et 
al., 2012; Wu et al., 2012). This Chapter has focussed on the identification of 
candidate genes dysregulated due to promoter hypermethylation in 3 DIPG short-
term cell cultures compared to NHA using Illumina Infinium HumanMethylation 450 
K BeadChip array.  
Promoter hypermethylation in DIPG short-term cell cultures 
The key role of promoter methylation in the inactivation of tumour suppressor genes 
has been widely explored in almost all cancers. Genome-wide evaluation of 
methylation profiles in normal and tumour samples is a valuable tool for the 
identification of tumour-specific changes that are either driver events in cancers or 
markers of disease progression. The clear separation of the 3 DIPG short-term cell 
cultures (IN2675, IN2102 and IN2087) from NHA, as summarised by the PCA plot 
in Figure 6.1 implies that these tumours can be distinguished from their respective 
normal tissues based on their methylation profiles. The comprehensive analyses of 
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methylation 450 K data from the 3 DIPG short-term cell cultures and NHA further 
revealed large number of differentially methylated probes in these tumours. There 
were 284 methylated probes with minimum β-value of 0.85 and 1054 methylated 
probes with minimum β-value of 0.75 that were differentially methylated in 2 of 3 
DIPG short-term cell cultures compared to NHA. The screening strategy employed 
in this analysis initially identified 40 candidate genes, and further validation 
confirmed downregulation of 20 of these genes in DIPG short-term cell cultures 
compared to NHA. Twelve genes were frequently differentially methylated (2/3 
cases) in DIPG and comprised ADAMTS18, RFX3, PRKG2, PTPRE, RHBDF2, 
DAB1, EYA4, DLK1, CXCL14, SBNO2, SH3BP4 and FGFR2. 
DIPG and non-DIPG did not differ significantly in their methylation profiles 
Comparison of the frequencies of downregulation of 20 candidate genes in DIPG and 
non-DIPG short-term cell cultures did not reveal significant differences between the 
two tumour subgroups in the majority of the cases. The lack of differences in the 
global methylation profiles of DIPG and non-DIPG short-term cell cultures was 
further demonstrated in the PCA scatter plot, as the 2 tumour groups did not cluster 
separately (Figure 6.4), but this may be due to the small number of DIPGs available 
for this study. However, 2 genes (FGFR2 and APBB2) demonstrated differences in 
their frequencies of downregulation between the 2 groups. While FGFR2 was 
relatively more frequently downregulated in the DIPG (67% versus 7%, p=0.063), 
APBB2 was more frequently downregulated in the non-DIPG (93% versus 33%, 
p=0.063) short-term cell cultures.  
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FGFR2 plays crucial roles in cellular signaling as the encoded protein can interact 
with fibroblast growth factors affecting mitogenesis and differentiation. 
Dysregulation of FGFR2 has been linked to several developmental disorders 
highlighting its importance in organ development (Larbuisson et al., 2013; Zhigang 
et al., 2013). It has been reported to play a role in skeletal development, proliferation, 
differentiation and apoptosis in human calvaria osteoblasts, indicating its connection 
with BMP signaling (Marie et al., 2002). This is interesting as a subset of DIPGs 
have been associated with deregulations in BMP signaling (Song et al., 2010). 
APBB2/Fe65 encodes a neuronal adaptor protein that functions both within the 
nucleus regulating transcription and at the cell surface regulating cell migration and 
motility (Standen et al., 2003). The transcriptional activity of this gene can regulate 
genes involved in DNA damage signaling pathways (Ryu et al., 2015). It is therefore 
likely that DIPG and non-DIPG may differ in their level of susceptibility to DNA 
damage and subsequently, different DNA damage signaling pathways may operate 
between them. SH3BP4 is involved in the internalisation of specific protein 
receptors, and in the negative regulation of the mTOR pathway leading to regulation 
of cell growth, differentiation and autophagy (GeneCards (www.genecards.org)). 
Aberrant expression of SH3BP4 in DIPG may indicate a potential role of mTOR 
pathway in these tumours. The protein encoded by RANBP17 is a relatively new 
member of the importin β-like family of nuclear transport receptors sharing about 
67% amino acid similarity with importin β proteins (Lee et al., 2010). Members of 
the importin β superfamily are involved in the transport of substrates such as proteins 
and large RNAs from cytoplasm to nucleus across nuclear pore complexes (Kutay et 
al., 2000). Recently, RANBP17 mutations have been identified in a patient with 
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urothelial carcinoma (Wagle et al., 2014). Chromosomal aberration in this gene has 
been reported in osteosarcomas (Both et al., 2014). MYH10 belongs to the myosin 
family of genes that encode actin-dependent motor proteins and are involved in a 
range of functions including regulation of cytokinesis, cell motility and cell polarity 
(Catherine et al., 2010; GeneCards (www.genecards.org)). It has a role in the PI3K 
regulation of trophoblast cell differentiation, in which it is negatively regulated by 
this pathway (Lindsey et al., 2010). 
Candidate tumour suppressor genes frequently methylated in DIPG short-term cell 
cultures 
One of the important aspects of this study was the experimental validation of 
candidate genes identified by the microarray analysis. Seven of 40 genes 
(ADAMTS18, DAB1, EYA4, PRKG2, PTPRE, RFX3 and RHBDF2) were 
downregulated in all DIPG short-term cell cultures (3/3 cases). These genes were 
further validated to confirm the role of promoter methylation in the downregulation 
of these genes. Treatment of cells with demethylating agent (5-AZA) to reactivate 
downregulated genes is an indirect, yet useful strategy to evaluate promoter 
methylation of genes. Re-expression of genes post demethylation were evaluated in 1 
DIPG and an additional cohort of 10 non-DIPG short-term cell cultures. The 
remaining paediatric HGG short-term cell cultures had comparatively slower growth 
rate and were couldn‘t be treated for sufficient time periods that ensured 
demethylation. The majority of these genes were re-expressed in a minimum of 4 
paediatric HGG short-term cell cultures following demethylation, confirming the role 
of DNA methylation in the downregulation of these genes in these tumours.  
271 
 
Interestingly, there were also several cases with gene downregulation but no re-
expression following demethylation. It is therefore possible that additional 
mechanisms such as deletions, mutations, histone modifications or non-coding RNAs 
may operate as alternative mechanisms in inducing downregulation of these genes in 
DIPG short-term cell cultures. The requirement of coordinated activities of DNA 
methylation and histone modifications for the establishment of gene silencing has 
been studied in many cancers (Zhang et al., 2005; Cedar and Bergman, 2009; Rose et 
al., 2014). It was also observed that some of the tumour cultures which expressed 
basal levels of gene expression that were included in the experiment as positive 
controls, exhibited downregulation after treatment. This may be due to the global 
demethylating effect of 5-AZA which could cause gene body DNA demethylation, 
resulting in gene silencing (Yang et al., 2014). Gene body methylation and the 
associated downregulation of gene expression have been previously reported 
(Maunakea et al., 2010; Varley et al., 2013; Yang et al., 2014).  
Each of 7 genes has been reported to have associations with other cancers and also 
with altered cellular processes linked to cancer and may contribute to DIPG 
pathogenesis. None of these genes have previously been reported to be methylated in 
DIPG, although some genes were previously reported to be dysregulated by other 
mechanisms. The tumour suppressive roles of 2 genes (DAB1 and PTPRE) were 
further investigated. 
The ADAMTS family of disintegrin-like and secreted metalloproteinases with 
thrombospondin motifs consist of 19 members, which participate in diverse functions 
such as collagen processing, degradation of matrix proteoglycans, inhibition of 
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angiogenesis and regulation of homeostasis (Porter et al., 2005). ADAMTS18 is a 
relatively new member of this group, which is expressed abundantly in almost all 
normal human tissues including brain. Mutation in this gene is reported to cause a 
developmental disorder, called Knobloch syndrome characterised by occipital skull 
defect and vision problems (Aldahmesh et al., 2011). It is frequently mutated in RCC 
and colorectal cancers, downregulated in breast cancers and hypermethylated in 
RCC, pancreatic, gastric and colorectal cancers (Porter et al., 2004; Jin et al., 2007; 
Xu et al., 2015). A potential role for this gene in paediatric HGG may be postulated 
as 16q has been identified as a critical region of loss in paediatric HGG including 
DIPG and non-DIPG at a frequency much higher than in adult HGG (18% versus 
7%) (Bax et al., 2010; Qu et al., 2010; Jones et al., 2012).  
EYA4 encodes a member of the eyes absent homolog family of proteins that possess 
separate domains for tyrosine phosphatase and threonine phosphatase activities and 
can also act as transcription factors (Tadjuidje et al., 2013). These activities enable 
these proteins to participate in diverse functions including DNA damage repair, 
innate immunity and development of organs such as eye, inner ear and kidney. It has 
been shown to promote dephosphorylation of H2AX, thereby promoting repair and 
survival in response to DNA damage (Cook et al., 2009). Mutations in this gene have 
been identified to cause deafness (Wayne et al., 2001; Huang et al., 2015). Recently, 
De Carvalho and colleagues (2012) attempted to identify methylation in driver genes 
involved in tumourigenesis. They found that EYA4 methylation was cancer-specific 
and that it did not cluster with genes influenced by culture-induced methylation. 
Increased methylation of the gene was present in viable cancer cells than early 
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apoptotic cells indicating a beneficial role for methylation of this gene in cancer cell 
survival. EYA4 has been identified as a prognostic marker in hepatocellular 
carcinoma (Hou et al., 2014). Methylation of this gene has been widely studied in 
colorectal cancer (Oster et al., 2011; Kim et al., 2015) which has led to the 
development of its role as biomarker in stools. It is also found to be methylated in 
Barret‘s oesophagus and oesophageal adenocarcinoma, (Zou et al., 2005) and breast 
carcinoma (Conway et al., 2014).  
PRKG2, which encodes cyclic guanosine monophosphate (cGMP)-dependent protein 
kinase II is a serine/threonine kinase involved in the phosphorylation of genes 
essential for the proper development of growth plate (Koltes et al., 2015). It has been 
identified to control differentiation and proliferation of chondrocytes in mice cells. 
The enzyme is abundantly expressed in brain and its decreased activity in glioma 
cells has shown correlation with increased levels of Akt phosphorylation (Swartling 
et al., 2009). Ectopic expression of PRKG2 in glioma cells was found to inhibit 
SOX9 production resulting in decreased Akt levels and reduced proliferation. It is 
possible that the altered expression of PRKG2 observed in paediatric HGG short-
term cultures in this study may therefore have links to alterations in the PI3K/Akt 
pathway in these tumours. The inhibitory effects of PRKG2 on cell proliferation have 
also been demonstrated in colon (Wang et al., 2012), gastric (Chen et al., 2010) and 
breast cancer cells (Ting et al., 2012). In breast cancer cells, the reduced proliferation 
was achieved through inhibition of EGF and its downstream pathway components 
including MAPK/ERK. Hence, downregulation of PRKG2 in paediatric HGG may 
likely contribute to dysregulation of EGFR. In addition, PRKG2 has also 
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demonstrated both anti-proliferative and anti-apoptotic effects in prostate cancer cells 
(Cook et al., 2004). A recent study revealed that the downstream targets of PRKG2 
are associated with p53 pathway (Koltes et al., 2015).  
RFX3 encodes regulatory factor X-3, 1 of 5 TFs belonging to the regulatory factor X 
family of genes involved in the control of expression of genes essential for 
ciliogenesis (Choksi et al., 2014). Primary cilia projecting from the plasma 
membrane on the cell surface are capable of acting as sensory structures in cell 
signalling. Many cancers such as pancreatic cancer, renal cell carcinoma, melanoma 
and ovarian cancers display very low frequencies of primary cilia. Primary cilia play 
vital roles in regulating proliferation of neural cells (Han et al., 2008), migration 
(Higginbotham et al., 2012), and survival (Yoshimura et al., 2011) in childhood and 
adult CNS. They are also associated with signalling pathways such Hedgehog (Hh) 
signalling (Hassounah et al., 2012). Interestingly, Hh pathway has been implicated in 
many cancers and has been reported to be active in a subgroup of DIPG tumour cells 
(Michelle et al., 2010). In a DIPG cell culture model, it was observed that the self-
renewal ability of the tumour cells in neurospheres was positively regulated by the 
level of activation of Hh signalling. The Hh inhibitors targeting Smoothened (Smo) 
require proper functioning of clilia. Therefore, downregulation of RFX3 may 
contribute to dysregulated ciliogenesis and tumours with decreased RFX3 may not be 
ideal candidates for Hh inhibitors targeting Smo. Ina et al., (2014) reported that 
dysregulated formation of primary cilia was associated with pre-invasive breast 
cancer lesions indicating this as an early event in cancers. Moreover, genes required 
for formation and function of primary cilia were found to be disrupted in these 
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cancers. Therefore, further functional studies to elucidate the role of altered 
ciliogenesis in paediatric HGG may provide better insights into the biology of these 
tumours. 
RHBDF2 encodes one of two inactive homologues of rhomboid proteases iRhom 2 
that lacks the proteolytic residues of its active counterpart but possess additional 
domains acquired during its evolutionary process (Zettl et al., 2011; Adrain and 
Freeman, 2012). The inactive rhomboid (iRhom) family of proteins have been 
discovered recently and are thought to have crucial regulatory roles as they are 
preserved during evolution under continuous selective pressure. iRhoms have been 
identified to inhibit EGFR signalling by regulating the release of EGF ligands 
mediated by the endoplasmic reticulum-associated protein degradation (ERAD) 
pathway. Deletion and loss of expression of RHBDF2 have been identified in both 
benign and malignant types of epithelial ovarian cancer cells (Paulina et al., 2012). 
Mutations in this gene have been linked with tylosis esophageal cancer and 
contribute to dysregulated EGFR signalling, increased migration and proliferation of 
tumours cells in comparison to their normal tissues (Blaydon et al., 2012). 
DAB1 and PTPRE demonstrate tumour suppressive activities in vitro 
The regulatory potential of DAB1 and PTPRE on growth characteristics of cells 
investigated in this study suggests potential tumour suppressive roles for these genes 
in DIPG short-term cell cultures. The role of DAB1 on regulating growth has 
previously been demonstrated in breast cancer cell lines (McAvoy et al., 2008). The 
re-expression of DAB1 in a breast cancer cell line resulted in decreased growth. The 
role of PTPRE has not been previously explored in cancers. In this study, re-
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expression of DAB1 or PTPRE in a cell culture model with no expression of these 
genes showed reduction in colony forming ability of cells, indicating a potential role 
for these genes in regulating growth characteristics of cells.  
DAB1 encodes the intracellular adaptor protein of reelin, a large ECM-associated 
glycoprotein secreted by the Cajal-Retzius cells in the CNS that is critical for normal 
brain development. Reelin binds to the 2 lipoprotein receptors (VLDLR and 
ApoER2) on cell surface activating the src family of kinases (SFKs) (D‘ Arcangelo 
et al., 1999). Upon clustering of these ligands, DAB1 binds to the intracellular 
domain of these receptors followed by its phosphorylation by SFKs (Howell et al., 
1999; Kuo et al., 2005). Phosphorylated DAB1 further activates multiple downstream 
signaling pathways such as Crk/Rap1 signaling regulating cell adhesion and 
PI3K/Akt and mTOR signaling, which contributes to formation of spine (Beffert et 
al., 2002; Niu et al., 2004; Feng and Cooper, 2009; Franco et al., 2011). Reduced 
expression of DAB1 in GBM cell lines and xenograft models and endometrial 
cancers has been previously reported (McAvoy et al., 2008). Teixeira et al. (2014) 
demonstrated that downregulation of DAB1 caused altered structural layering in the 
neocortex and hippocampus while inactivation of DAB1 in adult brain did not show 
additional abnormalities in layering. This may suggest a specific role for DAB1 in the 
developmental phase. In addition, DAB1 can also affect F-actin stabilisation through 
its interaction with LIMK1 and n-cofilin as shown in Figure 6.12 (Assadi et al., 
2003). 
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Figure 6.11 Role of DAB1 in reelin pathway. DAB1 encodes the intracellular adaptor in reelin 
signaling pathway. DAB1 plays a major role in the transduction of extracellular signals from reelin 
and participates in F-actin-stabilization (Assadi et al., 2003) 
 
DAB1 is a common fragile site (CFS) gene that has been reported to be inactivated in 
multiple cancer types, suggesting its role as a tumour suppressor (McAvoy et al., 
2007; McAvoy et al., 2008; Smith et al., 2006). Other major tumour suppressors that 
are also CFS genes include FHIT and, VWOX. Methylation of DAB1 been reported in 
a subtype of HCC that was associated with PIK3CA mutations, Akt hyperactivation 
and poor prognosis (Calvisi et al., 2007). In this study, overexpression of DAB1 in a 
cell culture lacking DAB1 expression has shown significant reduction in growth as 
well as migratory potential of cells in vitro, further supporting its role as a potential 
tumour suppressor. In addition, knockdown of DAB1 in a paediatric HGG-derived 
short-term cell culture showed significant increase in cell migration. These suggest a 
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putative role for DAB1 in paediatric HGG in the regulation of tumour cell migration. 
Taken together, it is likely that promoter hypermethylation of DAB1 may be an early 
event in paediatric HGG tumourigenesis and warrants further investigation.  
PTPRE is a member of the family of protein tyrosine phosphatases (PTPs) that play 
crucial roles in mediating signal transduction and cell adhesion in the developing 
nervous system (Ostman et al., 2006). Putative regulatory roles for PTPRE in Ras-
related signal transduction pathways, and in the inhibition of MAPK cascade through 
the ERK 1 and 2 pathways have been demonstrated in animal models (Wabakken et 
al., 2002; Toledano-Katchalski et al., 2003). Although promoter hypermethylation of 
PTPRE has not previously been reported in other cancers, other mechanisms of 
disruption of this gene have been identified in few cancers. For instance, inactivation 
of PTPRE by homozygous deletion (10q26.2) has been identified in adult GBM has 
been identified (Nord et al., 2009). More importantly, intragenic deletion of this gene 
has been reported in paediatric HGG (Carvalho et al., 2014).  
PTPRE was found to be associated with decreased expression and repressive histone 
mark, H3K27Me3 in malignant pheochromocytoma (Sandgren et al., 2010). It has 
been identified as a negative regulator of insulin signaling in primary liver cells 
(Nakagawa et al., 2005), and as an essential factor for the maintenance of proper 
structure and function of osteoclasts in vitro and in vivo (Chiusaroli et al., 2004).. 
Considering its significance in tumour-related processes in other cancers, 
dysregulation of PTPRE may be a key biomarker in DIPG. 
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H3F3A (K27M) mutation differentiates methylation profiles in DIPG short-term 
cell cultures 
Of the 3 DIPG short-term cell cultures investigated in this study, the methylation 
profile of the H3F3A (H3K27M)-mutant sample (IN2675) was different from the 
others, as was evident from the PCA scatter plot (Figure 6.4). Interestingly, the 
mutant sample also did not share similarities in the global methylation profile with 
the majority of the non-DIPG short-term cell cultures, which also included the 
H3F3A (H3K27M)-mutant non-DIPG short-term cell culture (IN1566). This may 
indicate that H3F3A (K27M) may influence the methylation profiles of tumours 
depending on their different microenvironment in the brain. This was further 
supported by the fact that the remaining 2 DIPG short-term cell cultures grouped 
together with the majority of the non-DIPG short-term cell cultures. Thus, DIPG may 
share similarities in their methylation profiles with non-DIPG short-term cell 
cultures, but may also have unique subgroups within them that may be different from 
their non-brainstem counterparts. The presence of 3 distinct genomic subgroups 
within DIPG has recently been identified in a large-scale microarray-based 
integrative analysis involving copy number, gene expression and methylation 
profiles of 44 DIPG tumours. These consisted of a MYCN-amplified subgroup, a 
silent subgroup with stable genomes and a H3-K27M-mutant subgroup (Buczkowicz 
et al., 2014). The H3-K27M mutant subgroup had unstable genomes, and decreased 
levels of H3K27me3 histone marks. Interestingly, the H3F3A-mutant DIPG short-
term cell culture (IN2675) had a relatively unstable genome compared to the other 
DIPGs, as described in Table 4.2. In IN2675, 3.57% of the genome was gained or 
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lost compared to 0.24% and 0.22% of alterations in IN2087 and IN2102, 
respectively. The identification of such different methylation profiles within such a 
small cohort of DIPG may indicate the genomic complexity of these tumours. A total 
of 37 probes representing 23 genes were identified to be hypermethylated (β value of 
methylated probe>0.85) in the H3F3A (K27M)-mutant DIPG short-term cell culture, 
while these genes were hypomethylated (β value of methylated probe<0.15) in the 
wild-type DIPG short-term cell cultures. The majority of these genes serve as 
biomarkers of tumour aggressiveness in other cancers, indicating that further 
investigation of these genes may lead to the development of potential biomarkers for 
a subset of DIPG with H3F3A mutation. Genes regulating stem-cell self renewal 
such as ENTPD2 and PIWIL1 were also hypermethylated in this subgroup. This may 
indicate that these tumours may harbour cancer stem-cell-like population of cells 
which may be one of the reasons for their highly aggressive and chemoresistant 
phenotypes. This is interesting as dysregulated miRNAs identified to be associated 
with H3F3A (K27M)-mutant paediatric HGG short-term cell cultures, described in 
Chapter 5 also suggested the potential role of pathways related to stem cell renewal 
in this tumour subgroup Table 5.15. This is therefore an area that is worth further 
investigation. 
Promoter methylation of miRNA genes in DIPG short-term cell cultures 
This study also identified promoter-hypermethylation in miRNA genes in DIPG 
short-term cell cultures. Twenty one probes representing 15 miRNA genes were 
identified to be frequently hypermethylated in DIPG short-term cell cultures 
compared to NHA (β value>0.75 in 2/3 DIPG, and β value<0.25 in NHA). However, 
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these represent interesting targets for future investigation owing to their potential 
tumour-related roles in other cancers. In addition, this also highlights the possibility 
of alternative mechanisms of miRNA dysregulation in DIPG pathogenesis.Of 
particular interest was MIR193B that has been identified to have tumour suppressing 
roles in many cancers. Downregulation of mir-193b has been identified in non small 
cell lung cancer in comparison to matching normal tissues and its ectopic 
overexpression in these cancers resulted in reduced migration, invasion and 
proliferation (Xu et al., 2010; Hu et al., 2012).  CCND1, a key regulator of cell cycle 
and DNA damage control has been identified as an important target of mir-193b 
(Chen et al., 2010). A recent study by Kaukoniemi et al. (2015) has reported 
hypermethylation of mir-193b in prostate cancer and also demonstrated its ability to 
target CCND1 in these tumour cells. Other important targets of mir-193b include 
SMAD and KIT (Gao et al., 2011). CCND1 and KIT are frequent targets of 
amplification in paediatric HGG including DIPG and the importance of Smad 
signalling in these tumours has been implicated recently (Barrow et al., 2011; Bax et 
al., 2010; Wu et al., 2014). Taken together, hypermethylation of MIR193B may have 
roles in paediatric HGG pathogenesis. Some of the other miRNAs with putative 
functional significance in DIPG were MIR1179 and MIR549.  MIR1179 has shown 
metastasis promoting roles in colorectal cancers and pro-invasive properties in 
eosaphageal squamous cell carcinoma (Jiang et al., 2015). One of the prime predicted 
targets of MIR1179 using miRDB is anoctamin 3 (ANO3), a member of the family of 
anoctamins that are highly expressed in many cancers contributing to proliferative, 
migratory and metastatic abilities (Wanitchakool et al., 2014). Although not 
completely clear, a link between ANO1 upregulation and HDAC has been reported in 
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head and neck squamous cell carcinoma where a dose-dependent decrease in 
proliferation of cells was observed upon treatment with HDAC inhibitors. 
Considering the important roles of HDAC in DIPG, downregulation of MIR1179 
may have novel implications in DIPG tumourigenesis.  The role of MIR549 in 
cancers has not extensively been investigated studied so far. It is located within 
KIAA1199, which has been recently identified as a regulator of EGFR stability and 
has demonstrated to promote cell survival in keratinocytes (Shostak et al., 2014). 
Another study in colorectal cancers has reported upregulation of mir-549 (Hamfjord 
et al., 2012). An attempt to predict the potential targets of MIR549 using miRDB and 
TargetScan revealed that frequently upregulated genes in cancers such as HIF1A and 
HMGB1. A recent study by Li et al. (2015) reported that HMGB1 mediates 
epithelial-mesenchymal transition via increased expression of TGF-B1 and 
phosphorylation of Smad 2/3 signalling. Dysregulation of Smad signalling has been 
reported in paediatric HGG, particularly DIPGs (Wu et al., 2014).  
Experimental validation of candidate genes is critical 
This study emphasises the importance of experimental validation of candidate genes 
identified from microarray data analysis. The initial analysis of the Methylation 450 
K data and Affymetrix U133a plus data in this study identified 40 candidate genes. 
Of these, only 20 genes showed satisfactory correlation with the microarray data, 
while the remaining 20 genes (50%) did not show correlation with the analysed data. 
Fourteen of 20 genes were not expressed in the control sample (NHA). Of the 14 
genes that did not show expression in NHA, 7 genes were frequently downregulated 
in the DIPG short-term cell cultures and included genes with potential associations 
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with paediatric HGG, as well as with other cancers. A notable member among these 
genes was A2BP1, which was deleted in paediatric GBM, deleted (10%, 430 TCGA 
GBM tumour samples) and downregulated in adult GBM, deleted in other nervous 
system tumours such as medulloblastoma and neuroblastoma, as well as in other 
cancers such as colon cancer cancer and sarcoma indicating a tumour suppressive 
role for this gene (Beroukhim et al., 2010; Jian et al., 2013; Novara et al., 2014). 
There were also known tumour suppressors like FHIT and genes with potential 
tumour suppressive roles like KRT8 in this subgroup (Jayachandran et al., 2007; 
Mizuuchi et al., 2009). The role of promoter hypermethylation induced 
downregulation has been reported for FHIT, and it has also been demonstrated to 
induce apoptosis via inactivation of PI3K/Akt pathway (Semba et al., 2006; Kelley 
and Berberich, 2011; Huang et al., 2014; He et al., 2015). It is not clear why these 
genes did not show expression in NHA. The availability of only 1 normal sample 
was therefore a limitation in this analysis. The suitability and availability of normal 
control samples for paediatric HGG studies remains a contentious issue. 
Six of 20 genes were expressed in NHA, but failed to show downregulation in any of 
the DIPG short-term cell cultures. This could be due to several reasons. One of the 
possibilities is the interference of background noise from the microarray leading to 
technical artefacts. These could affect the signal intensities of probes leading to false 
positives. The other reason could be attributed to the location of the methylated 
probes around the promoter region. In this analysis, probes located up to 1500 base 
pairs from TSS were analysed. The proximity of a methylated probe to the core 
promoter region where transcription factors bind may influence the degree of 
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transcription. It would be interesting to evaluate the location of the methylated 
probes in these genes that failed to demonstrate correlation with the microarray data. 
Furthermore, discrepancies may also arise as cell culture conditions can influence 
gene methylation. Cells in culture tend to acquire more changes in methylation, 
which can influence the expression of transcription factors leading to global changes 
in gene expression. The various analyses to validate the genes identified in this 
analysis therefore raise confidence in their suitability for further investigations in 
DIPG. 
6.3 Conclusions 
To conclude, this study highlights the importance of promoter hypermethylation in 
the dysregulation of coding and non-coding genes in the development and 
progression of paediatric HGG. The candidate genes identified in this study are 
found to have significant associations with tumourigenesis and may be developed as 
potential biomarkers in the treatment of DIPG and/or non-DIPG tumours in future. 
Importantly, the tumour suppressive potential of DAB1 and PTPRE demonstrated in 
this study highlights aberrations in novel pathways in DIPG. Further investigations 
of these genes may lead to their development into useful biomarkers of 
tumourigenesis in DIPG. However, it has to be taken into account that culture 
conditions may cause changes in methylation, and therefore additional validation in 
more samples are indispensable to confirm the genuine associations of these genes 
with the tumour. Furthermore, although microarrays provide rich sources of 
information, this study emphasises the importance of experimental validation of 
genes identified by microarray analysis, in order to limit false positives.  
285 
 
 
 
 
 
 
CHAPTER 7 
Preliminary investigation of targeted 
therapeutics in paediatric HGG short-term 
cell cultures 
 
 
 
 
 
 
286 
 
7.1 Introduction 
Children with high grade glioma commonly develop serious late effects associated 
with endocrine dysfunction and neurocognitive delay as a result of conventional 
radio- and chemotherapy (Merchant et al., 2010; Sands et al., 2012). The sensitivity 
of the brain and its developmental stage in children are some of the major issues 
which need to be considered in the generation of novel treatment agents for HGG in 
this age group. 
One of the peculiarities of tumour cells is their requirement for particular amino 
acids to accommodate the demands of increased proliferation (Hanahan and 
Weinberg, 2011), which has laid the foundation for the development of anti-cancer 
agents that can deplete specific amino acids in the circulation (Delage et al., 2010; 
Agrawal et al., 2011; Covini et al., 2012; Phillips et al., 2013). The preference of 
tumour cells for glutamine has long been established and recent metabolomic 
profiling in some tumours has provided evidence of the critical roles of glycine and 
serine in the rapid proliferation of tumour cells (DeBerardinis et al., 2007; Possemato 
et al., 2011; Jain et al., 2012; Zhang et al., 2014; Boroughs and DeBerardinis, 2015). 
Recent discoveries of arginine-dependency in tumours have raised the therapeutic 
possibilities of using arginine-degrading enzymes for such tumours (Delage et al, 
2012; Feun et al., 2015).  
Arginine is involved in various cellular activities, notably growth and proliferation, 
and tumour cells exhibit higher demands for arginine than normal cells (Caso et al., 
2004; Morris, 2007; Morris, 2009). In a healthy individual, cells can synthesise 
287 
 
arginine de novo from its precursor citrulline via the arginine biosynthesis machinery 
as well as obtaining it from external sources. Cellular arginine renewal is controlled 
by two primary enzymes, argininosuccinate synthetase (ASS1) and argininosuccinate 
lyase (ASL) encoded by ASS1 and ASL respectively.  The coordinated activities of 
these enzymes regulate the conversion of citrulline to arginine through 
argininosuccinate (Morris, 2004; Haines et al., 2011). Tumours with deregulated 
ASS1 and/or ASL fail to synthesise arginine de novo, which forces them to rely on 
external arginine sources. Therefore, starving such tumours of arginine using agents 
that can deplete arginine from the circulation can selectively eradicate tumour cells 
(Qiu et al, 2015).  
Deficiency of ASS1, the enzyme that catalyses the rate-limiting step in the arginine 
pathway, has been reported in a number of cancers including melanoma, HCC, RCC, 
small cell lung, prostate, pancreatic and bladder cancers (Cheng et al., 2007; Yoon et 
al., 2007; Bowles et al., 2008; Kim et al., 2009; Feun et al., 2012; Kelly et al, 2011; 
Allen et al., 2013). Decreased expression of ASS1 expression was correlated with 
advanced tumour stage and poor survival in nasopharyngeal carcinoma and 
myxofibrosarcoma (Huang et al., 2013; Lan et al., 2013). In ovarian and bladder 
cancers, ASS1-deficiency was associated with reduced overall survival rates 
(Nicholson et al., 2009; Allen et al, 2013). ASL has also shown tumour suppressive 
roles in some cancers (Syed et al., 2013). 
Of particular interest, deregulation of ASS1 and ASL by promoter methylation was 
recently reported in adult GBM primary cultures, which also demonstrated anti-
proliferative responses to ADI-PEG20 (Syed et al., 2013). Interestingly, the anti-
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tumour activity of ADI-PEG20 in GBM cells was due to the induction of autophagic 
cell death, circumventing the apoptotic route to which these cells are intrinsically 
resistant. Autophagy acts as an initial pro-survival mechanism during conditions of 
nutrient stress, but can mediate caspase-independent cell death when pushed beyond 
a particular threshold (Fulda and Kogel, 2015). In addition, a study by Pavlyk et al. 
(2014) reported that arginine deprivation in GBM cell lines reduced migration and 
invasion in vitro. 
ADI-PEG20 is a polyethylene glycol-conjugated formulation of a microbial-derived 
arginine hydrolysing enzyme and possesses reduced immunogenicity and extended 
half life in serum than native ADI (Feun and Savaraj, 2006; Feun et al., 2008). The 
clinical performance of ADI-PEG20 has been evaluated in adults with melanoma 
(Ascierto et al., 2005, Ott et al., 2012), HCC (Izzo et al., 2004), and malignant 
pleural mesothelioma (Szlosarek et al., 2013). In phase I/II clinical trials conducted 
in these patients, the use of very low doses of the drug has shown improved overall 
survival with minimal side effect, and a phase III trial for HCC is in progress 
(clinical trial identifier NCT01287585).  
The PI3K/Akt/mTOR signaling pathway, which plays an integral role in cancer cell 
growth and survival, is one of the most frequently altered signaling networks in 
human tumours (Samuels et al., 2004; Cancer Genome Atlas Research Network 
2008). The PI3Ks are a group of intracellular lipid kinases that phosphorylate the 
3-OH group of phosphatidylinositides (PtdIns) in response to extracellular cues such 
as growth factors and hormones. This triggers a series of events leading to the 
regulation of cell growth, survival and metabolism (Cantley, 2002; Engelman et al., 
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2006; Vanhaesebroeck et al., 2012; Thorpe et al., 2014). Among the three classes of 
PI3Ks (I-III), class I PI3Ks are the most frequently deregulated in cancer and are 
divided into two subgroups-class 1A and 1B. Class 1A, activated by growth factor 
RTKs are heterodimers composed of regulatory (p85) and catalytic (p110) subunits. 
The genes PIK3R1, PIK3R2 and PIK3R3 encode p85α, p85β and p55γ isoforms of 
the p85 subunit respectively. The p110α, p110β and p110δ isoforms of p110 catalytic 
subunit of class 1A are encoded by PIK3CA, PIK3CB and PIK3CD respectively. 
Class IB PI3Ks, activated by GPCRs are heterodimers consisting of a single catalytic 
subunit p110γ (PIK3CG) and two regulatory subunits p101 and p87 encoded by 
PIK3R5 and PIK3R6 respectively (Engelman et al., 2006). Upon ligand-receptor 
binding, the activated PI3Ks catalyse the phosphorylation of PIP2 to PIP3, which 
recruits Akt, a serine/threonine kinase that is the immediate effector of the PI3K 
pathway to the plasma membrane (Franke et al., 1997; Klippel et al., 1997). 
Phosphorylated Akt activates mTOR leading to stimulation of protein synthesis and 
cell growth. The PI3K pathway is further regulated by the intricate feedback loop of 
PTEN (Maehama et al., 1998) as well as the crosstalk between components of the 
PI3K pathway and other signaling networks (Lee et al., 2008). 
Hyperactivation of the PI3K pathway has been widely investigated in adult HGGs 
and occurs commonly through gain of function mutations in PIK3CA (Samuels et al., 
2004) or loss of the tumour suppressor, PTEN. In contrast, very few studies have 
investigated the role of PI3K activation in paediatric HGG. It has been reported that 
the frequency of PIK3CA mutations in paediatric HGG occur at relatively lower rates 
compared to those in adults (Jones et al., 2012). In a study by Mueller et al. (2012), 
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aberrant activation of PI3K/Akt/mTOR pathway was identified in 80% (12/15) of 
paediatric HGG and the evaluation of PTEN alterations revealed correlation of lack 
of PTEN protein expression and promoter methylation in 50% (5/10) cases. It is 
therefore likely that constitutive PI3K activation exist in paediatric HGG, possibly 
initiated through alternative mechanisms. A number of small molecule inhibitors that 
can target PI3K and/or its network components have been developed, some of which 
are being evaluated in clinical trials. PI-103, a dual inhibitor of class1 isoform of 
PI3K and mTOR (molecular weight of 348.36), has shown significant anti-
proliferative effect in xenograft models of glioma (Fan et al., 2006; Fan et al., 2007).  
In this study, the expression of ASS1 and/or ASL in paediatric HGG has been 
investigated and the response of these tumours to ADI-PEG20 treatment in vitro has 
been assessed. The growth inhibitory effect of PI-103 in paediatric HGG short-term 
cell cultures has also been evaluated.   
7.2. Results 
7.2.1 Evaluation of arginine biosynthesis pathway as a therapeutic target in 
paediatric HGG short-term cell cultures 
7.2.1.1 Promoter methylation of ASS1/ASL in paediatric HGG short-term cell 
cultures 
To investigate if ASS1/ASL was deregulated by promoter hypermethylation in 
paediatric HGG short-term cell-cultures, the Illumina Infinium HumanMethylation 
450 K data generated from NHA and 17 paediatric HGG short-term cell cultures 
(consisting of 3 DIPG and 14 non-DIPG) were screened for differentially methylated 
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probes representing ASS/ASL. Data were also available for 5 paediatric HGG biopsy 
samples, which included 3 paired biopsies and their derivative cell cultures. To 
ensure only promoter-associated probes were screened, the probes located in 5‘UTR 
and up to 1500 bases upstream of TSS (n=132,665) were identified, as described in 
6.2.1. Of these, 7 probes represented ASS1 and 3 probes represented ASL. To identify 
the differentially methylated probes in paediatric HGG compared to NHA, these 
probes were evaluated based on their beta values (ranging from 0 to 1, indicative of 
percentage of methylation). To ensure that ASS1/ASL methylation in paediatric HGG 
short-term cell cultures was not disregarded because of stringent probe beta value 
thresholds for methylation, a relaxed criterion was initially defined to identify 
differentially methylated probes. Those probes that had beta value>0.50 in paediatric 
HGG short-term cell cultures and beta value<0.5 in NHA were considered 
differentially methylated, which identified a single probe representing ASS1 
(cg22791453) and a single probe representing ASL (cg22723802), respectively. The 
probe beta values of ASS1 and ASL in NHA, 17 paediatric HGG short-term cell 
cultures and 5 biopsy samples are given in Figure 7.1. Methylation of the probes 
representing ASS1 and ASL were detected in 17/17 (100%) and 15/17 (88%) 
paediatric HGG short-term cell cultures, respectively. Methylation of the ASS1 probe 
was not detected in any of the paediatric HGG biopsy samples in the cohort. 
However, ASL methylation was detected in 4/5 paediatric HGG biopsy samples, 
which included the 3 paired samples. Of these pairs, methylation was present in 
biopsy and its derived short-term cell culture in 2 cases (IN3182 and IN3183). 
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Figure 7.1 Probe beta values of ASS1/ASL in NHA, 17 paediatric HGG short-term cell cultures and 5 biopsies.  The Illumina Infinium HumanMethylation 
450 K data from NHA, 17 paediatric HGG short-term cell-cultures and 5 biopsy samples were analysed to identify promoter-associated and differentially 
methylated probes (probe β value>0.50 in tumour and <0.50 in NHA) corresponding to ASS1/ASL. A. Probe beta values of ASS/ASL in NHA and paediatric HGG 
short-term cell cultures. B. Probe beta values of ASS1/ASL in 5 paediatric HGG biopsies including 3 paired biopsies (IN3182 B/CC, IN3183 B/CC and IN3205 
B/CC). C. Location of ASS1/ASL methylated probe in the promoter region. Colour codes of probe beta values range from 0 (unmethylated) to 1 (complete 
methylation). N_shore indicates north shore, the region upstream (up to 2 kb) from the CpG Island; B-Biopsy; CC cell culture. 
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7.2.1.2 Validation of promoter methylation of ASS1/ASL in paediatric HGG 
short-term cell cultures 
To validate methylation of ASS1/ASL in paediatric HGG short-term cell cultures, 
DNA was extracted from 17 paediatric HGG short-term cell cultures and CpG 
methylation in the promoter region was determined using combined bisulfite 
restriction analysis (CoBRA), as described in 2.2.8.3. DNA available for 2 paired 
biopsies was also included for validation. For ASS1 methylation analysis, the location 
of the methylated probe (cg22791453), as described in the UCSC genome browser 
(www.genome.ucsc.edu) was identified (Figure 7.2) and methylation of CpGs within 
and/or around the promoter region containing the probe was determined. The details 
of the probe CpGs of ASS1 are shown in Figure 7.2.  
 
 
 
 
Figure.7.2 Methylated probe CpG in ASS1 promoter CpG Island.  The ASS1 methylated probe 
(cg22791453) located on the CpG Island was retrieved from the UCSC genome browser. Methylated 
CpG is highlighted in red. BstUI recognition sites are highlighted in aqua. Forward and reverse 
CoBRA primers are highlighted in green. 
The PCR amplified products were digested with the restriction enzyme, BstUI 
(recognition sequence-CGCG). The methylation status of ASS1 in 17 paediatric HGG 
short-term cell cultures including 2 paired biopsies, as determined by CoBRA is 
shown in Figure 7.3 A. ASS1 was methylated in 8/17 (24%) paediatric HGG short-
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term cell cultures consisting of 6 non-DIPG (IN1163, IN1262, IN1419, IN3032, 
IN3180 and IN3183) and 2 DIPG (IN2087 and IN2102) samples. With the exception 
of IN3182, all the remaining samples (9/17) consisting of 7 non-DIPG (IN178, 
IN179, IN1523, IN1566, IN1930, IN3046 and IN3205) and 1 DIPG (IN2675) short-
term cell cultures had partial methylation of ASS1. The lack of ASS1 methylation 
observed in IN3182 CC was also observed in its respective biopsy. ASS1 was 
methylated in IN3183 CC, but only partially methylated in its respective biopsy.  
For methylation analysis of ASL, primers were designed to amplify regions within its 
promoter region and the amplified products were digested with BstUI. The results of 
methylation analysis of ASL in paediatric HGG as determined by CoBRA is shown in 
Figure 7.3 B. In contrast to ASS1, ASL was not methylated in any of the samples 
analysed. 
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Figure 7.3 Methylation status of ASS1 and ASL in paediatric HGG as determined by CoBRA. CoBRA was used to determine the methylation status of ASS1 
and ASL in 17 paediatric HGG short-term cell cultures. Methylation in a sample is indicated by digested (D) PCR products compared to undigested (U). ** 
indicates partial methylation. B. ASL was not methylated in paediatric HGG short-term cell cultures or paired biopsies.   
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To further investigate ASS1/ASL CpG methylation in paediatric HGG short-term cell 
cultures, methylation in additional CpG sites in the promoter regions of these genes 
were analysed. Previously, Syed et al. (2013) has shown ASS1 promoter CpG 
methylation in 2 regions (regions 1 and 2 in Figure 7.4 A), and ASL promoter CpG 
methylation in 2 regions (regions 1 and 2 in Figure 7.5A), respectively, which 
correlated with silencing of these genes in adult GBM primary cultures. To 
investigate if ASS1/ASL CpGs in these regions were methylated in paediatric HGG 
short-term cell cultures, DNA was extracted from 17 paediatric HGG short-term cell 
cultures and 2 paired biopsies and the methylation status of these regions was 
determined by MSP, as described in 2.2.8.3. The methylation status of ASS1 CpG 
sites in regions 1 and 2 is shown in Figure 7.4 B, and that of ASL CpG sites in 
regions 1 and 2 in these samples is shown in Figure 7.5 B.  
ASS1 methylation in region 1 was detected in 7/17 (41%) paediatric HGG short-
term cell cultures consisting of 5 non-DIPG (IN1163, IN1262, IN1419, IN3032 and 
IN3205) and 2 DIPG (IN2087 and IN2675) cases. Methylation of ASS1 in this region 
was not detected in either the biopsy or the cell culture of the 2 paediatric HGG 
paired samples (IN3182 B/CC and IN3183 B/CC) analysed. Methylation of ASS1 in 
region 2 was detected in 8/17 (47%) paediatric HGG short-term cell cultures 
consisting of 6 non-DIPG (IN179, IN1163, IN1262, IN3032, IN3182 and IN3205) 
and 2 DIPG (IN2087 and IN2675) samples. The methylation detected in IN3182 CC 
was also detected in its respective biopsy, but at comparatively lower levels than 
observed in the cell culture. For the IN3183 pair, partial methylation of ASS1 was 
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detected in IN3183 biopsy, which was comparable to the amounts of methylation in 
its derived short-term cell culture. 
In contrast, ASL CpG methylation in regions 1 and 2 was not detected in any of the 
paediatric HGG samples including the 2 paired biopsies (Figure 7.5). 
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Figure 7.4 Methylation status of ASS1 in paediatric HGG short-term cell cultures and biopsies determined using MSP. Methylation of 2 CpG rich sites in 
ASS1 promoter was determined in paediatric HGG short-term cell cultures using MSP. A. ASS1 promoter CpG site used for methylation analysis by MSP (Syed et 
al., 2013). B. Methylation (*) was detected in IN1163, I1419, IN3032, IN3205 and IN1262 in region 1, and in IN179, IN1163, IN3182, IN3032, IN3205, IN1262, 
IN2675 and IN2087 in region 2, respectively.  
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Figure 7.5 Methylation status of ASL in paediatric HGG short-term cell cultures and biopsies determined using MSP.  Methylation of ASL in paediatric 
HGG short-term cell cultures was determined using MSP. Methylation was not detected in any of the samples analysed. A. ASL promoter CpG site used for 
methylation analysis by MSP (Syed et al., 2013). B. Methylation of ASL in regions 1 and 2 was absent in paediatric HGG short-term cell cultures. 
300 
 
In addition to the investigation of ASS1/ASL methylation in specific CpG sites in 
their promoter regions by CoBRA and MSP, promoter methylation of these genes in 
paediatric HGG short-term cell cultures were evaluated based on upregulation in 
their expression following treatment with the demethylating agent 5-AZA. Nine 
paediatric HGG short-term cell cultures (8 non-DIPG and 1 DIPG) were treated with 
5µM 5-AZA and changes in expression of ASS1/ASL following demethylation were 
determined by quantitative PCR (Q-PCR), as described in 2.2.9.4. The results of Q-
PCR analysis of ASS1/ASL expression in 9 paediatric HGG short-term cell cultures 
following demethylation with 5-AZA are shown in Figure 7.7. ASS1 was upregulated 
in 4/9 (IN1419, IN2102, IN3182 and IN3205) cultures and ASL was upregulated in 
4/9 (IN1163, IN1930, IN3182 and IN3205) cultures. Interestingly, ASS1 and ASL 
were both upregulated in 2 cases (IN3182 and IN3205).  
It was also observed that expression of ASS1 was reduced following demethylation in 
3/9 paediatric HGG short-term cell cultures (IN178, IN179 and IN1163) and 
expression of ASL was also reduced following demethylation in 3/9 cultures (IN179, 
IN1523 and IN2102). This is not surprising as these genes are involved in complex 
networks of regulation and 5-AZA treatment indiscriminately demethylates the 
whole genome. 
 
 
301 
 
0
0.5
1
1.5
2
2.5
3
3.5
IN
1
7
8
 U
IN
1
7
8
 T
IN
1
7
9
 U
IN
1
7
9
 T
IN
1
1
6
3
 U
IN
1
1
6
3
 T
IN
1
4
1
9
 U
IN
1
4
1
9
 T
IN
1
9
3
0
 U
IN
1
9
3
0
 T
IN
1
5
2
3
 U
IN
1
5
2
3
 T
IN
3
1
8
2
 U
IN
3
1
8
2
 T
IN
3
2
0
5
 U
IN
3
2
0
5
 T
IN
2
1
0
2
 U
IN
2
1
0
2
 T
F
o
ld
 C
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 u
n
tr
e
a
te
d
Paediatric HGG short term cultures
Treated (+5-AZA)
Untreated 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 Upregulation of ASS1 in paediatric HGG short-term cell cultures following demethylation. Paediatric HGG short-term cell cultures were treated 
with the demethylating agent (5-AZA) and changes in ASS1/ASL expression following treatment were measured using Q-PCR. A. Increase in expression of 
ASS1following treatment was detected in IN1419, IN2102, IN3182 and IN3205.  B. Increase in expression of ASL following treatment was detected in IN1163, 
IN1930, IN3182 and IN3205. 
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7.2.1.3 Downregulation of ASS1/ASL in paediatric HGG short-term cell cultures 
To determine the basal levels of expression of ASS1/ASL in paediatric HGG short-
term cell cultures, RNA was extracted from NHA and 17 paediatric HGG short-term 
cell cultures and all 3 biopsies and ASS1/ASL mRNA expression levels in these 
samples were determined using Q-PCR, as described in 2.2.9.4. ASS1/ASL 
expression in these samples was normalised to the expression levels of an 
endogenous control (GAPDH). The expression of ASS1 and ASL in paediatric HGG 
short-term cell cultures in comparison to NHA as determined by Q-PCR analysis are 
shown in Figures 7.9 and 7.10 respectively.  
Of the 4 ASS1-methylated paediatric HGG short-term cell cultures as determined by 
the upregulation of ASS1 expression following demethylation with 5-AZA (IN1419, 
IN2102, IN3182 and IN3205), very low expression was observed in 1 culture 
(IN3205) in comparison to the expression of ASS1 in NHA demonstrating correlation 
of promoter hypermethylation with reduced transcription. However, the other 3 
paediatric HGG short-term cell cultures had higher expression of ASS1 compared to 
the expression level in NHA, but this might be because NHA in this analysis 
demonstrated very little basal ASS1 mRNA levels. In addition to IN3205, low 
expression of ASS1 was found in 2 paediatric HGG short-term cell cultures, both of 
which were DIPG (IN2087 and IN2675). Among the 3 paired biopsies, ASS1 was 
downregulated in all 3 biopsies, with relatively higher expression in their respective 
cell cultures. However, it was interesting to note that the increase in expression of 
ASS1 in 2/3 pairs (IN3182 and IN3183) was <2-fold. For the IN3180 pair, ASS1 
expression in the cell culture was relatively higher compared to its parent biopsy.  
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Figure 7.8 Reduced expression of ASS1 in paediatric HGG. Expression of ASS1 in NHA, 17 paediatric HGG short-term cell cultures and 3 biopsy samples was 
determined using q-PCR. GAPDH was used as an endogenous control. The fold change in expression of ASS1 is shown with respect to NHA. (*) indicates 
paediatric HGG short-term cell cultures that demonstrated upregulation of ASS1 following treatment with 5-AZA. IN3205 had very low levels of ASS1 mRNA. 
304 
 
Expression of ASL was lower than NHA in 11/17 (57%) paediatric HGG short-term 
cell cultures comprising 9 non-DIPG (IN178, IN1163, IN1419, IN1930, IN3032, 
IN3180, IN3182, IN3183 and IN3205) and 2 DIPG (IN2102 and IN2675) samples. 
Notably, ASL expression was much lower in all 3 paired biopsies in comparison to 
NHA. There were 4 paediatric HGG short-term cell cultures with comparatively 
higher levels of ASL expression comprising 3 non-DIPG (IN1262, IN1566 and 
IN3046) and 1 DIPG (IN2087) short-term cell culture respectively. 
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Figure 7.9 Reduced expression of ASL in paediatric HGG.  Expression of ASL in NHA, 17 paediatric HGG short-term cell cultures and 3 biopsy samples was 
determined using q-PCR. GAPDH was used as an endogenous control. The fold change in expression for each sample with respect to NHA is shown. (*) indicates 
paediatric HGG short-term cell cultures which demonstrated upregulation of ASL following treatment with 5-AZA. All ASL- methylated paediatric HGG short-term 
cell cultures (IN1163, IN1930, IN3182 and IN3205) had very low levels of mRNA. 
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To investigate if downregulation of ASS1 in paediatric HGG short-term cell cultures 
caused decreased protein expression, the expression of ASS1 protein was determined 
using western blot analysis as described 2.2.11.2. Only 2 of the 4 cultures with 
methylated ASS1 as determined by Q-PCR analysis following demethylation with 5-
AZA (IN1419 and IN3182), were included in this analysis as it was not possible to 
extract good quality protein from the others. Seven additional cultures (IN178, 
IN179, IN1163, IN1930, IN1523, IN1566 and IN3032) were included in the western 
blot analysis and the results are shown in Figure 7.10. ASS1 protein expression was 
detected in both the ASS1-methylated paediatric HGG short-term cell cultures. This 
was surprising as both these cultures had shown upregulation of ASS1 following 
demethylation with 5-AZA.  
 
 
 
 
Figure 7.10 Loss of ASS1 protein in paediatric HGG short-term cell cultures. Using western blot 
analysis, ASS1 protein expression was determined in 9 paediatric HGG short-term cell cultures. 
Proteins were extracted from cells; 50µg of the extracted protein was used for protein detection; 
tubulin was used as loading control. (*) indicates ASS1-methylaed paediatric HGG short-term cell 
cultures as determined by Q-PCR analysis following treatment of cells with 5-AZA. 
However, similar findings were reported by Syed et al. (2013) in adult GBM primary 
cultures. They showed that CpG methylation in ASS1/ASL inhibits the adaptive 
transcriptional upregulation of these genes and it is this factor that determines the 
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sensitivity of cells to ADI-PEG20 rather than the absolute expression levels of these 
genes.  
Among the other paediatric HGG short-term cell cultures assessed for ASS1 protein 
expression, 5 paediatric HGG short-term cell cultures (IN178, IN1163, IN1930, 
IN1523 and IN3032) had little or no expression of ASS1, while the remaining 
paediatric HGG short-term cell cultures (IN179 and IN1566) had relatively higher 
amounts of ASS1 protein. On comparison of ASS1 protein expression with ASS1 
mRNA in these cultures, it was observed that paediatric HGG short-term cell cultures 
with relatively similar amounts of mRNA expression had large differences in the rate 
of translation. For instance, IN179 and IN3032 had comparatively similar mRNA 
expression with respect to NHA, but the protein product was detected in only IN179. 
Also, IN1523, which showed highest expression of ASS1 mRNA had very little 
protein product compared to other paediatric HGG short-term cell cultures with 
much less ASS1 mRNA (IN1566). The disparities in mRNA expression and the 
translation rate of ASS1 clearly indicate the complexity of ASS1 regulation in 
paediatric HGG short-term cell cultures. 
7.2.1.5  Methylation of ASS1/ASL predicts sensitivity of paediatric HGG short-
term cell cultures to ADI-PEG20  
To investigate if ASS1/ASL-deficient paediatric HGG short-term cell cultures respond 
to arginine deprivation therapy using ADI-PEG20, the viability of cells treated with 
ADI-PEG20 was measured over a period of up to 9 days following initial treatment 
using SRB cytotoxicity assay, as described in 2.2.3. Initially, the effect of ADI-
PEG20 was investigated in 1 of 2 paediatric HGG short-term cell cultures that 
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demonstrated upregulation of both ASS1 and ASL following treatment with 5-AZA 
(IN3205). The ASS1-methylated adult GBM cell line, LN229 was used as a positive 
control. Cells were treated with increasing concentrations of ADI-PEG20 (range 0-1 
µg/mL) in the presence of citrulline (1 mM) (Sigma-Aldrich Ltd,  Dorset, UK), a key 
precursor of arginine, and cell viability was determined on 1, 3 and 5 days after 
treatment. Following 5 days of treatment, IN3205 showed comparatively less 
sensitivity to ADI-PEG20 than LN299. However, the number of IN3205 cells treated 
with 1µg/mL of ADI-PEG20 was significantly less (p=0.002) compared to the 
untreated control cells. Interestingly, this sensitivity to ADI-PEG20 was comparable 
to that of LN229 treated with the same concentration of the drug (p=0.006). The 
difference in sensitivity between the 2 ASS1-methylated cultures may be due to the 
difference in their cell type. LN229 is a cell line, while IN3205 is a short-term cell 
culture. Also, there could be differences in ADI-PEG20 sensitivity between adult and 
paediatric tumours. However, having observed an encouraging response in the 
sensitivity to ADI-PEG20 in IN3205, this investigation was extended in additional 
paediatric HGG short-term cell cultures. 
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Figure 7.11 Effect of ADI-PEG20 on cell proliferation in paediatric HGG short-term cell culture. IN3205 (ASS1 and ASL methylated) cells were treated with ADI-
PEG20 in varying concentrations (0-1µg/mL) and the reduction in cell number was determined in a SRB cytotoxic assay following treatment for 1, 3 and 5 days. LN229, 
an ASS1-methylated adult GBM cell line was used as positive control. The bar chart shows the percentage viability of IN3205 and LN229 cells 5 days following 
treatment. IN3205 (p=0.002) and LN229 (p=0.006) demonstrated statistically significant reduction in cell number compared to the untreated control cells. 
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Syed et al. (2013) has demonstrated that methylation of ASS1, but not ASL is the 
decisive factor that predicts sensitivity of adult GBM cells to ADI-PEG20 and that 
co-methylation of ASS1 and ASL results in hypersensitivity to the drug (Syed et al., 
2013). To investigate this in paediatric HGG short-term cell cultures, 3 cell cultures 
with varying ASS1/ASL methylation status (IN178-ASS1-unmethylated, ASL-
methylated; IN1419-ASS1-methylated, ASL-unmethylated and IN3182-ASS1-
methylated, ASL-methylated) were assessed for their sensitivity to ADI-PEG20 using 
SRB assay as described above. The ASS1 and ASL-unmethylated paediatric HGG 
short-term cell culture, IN179 was used as a negative control. The antiproliferative 
effect of ADI-PEG20 in 4 paediatric HGG short-term cell cultures including the 
negative control is shown in Figure 7.12. 
The paediatric HGG short-term cell culture with co-methylation of ASS1 and ASL 
(IN3182) or methylation of ASS1, but not ASL (IN1419) demonstrated similar dose 
response curves for ADI-PEG20. By contrast, the paediatric HGG short-term cell 
culture with unmethylated ASS1, but methylated ASL (IN178) showed little/no 
sensitivity to ADI-PEG20, demonstrating similar response to that of the negative 
control (IN179). These results showed that ASS1 is the key determinant of ADI-
PEG20 in paediatric HGG short-term cell cultures and were in agreement with the 
findings of Syed et al. (2013) in adult GBM primary cultures. However, unlike adult 
GBM cell cultures, co-methylation of ASS1 and ASL did not result in increased 
sensitivity to ADI-PEG20 compared to methylation in only ASS1 or ASL. 
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Figure 7.12 Antiproliferative effect of ADI-PEG20 in paediatric HGG short-term cell cultures. Cells were treated with ADI-PEG20 (0-1 µg/mL) and reduction in cell 
number treatment were determined at 3, 5, 7 and 9 days following treatment using a SRB cytotoxicity assay. Methylation status of ASS1 and ASL in each samples are shown M 
indicates methylated and U indicates unmethylated. 
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7.2.2 Targeting PI3K/Akt pathway in paediatric HGG short-term cell cultures 
7.2.2.1 Aberrations in the PI3K pathway network in paediatric HGG short-term 
cell cultures 
The majority of the investigations to identify PI3K pathway alterations in cancers 
have focused on alterations in the core components of the pathway such as PIK3CA, 
PIK3R1, AKT, PTEN and mTOR. However, alterations in these targets occur at 
relatively lower frequencies in paediatric HGG. In this study, alterations in genes that 
may indirectly contribute to aberrant activation of the PI3K pathway in paediatric 
HGG were identified. Genetic and/or epigenetic changes that contribute to aberrant 
activation of PI3K pathway were identified from genome-wide copy number changes 
and genetic mutations (described in Chapter 4), gene and miRNA expression 
(described in Chapters 5 and 6) and methylation changes (described in Chapter 7) 
identified in paediatric HGG short-term cell cultures. A summary of these genes is 
given in Figure 7.13. 
Copy number gain of PIK3CA, one of the core components of the PI3K subunit was 
altered in 17.65% paediatric HGG short-term cell cultures (Table 4.12). 
BRAFV600E mutation was detected in 1 paediatric HGG short-term cell culture 
(IN179). There were 3 miRNAs that were upregulated in these cultures consisting of 
miR142-3p, miR-16-2-3p, miR-138 and miR-183. PIK3CA and the 2 major 
downstream signaling components, AKT1 and AKT2 were upregulated in these 
tumours. Interestingly, there were several genes that were hypermethylated and/or 
downregulated in these short-term cell cultures that have potential roles in the 
aberrant activation of PI3K pathway. These comprised MYH10, PTPRE, ITGB2, 
313 
 
KRT8, DAB1, FHIT, PIK3R5 and PRKG2. PIK3R5 encodes the regulatory subunit of 
PI3K, which has not previously been investigated. Two miRNAs, associated with 
PI3K pathway were downregulated in these cultures.  
PIK3R5 encodes the core component of PI3K complex and has not previously been 
investigated. Promoter hypermethylation of PIK3R5 in paediatric HGG short-term 
cell cultures was validated by CoBRA, as described in 2.2.8.3. Methylation was 
detected in 13/17 (76.5%) paediatric HGG short-term cell cultures (Figure 7.14 A). 
To assess if promoter hypermethylation of PIK3R5 induced downregulation in 
paediatric HGG short-term cell cultures, the expression of this gene was determined 
in 10 paediatric HGG short-term cell cultures following demethylation with 5µM 5-
AZA. PIK3R5 was re-expressed in 6/10 (60%) paediatric HGG short-term cell 
cultures treated with 5-AZA compared to the untreated control cells (7.14 B). 
Furthermore, RT-PCR analysis was carried out to determine the differential 
expression of PIK3R5 in paediatric HGG short-term cell cultures in comparison to 
NHA. PIK3R5 was absent in 12/17 (71%) paediatric HGG short-term cell cultures 
consisting of 9 non-DIPG (IN178, IN179, IN1163, IN1419, IN1523, IN1566, 
IN3046, IN3182 and IN3183) and all 3 DIPG (IN2087, IN2102 and IN2675) (Figure 
7.14 C). The only paediatric HGG short-term cell culture with relatively higher 
expression of PIK3R5 was IN3205, but this difference is more likely due to the low 
expression observed in NHA as upregulation of this gene was observed in IN3205 
following demethylation with 5-AZA (Figure 7.14 B). 
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Figure 7.13 Genes contributing to aberrant PI3K signaling in paediatric HGG short-term cell cultures. Using microarray technology, genomic CNAs, promoter 
DNA methylation, mRNA and micro RNA expression in 17 paediatric GBM short-term cell cultures, including 3 diffuse intrinsic pontine glioma (DIPGs) were 
assessed. Dysregulated genes that may contribute to aberrant PI3K signaling were identified. A summary of the most relevant genes is shown. 
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Figure 7.14 Promoter hypermethylation-induced down regulation of PIK3R5 in paediatric HGG short-term cell cultures. Dysregulation of PIK3R5 was assessed 
in 17 paediatric HGG short-term cell cultures. A. CoBRA PCR was used to determine methylation status of PIK3R5 (Sam DNA- Fully methylated DNA used as 
positive control; U-undigested, D-digested; (*) indicates methylation). B. Cells were treated with 5µM 5-AZA and the mRNA expression of PIK3R5 following 
treatment was determined in untreated (-) and treated (+) cells using RT-PCR analysis (*indicates re-expression after treatment). C. Endogenous expression of PIK3R5 
in paediatric HGG short-term cell cultures as determined by RT-PCR analysis. With the exception of IN3205, PIK3R5 was downregulated in the majority of the 
paediatric HGG short-term cell cultures in comparison to a normal control (NHA). 
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7.2.2.2 Investigation of the effect of PI-103 on cell viability in paediatric HGG 
short-term cell cultures 
To investigate the growth inhibitory effect of PI-103 in paediatric HGG short-term 
cell cultures, 3 paediatric HGG short-term cell cultures that had genetic aberrations  
associated with aberrant PI3K signaling (IN3182, IN179 and IN1523) were treated 
with a PI3K-inhibitor, PI-103 (Selleckchem, USA) and the reduction in cell viability 
after 72 hours was assessed using MTT cytotoxicity assay, as described in 2.4.2. 
IN3182 had gain of EGFR, and IN179 and IN1523 had gain of PIK3CA (Table 
4.12). The antiproliferative effect of PI-103 was also assessed in NHA. The results 
are shown in Figure 7.15. 
Following treatment with PI-103, all 3 paediatric HGG short-term cell cultures 
demonstrated dose-dependent effects on cell proliferation. The reduction in cell 
number following 72 hours of treatment with PI-103 was much higher in IN1523 
(IC50-105.7nm) compared to IN3182 (IC50-582.9nm) and IN179 (IC50-634.6nm). 
Interestingly, PI-103 showed very little effect on NHA (IC50-6684.9 nm). The main 
difference between IN1523 and the other cultures was that IN1523 had higher 
number of CNAs (Table 4.4) and it also had a unique genetic profile and clustered 
independently of all other samples analysed in this study (Figure 4.16).  
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Figure 7.15 PI-103 reduced cell proliferation in paediatric HGG short-term cell cultures in vitro. 
MTT cytotoxicity assay was performed using PI-103 (0-10000nm) in NHA and 3 paediatric HGG 
short-term cell cultures. A. PI-103 reduced cell viability in paediatric HGG short-term cell cultures 
and demonstrated much reduced anti-proliferative effect on NHA. B. IC50 of PI-103 in NHA, 
IN3182, IN179 and IN1523 are shown. Error bars indicate standard deviation. 
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7.3 Discussion 
HGG in children are extremely aggressive with no effective treatment that can 
significantly prolong the survival rates in the affected population (Fangusaro, 2012; 
Gerges et al., 2013). As such, the requirement to identify novel therapeutic strategies 
that are less damaging to the developing brain is critical. This Chapter has focussed 
on the investigation of deregulations in 2 important cellular pathways in paediatric 
HGG short-term cell cultures; the arginine biosynthesis pathway and the PI3K/Akt 
pathway. The data presented here show that these pathways are disrupted in a 
proportion of paediatric HGG short-term cell cultures including DIPG. The potential 
clinical utility of specific small molecule inhibitors that can target these pathways 
were investigated in paediatric HGG short-term cell cultures in vitro. 
Dysregulation of arginine biosynthesis pathway in paediatric HGG short-term 
cell cultures 
Promoter hypermethylation of ASS1/ASL in paediatric HGG short-term cell 
cultures 
Tumour cells with deficient ASS1 and/or ASL, the 2 key elements of the arginine 
biosynthesis pathway have shown increased dependency on external arginine 
resources making them sensitive to cell death induced by arginine deprivation (Scott 
et al., 2000; Seyfried et al., 2013). Although deregulation of ASS1/ASL has been 
identified in a number of tumour types, its incidence in paediatric HGG has not been 
widely investigated (Huang et al., 2013; Syed et al., 2013; Lan et al., 2014). This 
study reports that ASS1 and/or ASL are deregulated in a subset of paediatric HGG 
short-term cell cultures, and promoter hypermethylation plays a major role in their 
downregulation in a proportion of these tumours. 
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The Illumina Infinium HumanMethylation 450 K microarray analysis conducted on 
NHA, 17 paediatric HGG short-term cell cultures and 5 biopsy samples revealed that 
ASS1 and ASL were frequently methylated in these tumours compared to NHA with 
relatively higher frequency of methylation of ASS1 over ASL. Three independent 
techniques (CoBRA, MSP and Q-PCR analysis following global demethylation by 5-
AZA) were used to validate promoter methylation of ASS1/ASL in paediatric HGG 
short-term cell cultures. Using CoBRA and MSP, ASS1 methylation was identified in 
paediatric HGG short-term cell cultures in specific CpG rich regions in its promoter 
CpG Island. However, as these two techniques were designed to determine 
methylation in different CpG sites, there was little concordance between these 
techniques in most cases. Nevertheless, both the techniques uniformly detected 
methylation of ASS1 in a minimum of 3/17 (18%) paediatric HGG short-term cell 
cultures (IN1163, IN1262 and IN3032), which provided the first experimental 
evidence for ASS1 methylation in these paediatric HGG short-term cell cultures. 
Independently, ASS1 methylation was detected by CoBRA in 24% and by MSP in 
41-47% (regions 1 and 2) of paediatric HGG short-term cell cultures, respectively. 
The role of promoter hypermethylation as a crucial epigenetic mechanism regulating 
the expression of tumour suppressor genes is widely established (Estellar, 2007). 
Methylation of ASS1 in the promoter CpG sites in paediatric HGG short-term cell 
cultures indicates a potential tumour suppressive role for this gene in these tumours. 
In comparison to ASS1, ASL methylation in paediatric HGG short-term cell cultures 
could not be detected by the PCR-based methods used in this study, but this may be 
mainly due to the limited number of CpG sites that could be analysed for 
methylation using these techniques. 
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Interestingly, promoter methylation of ASS1 in paediatric HGG short-term cell 
cultures was demonstrated by its upregulation in cells following global 
demethylation with 5-AZA. Upregulation of ASS1 was detected in 4/9 (44%) 
paediatric HGG short-term cell cultures (IN1419, IN2102, IN3182 and IN3205), and 
that of ASL was identified in 4/9 (44%) paediatric HGG short-term cell cultures 
(IN1163, IN1930, IN3182 and IN3205), with co-methylation of ASS1 and ASL in 2 
cases (IN3182 and IN3205). One of the commonalities of IN3182 and IN3205 
cultures was their highly unstable genetic profiles relative to the majority of the other 
samples analysed here (as described in Chapter 4, Table 4.14). IN3182 and IN3205 
had CNAs in 17.24% and 5.81% of their genomes respectively, whilst the majority 
of the paediatric HGG short-term cell cultures had relatively normal karyotypes 
(<1% genome changed). This indicates a potential association of ASS1 methylation 
with tumour aggressiveness. The incidence of co-methylation of ASS1 and ASL has 
not been reported in many cancers, but has been identified in adult GBM (Syed et al., 
2013). The overlap of this epigenetic event in paediatric HGG short-term cell 
cultures may therefore reflect the unique microenvironment persisting in the brain in 
comparison to any other organ in the body that may cause larger selective pressure to 
disrupting the arginine biosynthetic pathway in tumours originating from brain. 
However, the investigation of the therapeutic intervention of arginine biosynthetic 
pathway in cancers is in its early stage. Therefore, further investigations of these 
specific epigenetic mechanisms in brain tumours may provide better insights into the 
possibility of such unique selection pressure in these tumours. 
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Paediatric HGG short-term cell cultures demonstrate sensitivity to AD1-PEG20 
Promoter hypermethylation of ASS1 in cancers such as lymphoma, melanoma and 
adult GBM has been identified as a biomarker for predicting sensitivity to cell death 
induced by arginine depleting agents like ADI-PEG20 (Delage et al., 2012; Feun et 
al., Syed et al., 2013). The sensitivity of paediatric HGG short-term cell cultures to 
ADI-PEG20 observed in this study identifies a similar role for ASS1 methylation in 
these tumours. ADI-PEG20 readily induced a decrease in cell viability in ASS1- 
methylated paediatric HGG short-term cell cultures (IN1419, IN3182 and IN3205) 
compared to the unmethylated cell culture (IN179) at very low concentrations of the 
drug (up to 1µg/mL). In addition, the paediatric HGG short-term cell culture with 
methylation of only ASL and not ASS1 (IN178) demonstrated less sensitivity to ADI-
PEG20 in comparison to the cell culture with methylation of only ASS1 but not ASL 
(IN1419) or methylation of both ASS1 and ASL (IN3182), which supports the 
previous findings on the predictive role of ASS1 methylation on ADI-PEG20 
sensitivity in adult GBM primary cultures (Syed et al., 2013). However, unlike in 
adult GBM cultures, there was no increase in the sensitivity to ADI-PEG20 in 
paediatric HGG short-term cell cultures that had co-occurrence of ASS1 and ASL 
methylation compared to the cell culture with only ASS1 methylation, although this 
may be due to the small number of samples available for this study. In this analysis, 
there were only 2 paediatric HGG short-term cell cultures with methylation in both 
ASS1 and ASL, of which only 1 (IN3182) could be included in the comparison study 
of ADI-PEG20 sensitivity using samples with varying ASS1/ASL methylation status. 
The other paediatric HGG short-term cell culture (IN3205) had a very low growth 
rate and was difficult to utilise for drug testing over a period of 9 days (Figure 7.11). 
322 
 
However, there is also a possibility that the co-disruption of ASS1 and ASL and the 
consequent failure in arginine renewal may modulate different downstream cellular 
processes in paediatric HGG compared to those in an adult setting, or may affect 
similar processes but in different ways. For instance, ADI-PEG20 has demonstrated 
induction of an initial autophagic response in adult GBM cells and showed enhanced 
antiproliferative activity upon blockade of such response using an autophagy 
inhibitor, chloroquine (Syed at al., 2013). Increased autophagic responses to nutrient 
starvation have been demonstrated in paediatric brain tumours such as 
medulloblastoma and teratoid/ rhabdoid tumour cell lines (Levy and Thornburn, 
2012). However, the differences in responses to specific nutrient depletion between 
adult and paediatric brain tumours are not very clear.  
One of the main hurdles in the development of efficient chemotherapeutics for 
treatment of brain tumours is the failure of these agents to cross the BBB. As ADI-
PEG20 works by depleting arginine from peripheral blood, crossing of the BBB is 
not a requirement for its anti-tumour activity (Syed et al., 2013). In addition, as ADI-
PEG20 acts in a tumour-specific manner, it should cause little/no damage to the 
normal brain. This is extremely important in paediatric HGG patients as 
chemotherapeutic agents can cause irreversible damage to the developing brain 
leaving the survivors of this age group with poor quality of life due to serious late 
effects on cognition and in some cases, making them vulnerable to secondary 
malignancies (Karremann et al., 2015). Taken together, the sensitivity to ADI-
PEG20 demonstrated in paediatric HGG short-term cell cultures in this preliminary 
investigation holds promise for the therapeutic intervention of arginine biosynthesis 
pathway in the management of these tumours. 
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Complexity of ASS1 regulation in paediatric HGG may be cell type dependent 
In comparison to ASL, ASS1 displayed a high degree of complexity in its regulation 
in the paediatric HGG short-term cell cultures analysed here. In all 3 cases of ASL 
promoter methylation identified in this study, ASL mRNA was downregulated 
supporting the role of promoter methylation in ASL regulation. However, such 
straightforward correlation was absent for ASS1. Although ASS1 was upregulated in 
paediatric HGG short-term cell cultures following demethylation with 5-AZA, 
methylation of ASS1 did not always induce its transcriptional down regulation in 
these cells. One of the reasons for this lack of correlation between promoter 
methylation and relatively high expressions of ASS1 in these paediatric HGG short-
term cell cultures could be due to the low basal levels of ASS1 detected in the control 
NHA that was available for this study, making the absolute expression levels of this 
gene in the tumour cells appear much higher. Further investigations using additional 
normal controls such as normal brain may provide better understanding of the level 
of ASS1 expression in such samples. The other reason for ASS1 methylation not 
always resulting in its down regulation could be attributed to the requirement of 
additional mechanisms of gene regulation such as histone modifications that may be 
essential for the establishment of ASS1 silencing in these tumours.  
In addition, the expression of ASS1 was found to decrease in some cells following 
demethylation with 5-AZA. This is not unexpected to occur as 5-AZA is a global 
demethylating agent of CpGs across the whole genome that may relieve the 
repression of some transcription factors leading to changes in gene expression 
(Maunakea et al., 2010). For instance, transcription factors such as c-Myc/Myn, have 
recognition sites containing CpG sites that are inhibited by methylation (Allis et al., 
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2007). De-repression of such TFs may have significant consequences in the 
expression levels of genes regulated by them. Thus, the downregulation of ASS1 
post-demethylation in paediatric HGG short-term cell cultures provide clues about 
additional metabolic players in the regulation of ASS1 that may be valuable 
indicators of therapeutic resistance to metabolism-based treatment strategies in 
paediatric HGG. 
Moreover, ASS1 demonstrated differences between its mRNA expression levels and 
translation rates that varied between cell cultures, indicating inter-tumour 
heterogeneity in the regulation of this gene. For instance, IN1523 demonstrated the 
highest ASS1 mRNA expression but had very low levels of ASS1 protein, and 
cultures with similar mRNA expression (IN179 and IN3032) demonstrated large 
differences in their levels of protein expression. These imply that different 
mechanisms of post translational events such as regulation by non-coding RNAs 
could operate in different tumours that may affect the rate of translation of ASS1. 
Furthermore, although promoter methylation is widely recognised in inducing gene 
silencing, 2/3 ASS1-methylated paediatric HGG short-term cell cultures (IN1419 and 
IN3182) demonstrated a considerable amount of ASS1 protein expression. 
Interestingly, a similar finding was also reported by Syed et al. (2013) in adult GBM 
cell lines in which methylation of ASS1/ASL rather than their absolute expression 
levels was the key predictor of sensitivity to arginine deprivation therapy. These 
authors demonstrated that treatment with ADI-PEG20 caused adaptive increase of 
ASS1/ASL mRNA in unmethylated GBM cell line, but not in the methylated GBM 
cell line. However, upregulation of these genes in the methylated GBM cell line was 
induced upon demethylation with 5-AZA. It has been reported that modifications in 
gene promoters not always result in gene repression as transactivators can compete 
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with methyl binding proteins to maintain an open chromatin state (Curradi et al., 
2002). This genomic complexity of ASS1 may explain some of the discrepancies 
observed between different levels of ASS1 regulation in the paediatric HGG short-
term cell cultures analysed here.  
The exact impact of ASS1/ASL loss in cancers is not clear. However, methylation-
induced down regulation of ASS1 in many cancers including osteosarcoma, ovarian 
and pancreatic cancers is reported to be associated with poor clinical outcome 
(Nicholson et al., 2009; Kobayashi et al., 2010; Allen et al., 2014). In paediatric 
HGG, aberrations in this pathway may have crucial impact on the development of 
brain as arginine is an important amino acid required for normal brain development 
and developmental disorders in children may have an impact on predisposing them 
to cancer.  
Limitations of the analysis 
Promoter CpG methylation of ASS1 and/or ASL as determined by CoBRA and MSP 
reported in this study did not demonstrate satisfactory correlation between 
methylation and mRNA/protein expression of these genes. This could be due to the 
limitations of such PCR-based techniques that can only examine methylation in 
specific lengths of DNA. More efficient techniques such as pyrosequencing may 
provide better in-depth analysis of ASS1/ASL CpG methylation in these tumours. In 
addition, although demethylation by 5-AZA and the presence of mRNA expression 
post-treatment is a good indicator of promoter methylation the use of 5-AZA alone 
does not always result in reactivation of hypermethylated genes. The role of the 
cross-talk between DNA methylation and histone modifications in gene silencing has 
been increasingly understood, which involves the recruitment of histone deacetylases 
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to methylated DNA and MeCP2 (Jones et al., 1998). Therefore, treatment with 5-
AZA alone may not restore hypermethylated genes in sufficient amounts to be 
detected by PCR. This could be one of the reasons why re-expression of ASS1 was 
not detected following treatment with 5-AZA in at least some cases of low basal 
expression. Treatment of cells with 5-AZA and HDAC inhibitors may be useful for 
future investigations.  
Dysregulations in the PI3K pathway in paediatric HGG short-term cell cultures 
Genetic and/or epigenetic changes contribute to aberrant activation of PI3K 
pathway in paediatric HGG short-term cell cultures 
The PI3K pathway is regulated by a complex network of genes that operate in a 
coordinated fashion in normal cells to maintain their growth, survival and 
proliferation (Liu et al., 2009). The high frequency of PI3K pathway aberrations in 
cancers has elicited great interest in targeting this pathway using small molecule 
inhibitors that can specifically inhibit various isoform of PI3K. The majority of the 
investigations on PI3K pathway alterations in cancers have focused on alterations in 
the core components of the pathway such as PIK3CA, PIK3CB, PIK3R1, AKT, 
PTEN and mTOR. However, alterations in these targets occur at relatively lower 
frequencies in paediatric HGG (Jones et al., 2012). The data from this analysis reveal 
that genetic and/or epigenetic alterations in paediatric HGG short-term cell cultures 
contribute to aberrant signaling by PI3K and offer therapeutic opportunity to target 
such tumours using specific small molecule inhibitors like PI-103. The major genetic 
changes that contribute to dysregulated PI3K pathway signaling in a subset of the 
paediatric HGG short-term cell cultures analysed here included gain of PIK3CA, 
activating mutations in BRAF and overexpression of AKT1, AKT2 and PIK3CA.  
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Interestingly, there were genes with known associations with aberrant PI3K 
signalling that were hypermethylated and/or downregulated in paediatric HGG short-
term cell cultures, indicating the role of epigenetic mechanisms in regulating PI3K 
pathway. One of the frequently hypermethylated gene identified in this study was 
PIK3R5, a gene that encodes the 101 kDa regulatory subunit of the PI3K enzyme 
complex. Promoter hypermethylation-induced down regulation of PIK3R5 was 
identified in 60% of the paediatric HGG short-term cell cultures investigated here. 
Deregulation of PIK3R5 by promoter hypermethylation in paediatric HGG has not 
previously been reported. However, cancer-specific genetic and epigenetic changes 
in this gene have been previously identified. For instance, novel activating mutations 
in PIK3R5 have been reported in metastatic melanoma and a high frequency of 
differential hypermethylation has been reported in primary oral squamous cell 
carcinoma (Khor et al., 2014). It has also been identified to be downregulated in 
gastric cancers, while overexpression of this gene has been demonstrated to induce 
sarcomagenesis (Martin et al., 2011; Shull et al., 2012; Khor et al., 2014). It is likely 
that down regulation of PIK3R5 may be a potential biomarker that would be useful 
as a prognostic indicator in paediatric HGG. 
Other frequently dysregulated genes included DAB1 and PTPRE, the anti-growth 
effects of which have been demonstrated in paediatric HGG short-term cell cultures 
in vitro (6.2.4.1). DAB1 has important roles in neuronal migration and in mediating 
extracellular signals from reelin through PI3K/Akt pathway (Beffert et al., 2002; 
Franco et al., 2011; Niu et al., 2004). Recently, PTPRE has been identified as a 
regulator of autophagy and this perhaps relates its functional activity to PI3K 
pathway activation in these tumours (Puustinen et al., 2014).  
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The incidence of FHIT aberrations in cancers has been widely studied, and its two-
way functionality as tumour suppressor or oncogene in different cancers has been 
reported. The down regulation of this gene by promoter hypermethylation in 
paediatric HGG short-term cell cultures indicates that is likely to have tumour 
suppressive roles in paediatric HGG; this requires additional validation of this 
finding in an extended cohort of samples. FHIT has been identified as an inhibitor of 
proliferation and facilitator of apoptosis in cholangiocarcinoma cells through the 
inhibition of PI3K/Akt pathway, while FHIT itself is repressed by PI3K and AKT 
through the PI3K/Akt/FOXO pathway (Kelly and Berberich, 2011; Huang et al., 
2014).  
PRKG2, which encodes a cyclic guanosine monophosphate (cGMP)-dependent 
protein kinase that belongs to the family of serine/threonine protein kinases has been 
demonstrated as an inhibitor of cell proliferation in adult glioma cells through 
suppression of Akt phosphorylation (Swartling et al., 2009). It has also been 
identified as an inhibitor of EGFR activation in breast and gastric cancer cells (Lan 
et al., 2012; Jiang et al., 2014).  
MYH10 belongs to the myosin family of genes that encode actin-dependent motor 
proteins called myosins involved in a variety of functions such cell division and 
motility (Catherine et al., 2010). It is negatively regulated by PI3K pathway (Lindsey 
et al., 2010).  
One of the important miRNAs identified in this study was miR-142-3p, recently 
identified as a regulator of cancer stem cell-like characteristics (Chai et al., 2014). 
MiR-142-3p regulates stem-cell like properties in HCC by directly targeting CD133 
and hyperactivation of PI3K pathway is critical for cancer stem cell renewal 
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(Dubrovska et al., 2009). Identification of the mRNA targets of this miRNA in 
paediatric HGG short-term cell cultures may lead to better insights into its role as a 
modulator of the PI3K pathway in stem cell-like phenotypes in these tumours. 
Further investigations into the role of these genes in PI3K pathway activation in 
paediatric HGG may lead to the development of predictive biomarkers for 
therapeutic intervention of this pathway in the clinical management of these tumours. 
Targeted therapy in paediatric HGG short-term cell cultures using PI-103 
PI-103, a dual inhibitor of PI3K and mTOR signaling pathway has shown promising 
results in preclinical studies conducted in vitro as well as in vivo preclinical models 
in cancers including adult glioma (Fan et al., 2008; Zou et al., 2009). However, its 
therapeutic efficacy in paediatric HGG has not been previously demonstrated. The 
preliminary drug testing assays in this study have shown that paediatric HGG short-
term cell cultures are sensitive to PI-103, at very low concentrations (range of IC50-
100-700nM). In addition, the normal astrocytoma cells (NHA) were much less 
sensitive to PI-103, suggesting the tumour-specific hyperactivation of this pathway, 
thus providing hopes for therapeutic targeting of this pathway in paediatric HGG. 
However, considering the essential role of this pathway in the regulation of growth 
and survival in normal cells in the body and its position in cellular metabolism as a 
master regulator of various intricate signalling networks essential for normal 
development, the successful manipulation of this pathway in cancer cells is an open 
challenge, particularly in paediatric brain tumours due to concerns of damage to the 
developing brain. Combination therapy involving low concentrations of small 
molecule inhibitors of PI3K with inhibitors targeting other aberrant pathways in 
paediatric HGG may be the key for a better exploitation of this pathway as a 
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therapeutic strategy in these tumours. The therapeutic efficacy of combination 
therapy with PI-103 and stem cell-delivered secretable tumour necrosis factor 
apoptosis-inducing ligand (S-TRAIL) has been demonstrated in vitro as well as in 
intracranial glioma mouse models, offering the scope for the potential extension of 
such investigations in the paediatric population (Bagci-onder et al., 2010). The 
occurrence of epigenetic dysregulation of genes contributing to aberrant PI3K 
signaling in paediatric HGG short-term cell cultures in this study together with the 
increasing understanding of the role of chromatin and histone modifications in the 
development of these tumours offers opportunities for the investigation of 
combination strategies targeting such events in these tumours. The combined use of 
BEZ235, a PI3K inhibitor and panobinostat, a histone deacetylase inhibitor has 
shown significant anti-tumour response in other cancers such as prostate cancer in 
comparison to the independent use of each treatment by attenuating the DNA 
damage repair protein ATM (Ellis et al., 2013). 
7.3 Conclusions 
One of the important aspects of this study was the use of well-characterised 
paediatric HGG short-term cell culture models, which were demonstrated to 
maintain a considerable proportion of genomic changes, originally present in their 
parent biopsies (see 3.2.1, 3.2.2, 3.2.3 and 3.2.4). This raises confidence in the 
observed sensitivity of paediatric HGG short-term cell cultures to the anti-cancer 
agents tested in this study. These therapeutic opportunities generated by genetic 
and/or epigenetic changes in paediatric HGG short-term cell cultures may provide 
better approaches to effective management of these tumours.
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CHAPTER 8 
Final discussion and conclusions 
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8.1 Discussion 
Paediatric HGG are a group of heterogeneous tumours that represent 8-12% of CNS 
tumours in children (Bondy et al., 2008). The current treatment strategies for these 
tumours largely involve focal radiotherapy and chemotherapy, but unfortunately, 
they fail to respond to such treatments and continue to remain fatal tumours of 
childhood. Even in patients who survive, the complications of serious late effects on 
cognition and endocrine dysfunction have undesirable impacts on the quality of life 
(Reimers et al., 2003; Mulhern et al., 2004; Sanders et al., 2007). As such, there is a 
compelling need for the development of effective therapeutics for the management 
of these tumours in children. 
One of the major obstacles in the development of effective chemotherapeutics for the 
treatment of paediatric HGG is the lack of understanding of the molecular biology of 
underlying pathogenesis. Very few investigations have been carried out in paediatric 
HGG in comparison to adult HGG (Bax et al., 2010; Jones et al., 2012). One of the 
main hindrances in conducting paediatric HGG studies is the difficulty in obtaining 
tumour samples as well as the lack of availability of well-characterised, 
representative pre-clinical models. Furthermore, the approaches followed by the 
majority of previous studies in paediatric HGG was largely based on evaluating the 
similarities and differences in selected candidate genes between adult and paediatric 
HGG. It is only recently that genome-wide analyses of these tumours have begun to 
reveal unique genomic changes associated with paediatric HGG. This study, to an 
extent, has addressed these two issues encountered in paediatric HGG studies in 
order to improve the prospects of future investigations.  
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Analysis of paired biopsy and culture samples in this study revealed that the patient-
derived paediatric HGG short-term cell cultures maintained a considerable 
proportion of genomic changes present in the original tumour biopsies and may be 
used as pre-clinical models for paediatric HGG molecular biology studies. Although 
there were relatively more genomic changes in the cell cultures compared to the 
biopsies in each pair that reflected the influence of artificial culture conditions, these 
patient-derived cell cultures retained some of the characteristic signatures of 
paediatric HGG making them appropriate in vitro models for evaluation of targeted 
therapeutics. This was further supported by the identification of paediatric HGG-
associated mutations in these cell cultures. For instance, H3F3A (K27M) mutation 
was detected in 2/17 (12%) cases (1/14 non-DIPG and 1/3 DIPG) and BRAFV600E 
mutation in 1/17 (1 non-DIPG) (6%) case, respectively. Although this study was 
constrained by small sample size, these frequencies were comparable to the reported 
frequencies in paediatric HGG (Wu et al., 2012). Moreover, H3F3A (K27M) are 
relatively more frequent in DIPGs than supratentorial HGGs, and BRAFV600E has 
been restricted to non-DIPG; these are in agreement with the data presented here. 
The potential utility of patient-derived cell cultures has been demonstrated in other 
cancers including adult GBM (Bignotti et al., 2006; Potter et al., 2009; Yost et al., 
2013). In the study by Yost et al. (2013), adult GBM-derived cultures retained 
mutations in classic GBM genes such as PTEN and TP53.  
 The evidence for cross talk between genetic and epigenetic mechanisms in 
paediatric HGG was laid with the identification of histone mutations in these 
tumours (Schwartzentruber et al., 2012; Wu et al., 2012). Taking these into account, 
high-resolution microarray technology was used to conduct genome-wide profiling 
of copy number, gene and miRNA expression, and methylation changes in 17 
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paediatric HGG short-term cell cultures including 3 DIPG. This also incorporated 
integrated approaches for data analysis and algorithms for identification of small, yet 
non-random changes. This study has identified genomic changes in paediatric HGG 
distinct from those arising in HGG in adults with distinct subsets within them, with a 
few notable similarities with adult HGG. Unlike in adult HGG, about 65% (11/17) of 
paediatric HGG short-term cell cultures in this study had balanced genomic profiles 
with no large scale chromosomal rearrangements, but had unique genomic changes 
associated with this subset, with one of them harbouring H3F3A (K27M) mutation. 
Similar subgroups of paediatric HGG with such balanced profiles have previously 
been reported in paediatric HGG (Bax et al., 2010; Barrow et al., 2011). A subset 
(17.65%) of paediatric HGG shared similarities with adults with copy number events 
such as gain of chromosome 7 and loss of 10q. 
The unbiased approach in this study identified gains at 14q11.2 and 7p14.1 as the 
most frequent (94% and 76.4% respectively) CNAs in the paediatric HGG short-term 
cell cultures. Both these focal CNAs were present in the biopsy and cell culture of 
the 2 paired biopsy samples analysed here raising the confidence in the validity of 
this finding. These 2 regions have not been previously reported in paediatric glioma. 
CNVs at 7p14.1and 14q11.2 have been reported to be associated with Dupuytren‘s 
disease, a fibroproliferative disorder characterised by deformities in the fingers and 
may suggest a potential link between developmental errors in children and their 
susceptibility to HGG development (Shih et al., 2012).There was also gain of 2q32 
present in 30% of paediatric HGG short-term cell cultures that was linked with a 
connective tissue disorder, Ehler-Danlos syndrome (Ritelli et al., 2013). Similar 
observations connecting paediatric HGG and developmental disorders have been 
reported in DIPG patients with ACVR1 mutations, which were also found in patients 
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with Fibrodysplasia ossificans progressiva (FOP), a disorder that causes ossification 
of soft tissues leading to muscular deformities (Taylor et al., 2014). It is therefore 
likely that developmental process may have a role in tumourigenesis of paediatric 
HGG.  
Some of the previously known genetic aberrations associated with paediatric HGG 
were identified in this study. Notable genetic changes included homozygous loss of 
8p11.23-p11.22 encompassing ADAM3A (35%) and cooperative loss of CDKN2A 
and BRAFV600E (6%) (Schiffman et al., 2010; Barrow et al., 2013). Loss of 
ADAM3A was the most frequent event of copy number loss identified in the 
paediatric HGG short-term cell cultures in this study. Loss of ADAM3A in a subset 
of paediatric HGG short-term cell cultures was concordant with losses of regions 
containing novel non-coding RNA genes (MIR1268A) and pseudogenes associated 
with embryonic development (DUXAP10) and ribosome biogenesis (BMS1P18). In 
addition, 3 miRNAs (miR-3142, miR-3140-3p and miR-4503) were uniquely 
differentially expressed in paediatric HGG short-term cell cultures with ADAM3A 
loss and their predicted targets were associated with important cancer-related 
pathways including Ras and ErbB signaling and stem cell renewal. Considering the 
significance of miRNA and pseudogene signatures as prognostic biomarkers in 
tumours, along with the existing evidence of deletion of ADAM3A in other 
aggressive cancers, this study not only strengthens the potential role that ADAM3A 
may have as a prognostic/therapeutic biomarker in paediatric HGG, but also 
highlights the importance of further investigations on the non-coding elements of the 
genome in paediatric HGG. 
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Paediatric HGG short-term cell cultures in this study could be distinguished from 
normal controls based on their miRNA and methylation signatures, emphasising the 
role of epigenetic mechanisms in these tumours. Unique patterns of miRNA 
expression were associated with these tumours, with specific miRNA signatures that 
could distinguish between tumour types (DIPG or non-DIPG) as well as between 
H3F3A (K27M)-mutant and wild type cultures. Similar studies in adult HGG have 
identified miRNA-signatures that could predict response to therapy (Hayes et al., 
2015; Tumilson et al., 2014). The miRNAs identified in this study were informative 
of the aberrant signalling pathways in these subgroups. Some of the pathways such 
as mucin type-o-glycan biosynthesis and ECM-receptor interactions have not been 
previously reported in paediatric HGG short-term cell cultures. Integration of 
miRNAs with their dysregulated mRNA targets in these cultures revealed aberrations 
in phosphoinositide signaling pathway. The evidence for this pathway dysregulation 
in paediatric HGG was also observed from genes dysregulated due to promoter 
methylation, indicating the interconnections between various epigenetic 
mechanisms. Preliminary investigations of a PI3K inhibitor, PI-103 showed 
antiproliferative responses in a subset of paediatric HGG short-term cell cultures. 
This warrants further validation of this therapeutic agent in a larger cohort of 
samples.  
This study also identified and validated 7 candidate genes comprising ADAMTS18, 
RFX3, PRKG2, PTPRE, RHBDF2, DAB1 and EYA4 that were frequently 
downregulated in paediatric HGG short-term cell cultures. Of these, PTPRE was 
demonstrated to have anti-growth, and DAB1 was demonstrated to have anti-growth 
and anti-migratory properties in vitro. An important finding of this study is the 
identification of promoter CpG methylation of ASS1 and ASL, the 2 key components 
337 
 
of the arginine metabolic pathway in a subset of paediatric HGG short-term cell 
cultures. Paediatric HGG short-term cell cultures with methylated ASS1 and/or ASL 
demonstrated sensitivity to the arginine deprivation agent, ADI-PEG20, with ASS1 
being the predominant determinant of sensitivity to the drug. This was in agreement 
with the findings of Syed et al. (2013) in adult GBM primary cultures. However, 
unlike in adults, the sensitivity of paediatric HGG short-term cell cultures with co-
methylated ASS1 and ASL was not higher than either ASS1 or ASL only methylated 
cultures, but this could be an artefact due to the small number of samples available 
for this study. ADI-PEG20 has the advantage of overcoming some of the common 
problems associated with chemotherapy failure in glioma. For instance, as it exerts 
its anti-tumour activity by depleting arginine from peripheral blood, crossing of BBB 
is not required (Syed et al., 2013). In addition, as this therapeutic strategy targets 
only tumour cells, this should cause very little damage to normal brain structures.  
This study has revealed evidence for the potential interplay of genetic and epigenetic 
changes in paediatric HGG. For instance, loss of 17q21.31 detected in approximately 
35% of paediatric HGG short-term cell cultures including 1 DIPG (IN2102), 
contains genes encoding chromatin modifiers such as KANSL1 that encodes a 
nuclear protein involved in histone acetylation. A potential association of this locus 
with susceptibility to ovarian cancer has been previously reported (Couch et al., 
2013). In addition, the unique miRNAs and promoter methylated genes associated 
with H3F3A (K27M)-mutant paediatric HGG short-term cell cultures and the 
identification of frequent copy number changes in miRNA genes and pseudogenes in 
this study further supports the importance of both genetic and epigenetic 
dysregulation in paediatric HGG. Thus, integrated data analysis approaches may be 
the key for better understanding of these tumours. 
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8.2 Conclusions 
Through genome-wide studies on well-characterised paediatric HGG short-term cell 
cultures, this study has identified genetic and/or epigenetic dysregulations in several 
candidate genes involved in important cellular processes and druggable metabolic 
pathways associated with cancer. Some of these, such as methylation of genes 
involved in arginine biosynthesis pathway (ASS1 and ASL) are exciting findings as 
this provides opportunity for selectively targeting HGG patients with such 
aberrations using a non-toxic drug, ADI-PEG20. The therapeutic response displayed 
by a subset of paediatric HGG short-term cell cultures to ADI-PEG20 in preliminary 
investigations in this study holds promise for further validation. The identification of 
candidate genes deregulated due to methylation involved in ECM-interactions 
(ADAMTS18), reelin/PI3K signaling (DAB1), DNA damage repair (EYA4), PI3K 
signaling (PRKG2), RTK signaling (PTPRE), ciliagenesis (RFX3) and EGFR 
signaling (RHBDF2) highlights the roles of promoter methylation in regulating 
important tumourigeneic events in paediatric HGG. The anti-growth and anti-
migratory properties of DAB1 and PTPRE demonstrated in vitro strengthens their 
role in paediatric HGG. Further validation of these and the other candidates may lead 
to the identification of potential biomarkers in paediatric HGG. Some of the other 
changes such as gains at 14q11.2 and 7p14.1, and gain at 2q32 associated with 
developmental disorders may provide novel insights into the development of HGG in 
children. This study also emphasises the potential role of cooperative genetic and 
epigenetic changes in these tumours.  
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Appendix I: aCGH profiles of paediatric HGG short-term cell cultures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A1 . aCGH profile of IN178 paediatric HGG short-term cell culture (non-DIPG)  
 
 
 
 
 
 
 
 
 
 
340 
 
IN1163
IN1262
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2. aCGH profile of IN1163 paediatric HGG short-term cell culture (non-DIPG) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A3. aCGH profile of IN1262 paediatric HGG short-term cell culture (non-DIPG) 
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Figure A4. aCGH profile of IN1419 paediatric HGG short-term cell culture (non-DIPG) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A5. aCGH profile of IN1566 paediatric HGG short-term cell culture (non-DIPG) 
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Figure A6. aCGH profile of IN1930 paediatric HGG short-term cell culture (non-DIPG)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A7. aCGH profile of IN3032 paediatric HGG short-term cell culture (non-DIPG)  
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IN3046
IN3180
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A8. aCGH profile of IN3046 paediatric HGG short-term cell culture (non-DIPG)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A9. aCGH profile of IN3180 paediatric HGG short-term cell culture (non-DIPG)  
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IN2087
IN3183 
 
 
 
 
 
 
 
 
 
 
            
               
Figure A10. aCGH profile of IN3183 paediatric HGG short-term cell culture (non-DIPG)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A11. aCGH profile of IN2087 paediatric HGG short-term cell culture (DIPG)  
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IN2102
IN2675
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A12. aCGH profile of IN2102 paediatric HGG short-term cell culture (DIPG)  
 
 
 
 
              
 
 
 
 
 
 
 
 
Figure A13. aCGH profile of IN2675 paediatric HGG short-term cell culture (DIPG)  
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RT PRIMERS
ADAMTS18 F AGACACTGCAATAACCCCAAG
R TCACAAACCCCGTCAATACA
APBB2 F TTCTGTAACGCCATCTCCA
R TTTCCCCTCTCCCCAAATCC
BMP3 F ATGAGGTGTGGGAGGAGAGA
R AGACTTTGGCATGGGGAAC
CABLES1 F ATCTTCCTTGGAGACCCTGG
R ACAGTCTTCCCATCAGCACC
CASZ1 F CGTCTCCACTGTCAAGAACG
R GCATGCAGTGATAGTGGGTG
CAV1 F TCTACAAGCCCAACAACAAGG
R AGGAAAGAGAGAATGGCGAAG
COL14A1 F AAGTATGTAAGGCGGCCAAG
R CCACGATAACCTTTGGGATG
CXCL14 F GTGGACGGGTCCAAATGCAA
R CCAGGCGTTGTACCACTTGA
DAB1 F AAGGTCAGGATCGCAGTGAA
R AAAGGCCCGGTGATCTGTAA
DAB2IP F CAGGACAAGCTGCGAATCTC
R GCTTCTCCTGGGCATCAATG
DLK1 F TGGCCTCTATGAATGCTCCT
R ACCTGTGAACTCGGGCTTG
EYA4 F TCCCCACAGCTGTATCCTTC
R AACTGAGGCAGCCACTCTGT
FGFR2 F GATGGTGCGGAAGATTTTGT
R CCAGGTGGTACGTGTGATTG
GRM8 F CCCTGATCTCCTTTCCAACA
R CAATGCAAACACCACCAATC
Appendix II  Primer sequences  
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GULP1 F GACAGCGAAAAGTGTGCTGA
R GGGTCAAAAGGTTCTGCTCC
KRT8 F GTAGGGGTTGGGTGGTTATG
R ATGGTAGAGGCAGGAGTGGA
MYH10 F AAGAGCAAGGTTCCCACTCC
R ATCCAATTTTCCAGCCCTCT
PARP4 F AATGCCCAAAGAAGTGAACC
R GGTAAAAGCAACCCTCGACA
PDE4D F CCCGGCCTGAAGAAATCCAG
R CAGACTGGCCAAGACCTGAG
PKNOX2 F CCCTCCATCAACCTTCACTC
R GGCAAGACTCCTCGTTTGTT
PLXNB1 F GTTCCTGTGGCTTCCTGTG
R GAAAACCTCCCTCGTCTCCT
PRKG2 F TGATGAACCCACCTCCAAA
R GCAAATCCAAAGTCAACCAA
PRR5L F ACCTTCCCCGATTCCAAG
R GCAGATTTTCACCTTCACACA
RHBDF2 F GGAGACTTTGGCCACTTTTG
R GGAGCAGAGTGTTGCTTCT
RANBP17 F TGCAATTCTGTGGTTCTTGG
R ACCATCAGAAGGCGAGTGAG
RFX3 F CGACTTCCGAAAGCAAAGCT
R CATCCCATGGTCACAGTTACACA
SBNO2 F GAGCGAGAAGCCCAGATAGA
R GGACGAGGAGAAGATGGAGA
SEMA6A F ACATTGCTGCTAGGGACCAT
R TCATCCCCGAATGGTTCCAA
SETBP1 F TCCAAAAAGAAGCTCCTCACA
R CCTGCACTGCCTTTCTTACC
SH3BP4 F TCCCTTCTCTCCTGGACAGA
R CAGTGTGGTGAAGTTGGTGG
SIPA1L3 F TCAACCTCATCTCCCTGACC
R AGCCACTGGTCATCACCTTC
TRIM2 F GGGAGATCCTGGACAACAAG
R CCTTTGGTACCCACTCGAAA
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CoBRA primers
PIK3R5
F GGGAGTTTTAGGTAGAGTTGGAG
R AAACAAAAAACTAAAAACACAAC
ASS1
F TAGTTTTGGTTTAAGGGATGAAAGT
R CCTAACCCTAAAAAAACAATTTAAAC
ASL
F GGCCGCTTAGCCTCCAGCTCAGC
R GTCAGTCCGGTCTTGTCTTCCAGAC
MSP primers
ASS1 Region 1
F TTTTCGTTGTTTATTTTTTAGTCGA
R CGAAACGAACGTCTTCTACG
F TTTTTGTTGTTTATTTTTTAGTTGA
R CCCAAAACAAACATCTTCTACAC
ASS1 Region 2
F GTAGGAGGGAAGGGGTTTTC
R GCAAAAAACAAATAACCCGAA
F GTAGGAGGGAAGGGGTTTTT
R ACAAAAAACAAATAACCCAAA
ASL Region 1
F ATGGAGGTAACGTTTATTTCGTC
R ACTAACCAAAACTTTTCTAACCGAA
F GGATGGAGGTAATGTTTATTTTGTT
R CCACTAACCAAAACTTTTCTAACCA
ASL Region 2
F AGTGTTTAGAATTCGGAGTTAGTTC
R ATATTAAACGATTCCTCGTCGTC
F TGTTTAGAATTTGGAGTTAGTTTGG
R CATATTAAACAATTCCTCATCATC
Sequencing primers
BRAF
F GCTTGCTCTGATAGGAAAATGAG
R GTAACTCAGCAGCATCTCAGG
ACVR1
F GATGCAACTCACCTAACCATTG
R GATGACATTTACTGTGTAGGTCGC
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